general Flashcards

1
Q

Harms of periodic screening

A

Overdiagnosis

False positive, anxiety, quality of life and consequences

Follow-up testing (infection, bleeding), medical intervention, hospitalization

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

cervical cancer screening age

A

25-69

≥ 70yo, stop if 3 successive negative Pap tests in last 10 years

Consider 21-69yo as per SOGC

Consider 21-65yo as per INSPQ

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

mammography screening age

A

Women 50-74yo q2-3y

recommends shared decision-making with women

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

colorectal cancer screening age and frequency in general population

A

50-74yo FOBT (or FIT) q2y or flexible sigmoidoscopy q10y (weak recommendation 50-59yo, strong recommendation 60-74yo)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

risk factors of colon cancer and age of screening

A

1st degree relative ≤60yo CRC, high risk adenomas, or 2+ relatives

40yo or 10y prior to index case

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

lung cancer screening age and criteria

A

55-74yo with ≥30 py smoking history (current or quit <15y ago) low-dose CT q1y x 3 (weak recommendation; low quality evidence)

: USPSTF 2021 recommends annual screening with low-dose CT for 50-80yo with 20py smoking history, and to discontinue once a person has not smoked for 15 years or develops a health problem that limits life expency or ability/willingness to have curative lung surgery

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

age and criteria of screening for AAA

A

Men 65-80yo with one-time screening ultrasound for abdominal aortic aneurysm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

age and frequency of db screening

A

≥40yo A1C or FPG q3y or earlier if high risk

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

age and frequency of DLP screening

A

≥40yo non-fasting lipids q5y (annually >20%) or earlier if risk

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

vit D and ca supplement doses

A

vitamin D 400-2000 IU daily, if age>50 years (or risk) 800-2000IU daily

Calcium 1200 mg/d from diet (increase to 1500-2000 mg/d if pregnant or lactating)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

when to screen for osteoporosis and risk factors

A

All men and women ≥ 65yo

≥ 50yo if risk factor:
Fragility fracture after age 40 (low trauma fractures) and risk of future fractures
Vertebral compression fracture or osteopenia on X-ray
Parental hip fracture
Prolonged use of glucocorticoids (3mo of >7.5 mg prednisone daily in past year)
Rheumatoid arthritis, malabsorption syndrome
Current smoker
High alcohol intake (>3 units/day)
Major weight loss (10% below body weight at age 25)
<50 yo if disorder associated with rapid bone loss
Fragility fractures
High-risk medications
Malabsorption
Inflammatory
Primary hyperparathyroidism

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

tests for secondary causes of osteoporosis

A

Calcium, Albumin
CBC
Creatinine
Alk phos
TSH
SPEP (if vertebral fractures on X-ray)
25-OH Vitamin D checked once after 3 month of supplementation in impaired instesinal absorption, or osteoporosis requiring pharmacotherapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

ways to prevent osteoporosis

A

Smoking cessation, alcohol reduction <3 drinks/day
Vitamin D 1000-2000 IU PO daily
Calcium intake 1200mg/day from diet (three servings of low fat milk products)
Can consider Calcium supplement ≤500mg PO daily in those who cannot meet recommended dietary allowance at high risk of fractures
Sufficient protein intake (1g/kg/day)
Exercise Multicomponent program includes
Resistance training ≥ 2x/wk
Back extensor muscles daily
Balance training daily
Aerobic physical activity 150 mins/week of moderate intensity
Fall awareness and prevention
Assistive devices
Medication review (fall risk)
Environmental hazards
Hip protectors
Urinary incontinence

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Name 6 classes of medication for osteoporosis treatment and an example

A

Oral bisphosphonate: Alendronate 70mg PO weekly or Risedronate 35mg PO weekly or 150mg PO monthly
Take 1 hour before breakfast with 250mL water, upright 30 mins, avoid any calcium for 2-3h
Adverse: Osteonecrosis of the jaw, atypical femur fractures, esophagitis, esophageal ulcers
Consider oral bisphosphonate holiday after 5y (10y in high risk, eg. previous fracture and T<-2.5)
IV bisphosphonate: Zoledronic acid 5mg IV once yearly if GI/esophageal disorders, or inability to tolerate (eg. sit upright for 30-60 mins)
Consider Drug Holiday after 3y (6y in high risk)
Monoclonal Ab (RANKL inhibitor): Denosumab (Prolia) 60mg sc twice yearly if impaired renal function
No drug holiday on Denosumab
Adverse: Joint/muscle pain, osteonecrosis of jaw, contraindicated in pregnancy
PTH Analog: Teriparatide (Forteo) 20mcg sc daily in severe osteoporosis who cannot tolerate bisphosphonate
Adverse: Hypercalciuria/emia, angioedema
SERM (Selective estrogen receptor modulators ): Raloxifene
Risk of thromboembolism
Other: Calcitonin intranasal, Hormone therapy (in menopausal symptoms)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

when to refer osteoporosis to a specialist

A

Multiple fractures despite adherence to therapy
Secondary causes of osteoporosis/metabolic bone disease outside expertise
Extremely low BMD not explained by risk factors
CKD (eGFR<30mL/min)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

age group in croup

A

6m-3yo

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

differential ddx of croup, name 6

A

bacterial tracheitis
retropharyngeal/ peritonsillar abscess
epiglottitis
aspiration of foreign body
allergic reaction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

treatment of croup

A

Dexamethasone 0.6mg/kg po or IM x 1

mod severe: nebulized epi over 15 min

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

when can u d/c croup

A

after observing 2- 4h after meds

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

T or F:
No evidence for Heliox (or helium-oxygen mixture), antibiotics, short-acting beta-2-agonist bronchodilators in treatment of croup

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

3 categories of croup and their caracteristics

A

Mild: no stridoe or significant wob - dex + d/c

Mod: stridor and chest wall indrawing at rest but no agitation - dex + observe

severe: stridor and chest wall indrawing at rest with lethargy or agitation : dex + epi + observe

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

when to give antibiotics in acute bronchitis

A

consider antibiotics in ≥ 75 years, >3 weeks or suspect B. pertussis (Whooping cough, >3 weeks, vomiting (related to coughing), exposure to pertussis, not vaccinated)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

name 6 symptomatic therapies for an URTI

A

Analgesics (Acetaminophen/NSAIDs)
Combination products (Antihistamine, decongestant, analgesics)
Consider Zinc lozenges 75mg PO daily, Pleragonium sidoides, Andrographis paniculata
Risk of irreversible anosmia in intranasal zinc preparations
Nasal symptoms
Nasal saline irrigation (poor evidence)
Intranasal cromolyn sodium 1 spray (5.2mg) in each nostril q2h PRN x 2 days then 4 times daily x 5 days
Intranasal ipratropium bromide 0.06% solution two sprays (42mcg/spray) in each nostril 3-4 times daily PRN x 4 days
Cough suppressant
Brompheniramine plus sustained-release pseudoephedrine
Ipratropium bromide inhaled
Dextromethorphan 30mg PO q6-8h PRN

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

two medication to help with flu

A

Zanamivir (Relenza) two inhalations (10mg) PO BID x 5d or oseltamivir (Tamiflu) 75mg PO BID x 5d

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
when to consider antiviral in elderly
Severe disease (requiring hospitalization or evidence of lower respiratory tract infection, eg. dyspnea, tachypnea, oxygen desaturation) High risk for complications (pregnancy) start within 48h
26
5 indication to consider CXR in URTI
Hemoptysis Pleuritic chest pain Dyspnea Systemic symptoms (fever, tachycardia >100, tachypnea>24) Abnormal physical exam (crackles, decreased breath sounds, bronchial breathing)
27
4 criterias for complicated UTI
Anatomic or functional abnormality of urinary tract (enlarged prostate, stone, diverticulum, neurogenic bladder) Immunocompromised host Multi-drug resistant bacteria Pyelonephritis
28
name 5 common bacterias for UTI
Klebsiella pneumoniae E Coli – most common (75-95%), especially in women Enterococci – most common in LTC facilities Proteus mirabilis – most common in men Staph saprophyticus
29
6 risk factors for UTI
Age Female Neurogenic bladder/urinary incontinence, vesicoureteral reflux, posterior urethral valves, prolapse, BPH Indwelling catheter, recent surgery/instrumentation Diabetes, other comorbidities Sexual activity
30
name 7 DDx of UTI
Infectious Cystitis, Pyelonephritis, Urethritis Vulvovaginitis, Cervicitis Prostatitis, epididiymo-orchitis Foreign body Urolithiasis Dermatologic Irritant/Contact dermatitis, lichen sclerosus, lichen planus, psoriasis, Stevens-Johnson, Behçet syndrome BPH, urethral stricture Neoplastic Trauma/surgery Interstitial cystitis (bladder pain syndrome)
31
name 4 conditions that can put UTI at risk of complications
pregnant, co-morbidity, exposure to antibiotics in past 3 months, travel, previous drug-resistant infection, children, diabetes, urolithiasis
32
name 3 causes of underlying causes of reurrent UTI
post-coital urinary tract infection, atrophic vaginitis, retention
33
T or F: A woman with dysuria/frequency, no risk factors for complicated infection, and no vaginal discharge had a 90% probability of UTI (LR+ = 24.6) and can be treated without :UA or UCx
true When a diagnosis of uncomplicated urinary tract infection is made, treat promptly without waiting for a culture result.
34
When should u order UA for UTI
if history not clear Both LE/Nitrites PPV+ 95% LE alone consider urethritis
35
when is UCx considered positive for UTI
Urine culture indicates UTI only if accompanied by symptoms Without indwelling catheter >10^5 cfu/mL of <2 species by void, or >10^2 by in-and-out With indwelling catheter >10^5 cfu/mL taken from new catheter or <14d since insertion
36
simple cystitis tx
Nitrofurantoin 100mg PO BID x 5-7d (careful in reduced creatinine clearance) TMP-SMX DS 1 tab BID x 3d (if resistance <20%, Quebec has 15% resistance) Fosfomycin 3g PO x 1 (appropriate but inferior efficacy)
37
cystitis in pregnancy tx
Nitrofurantoin 100mg PO BID x 7d Amoxicillin 875mg PO BID x 3-7d Avoid TMP-SMX in first trimester and at term
38
acute Pyelonephritis or complicated cystitis tx
Acute Pyelonephritis or complicated cystitis Ciprofloxacin 500mg PO BID x7d or Levofloxacin 500mg PO daily x 7d Can consider initial intravenous dose: Ceftriaxone 1g IV or 24h dose of aminoglyocoside If complicated pyelonephritis consider inpatient IV antibiotics initially and longer 14d course
39
treatment of UTI in men
Consider r/o prostatitis, urethritis Empiric antibiotics Fluoroquinolones (eg. Cipro 500mg PO BID or Levofloxacin 500mg PO daily) x 7-14d If afebrile, consider 7d course rather than 14d as per latest JAMA 2021 Consider shorter courses of fluoroquinolones for uncomplicated pyelonephritis (eg. 7d as per ACP) Consider TMP-SMX DS 1 tab BID if culture sensitive
40
how to properly tx uti with urinary catheter
Ideally remove catheter prior to antibiotics Otherwise intermittent catheterization if possible Otherwise replace catheter after antimicrobial therapy started 7-14 day antimicrobial treatment generally adequate
41
8 tips for prevention of UTI
Hydration, nutrition Perineal hygiene Healthy voiding habits Avoid unnecessary urinary catheters (consider intermittent cathterization) Aseptic technique for urinary catheters May consider cranberry prophylaxis (eg. juice or tablet) May consider discussing antibiotic prophylaxis (continuous x 1 year or postcoital) vs. self-treatment in recurrent UTI (eg. 2+/6mo, 3+/12mo) May consider vaginal estrogen therapy in peri/post-menopausal women
42
Name FOUR medical conditions that could be contributing to insomnia?
Mental health disorders/Anxiety/Depression/Stress/Adjustment Hormonal changes/perimenopause/menopause Substance use/alcohol/illicit drugs/caffeine Pain Restless Legs Syndrome Obstructive sleep apnea Hyperthyroidism
43
What advice about sleep hygiene do you discuss with Michelle. Name SIX.
Keep a sleep diary Regular exercise: 150 mins/wk of moderate intensity cardiovascular exercise + resistance training 2 days per week Avoid large meals close to bedtime Develop/Engage in a wind-down routine Turn off electronics 1/2 hour before bedtime Do not watch the clock Ensure comfortable temperature Sleep in a dark room Minimize alcohol use Use bedroom only for sleep and intimacy Keep regular sleep-wake schedule 7 days per week Avoid caffeine later in the day
44
Name ONE non-pharmacologic therapy that has been shown to be helpful for insomnia.
Cognitive behavioural therapy
45
Name THREE prescription medications, each from a different class, that could be used to treat insomnia?
Trazodone (FYI: Serotonin antagonist and reuptake inhibitor (SARI), Mirtazepine (FYI: Atypical antidepressants/tetracyclic antidepressants), triazolam/lorazepam/temazepam/nitrazepam (FYI: Benzodiazepines), zopiclone/zolpidem (FYI: Benzodiazepine receptor agonists), amitriptyline/doxepin (FYI: Tricyclic antidepressants), tryptophan (FYI: Serotonin precursors) Writing Benzodiazepines (BDZ) as an answer might have made you nervous, and for good reason! These are not good medications, but the way the question is worded ("drugs that could be used to treat her insomnia") makes them applicable answer. If the question was worded, "what are the preferred mediations to prescribe when someone has exhausted non-pharmacologic approaches?" then BDZs are not on the list. Also, suggest avoiding meds that are often used for sleep but are off-label, such as quetiapine (atypical anti-psychotics). In this case you also might have wondered about using hormone replacement therapy or oral contraceptive pills to normalize hormonal patterns. Those medications did not make the answer key because there is not enough information to know if they are appropriate. Melatonin is not on the answer key because it is over-the-counter.
46
What ocular symptoms are important to inquire about? List FOUR.
Blurred vision/visual acuity Photophobia Exudate/Discharge Itching Coloured halos in the visual field Sensation of a foreign body Double vision/Diplopia eye pain redness
47
name 8 ddx of red eye
Autoimmune: Iritis Keratitis Acute angle-closure glaucoma Foreign body Blepharitis Subconjunctival hemorrhage Pterygium Abrasion/trauma Chalazion/Hordeolum/Stye Chemical burn/irritant Allergic
48
3 potentially serious ocular side effects of prolonged use of topical corticosteroid drops
Cataracts Elevated intraocular pressure Optic nerve damage
49
if a patient were elderly, were complaining of acute pain in the eye, and had visual acuity of 20/200, what ophthalmic diagnosis would you be MOST concerned about? Be specific.
Acute angle-closure glaucoma
50
What technique is the "gold standard" for diagnosing glaucoma
Measurement of intraocular pressure/Tonometry
51
What is the DEFINITIVE treatment for acute angle-closure glaucoma
Surgical peripheral iridectomy/ Laser peripheral iridectomy/Iridectomy
52
You diagnose viral conjunctivitis. How do you educate her about her request for antibiotic eye drops? Describe TWO points of discussion
Since there is no evidence of a bacterial infection, and that viral conjunctivitis is far more common, there is no indication for antibiotic drops. She will likely get better at the same rate with or without drops Even if it was bacterial, it is usually a self-limiting condition Bacterial super-infection in viral conjunctivitis is uncommon
53
How do you counsel about return to work, preventing transmission to her other eye, and preventing transmission to others in terms of viral conjunctivitis? Name THREE.
Return To Work: Do not return to work until symptoms have resolved. Prevention of transmission to her other eye: Recommend do not touch her eyes. Prevention of transmission to others: Recommend frequent hand washing
54
otalgia DDx
AOM, acute mastoiditis, acute facial nerve palsy, labyrinthitis, venous sinus thrombosis, meningitis, trauma, cholesteatoma, tumor, otitis externa, r/o necrotizing/malignant otitis externa, Herpes zoster , Secondary otalgia, otitis media with effusion, otitis externa
55
name 3 patogens of AOM
S pneumoniae , M catarrhalis and H influenzae
56
name 6 risk factors of AOM
Smoking exposure Upper respiratory tract infection Daycare (sick contacts) Bottlefeed Pacifier Personal history, family history of AOM
57
name 3 alternative antibiotics to amoxicilline for tx of AOM in case of allergy
Non-anaphylactic: Cefuroxime 30 mg/kg/day ÷ BID-TID Anaphylactic: Clarithromycin 15mg/kg/day PO ÷ BID x5-10d or Azithromycin 10mg/kg PO day 1, then 5mg/kg PO x 4d
58
criterias for ENT referral for ear problems
recurrent AOM 3x/6 months or 4x/1 year Chronic OME >3 months With risk of speech/learning problems Bilateral OME with Hearing loss Symptoms attributable with OME (vestibular problems, poor school performance, behavioural problems, ear discomfort) AOM resistant to second-line antibiotics Perforated TM non-resolved after 6w
59
T or F: Water precautions should not be encouraged routinely in patients with tympanostomy tubes
T
60
Topical antibiotic eardrops (Eg. Ciprofloxacin (Ciprodex) = 4 drops BID x 5 days) without oral antibiotics should be prescribed for children with uncomplicated acute tympanostomy tube otorrhea
True
61
name 6 cognitive domainsLearning/memory
Language Executive function Complex attention Perceptual-motor Social cognition
62
name examples of Activities of Daily Living (ADL)
dressing, eating/self-feeding, ambulating/transferring, toileting, hygiene/grooming, bath/shower)
63
name exemples of Instrumental Activities of Daily Living (IADLs)
shopping, housework, accounting/finances, food prep, telephone, transportation, taking meds
64
name 6 MNCDs
Alzheimer (most common 50%) Gradual onset, normal CNS, initial and most prominent deficit = amnestic (associated with impairment in learning and recall of recently learned information) Mixed Alzheimer and vascular (20%) Vascular (15%) Abrupt, stepwise, cardiovascular risks (HTN, DLP), dysexecutive syndrome, focal neurological features Lewy Body (5%) Core features: Fluctuating cognition, detailed visual hallucinations, REM sleep behaviour disorder, Parkinsonism (bradykinesia, rest tremor, rigidity) Other suggestive: Severe neuroleptic sensitivity (irreversible parkinsonism, impaired consciousness), postural instability, falls, syncope, autonomic dysfunction, hypersomnia, hyposmia, delusions, apathy, anxiety, depression Frontotemporal (1%) Behavioural problems (disinhibition, loss of social awareness), language impairment Parkinson disease with dementia Impaired executive dysfunction and visuospatial function Differentiate from Lewy Body as parkinsonism is present >1y prior to dementia (whereas in DLB dementia occurs before or at the same time as the parkinsonian signs) Other: Progressive supranuclear palsy (vertical supranuclear gaze palsy and postural instability), Huntington disease Other ddx; delirium, depression, neuro: seizures, stroke/TIA
65
MNCD labs investigations
Labs (low yield <1%) CBC, TSH, electrolytes (Glucose, Cr, Ca), B12, Lipids Neurosyphilis screen only if high clinical suspicion Consider EKG prior to treatment Avoid AchEI if LBBB, 2nd/3rd degree block, sick sinus, HR<50
66
when to do CT head for MNCD
<60yo Abrupt, rapid decline Focal neurological symptoms (headache, seizure, hemiparesis, babinski reflex) Urinary incontinence, gait disorder (r/o normal pressurehydrocephalus) Previous malignancy, trauma Anticoagulants/Bleeding disorder or history of bleeding disorder If presence of cerebrovascular disease would change management
67
name 4 tools to dx MNCD
Highly educated -Hopkins Verbal Learning test -Word List Acquisition test MMSE <24 suggests dementia/delirium (1 in 10 false positive) MoCA <26 (MCI 78%, AD 100%,1 in 4 false positive) Clinical Dementia Rating (Lengthy) Mini-Cog (Brief) -Clock drawing task and uncued recall of three unrelated words
68
non pharmalogical treatment/management of MNCD- name 8
Refer to Alzheimer society Discuss will, power of attorney, personal directives Safety issues (driving, stove, smoke detector, microwave) Occupational Therapy Hearing and vision screen Social work / Homecare services Healthy diet, smoking cessation Exercise program Eliminate medication (narcotics, anticholinergics, benzodiazepines) Alternative therapy: Aromatherapy Multisensory stimulation Music/dance therapy Animal‑assisted therapy Massage/touch therapy Outdoor activities
69
pharmacotherapy for mild cognitive disorder
No pharmacotherapy for mild cognitive disorder Acetylcholinesterase inhibitors may be considered only in mild to moderate Alzheimer's Disease (lower quality evidence in Lewy bodies, vascular, Parkinson), where Healthcare professional has expertise in diagnosing and treating Alzheimer's Disease Adequate support and supervision Adequate adherence and monitoring of adverse effects, which generally requires the availability of a carer Baseline structured cognitive and functional assessment Follow up should be carried out on regular basis at least every 3 months Taper slowly before stopping May restart if decline shortly after stopping May reduce all-cause mortality in patient with dementia
70
Pharmacotherapy for Alzheimer's: name 2 classes and exemples
AchEI, eg. Donepezil (Aricept) 5mg-10mg PO daily, Rivastigmine, Galantamine Consider in mild to moderate (eg. MMSE 10-26) Titrate q4 weeks Discontinue when risks outweigh benefits (taper, and monitor 1-3 months, if declines can restart) 2-NMDA receptor antagonists (Memantine) in severe AD
71
side effects of AchEI
GI (nausea, diarrhea, vomiting) Bradycardia, hypotension, dizziness, syncope Insomnia / sleep disturbances QT prolongation and torsades de pointes (EKG prior to treatment as above)
72
Frontotemporal mncd tx
SSRI (paroxetine) or trazodone No evidence for AchEI
73
Vascular dementia tx
Manage HTN, DM, smoking No evidence for AchEI
74
Lewy Bodies pharm tx
Can consider AchEI (eg. Rivastigmine (Exelon) 1.5-6mg BID) Avoid antipsychotics Risk of NMS
75
Atypical depression in elderly tx
Trial of antidepressant, consider Citalopram (max 40mg po daily)
76
Parkinson's/Cerebrovascular disease pharmacological tx
Can consider AchEI levodopa
77
tx of Behavioral and psychological symptoms of dementia (BPSD)
1-r/o medication side effects or interactions, treatable medical conditions such as sepsis or depression 2-Severe agitation/Violent behaviour Correct underlying Physical (pain, constipation, infection) Environmental (set routines, sound/lights, position, daytime activity) Psychiatric conditions (depression) Review medications 3-Intervention Relaxation, social contact, sensory (eg. music/aromatherapy) Increased services/care 4-Consider newer antipsychotics (less EPS), eg. Risperidone, Olanzapine, Seroquel Caution as increased risk of death, CVA, EPS, falls, somnolence, weight gain, diabetes
78
elements to look for in p/e of dementia
Gait Neurological signs Extra pyramidal symptoms Parkinson (cogwheel rigidity, tremors)
79
4 ddx of dyspepsia
Functional/IBS (no organic cause) - 60% PUD - 25% -Upper abdominal pain prominent, back pain atypical -Gastric worse with food, Duodenal better with food -Postprandial belching, epigastric fullness, early satiation, N/V GERD -Retrosternal pain/regurgitation GI Malignancy Age Dysphagia, odynophagia Systemic signs (anemia, fatigue, weight loss) Drug-induced dyspepsia (NSAIDs and COX-2 inhibitors) Other: Celiac, chronic pancreatitis, gastritis, Crohn's, cardiac
80
name 6 red flags of dyspepsia
Vomiting Weight Loss (Involuntary) Blood loss (melena, hematemesis, anemia) Age >50 Anemia Abdominal mass or lymphadenopathy Dysphagia, odynophagia, early satiety Family history of upper GI cancer Jaundice
81
when to do endoscopy for dyspepsia
>50yo with new-onset dyspepsia Atypical features or red flags No response (or limited) after 4-8w of adequate PPI Consider in chronic GERD with 3 risk factors for Barrett's esophagus (male > 50 years old, Caucasian, central obesity, smokers and family history of BE)
82
5 lifestyle modifications for GERD
Weight loss if overweight Stop smoking, excessive alcohol Stop NSAID/ASA Avoid food/drinks that trigger (Alcohol, fried foods, spicy foods, garlic/onion, orange/citrus, chocolate/peppermint, coffee/caffeine, tomatoes) Eat smaller meals Elevate head of bed, avoid meal 2-3h before bedtime if nocturnal GERD
83
when to consider urea breath test
<50yo with dyspepsia but no red flags (especially if family history of peptic ulcer or cancer) -Active PUD (gastric or duodenal). -Confirmed history of PUD (not previously treated for H. pylori). -Gastric MALT lymphoma (low grade). -After endoscopic resection of EGC -functional dyspepsia -low dose ASA -idiopathic thrombocytopenic purpura (ITP) -Long term NSAIDS use -Iron deficiency anemia >no indication to test a pt with typical GERD
84
Medication that can cause or worsen dyspepsia, name 8
bisphosphonate, iron, prednisone, potassium suppl, NSAIDS, ASA, MTF, opiates, antibiotics (erythro, metronidazole)
85
investigations for dyspepsia
* H. Pylori * Hb * Iron studies * ALT, ALP, AST, GGT (possibly add liver function) * Calcium * Possibly Gluc AC/screen for diabetes * Possibly anti-TTG if suspect Celiac
86
3 Risk factors for being infected with H.pylori
Immigration from a developing country * Poor socioeconomic conditions * Family overcrowding
87
H. Pylori is a risk factor for what conditions?* (4)
Gastritis * Peptic ulcers * Gastric cancers * Gastric MALT (mucosa-associated lymphoid tissue) lymphoma
88
how to treat for H pylori
Quadruple therapy: bismuth, clarythromycin or tetracycline, metronidazole, PPI x 14 days
89
how to test for cure of H pylori
test at least 4 weeks after completion of antibiotics, with PPI withheld for 1-2 weeks
90
4 treatments of functional dyspepsia
The rate of response to placebo in trials 30% to 40% * A meta-analysis showed that PPIs were effective in reflux-like or ulcer- like FD but not with dysmotility-like FD * Prokinetic agents, including cisapride, domperidone, and itopride, have been shown to be more effective than placebo in a meta-analysis of 24 RCT (**but adverse effects) (lacking high quality studies for metoclopramide) * No benefit of venlaxafine or sertraline but some data suggest benefit of amitriptyline * Mirtazapine showed significant improvements compared to placebo in early satiety (not correlated to changes in anxiety/depression) but not in epigastric pain. * Possible benefits of psychological therapy * Attention to stress reduction is important, and dietary advice should be provided (e.g., ingestion of small, regular, low-fat meals and avoidance of foods that precipitate symptoms
91
factors that may reduce efficacy of contraception
delayed initiation of method, illness, medications, specific lubricants
92
how to manage side effects appropriately of hormonal contraceptived
recommend an appropriate length of trial, discuss estrogens in medroxyprogesterone acetate [Depo–Provera
93
barrier methods or when efficacy of hormonal methods is decreased, advise about post-coital contraception
94
in a patient who has had unprotected sex or a failure of the chosen contraceptive method, inform about time limits in post-coital contraception .
emergency contraceptive pill, intrauterine device time limits
95
side effects of progestin only pills
Irregular bleeding 9% pregnancy risk
96
Side effects of transdermal patch (Evra 1 patch per week x 3 weeks, one week off)
9% pregnancy risk 17% skin reaction
97
side effects of Combined vaginal ring (NuvaRing x 3 weeks, one week off)
9% pregnancy with regular use perfect use 0.3% May remove for 3h (eg. during coitus) 5% vaginitis, leukorrhea
98
Side effects of Injectable progestins (DMPA- Depo–Provera 150mg IM q12w
6% pregnancy risks Irregular bleeding, weight gain, decrease bone density Consider supplemental low-dose estrogen to reduce irregular bleeding if persists past 3 cycles
99
Side effects of Intrauterine devices (LNG-IUD Mirena q7y, CU-IUD q10y)
<0.1% pregnancy 44% amenorrhea at 6 months Risk of expulsion/perforation postpartum until 6 weeks
100
side effects of subdermal implants (Nexplanon - Etonogestrel)
very effective likely <0.1% Very rare risk of implant migration 15% bleeding irregularities Not studied in overweight >130% IBW
101
Permanent contraception riks of pregnancy
Tubal Ligation - 0.15% Vasectomy - 0.15%
102
(how to be certain she is not pregnant) when prescribing contraception
Pregnancy test >2w after last episode of unprotected intercourse ≤7d after start of normal menses or spontaneous/induced abortion No sex since start of last normal menses Correctly, consistently using reliable contraception 4w postpartum Fully breastfeeding and <6 months postpartum Back-up contraception for 7d if >7d after menses started
103
name 4 emergency contraceptions and when they are effective
1-Copper IUD - failure rate of <1% (>95% effective) Effective up to 5 days (limited evidence up to 7 days) after unprotected intercourse, provided pregnancy ruled out Hormonal/oral (less effective if BMI>30 or weight ≥80kg), side effects include headache, irregular bleeding , N/V 2-Ulipristal acetate 30mg PO x1 - failure rate of 1.4% (~75% effective) Effective up to 5 days Hormonal contraception can be initiated up to 5 days after unprotected sex with backup for first 14d 3-Levonorgestrel 1.5 mg PO x1 (or 0.75mg q12h x2) - failure rate of 2.2% (~50% effective) Effective up to 72h (proven efficacy up to 96h, limited efficacy up to 120h) Hormonal contraception can be initiated the day of (or after) with backup for first 7d 4-Combined OCP (Yuzpe) 100-120mcg ethinyl estradiol plus 500-600 mcg levonorgestrel (5 pills of Alesse) q12h x2 - least effective Effective up to 72h ___________ Note: Approx. 5% risk of pregnancy if unprotected sex, but up to 30% if 1-2d prior to ovulation Only contraindications are pregnancy (and active pelvic infection/cervicitis for IUD)
104
Name 3 OCP and their levels of estrogen
Standard 30mcg (Marvelon, Yasmin), 35mcg (Ortho 1/35) Low 25mcg (Tri-Cyclen Lo), 20mcg (Alesse) Very Low 10mcg (Lo Loestrin Fe)
105
name 8 Contraindications to Estrogen
Migraine with aura (≥5 min reversible visual/sensory/speech/motor symptom that is accompanied within 60 mins by a headache) Smoker age ≥35 years and smoking ≥15 cigarettes per day Uncontrolled hypertension (>160/100) Acute DVT/PE History of DVT/PE, not on anticogulation, with risk factor (history of estrogen-associated DVT/PE, pregnancy-associated DVT/PE, idiopathic DVT/PE, known thrombophilia including antiphospholipid syndrome/SLE, active cancer with the exception of non-melanoma skin cancer, history of recurrent DVT/PE) Current or history of vascular disease, ischemic heart disease, stroke, complicated valvular disease (pulmonary hypertension, risk of atrial fibrillation, history of subacute bacterial endocarditis) Liver disease (severe cirrhosis, hepatocellular adenoma, malignant hepatoma) <4 weeks postpartum or peripartum cardiomyopathy Major surgery with prolonged immobilization Complicated solid organ transplantation (graft failure, cardiac allograft vasculopathy) Active breast cancer
106
1contraindication to progestin-only pills and 1 relative C-I
current breast cancer, relative contraindications include liver disease
107
name 3 meds that decrease effectiveness of OCP
Decreased effectiveness with anticonvulsants (phenytoin, phenobarbitol), antiretrovirals, rifampin (not other antibiotics)
108
4 side effects of OCP
Nausea - Take pill at bedtime or with meal (consider lower estrogen) Breast tenderness (consider lower estrogen) Headache Breakthrough bleeding (r/o smoking, noncompliance, cervical/uterine disease, pregnancy, consider increase estrogen) No evidence of weight gain
109
6 Non-Contraceptive Benefits/Risks
Cycle regulation, predictable bleeds Decreased menstrual flow, anemia Decreased acne, hirsutism Decreased dysmenorrhea, premenstrual symptoms Decreased perimenopausal symptoms Decreased risk of fibroids, ovarian cyst
110
3 Risks of OCP
VTE RR 2-3 (compared to pregnancy RR 6 and postpartum RR 115) 10 / 10,000 woman-years (COC users) vs. 4-5 / 10,000 woman-years (non-users) UNCLEAR risk of gallbladder disease, possible increase in symptomatic gallstones when used for 15 years NOT associated with increased risk of MI or CVA if no risk factors NOT associated with increased risk of major birth defects if taken before/during pregnancy
111
counsel on risk of cancer with OCP
Decreased ovarian, endometrial, colorectal cancer Possible association with cervical cancer (causation not demonstrated) Decreased risk of benign breast disease Possible increase in breast cancer in current/recent COC users 5 / 1000 COC-users vs. 4 / 1000 non-users will be diagnosed with breast cancer before 39 years-old
112
Counsel on missed pills ( within 24h, in first week, after 2-3 weeks)
-If missed pill <24h in any week Take most recent pill ASAP (even if it means two pills the same day) and continue taking remaining pills until end of pack -If missed pills in first week Take most recent pill ASAP (even if it means two pills the same day) and continue taking remaining pills until end of pack Back up x 7d* -If missed pills during second or third week Take most recent pill ASAP (even if it means two pills the same day) and continue taking remaining pills until end of pack and start new cycle of OCP without a hormone-free interval Back-up contraception if 3 or more consecutive doses/days of OCP missed *if unprotected intercourse in last 5 days and not on active hormone x 7 consecutive days, there is a risk of ovulation and unintended pregnancy consider emergency contraception
113
what to do if missed pill
Missed Progestin only pills >3h delay Take most recent pill ASAP and continue taking remaining pills until end of pack Back-up x 48h If unprotected intercourse in last 5 days, Emergency contraception recommended
114
name 4 management points for idiopathic, refractory cough
-Speech pathology treatment -Neuromodulating medication Gabapentin (300-1800mg daily x 10w), Pregabalin 300mg PO daily x4w -CT scan if suspect lung cancer, bronchiectasis or ILD -Referral to specialty
115
persistent (or recurrent) cough DDX (5)
., gastroesophageal reflux disease [GERD], asthma, rhinitis, presence of a foreign body, pertussis
116
name 5 stages of readiness to change and definition
1 Precontemplation (Not ready) Highlight advantages for change and problems with current behaviour, Harm reduction 2 Contemplation (Getting ready) Weigh pros and cons, explore ambilance/alternatives, identify reasons for change/challenges, increase confidence 3 Preparation - Action (Ready) Goal setting, start date and strategy for change, as well as address challenges Support and praise, stress that episodes of relapse are normal 4 Maintenance (Sticking to it) Help identify and use strategies to prevent relapse 5 Relapse (Learning) Help renew process of contemplation and action without becoming demoralized
117
Five A's (Health risk behaviour)
Ask "Would you mind if I talked to you about your smoking? How often do you smoke/exercise/wear a seatbelt?" Advise "As your doctor, I strongly recommend that you ____. It is one of the most important things you can do for your health." Assess "Are you ready to quit smoking in the next 30 days?" Assist "Quitting smoking can be a real challenge. I can help you with this change, as well as pharmacotherapy/community resources/spousal support may help.” Arrange 'I'd like to see you again/call you next week to see how the plan is going."
118
5 ways to manage a crisis
Reassure Relaxation techniques (deep breathing) Focus on coping mechanisms that were successful in past Resources: Support system (friends/family) and Community resources Consider short-term anxiolytics/hypnotics Discourage inappropriate coping mechanisms (denial, withdrawal, harmful behaviours/substances)
119
T or F: In patients with high probability for thrombotic disease (e.g., extensive leg clot, suspected pulmonary embolism) start anticoagulant therapy if tests will be delayed
T
120
name 8 acquired risk factors for DVT
Prior thromboembolism Recent major surgery Trauma Immobilization Antiphospholipid antibodies Malignancy Pregnancy Oral contraceptives Myeloproliferative disorders
121
name 4 hereditary risk factors for DVT
Factor V Leiden Prothrombin gene mutations Protein S or C deficiency Antithrombin deficiency
122
name the wells criteria for DVT (10)
Paralysis, paresis or recent orthopedic casting of lower extremity Bedridden >3 days recently or major surgery within 4 weeks Localized tenderness of the deep veins Swelling of entire leg Calf swelling 3 cm greater than other leg (measured 10 cm below the tibial tuberosity) Pitting edema greater in the symptomatic leg Non-varicose collateral superficial veins Active cancer or cancer treated within 6 months Previously documented DVT -2 points for alternative diagnosis at least as likely as DVT (Baker's cyst, cellulitis, muscle damage, superficial vein thrombosis, post-thrombotic syndrome, inguinal lymphadenopathy, extrinsic venous compression)
123
name 3 upper extremity DVT causes
Central venous catheter, recent pacemaker, malignancy
124
Note distal thrombosis may extend proximally in 20% (repeat in 7 days if suspect DVT)
125
duration for anticoagulation of DVT and which Rx to use
Anticoagulate for initial 3 months, consider indefinite in unprovoked and cancer (and low risk bleeding) LMWH or IV heparin (5000 units bolus then 20 units/kg/hr target aPTT 2-3x control aPTT) overlap with warfarin for minimum 5 days and INR >2 for minimum 2 days Subcutaneous LMWH (eg. Dalteparin 100 U/kg SC daily or Enoxaparin 1.5mg/kg SC daily) or IV heparin x 5-10 days, then dabigatran 150mg PO BID LMWH x 1 month then DOAC or warfarin DOAC
126
when to consider warfarine more than DOAC for anticoagulation
Consider Warfarin in valvular A Fib, CrCl<30, Antiphospholipid syndrome, Weight >120kg, Gastric bypass, Liver failure
127
name 4 doacs for the tx of DVT
Apixaban 10mg PO BID x 1 week, then 5mg PO BID (can decrease to 2.5mg PO BID after 6 months) Rivaroxaban 15mg PO BID x 3 weeks then 20mg PO daily (can decrease to 10mg PO daily after 6 months) Note: Dabigatran and Edoxaban require 5-10 day initial treatment bridge with LMWH
128
which anticoagulant is better in pregnancy and cancer
LMWH preferred in Cancer and in Pregnancy, advantages include fixed/simple-dosing and lower HIT There is some evidence that apixaban can be used as an alternative for patient with cancer who do not want injections (but avoid in upper GI malignancy due to increased rate of bleeding)
129
can you use asa for anticoagulation, DVT
Only consider Aspirin in those who are adverse to long-term anticoagulation (32% reduction of recurrent VTE vs 82% when on oral anticoagulants)
130
Isolated distal DVT anticoagulation reasons to treat
if symptomatic and risk factors for extension (severe symptoms, >5cm in length, multiple deep veins, close to popliteal veins, no reversible risk factor, previous VTE, in-patient, positive D-dimer) or progression on imaging
131
treatment of superficial vein thrombosis
topical/oral NSAIDs for symptoms, if >5cm consider low-intermediate dose LMWH
132
when to do surgical intervention in thrombosis
Urgent surgical intervention for phlegmasia cerulea dolens (extensive thrombosis which can cause irreversible ischemia, necrosis, gangrene)
133
When to use anticoagulants as prophylaxis and for how long
Hip/knee arthroplasty, hip fracture = 14-35 days Major orthopedic trauma, Complicated Spine Surgery, Isolated below-knee fracture, L/E amputation, bedrest = until discharge
134
what are the sx of post-thrombotic syndrome
Signs of chronic venous insufficiency (usually 6 months) after a DVT (extremity pain, heaviness, cramps, paresthesias, pruritus, venous dilation, edema, pigmentation, skin changes, and venous ulcers) Occurs in 50% of patients within one year of thrombosis, 5-10% severe PTS
135
risk factors of post thrombotic syndrome
Elderly, obesity Smoking Primary venous insufficiency, varicose veins Proximal DVT, residual thrombus after treatment, recurrent DVT, inadequate anticoagulation
136
treatment of post thrombotic syndrome
(similar to chronic venous disease) Smoking cessation, weight loss if obesity Elevation Exercise training Compression stockings/bandages (30-40mmHg) or Compression device
137
prevention of post thrombotic syndrome
If at risk of PTS, consider compression stockings (start within two weeks of diagnosis, after anticoagulation started, and continue for two years)
138
sx of dehydration
Increased thirst Decrease urine/sweating/tears Weight loss Altered mental status, lethargy, irritability
139
P/E findings of dehydration
Vital signs Orthostatic vitals (HR↑ >30bpm, sBP ↓> 20 or dBP ↓> 10mmHg) Tachycardia, tachypnea Hypotension in severe hypovolemia Altered mental status Dry mucosa Sunken eyes Skin turgor Capillary refill >3s Decreased urine output
140
degrees of dehydration and treatment of each
Mild (3-5% volume lose) - Absent clinical signs Home-based treatment Moderate (6-9% volume loss) - Tachycardia, orthostatic hypotension, decreased skin turgor, dry mucous membranes, irritability, delayed capillary refill, deep respirations, possible decreased urine output/tearing and sunken fontanelle ORT (eg. Pedialyte, Enfalyte, breastmilk) x 1 hour, re-assess If concerned, see treatment for severe Severe (≥10% volume loss) - "Near-shock" hypotension, lethargy, altered mental status, delayed capillary refill, cool/mottled extremities, tachypnea Requires aggressive isotonic fluid resuscitation to prevent tissue injury 20-40mL/kg IV NS over one hour Consider labs (concern if pH < 7.32, bicarb ≤ 17 mEq/L)
141
indication for IV hydration in dehydration
Inability for oral intake (mental status, ileus) Inability to administer ORT (eg. no caregiver) Persistent vomiting Electrolyte abnormalities where ORT cannot be monitored Medications Can consider one dose of oral ondansetron to reduce vomiting and facilitate ORT
142
labs for dehydration
Venous or Capillary Blood Gas (pH, electrolytes) +/- serum electrolytes
143
fluid maintenance 4-2-1- rule
Maintenance in Children (4-2-1 rule) 1-10kg = 4 x Wt (kg) mL/hr >10-20kg = 40 + 2 x (Wt over 10kg) mL/hr >20kg = 60 + 1 x (Wt over 20kg) mL/hr Max of 100mL/hr Can use D5NS
144
causes of dehydration
Acute illness GI (N/V/D) Skin (Fever/burns) New medications (diuretics)
145
when to screen for DB2
Screen with FPG and/or A1C q3 years if ≥40 years old or high risk (33% chance of DM2 within 10y) Consider screening more frequently (q6-12 months) if very high risk (50% chance of DM2 in 10y) A1C not recommended for diagnosis in children, pregnant women or suspected DM1
146
Risk factor for DB2
≥40 years old First degree relative with DM2 High risk population (eg. Aboriginal, African, Asian, Hispanic, or South Asian descent) Prediabetes (IGT, IFG, A1C 6-6.4%) Gestational diabetes mellitus (GDM) or delivery of a macrosomic infant Presence of end organ damage associated with DM Microvascular – retinopathy, neuropathy, nephropathy Macrovascular – coronary, cerebrovascular, peripheral vascular disease Presence of vascular risk factors HDL cholesterol level <1.0 mmol/L in males, <1.3 mmol/L in females Triglycerides 1.7 mmol/L Hypertension, Overweight, Abdominal obesity Presence of associated diseases PCOS, Acanthosis nigricans, OSA Psychiatric disorders (bipolar, depression, schizophrenia), HIV Use of drugs associated with DM Glucocorticoids, atypical antipsychotics, HAART Other secondary causes
147
how to dx DB2
Diagnose Diabetes if two tests confirm (may do same test twice on different days) FPG ≥7.0 mmol/L (8h fasting) A1C ≥6.5% (falsely ↑ in anemia; ↓ in pregnancy and renal disease; ↕ in hemoglobinopathy) 2hPG in 75g OGTT ≥11.1 mmol/L or random PG ≥11.1 mmol/L Consider 2hPG in 75g OGTT to identify IGT (2hPG 7.8-11) vs. diabetes (2hPG ≥11.1) If FPG 6.1-6.9 or A1c 6-6.4% If FPG 5.6-6 or A1c 5.5-5.9% and ≥1 risk factor Diagnose Prediabetes if A1c 6–6.4% IFG (FPG 6.1-6.9) IGT (2hPG 7.8-11)
148
Dx of metabolic syndrome
Elevated waist circumference Elevated TG Reduced HDL-C Elevated BP Elevated FPG
149
name classes of antidiabetics
If A1c <1.5% above target, consider 3-6mo lifestyle Biguanide - Metformin Sulfonylurea (avoid with short-acting insulin) Gliclazide (Diamicron) -Least hypoglycemias out of sulfonylureas DPP4i (rare risk of pancreatitis) Sitagliptin (Januvia) 100mg PO daily / Janumet (Combo with metformin) Linagliptin (Trajenta) 5mg PO daily / Jentadueto (Combo with metformin) Saxagliptin (Onglyza) caution in heart failure / Komboglyze (Combo with metformin) GLP1R agonists (weight loss, contraindicated in thyroid cancer, rare risk of pancreatitis) Liraglutide (Victoza) 0.6mg SC daily x 1 week then 1.2mg SC daily (max 1.8mg SC daily) Dulaglutide (Trulicity) 0.75mg SC weekly (max 1.5 mg SC weekly) Semaglutide (Ozempic) 0.25mg SC weekly x 4 weeks then 0.5mg SC weekly (max 1mg SC weekly) SGLT2i (risk of genital infections/UTI, hypotension, caution with loop diuretics) Empagliflozin (Jardiance) 10mg PO daily x 1 week then 25mg PO daily / Synjardy (Combo with metformin) Canagliflozin (Invokana) Dapagliflozin (Forxiga) If clinical CVD consider empagliflozin (or canagliflozin) and liraglutide If comorbid NAFLD consider semaglutide, liraglutide, thiazolidinones If symptomatic hyperglycemia or DKA/HHS Consider starting insulin +/- metformin Long-acting: Glargine (Lantus) or Detemir (Levemir) Intermediate-acting: Humulin N, NPH Short-acting: Novorapid, Humalog, Apidra
150
target hba1c for DB2 patients
Diabetes Canada recommends 6.5 in healthy A1c ≤7.0 in most patients 7-8.5 in elderly, limited life expectancy, or recurrent severe hypoglycemia
151
target glycemia lebels when self-monitoring
Target preprandial 4-7 mmol/L, 2hr postprandial 5-10 mmol/L (or 5-8 if A1C not at target)
152
4 causes of glucose not at target
Missed dose, wrong dose (fear of hypoglycemia) Injection Technique, Lipodystrophy Insulin conservation (temperature exposure, expired) Infection/inflammation
153
complications of DM
Macrovascular: CVD, CVA, PAD Microvascular: Retinopathy, nephropathy, neuropathy Other: Erectile dysfunction (macro/microvascular) Foot complications (ulceration, Charcot arthropathy) Infection
154
How to FU DB2 and what to check for at follow ups
A1c q3 months (until stable) Each visit BMI (18.5-24.9)/waist circumference BP<130/80 Depression screening (PHQ-9) Erectile dysfunction (Consider PDE-5 inhibitor if no contraindications)
155
name 4 counselling points for DM patients
Nutrition (Mediterranean diet, low glycemic index) Physical activity (aerobic >150mins/week, resistance 3 sessions/week) Smoking cessation Pre-conception counselling Enquire about hypoglycemia Driving safety
156
tests to do to monitor for DB2
-Lipid profile q1y (until statin started) EKG -Nephropathy q1y (if evidence of nephropathy - follow q6months) eGFR (creat) and Urine ACR (albumin:creatinine ratio) At least 2 of 3 random urine ACR abnormal to diagnose nephropathy (2-20 microalbuminuria, >20 overt nephropathy) -Retinopathy optometry q1-2y If established retinopathy, refer to ophthalmology and consider fenofibrate/statins to slow progression -Neuropathy q1y Monofilament - Score 0, 0.5, 1 point x4 per foot arrhythmically Score 3/8=likely neuropathy, 3.5-5/8 = high risk in next four years, >5.5/8 = low risk neuropathy in next four years Vibration perception tests (tuning fork, one point if perceived, one point for when stopped) Treatment for pain: Consider Nortriptyline as first-line -Foot Care q1y Skin changes, structural abnormalities (e.g. range of motion of ankles and toe joints, callus pattern, bony deformities), skin temperature, evaluation for neuropathy and PAD, ulcerations and evidence of infection Foot care education (including counselling to avoid foot trauma), professionally fitted footwear and early referrals to a healthcare professional trained in foot care management if foot complications occur Treat ulcerations with glycemic control, infection, offloading of high-pressure areas, lower-extremity vascular status and local wound care.
157
indication to screen resting ECG q 3-5 years in pts with DB2
Age >40 years Duration of diabetes >15 years and age >30 years End organ damage (microvascular, macrovascular) Cardiac risk factors
158
when to test for EKG stress test as initial test
Typical or atypical cardiac symptoms (e.g. unexplained dyspnea, chest discomfort) Signs or symptoms of associated diseases Peripheral arterial disease Carotid bruits Transient ischemic attack Stroke Resting abnormalities on ECG (e.g. Q waves)
159
hypoglycemia definition
symptoms of hypoglycemia, a low plasma glucose level (<4.0 mmol/L for patients on antihyperglycemic agents), and symptoms responding to the administration of carbohydrate
160
sx of hypoglycemia, name 2 categories and 5 sx for each category
Neurogenic (autonomic) Trembling Palpitations Sweating Anxiety Hunger Nausea Paresthesias -____________ Neuroglycopenic Difficulty concentrating Confusion Weakness Drowsiness Vision changes Difficulty speaking Headache Dizziness
161
when and how to tx for hypoglycemia
Treatment (if glucose if <4.0 mmol/L) 15g carbohydrate (glucose or sucrose tablets/solution), recheck glucose 15 minutes and if <4.0 mmol/L can repeat If severe (unconscious), Glucagon 1mg SC/IM or D50W 20-50mL IV over 1-3 minutes (Glucose 10–25g)
162
which medications other than antidiabetics should we consider in DB2 and what are the indications
statin+ACEi/ARB+ ASA: if CAD, PAD, cerebrovasc/carotid disease statin+ACEi/ARB: if reinopathy, kidney disease, neuropathy, over 55 yo with other CV risk factors If over 40 yo or if over 30 yo with db over 15 years: statin
163
T or F: avoid canagliflozin in patients with risk factors for lower limb amputations
T
164
BP targets in DB
under 130/80
165
ABCDES of Diabetes Care
A A1C targets GUIDELINE TARGET (or personalized goal) A1C ≤7.0% If on insulin or insulin secretagogue, assess for hypoglycemia and ensure driving safety B BP targets BP <130/80 mmHg If on treatment, assess for risk of falls Cholesterol targets LDL-C <2.0 mmol/L ACEVARB (If CVD, age 255 with isk factors, OR diabetes complications) Statin (if CVD, age >40 for Type 2, OR diabetes D Drugs for CVD risk reduction complications) ASA (if CVD) SLGT2i/GLP1ra with demonstrated CV benefit (if have type 2 DM with CVD and A1 C not at target) 150 minutes of moderate to vigorous aerobic activity/ week and resistance exercises 2-3 times/week E Exercise goals and healthy Eating *Follow healthy dietary pattern (i.e. Mediterranean diet, low glycemic index) Cardiac: ECG every 3-5 years if age >40 OR diabetes complications Foot: Monofilament/Vibration yearly or more if S Screening for complications abnormal Kidney: Test eGFR and ACR yearly, or more if abnormal Retinopathy: yearly dilated retinal exam If smoker: Ask permission to give advice, arrange S Smoking cessation therapy and provide support Set personalized goals (see "individualized Goal S Self-management, Setting" panel) stress, other barriers Assess for stress, mental health, and financial or other concerns that might be barriers to achieving goals
166
Hyperosmolar Hyperglycemic State (HHS) sx
Polyuria, polyphagia, polydipsia Headache, fatigue, decreased LOC Nausea/vomiting Abdominal pain If abdominal pain does not improve as ketoacidosis improves, consider other pathologies for abdominal pain
167
Physical Examination findings of hhs
Dehydration, postural hypotension, tachycardia, tachypnea Resp: Kussmaul respiration, acetone-odoured (fruity) breath Abdo: Diffuse abdominal tenderness Neuro: LOC, pupils
168
dx of HHS and lab values
Develops over days Plasma glucose >33 pH >7.3, Bicarb >15, no ketones Serum osmolality >320mOsm/kg
169
dx of DKA and associated lab values
Develops over hours Typically, anion gap metabolic acidosis (although vomiting may cause a normal pH and normal bicarb) -Arterial/venous pH ≤7.3 -serum bicarbonate ≤15 mmol/L -anion gap >12 mmol/L Positive ketones in serum and/or urine (acetoacetate) -β-hydroxybutyrate level >1.5 mmol/L has a sensitivity of 98-100% and specificity of 78.6-93.3% Ketosis differential: -DKA -Alcoholic ketoacidosis -Starvation ketoacidosis -Isopropyl alcohol ingestion Plasma glucose usually ≥14.0 mmol/L -Can be euglycemic DKA (eg. SGLT2, pregnancy, chronic pancreatitis, bariatric surgery), will need immediate dextrose infusion
170
Triggers of hyperglycemia
Infection (30%) New diagnosis of diabetes (25%) Insulin non-adherence (20%) Infarction (ACS, CVA, mesenteric ischemia) Alcohol Trauma Medications (eg. glucocorticoids, diuretics, atypical antipsychotics) Abdominal pathology Pregnancy
171
investigation to ask in context of HHS or DKA
Blood gas, including lactate Anion gap = [Na+] – [Cl−] – [HCO3−], if >10-12mEq/L consider elevated anion gap differential Serum osmolality (HHS) CBC, Chem-10 (Ca, Mg, Phos) LFTs, albumin, CK bhCG Capillary Ketones Serum ketones +/- serum beta-hydroxybutyrate level Urinary ketones (more false negatives and false positives) Consider Lipase (note can be increased by DKA) Infectious work-up UA Blood/urine cultures CXR EKG Troponin (only if EKG suggests ischemia) Serum ketons (β-hydroxybutyrate) if diagnosis unclear
172
Treatment of HHS or DKA
ABC, vitals Fluid resuscitation Bolus NS 10mL/kg (or 1L) bolus IV If persistent tachycardia or hypoperfusion, repeat until euvolemic (HR<100) Maintenance See table below for rates in pediatrics In adults, eg. 0.9% NS 250mL/h x 4-6h then 0.45% NS 250mL/h (to avoid hyperchloremic metabolic acidosis Add IV dextrose when serum glucose <14.0 mmol/L (maintain glucose 12-14) eg. D5W 0.5%NS or D5W 0.45%NS If glucose <4, provide 1 amp of D50 and increase dextrose infusion Avoidance of hypokalemia Add KCl 40 mmol/L when serum K<5.0 mmol/L and patient has urinated (cardiac monitoring needed, caution in renal failure- ensure urine output) Consider oral potassium Magnesium/phosphate replacement as needed Insulin administration (avoid initially in HHS) Hold insulin if K<3.3 If mild-moderate DKA (pH 7.1-7.29, HCO3 5-14.9) After one hour of fluids, Humalog 0.15 Units/kg/dose (or 10 units) q2h If severe (pH<7.1, HCO3<5) After one hour of fluids, Humulin R infusion of 0.1 units/kg/h (0.05 units/kg/h for HHS) If glucose does not fall by 3mmol/L in first hour, check IV access and if normal consider doubling insulin Bolus may increase hypoglycemic events without clinical benefits If hypoglycemia give more glucose, do not stop insulin (to avoid more ketoacidosis) Avoidance of rapidly falling serum osmolality (risk of cerebral edema) Suspect cerebral edema if sudden headache, altered LOC and lethargy, irritability in young children, Cushing's triad (high BP, low HR, low RR) Manage ABC, raise head of bed 30 degrees, restrict fluid Consider mannitol 0.25-0.5g/kg IV over 30 mins OR hypertonic 3% NS 5-10mL/kg over 30 mins Search for precipitating cause (infection, drugs, thyrotoxicosis, adherence to medication, new diabetes, MI, stroke)
173
how to monitor a patient with HHS/ DKA
Repeat serum glucose q1h Repeat VBG (pH, electrolytes), plasma osmolality (for HHS) q2-4h until stable Anion gap = [Na+] – [Cl−] – [HCO3−] (may consider adjust for albumin with other more complicated formulas) Monitor for Osmolality Calculating osmolality Measure or calculate osmolality (2 [Na+] + [glucose] + [urea] in mmol/L) Aim for gradual decline, especially in patients under 40 years old (eg. 3 mmmol/kg/hr or 20mOsm/kg/day) If osmolality increase Fluid balance inadequate, increase rate of 0.9%NS Fluid balance adequate, consider switch to 0.45%NS If osmolality decreasing >8mosmol/kg/h, consider reducing IV fluids
174
Name goals of tx of DKA and HHS
Avoid overly aggressive therapy which will cause complications (hypokalemia, cerebral edema) Most patients with DKA (especially those with HHS) probably need admission and observation, DKA: Normalization of the plasma anion gap <12 mEq/L Ketoacidosis resolved Normalization of bicarbonate Glucose controlled <14 mmol/L HHS: Mentally alert, and osmolality <315 mOsmol/kg Patient eating and ideally hungry -Received full daily dose of long-acting insulin >2 hours (Consider SC insulin regimen once glucose <11.1)
175
DDX of acute diarrhea
Acute: 2-14 days of looser and more frequent stools (>3 stools/day or >200g stool/d) Parasitic - Giardia, cryptosporidia, cyclospora, isospora, amoebiasis Bacteria - Campylobacter, salmonella, shigella, listeria, C diff, S Aureus, Clostridium perfrigens Symptoms suggestive of invasive bacterial diarrhea include fever, tenesmus, gross bloody stool Viral - Hep A, rotavirus, norovirus Travel - ETEC, norovirus, shigella, salmonella, campylobacter, giardia Daycare - Campylobacter, cryptosporidia, parvum Hospital - C Diff, norovirus, rotavirus (children)
176
DDX of chronic diarrhea
Chronic: >4 weeks Function - IBS (10-20%), overflow constipation, incontinence Osmotic - Lactose, sugars (sorbitol, mannitol), laxatives Inflammatory - IBD, microscopic/collagenous colitis Metabolic - Addison's, hyperthyroid, uremia, cystic fibrosis Malabsorption - Pancreatitis, celiac, short bowel syndrome, bacterial overgrowth Neoplastic - Colorectal cancer, carcinoid, gastrinoma, medullary thyroid Iatrogenic - Drugs, alcohol, caffeine, surgery, radiation, laxatives
177
definitions/differences between secretory, osmotic, large bowel and small bowel diarrhea
Secretory: Continues despite fasting Osmotic: Decreases with fasting (malabsorption, drugs) Large Bowel: Small volume, frequent, pus, blood Small Bowel: Large volume, infrequent, watery
178
6 risks factors of diarrhea
Travel Immunocompromised Food outbreaks Antibiotics Family History Laxatives
179
7 red flags in hx of diarrhea
Age >50 (think of acute mesenteric ischemia, obstruction, diverticulitis, malignancy) Immunocompromised (HIV, steroid) Inflammatory features (fever, bloody, mucoid stool) N/V, fever, arthritis, skin rash, anorexia Night sweats, weight loss Nocturnal (pathologic) Recent antibiotics (C-diff)
180
targeted hx of diarrhea
Diarrhea onset, duration, severity, frequency, quality (watery, bloody, mucus, purulent, bilious) Signs of dehydration (decreased urine output, altered mental status) Vomiting (viral or toxin) Fever, tenesmus, bloody (invasive bacterial) Food/Travel Pregnant (12x risk of listeriosis - cold meats, soft cheeses, raw milk) Recent sick contacts, antibiotics, medications Immunosupression Exposures (daycare, fecal-oral sexual contact, hospital admission)
181
which investigations to ask in diarrhea
Usually not indicated unless severe illness or red flags Consider CBC, CRP, TSH, Celiac (IgA, anti-TTG) FOBT or FIT Stool leukocytes/lactoferrin/calprotectin (r/o IBD) Stool cultures if leukocytes positive or risk factor/red flag (eg. symptomatic bloody diarrhea) C-diff toxins A/B done if unexplained diarrhea after 3d of hospitalization or high risk (eg. antibiotic use) Ova and parasites if high-risk (travel to high-risk area, infants in day care, immunosuppresssed, MSM, waterborne outbreak, bloody diarrhea with few fecal leukocytes) If available, consider Giardia antigen test or PCR C-scope if altered bowel habit +/- rectal bleeding
182
Treatment of diarrhea
Rehydration (oral if possible) Consider reduced oral rehydration solution (ORS): water with salt and glucose Early refeeding No clear evidence for BRAT diet (banana, rice, applesauce, toast) and avoidance of dairy Loperamide/simethicone in non-bloody stool and afebrile Consider empiric antibiotics in severe symptomatic bloody diarrhea or immunocompromised Fluoroquinolone or Azithromycin (if resistance, eg. from South East Asia) Antibiotics effective in shigella, campylobacter, C diff, traveler's diarrhea, protozoal Avoid use in toxin (bloody, history of eating seed sprouts, rare beef, outbreak) risk Hemolytic uremic syndrome
183
2 tips for prevention of diarrhea
Hygiene (handwashing, diaper changing, water purification), safe food preparation, clean water Vaccine (rotavirus, typhoid fever, cholera) No clear evidence for probiotics, zinc supplementation Return to school ≥48h last diarrhea/vomiting (NICE)
184
classify the different types of dizziness
Vertigo: Sustained (r/o stroke) vs. Episodic Non-vertigo: Syncope (r/o CVS, seizure, hypoglycemia) Pre-syncope (r/o CVS) Disequilibrium (r/o neuromuscular) Lightheadedness
185
DDx of vertigo (10)/ dizziness
Acute prolonged severe vertigo (Stroke, demyelinating disease, vestibular neuronitis) Recurrent spontaneous attacks, minutes-hours (Meniere, Vestibular Migraine) Recurrent positional, seconds-minutes (BPPV) Chronic persistent dizziness (Psychogenic, cerebellar ataxia) arrhythmia, myocardial infarction [MI], stroke, multiple sclerosis measure postural vital signs to r/o orthostatism Exclude serious conditions (e.g., MI, abdominal aortic aneurysm, sepsis, gastrointestinal bleeding) prescription and over-the-counter medications
186
name 10 red flags in hx of vertigo
Diplopia, Dysarthria, Dysphonia, Dysphagia, Dysmetria Multiple transient prodromal episodes of dizziness over weeks/months Headache, neck pain, recent trauma (vertebral artery dissection/aneurysm) Auditory symptoms (despite mimicking benign peripheral causes, hearing loss in acute vestibular syndrome is frequently associated with stroke) Neuro signs: Facial palsy, sensory loss, limb ataxia, hemiparesis, oculomotor (Internuclear ophthalmoplegia, gaze palsy, vertical nystagmus) Gait unsteadiness
187
Difference in nystagmus to differentiate neuro vs peripheral vertigo
Peripheral: Unidirectional, Horizontal nystagmus, Suppressible with visual fixation, Positional Central: Uni or Bi-directional, Purely vertical/horizontal/torsional nystagmus, Not suppressible, Not positional (ie. Central is usually Spontaneous)
188
explain the HINTs exam
HINTS+ only in Acute Vestibular Syndrome (to differentiate stroke from vestibular neuritis) in patients with current nystagmus Head Impulse - Rapid head rotation towards mid-line with eyes fixed on object (normal suggests central cause) Nystagmus - Vertical/bidirectional/torsional (note torsional is expected in episodic BPPV, but not in acute vestibular syndrome due to peripheral cause) Test of Skew - Skew deviation or misalignment on cover-uncover test Presence of one INFARCT (impulse normal or fast-phase alternating or refixation on cover test) may be more accurate to diagnose stroke than urgent MRI Negative INFARCT (abnormal head impulse, horizontal unidirectional nystagmus, no skew deviation), but may not be enough to rule out stroke in the emergency room + Hearing loss, rule-out AICA infarct If no nystagmus, will need to rely on detailed neurological exam (CN, hearing, anisocoria, phonation, facial sensation, cerebellar ataxia, gait)
189
investigations to do in context of dizziness
EKG (r/o Arrhythmia, MI) CBC, Lytes, TSH (Low yield) MRI (83% sensitive), CT (16% sensitive) MRI can miss stroke (20% false negative) until 48h after symptom
190
Treatment of vertigo (BPPV, meniere, vestibular neuritis)
General acute symptomatic management of vertigo: Antihistamines, Benzodiazepines, Antiemetics Peripheral (early ENT referral as needed, and vestibular rehab) BPPV (episodic seconds, head position) Epley maneuver Sermont maneuver Gufoni maneuver in horizontal canal BPPV Betahistine 24mg PO BID limited evidence Meniere's (episodic minutes-hours, hearing loss, tinnitus/ear fullness) Limit salt, caffeine, nicotine, alcohol Betahistine, Diuretic Vestibular neuritis and Labyrinthitis (single acute onset, lasts days, possible viral syndrome) Methylprednisone 22-day tapering dose schedule Supportive Central Vestibular migraine (episodic minutes-hours with migraine headache) Brainstem or cerebellar infarct (persistent over days-weeks, vascular risk factors, prominent gait impairment) or TIA (episodic minutes-hours, vascular risk factors) MRI Evaluation for Thrombolysis/Thrombectomy Secondary risk management Antihypertensives if BP >140/90 Aspirin or clopidogrel Atorvastatin 80mg/day (SPARCL trial) Carotid endarterectomy for recent symptom Holter-24-48h r/o Afib Echocardiography Lifestyle Glucose control if diabetic Eliminate alcohol, smoking Exercise Referral ENT, Neurology, Psychiatry Vestibular rehab PT/OT
191
Risk factors of domestic abuse (4)
Young female (<24yo) Low SES Pregnancy Disability Unemployment Witnessing or experiencing violence as a child Substance abuse (alcohol/drug use) History of mental illness
192
Risk factors for perpetration of domestic abuse
Unemployment Witnessing or experiencing violence as a child Substance abuse (alcohol/drug use) History of mental illness
193
Woman Abuse Screening Tool (WAST), 90% sensitivity with first two questions name questions and how to communicate with patient if abuse is detected
In general, how would you describe your relationship? No tension, some tension, a lot of tension? Do you and your partner work out arguments with no difficulty, some difficulty, or great difficulty? Do arguments ever result in you feeling down or bad about yourself? Do arguments ever result in hitting, kicking, or pushing? Do you ever feel frightened about what your partner says or does? Does your partner ever abuse you physically? Does your partner ever abuse you emotionally? Does your partner ever abuse you sexually? Listen Acknowledge the injustice "This is abuse" "I am very sorry this is happening to you" Frame the violence due to perpetrator's behaviour and not the survivor's "You do not deserve this, and it is not your fault" Respect autonomy and patient's decisions "I want to help you through this in any way I can."
194
questions to assess for safety in domestic abuse
Violent outside the home Violent to children Threatening to kill Escalating threats Drugs, alcohol Abusive during pregnancy Obsessive, controlling relationships Serious prior injury Owns weapons, especially handguns Threatened others (family/friends)
195
management of domestic abuse
Safety planning, resources, community services including local shelters Emergency kit with important documents, keys, money, essential items - stored outside the home Place to go (friend, family shelter) Signal to alert others (children/neighbours) to call 911 Document findings Quotes from patient Physical exam findings and photographs Labs/radiology Mandatory reporting may be required in the following instances: Abuse involving children Contact Youth Protection Abuse of elderly (in retirement home) Abuse of disabled persons Weapon use Frequent follow-up Counsel on possible escalation/cycles of violence (tension build up, violent outburst, honeymoon phase) Update safety plan
196
anorexia nervosa definition
Restriction of energy intake relative to requirements, leading to a significantly low body weight (BMI<18.5 or <5th percentile in children, or rate of weight loss) in the context of age, sex, developmental trajectory, and physical health. Intense fear of gaining weight or of becoming fat, or persistent behavior that interferes with weight gain, even though at a significantly low weight. Disturbance in the way in which one’s body weight or shape is experienced, undue influence of body weight or shape on self-evaluation, or persistent lack of recognition of the seriousness of the current low body weight.
197
2 types of anorexia nervose
Restricting type: During the last 3 months, the individual has not engaged in recurrent episodes of binge eating or purging behavior (i.e., self-induced vomiting or the misuse of laxatives, diuretics, or enemas). This subtype describes presentations in which weight loss is accomplished primarily through dieting, fasting, and/or excessive exercise. Binge-eating/purging type: During the last 3 months, the individual has engaged in recurrent episodes of binge eating or purging behavior (i.e., self-induced vomiting or the misuse of laxatives, diuretics, or enemas).
198
Bulimia nervosa definition
Recurrent episodes of binge eating, characterized by both of the following: Eating, in a discrete period of time (e.g., within any 2-hour period), an amount of food that is definitely larger than what most individuals would eat in a similar period of time under similar circumstances. A sense of lack of control over eating during the episode (e.g., a feeling that one cannot stop eating or control what or how much one is eating). Recurrent inappropriate compensatory behaviors in order to prevent weight gain, such as self-induced vomiting; misuse of laxatives, diuretics, or other medications; fasting; or excessive exercise. The binge eating and inappropriate compensatory behaviors both occur, on average, at least once a week for 3 months. Self-evaluation is unduly influenced by body shape and weight. The disturbance does not occur exclusively during episodes of anorexia nervosa.
199
Avoidant/Restrictive Food Intake Disorder (ARFID)
An eating or feeding disturbance (e.g., apparent lack of interest in eating or food; avoidance based on the sensory characteristics of food; concern about aversive consequences of eating) as manifested by persistent failure to meet appropriate nutritional and/or energy needs associated with one (or more) of the following: Significant weight loss (or failure to achieve expected weight gain or faltering growth in children). Significant nutritional deficiency. Dependence on enteral feeding or oral nutritional supplements. Marked interference with psychosocial functioning. The disturbance is not better explained by lack of available food or by an associated culturally sanctioned practice. The eating disturbance does not occur exclusively during the course of anorexia nervosa or bulimia nervosa, and there is no evidence of a disturbance in the way in which one’s body weight or shape is experienced. The eating disturbance is not attributable to a concurrent medical condition or not better explained by another mental disorder. When the eating disturbance occurs in the context of another condition or disorder, the severity of the eating disturbance exceeds that routinely associated with the condition or disorder and warrants additional clinical attention.
200
screening questions for eating disorders
Does your weight/body shape cause you stress? Recent weight changes? Dieted in the last year? SCOFF Do you make yourself Sick (induce vomiting) because you feel uncomfortably full? Do you worry that you have lost Control over how much you eat? Have you recently lost more than One stone (14 lb {6.4 kg}) in a three-month period? Do you think you are too Fat, even though others say you are too thin? Would you say that Food dominates your life?
201
8 risk factors of eating disorders
Early puberty Poor or abnormal growth curves in children and adolescents Low or high body mass index, or weight fluctuations Weight concerns among normal weight individuals Activities and occupations that emphasize body, shape, and weight (e.g. ballet, gymnastics, modeling) Amenorrhea (primary or secondary) Type 1 diabetes Family history of ED
202
10 associated physical symptoms of eating disorders
Exertional or chronic fatigue, weakness, dizziness, pre/syncope, hot flashes, cold intolerance, depression Cardio: Palpitations, CP, SOB, peripheral edema Dental: Tooth pain (decay/cavities), mucosal bleeding/trauma and parotid gland enlargement GI: Abdominal pain, early satiety, bloating, constipation Endo: Amenorrhea, decreased libido, infertility Derm: Hair loss, brittle nail and skin changes, poor healing (other questions to ask: Rate/amount of weight loss Dietary intake (quantity, restriction) Compensatory behaviour (vomiting, laxatives, diuretics, exercise) Attitudes about weight / Body image Mood symptoms, suicidality Menstrual history)
203
10 physical exam of Eating disorder
Vital Signs (eg. HR<60, BP<90/60, Temp<36) Orthostatic vitals (supine, standing) General Appearance Height/Weight and BMI; weight in kilograms divided by height in meters squared Hydration status HEENT Enlargement of parotid or submandibular salivary glands in BN Dental erosion due to frequent vomiting Cardiac, r/o murmur Skin Brittle hair and fingernails Lanugo hair Dry skin Pretibial edema Russell sign (callous on MCP from teeth abrasion during self-induced emesis) MSK Muscle strength Sit-up Squat Stand test (muscle weakness)
204
10 Investigations of eating disorder
Determine level of medical acuity EKG Bradycardia, non-specific ST-T wave changes including ST segment depression, U waves in the presence of hypokalemia and hypomagnesemia CBC (hemoglobin, leukocytes, platelets) Serum electrolytes (Na, K, Glucose, Blood urea nitrogen, Creatinine, Calcium, Magnesium, Phosphate) TSH, T4, T3 Liver function tests (AST, ALT, bilirubin) Amylase/lipase Albumin, transferrin UA BhCG r/o pregnancy Consider celiac screen If underweight > 6 months Bone densitometry to assess for osteopenia and osteoporosis Abdominal ultrasound to assess maturity of ovaries and uterus FSH, LH, and estradiol levels in females Testosterone levels in males
205
10 non-negotiable physical and nutritional indicators for hospitalization
Suicide risk, food refusal Vitals unstable Core temperature < 35.5°C or 95.5°F Heart rate < 40 beats per minute or severe bradycardia Blood pressure < 90/60 mm Hg or orthostatic hypotension ECG arrhythmia Electrolyte abnormalities Sodium < 127 mmol/l Potassium < 2.3 mmol/l Hypoglycaemia; blood glucose < 2.5 mmol/l Hypophosphataemia; phosphorous below normal on fasting Magnesium < 0.6 mmol/l (normal above 0.7 mmol/l) Rapid and progressive weight loss Acute medical complications of malnutrition Signs of inadequate cerebral perfusion (confusion, syncope, loss or decreased level of consciousness, organic brain syndrome, ophthalmoplegia, seizure, ataxia) Seizure Heart failure Pancreatitis Severe acrocyanosis Dehydration that does not reverse within 48 hrs Muscular weakness Comorbid psychiatric or medical (poorly controlled diabetes type 1) Pregnancy with an at risk foetus Inadequate weight gain, failure of outpatient treatment
206
3 pharmacology tx to consider in eatign disorder
SSRI / Fluoxetine at higher doses (60mg/d) in BN Multivitamins with iron and Vitamin D Consider Zinc 50mg PO daily (aids in weight gain) Treat acne (as patient re-experience puberty as they gain weight)
207
3 pharmacology tx to consider in eatign disorder
SSRI / Fluoxetine at higher doses (60mg/d) in BN Multivitamins with iron and Vitamin D Consider Zinc 50mg PO daily (aids in weight gain) Treat acne (as patient re-experience puberty as they gain weight)
208
5 non pharmalogical managements of eating disorder
Medical stabilization Assess outpatient vs. admission if needed for safety Assess and treat coexisting psychiatric conditions (MDE, anxiety, substance use) Nutritional rehabilitation with multidisciplinary approach Family-based treatment Individual Psychotherapy, FBT/CBT (TRY THIS FISRT) Psychiatry Dietician / nutritional rehab School Support groups / resources Consider referral to specialiset child and adolescent eating disorder team Target weight range in AN (90% of expected weight) Gradual weight gain in AN (1lb/week) Limit exercise Regular appointments with vitals, weight/BMI, and blood tests repeated Complications (tooth decay, amenorrhea, electrolyte) Disease activity (eating patterns, exercise, laxative)
209
questions to ask in motivational interviewing of eating disorder
Establishing rapport: Open-ended questions such as, “How have things been going with your eating?” or “Do you have concerns about your eating?” or “What is most important to you about your eating and health?” Assessing Readiness: “How do you feel about making changes to your eating?” or “How do you feel about making changes to improve your physical health?” Provide Feedback: “What is your reaction to these test results?” or “Would more information be helpful?” Offer further support targeted to level of readiness for change: For clients who are not “ready” to make change: “What would it take for you to consider thinking about change?” For clients who are unsure about change: “What are the things you like and don’t like about your eating disorder?” For clients who are ready to make change: “What would you like to work on changing?”
210
refeeding syndrome definition and name 3 risks/complications
Metabolic changes during refeeding of a malnourished patient Risk of hypophosphatemia leading to heart failure, arrhythmia, respiratory failure Prevent with careful slow refeeding/monitoring and phosphate supplementation
211
6 ddx of eating disorder/weight loss
anorexia nervosa, bulimia,Avoidant/Restrictive Food Intake Disorder (ARFID) diabetes, coeliac disease, hyperthyroidism, malignancies, depression, anxiety, OCD< alcohol misuse/depensdance
212
important questions to include in a hx for eating disorder
Eating patterns, relationship with food, body image, distress Underlying mental health, alcohol, and substance use problems, including previous psychological trauma Use of prescribed and over-the-counter medications, tobacco, caffeine, laxatives, and supplements
213
When assessing a patient presenting with a problem that has defied diagnosis (e.g., arrhythmias without cardiac disease, an electrolyte imbalance without drug use or renal impairment, amenorrhea without pregnancy) include “complication of an eating disorder” in the differential diagnosis.
214
10 complications of eating disorder
amenorrhea, electrolite imbalance, muscle weakness, spinal compression/osteoporotic fractures, decreased height/weight, slow pulse, depreased core temperature, postural hypotension, gastric dilation, pressure sores, depression/SI, cardiac arrythmia, prolonged QTc, sinus bradycardia, signs of electrolyte disturbance on EKG malnutrition: -anemia, thrombocytopenia, neutropenia, hypophosphataemia, low ca/mg/po4, hypoglycemia,
215
You are seeing 3 year-old son Jaxson who is noted to have intermittent rashes over the face and extremities. You suspect atopic dermatitis. He is otherwise healthy. They have no pets at home. What are the historical/physical exam features of this condition that will support your diagnosis? List 4.
Chronic, relapsing dermatitis Typical morphology of the lesion: erythematous, rough/scaly, patchy Pattern of distribution: facial and extensor involvement, joint surfaces Pruritus/ Intense itching Personal history of asthma Personal history allergic rhinitis Family history of atopy Hyperactivity to environmental triggers Age of onset (most common age 2-4)
216
4 ddx of atopic dermatitis
Psoriasis Seborrheic dermatitis Contact/irritant dermatitis Impetigo Systemic viral illness Neurodermatitis Dermatitis herpetiformis Dermatophytic infection Immunodeficiency disorder
217
4 treatment options of atopic dermatitis
Avoid dry skin / Optimal use of emollients/moisturizer Topical corticosteroid cream/ointment Avoidance of known triggers: soaps, fabrics, cleansers, metals, sweat/heat, sunscreens, stress Topical calcineurin inhibitors/protopic/tacrolimus Antimicrobial if infected Oral anti-histamine for pruritus
218
Other than viral hepatitis, name FIVE causes of elevated hepatocellular-pattern liver enzymes.
Non-alcoholic fatty liver disease/steatohepatitis (NASH) - recommend do not abbreviate this Chronic alcohol use/alcoholic liver disease medication toxicity/prolonged acetaminophen use hemochromatosis autoimmune hepatitis Wilson’s disease Alpha-1-anti-trypsin deficiency Primary biliary cirrhosis
219
Hepatitis B can be transmitted by various mechanisms. Name FOUR.
1. Blood exposure/blood transfusion/direct contact with infected blood/Sharing personal hygiene products (razors, nail clippers, toothbrushes, jewelry)/Intravenous drug use/needle sharing/needlestick injuries 2. Sexual/unprotected sex/semen/vaginal secretions 3. Perinatal/vertical transmission/trans-placental 4. Exposure to open sores of an infected person
220
Name THREE chronic complications of hepatitis B.
cirrhosis end-stage liver disease/liver failure hepatocellular carcinoma
221
If we assume a patient is chronically infected with hepatitis B, name FIVE tests or investigations that can determination the stage of his chronic infection.
HBeAg ALT AST Hepatitis B DNA abdominal ultrasound Fibroscan Biopsy This is a tough one. The question states there is no doubt about the diagnosis and wants to know how we assess the phase of chronic infection. That is why Hep B core antibody, Hep B IgG and Hep B IgM are not on the answer key.
222
Mrs. Elouise Santos, age 54, presents at the emergency department (ED) complaining of severe right upper quadrant abdominal pain, which at times radiates to the right shoulder. She feels nauseated and has vomited twice without relief of the pain. She has been in good health in the past. Her vital signs are as follows: Blood pressure: 142/90 mm Hg; Pulse rate: 90 bpm; Temperature: 38.2 degrees Celsius; Respiration rate: 17 bpm What is the MOST likely diagnosis?
Acute Cholecystitis /Cholecystitis /Biliary colic
223
What are the possible complications of cholecystitis? List five.
Choledocholithiasis/Jaundice/Biliary obstruction Hydrops Empyema Emphysematous cholecystitis Duodenal perforation Gallstone ileus Pancreatitis Hepatitis Ascending cholangitis Peritonitis/Perforation of the gallbladder/Necrosis/Gangrene Sepsis This question only asks for three answers. The exam could ask for more. Use this answer key as a study guide
224
Which imaging test would be BEST to confirm the diagnosis of choledocholithiasis ? Name ONE.
Endoscopic retrograde cholangiopancreatography (ERCP) Hate to say this, but better to write out "Endoscopic retrograde cholangiopancreatography" than to rely on "ERCP" alone as your answer. It is possible that ERCP is acceptable, but since answers keys are not released, it's hard to know for sure.
225
What blood tests would you consider ordering for cholecystitis (name 4)
White blood cell count (WBC) Total Bilirubin Alkaline phosphatase Lipase International Normalized Ratio (INR)/ Prothrombin time (PT) measurement Partial thromboplastin time (PTT) GGT Alanine transaminase (ALT)
226
A 49 year-old man presents to your office with a two-week history of paraspinal lumbar pain. It started during a family vacation after a long drive. He was more active than usual while on vacation. There was no trauma. He has a desk job, and is generally sedentary. He had a knee injury playing baseball in the past, but otherwise has not had any musculo-skeletal complaints over the years. There is no significant past medical history. He denies alcohol, smoking, and IV drug use. His energy is good, and he denies night sweats, fever, and weight loss. His body mass index (BMI) is 28. What other items on history of present illness are relevant to the presenting case? List EIGHT.
bladder changes/retention bowel changes/incontinence saddle anesthesia radiation pattern severity quality of pain timing of pain/is it worse at night aggravating factors: for example, is it worse with certain movements alleviating factors: for example, positional changes associated features: rashes associated features: eye/vision changes is he taking pain killers?/need for analgesics radicular symptoms: leg weakness radicular symptoms: sensory changes morning stiffness changes in sexual function/erectile dysfunction One buzzword in this question is "other". It is subtle, but it means you cannot use historical items from the preamble as answers. For history questions, most of them will relate to the history of present illness (HPI), which means that past medical history, surgical history, allergies etc are not what the question is looking for. Read the question carefully. Using a mneumonic to help you remember an approach to HPI questions can be helpful, such as OD PQRST AA. O - onset; D- duration; P - pain, Q - quality, R - radiation, S - severity, T - timing; A - associated features (rash/GI/eye etc), A - aggravating and alleviating factors. Or use another system if you have one.
227
What non-pharmacologic recommendations would you offer for lumbar hernia? Name FOUR.
recommend physical activity/exercise/core strengthening encourage walking education about self-limiting nature of most cases of back pain education: avoidance of bed rest symptomatic strategies: heat/cold encourage weight loss (goal of 10% of body weight) ergonomic assessment at work As per guidelines, most causes of low back pain are self-limiting. The guideline in the links document suggests not referring for physiotherapy or chiropractic right away, but rather waiting for natural resolution of symptoms before embarking on formal therapy. Since there are no red flags identified in this case, expectant management as above is indicated.
228
Name THREE medications in three different classes that you would consider recommending for back hernia without radicular pain
Tylenol/acetaminophen ibuprofen/Advil cyclobenzaprine/Flexeril
229
Pt returns after 12 weeks of back pain, having followed your conservative management. He continues to work. His pain is now worse. It has localized somewhat to the left side. The physical exam is unchanged. what investigation do you want to do
Acceptable answers: lumbar x-ray AP and lateral (oblique not required given no pain with extension so you are not worried about a pars interarticularis fracture) Imaging may be considered now because his symptoms have become chronic.
230
You are seeing a 2 year 6 month old Ava in your clinic for a well child check. Along with her parents, Ava has two step-siblings who live with her: a 5 year old girl, and 7 year old boy. Mom reports noticing that Ava isn’t as affectionate as the other children. She also wonders if Ava should have more language skills at her age. Name TWO conditions on your differential that must be addressed at this visit.
Autism spectrum disorder Child abuse Rett’s syndrome Hearing problems
231
Name FOUR domains that are assessed when determining if a child has developmental delay.
Gross Motor Fine Motor Speech/language Social/emotional Cognitive/problem solving
232
What TWO developmental domains are most impacted in a child with autism spectrum disorder (ASD)?
Social/emotional speech/language
233
Name FIVE diagnostic features of a child with autism spectrum disorder.
inability to participate in social/emotional interactions deficits in nonverbal communication: no/limited understanding of gestures/body language poor eye contact difficulties in developing relationships evidence of repetitive movements evidence of repetitive speech inflexibility/adherence to routines restricted/fixated interests Altered/Hyper-/hypo-reactivity to sensory input
234
Before what age must these features be present in order to make a diagnosis of Autism Spectrum Disorder?
3 years
235
Name TWO classes of medications that may be used in patients with ASD to treat their co-morbid conditions.
selective serotonin re-uptake inhibitors (SSRI) atypical anti-psychotics anticonvulsant mood stabilizers stimulants alpha 2 antagonist (mirtazapine) melatonin
236
Name TWO classes of medications that may be used in patients with ASD to treat their co-morbid conditions.
selective serotonin re-uptake inhibitors (SSRI) atypical anti-psychotics anticonvulsant mood stabilizers stimulants alpha 2 antagonist (mirtazapine) melatonin
237
Nineteen year-old Tucker presents to your emergency department with a nosebleed which was severe three days ago and has trickled ever since. Today, he was dizzy when getting out of bed, so a friend brought him to hospital. He has never had a serious nosebleed before, but he gives a history of easy bruising. Once, after a dental extraction, he bled continuously, and was eventually given plasma and an intravenous medication which his doctor explained could also be given "up the nose". Later he was told that he had a clotting problem, but he can't recall the exact diagnosis. He was adopted as an infant. No medical records are available. He takes no regular medication. On examination: HR 105 supine, 130 sitting, BP 98/60, RR 24, afebrile Skin pale, slightly clammy HEENT: active bleeding from L nare; controlled with pressure; gag reflex intact, airway patent Assuming the bleeding is currently well controlled with pressure, list the THREE most important interventional steps at this point. Be specific.
1. type and crossmatch for 2-4U of packed red blood cells 2. Two large bore IVs with 1L normal saline running in each 3. 100% oxygen by rebreather mask
238
List THREE laboratory investigations which will be most helpful in managing severe epistaxis
Hemoglobin Hematocrit Platelet count PT/INR PTT Bleeding time
239
Where do you expect to find the source of the bleeding for epistaxis?
Little's area/anterior inferior nasal septum/Kisselbach's plexus
240
19 yo patient in ER for epistaxis was told in the past that he has a bleeding diasthesis. Name the THREE most likely diagnoses.
Hemophilia A, Hemophilia B, Von Willebrand's disease
241
Pt's previous test results become available. They are: Prothombin time (PT): normal Partial thromboplastin time (PTT): prolonged Von Willebrand's Factor Activity: pending Factor VIII-C: decreased Bleeding Time: prolonged Factor IX: normal Given these results, what is the MOST likely diagnosis? Answer: liver disease
von Willebrand disease
242
Other than silver nitrate, name TWO oral or IV medications that can be used to help control the bleeding.
fresh frozen plasma/cryoprecipitate, tranexamic acid, DDAVP
243
Your nasal examination confirms active bleeding from the expected site. Cautery with silver nitrate is unsuccessful. List THREE other local interventions which might now be employed to control haemorrhage.
packing with petrolatum gauze packing with lidocaine soaked in epinephrine packing with cocaine packing with sponge/merocel/nasaspore packing with hemostatic balloon
244
List TWO important infectious complications from the treatment of packing nose in epistaxis
toxic shock syndrome acute sinusitis bacterial rhinitis putrefication of packing
245
Maria is a 29 year-old female who ingested an unknown quantity of acetaminophen 12 hours ago in a suicide attempt and is brought to the ED by her mother. Her mother found no other pill bottles nearby. What is the toxic dose of acetaminophen in mg/kg?
Acceptable answer: 150-200mg/kg (anywhere within this range) You will not be asked many numbers on this exam, and usually the answer will only be worth 1 point, so not enough to make you fail the case if you get it wrong. Most number-related answers will accept a range. If one of your two numbers is outside the range, you risk being marked wrong, so the safest approach is to give a specific number rather than a range.
246
At what time point after ingestion can activated charcoal be used for decontamination?
Acceptable answer: 1-2 hours (anywhere in this range)
247
Name FIVE drugs or compounds that do not bind to charcoal.
Lithium, lead, solvents, iron, alcohols, hydrocarbons, potassium, pesticides, alkali, acids There are mnemonics to help remember this list. It is unlikely that any question will ask you for the whole list.
248
Other than nausea, what are the TWO most likely symptoms that a patient with acetaminophen intox?
diaphoresis, vomiting Poisoning pearls: Know indications for dialysis (AEIOU), causes of anion gap (MUDPILES) Other poisonings/toxidromes to review: alcohol, opioids, TCAs, anti-cholinergics, cholinergics, ASA, hallucinogens (unlikely to show up on the exam), sedatives, sympathomimetics (ie cocaine: more likely to show up on the exam), salicylates, serotonin syndrome, benzodiazepines, dilantin, carbamazepine Some years there are a couple of poisoning questions, and other years none. Best to prepare to that you will get at least one.
249
Other than an acetaminophen level, and levels for any other toxin, what bloodwork would you order in a case of acetaminophen intox? Name SIX.
aspartate aminotransferase (AST) alanine aminotransferase (ALT) international normalized ratio (INR) partial thromboplastin time (PTT) Alkaline phosphatase gamma glutamyltransferase (GGT) total bilirubin direct bilirubin serum albumin serum creatinine serum sodium serum bicarbonate serum phosphate serum glucose serum lactate (via arterial blood gas) serum/arterial pH (via arterial blood gas) Arterial blood gas is considered a grouped test and is never an answer on this exam. Choose the part of the ABG that you want, and use that as your answer. In this question, I recommend not populating all six of your answers with liver tests. Choose the most important two or three.
250
Mr. Koph, a 59 year-old businessman, presents to your local emergency room with a three-day history of fever, productive cough, fatigue and dyspnea. He denies infectious contacts, recent travel, or recent illness. He had his second Covid-19 vaccination three months ago. He denies rhinorrhea and sore throat. He is a current smoker and has a 25 pack-year smoking history. He denies other significant past medical history apart from mild hyperlipidemia. He has no allergies. Name FOUR items on your differential diagnosis.
Bacterial pneumonia Viral pneumonia Influenza COPD exacerbation Acute bronchitis The reference to Covid-19 vaccination status is meant to communicate that this is most likely NOT Covid-19 infection. Users have asked whether "asthma exacerbation" could be an answer, but this is less likely as he has no history of asthma, and this diagnosis doesn't explain his fever. The way the question is worded, it is pointing to an infectious cause. It is hard to know whether each answer should be a different type of infection (ie mycoplasma pneumonia, streptococcal pneumonia etc) or whether the answers should be more broad. Specific types of pneumonia could populate all four answers, but you don't want to exclude reasonable options such as COPD and acute bronchitis. Therefore, in this case, the recommendation is to stay broad and use categories of viral vs bacterial pneumonia only.
251
You have a pt suspected to have pneumonia. On examination, his blood pressure is 120/80, heart rate is 96 and regular, respiratory rate is 24, O2 saturation is 93% on room air, and temperature is 38.2 degrees celcius. What investigations do you order? Name FOUR.
serum white blood cell count and differential chest x-ray, PA and lateral serum hemoglobin serum creatinine serum sodium Sputum cultures are rarely helpful and therefore are rarely collected in pneumonia. The culture takes at least a week and sometimes two to come back, by which time the information is usually irrelevant. Additionally, the patient is not sick enough for blood cultures (usually the patient would be admitted and septic). See the links document for exam 2 for more information.
252
Other than vital signs, name SIX signs on respiratory examination that would support a diagnosis of pneumonia.
diminished chest expansion increased tactile fremitus increased vocal fremitus/vocal resonance dullness on percussion diminished air entry on auscultation bronchial breath sounds whispering pectoriloquy crackles pleural rub egophony bronchophony
253
Name THREE first line antibiotics, each from a different class, that you could use to treat pneumonia in a healthy patient.
doxycycline amoxicillin or amoxicillin/clavulanate (clavulin for comorbidities - smoking could be considered a comorbidity) azithromycin/clarithromycin/erythromycin Note: 1st line use of fluoroquinolone not recommended Canadian guidelines in this area are old. In general, newer resources (such as Bugs and Drugs) are steering away from macrolides as a first-line choice due to mounting resistance. Having said that, macrolides still make the list as a first-line option with a caveat to avoid in areas where there is evidence of mounting macrolide resistance. Macrolides are still recommended for inpatient or severe pneumonia. Here is a link to an American guideline (which I usually do not prefer to recommend) which is far newer than anything we have in Canada. See table 3. Let's hope the exam only asks for TWO answers. In that case, it's easy: amoxil and doxy in healthy patients; clavulin + doxy or clavulin + azithro in patients with co-morbidities.
254
Explain why you would or would not admit this patient. 59 yo with 25 pack year smoking hx, otherwise healthy, LLL PNA on CXR. On examination, his blood pressure is 120/80, heart rate is 96 and regular, respiratory rate is 24, O2 saturation is 93% on room air, and temperature is 38.2 degrees celcius.
NO side: You would not admit him because he doesn’t meet criteria as per the PSI /Curb-65 score. Not hemodynamically compromised. Other than smoking no active significant co-morbid conditions. No hypoxemia (considered to be 02 sat <90%). You may also explain answer using Curb-65, but PSI has been validated whereas Curb-65 has not been. However, PSI has higher specificity than Curb-65 YES side: You may get points as long as you explain your rationale: ie he appears septic. Then support why you feel that he is septic. You will not be asked to regurgitate the Curb 65 or PSI criteria on the exam, but you may be asked to make a decision that utilizes the scores so you should memorize one of them (Curb 65 much easier to memorize than PSI). On this question, most previous exam writers have answered NO.
255
You order a follow-up chest x-ray to ensure the absence of malignancy after you diagnose pneumonia. When would you ask the pt to do this follow-up x-ray?
6-8 weeks (any answer in this range is acceptable)
256
You counsel patient about preventing future episodes of pneumonia. Identify FOUR items that you would include in your discussion.
smoking cessation avoidance of 2nd hand smoke limit the spread of viral infections/handwashing/hand hygiene annual flu shot pneumococcal vaccine
257
Thirty year-old Brittany sees you in the office about headaches. Her headaches have been more frequent over the past six months. They are characterized by episodes of throbbing, unilateral head pain, and are associated with nausea, vomiting, and sensitivity to sound. Initially, they lasted only a few hours and occurred less than once a month. Now they are more severe and more frequent. She experienced similar headaches as a teenager. What is the most likely diagnosis?
migraine, migraine headache, migraine without aura, classic migraine
258
List THREE broad non-pharmacologic approaches that may help to prevent migraines
regular sleep/optimize sleep regular meals regular exercise: 30 mins/day 5d/wk to goal of 150mins/wk aerobic activity stress management avoid dietary triggers (ie. caffeine, MSG, chocolate, alcohol) stay well hydrated avoid analgesic overuse (>9d/month)
259
Other than narcotics, list FOUR agents, all from different classes, that could be used in the management of acute migraine attack in ER
aspirin, ibuprofen, naproxen (or any other NSAID) metoclopramide sumatriptan (or any other listed triptan) acetaminophen intravenous fluids/normal saline
260
List FOUR oral medications, all in different classes, that you can prescribe for migraine prophylaxis (not acute treatment)
amitriptyline/nortriptyline divalproex/valproic acid propranolol/metoprolol/nadolol topiramate gabapentin candesartan lisinopril verapamil/flunarizine pizotifen venlafaxine B-blockers and TCAs are considered first line. Some resources indicate that anti-convulsants are also first line, but there is not general consensus on this, so if they ask for classes of meds, stick with TCAs and B-blockers as preferred classes, and anti-convulsants next, followed by CCB/ACEI. Botox is recommend for prophylaxis when there are over 15 headache days per month, as per Headache Society of Canada. Since botox is not an oral medication, it is not an answer for this question. If the question reads, "What pharmacologic agents could you use for prevention?" then botox is an answer. There are newer injectable immunologic agents (Aimovig) that are also gaining popularity. Again, these are injectable agents so not on this answer key
261
over-the-counter preventative products for migraines. Which over-the-counter agents can be recommended? List THREE.
Butterbur Magnesium Vitamin B2/riboflavin Coenzyme Q10
262
Red flags in a patient with migraines, that would require imaging
Red flags include recent onset, rapidly increasing frequency and severity of headache; headache causing the patient to wake from sleep; associated dizziness, lack of coordination, tingling or numbness, new neurologic deficit; new onset of a headache in a patient with a history of cancer or immunodeficiency; new headache disorder in patient over 50. "The yield of neuroimaging in patients with typical recurrent migraine attacks is very low. Any imaging study, particularly MRI, can identify incidental findings of no clinical significance which may lead to patient anxiety and further unnecessary investigation. For patients with typical migraine and a normal clinical examination who desire reassurance, careful explanation of the diagnosis and patient education may be more advisable." - Choosing Wisely
263
Physical Exam of wellbaby and normal weight gain pattern
Height, weight, head circumference (WHO Canadian Growth Chart) Correct percentiles if born <37w until 2-3yo Max 10% weight loss by 4-5d, regain birthweight by 2w 30g/d until 3 mo, 20g/day until 6 mo, 10g/day until 12 mo Double BW by 4mo, triple BW by 1y
264
when to do wellbaby visits
Recommended at 1 week, 2 months, 4 months, 6 months, 12 months, 18 months, 4-5 years
265
when should fontanelles be closed
Posterior closed by 2mo, anterior closed by 18mo
266
which hip exam to do in children depending on age
Hip exam until walking 0-3 months: Ortolani, Barlow >3 months: Limited hip abduction, Galeazzi
267
when to refer for undescended testes
6 months (4-12 months) Refer if undescended (palpable, ectopic, nonpalpable) at 6 months Consider earlier if ascended testis, bilateral nonpalpable, or associated hypospadias/ambiguous genitalia Ultrasound not recommended as unhelpful Retractile testis can be followed until puberty
268
benefits of circumcision
Decrease Penile cancer (NNT 900-322,000) Phimosis (NNT 67) UTI (NNT 111) HPV (NNT 5), HIV (NNT 298), HSV (NNT 16) Decrease cervical cancer and STI in partner
269
3 cons of circumcision and name a contraindication
Surgery risks: Infection (NNH 67), bleeding (NNH 67) Meatal stenosis (NNH 10-50) Ethical concerns Contraindicated: Hypospadias
270
until when should a women breastfeed and which supplement to give? when to start regular milk
Exclusive breastfeeding recommended for first 6 months and continued into second year of life Breastfed babies should receive Vitamin D 400 units PO daily Vitamin D 800 units daily if high risk (limited sun exposure, darker skin, obesity) Express breast milk can refrigerate up to 3d and freeze up to 6mo Warm milk by placing in warm water Switch from formula to homogenized milk at 500-750 mL/day at 12 months Discontinue bottle by 18 months Transition to 1-2% milk (500mL/day) at 2-3 years
271
6 tips for introduction of solids in baby
No evidence to delay food beyond 6-12 months Introduce foods one at a time q3d (monitor for reactions) Avoid solid round smooth dry/sticky foods risk of choking Avoid sugary food/drinks No beets, carrots, spinach, turnips before 6 months (nitrates) No honey in first year Inquire about vegetarian diets Iron-containing foods should be encouraged when introducing solids Iron-fortified cereals and grain products Consider screen at 6-12mo for anemia in at-risk (eg. low SES)
272
5 tips for safe sleep
Safe crib (no soft objects/loose items, firm mattress) On Back Room sharing for <6 months Pacifier if <6 months Avoid bed sharing (consider bed box)
273
3 advice on car seats and children
Rear-facing car seat -Infant must use rear-facing car seat -Use a larger seat once baby outgrows infant seat, and keep rear facing until at least 2 years of age or reaches the maximum weight or height limit of the rear-facing seat, as stated by the manufacturer Forward-facing car seat with a 5-point harness -Once child outgrows larger rear-facing seat and is at least 2 years old, use 5-point harness seat until at least 18kg (40lbs) and can sit straight/tall without moving out of position or unbuckling (this may be 4-6 years old) Booster seats with belt-positioning -When child has outgrown forward-facing car seat with a 5-point harness, use a booster seat until 145cm (4'9") tall and they safely fit in adult seat belt without slouching (for most children this is 9-12 years old) Rear seat with adult seatbelt until 13 years old
274
counsel on use of acetaminophen and ibuprofen with correct dosing in pers
Acetaminophen 10-15mg/kg/dose q4-6h Ibuprofen 4-10mg/kg/dose q6-8h in >6mo Avoid OTC medication (especially if using acetaminophen/ibuprofen)
275
at which frequency should mothers breastfeed
Mothers should breastfeed when infant shows signs of hunger or q4 hours (8-12 feeds in first 24h, which decreases slowly to seven feeds per day by 1-2 months) Infant should urinate one void per number of days of life until 6-8 times daily by day 5 Suspect inadeqaute milk intake if >7% weight loss or if the infant does not regain their weight by 2w
276
cause leading to breastfeeding issues
Inadequate milk production -Breast development (previous surgery, radiation, endocrine -prolactinoma) -Delay in lactogenesis within first 5d -Usually due to obesity, hypertension, PCOS -Medications (oxytocin, SSRI, estrogen) -Offering only one side per feeding Poor milk extraction -Infrequent feeding -inadequate latch-on -Maternal-infant separation -Use of supplemental formula
277
differential diagnosis of nipple pain
Trauma Vasoconstriction Engorgement/Excessive milk supply Plugged ducts Infection Dermatitis/psoriasis
278
non pharmalogical tips for helping to breastfeed better
Proper positioning and latch Support breast with hand in shape of "C" (fingers under breast, thumb on top) Place baby's chin below areola Top and bottom lips wide open Lower lip turned outward against breast Chin touching breast, nose close to breast Full cheeks Re-try latch if discomfort, noisy sucking, does not swallow rhythmically If unable to get proper latch, consider pumping with expressed breastmilk until problem is addressed Lactation consultant No data for galactogogues (domperidone, metoclopramide, fenugreek) over breastfeeding technique interventions Cool or warm compresses, breastmilk to nipple
279
pharmalogical treatment of cracked nipples in breastfeeding
Antibiotic ointment (bacitracin or mupirocin) on cracked nipples to prevent infection and form a barrier All Purpose Nipple Ointment (APNO) Mupirocin ointment 2%: 15 grams Betamethasone ointment 0.1%: 15 grams Miconazole powder added to a concentration of 2% miconazole Total ~30g, Apply sparingly after each feeding. Do not wash or wipe off.
280
when should a mother wean from breastfeeding
Natural weaning or “child-led weaning” happens when your baby starts to accept more—and different types—of solid foods while still breastfeeding on demand. With this type of weaning, you watch your baby’s cues and wean at their pace. Babies who are weaned naturally usually stop breastfeeding completely sometime between 2 and 4 years of age. Planned weaning or “mother-led weaning” happens when mothers decide to start the weaning process. A “partial wean” means substituting one or more feedings with a cup or bottle and breastfeeding at other times. This can work well if you are going back to work or school, but still want to breastfeed. Early morning, evening and night feedings can continue even if you are separated from your baby during the day.
281
how to wean breastfeeding
follow baby cues do it gradually start by substituting one feed and continue this way hold and cuddle your baby: never prop a bottle watch the cues you give to your baby
282
how to counsel parents who do not want to vaccinate their child
-explain that Vaccines are made with a tiny amount of dead or weakened germs. They help the immune system learn how to protect itself against disease. Vaccines are a safe and effective way to keep your child from getting very sick from the real disease. -consequences of not vaccinating: congenital rubella, death, possible complications of preventable disease -no third world country travel
283
vaccination schedule
depends on each province.
284
6 risk factors of violent patient
Young Male Low SES History of violence Legal history History of physical abuse Substance use disorder Mental illness Victimization
285
8 causes to rule out in violent patient
hypoxemia/hypoxia, hypoglycemia, neurologic disorder (injury, hemorrhage, cva, seizure), schizophrenia, infection (meningitis, encephalitis, sepsis), metabolic (hyponatremia, hypoglycemia, thiamine deficiency, hypercalcemia), hyper/hypothermia, liver/renal failure, withdrawal (alcohol, benzodiazepine), medication/substance (amphetamine, steroids, alcohol), psychiatric
286
8 labs to consider ordering in suddenly violent patient
CBC, electrolytes (glucose), LFT, renal function Blood alcohol level, urine drug screen UA, urine culture CT head +/- LP
287
how to manage a violent patient
Consider personal safety at all times Never turn back to individual (don't walk ahead of patient) Ensure adequate personal space Ensure access to personal duress alarm Ensure you have a safe escape route Remove dangerour objects Consider safety of other patients and visitors Place patient in quiet secure area, inform other staff
288
de escaladation tricks to deal with violent patient
Empathic nonconfrontational approach, but set boundaries Address agitation directly (name the emotion) Listen to the patient, avoid excessive stimulation Recruit family, friends, case managers to help Address medical issues (pain, discomfort) Ascertain the patient's wishes and the level of urgency
289
indications to restrain and sedate agressive patient
Prevent harm to patient/other patients/caregiver/staff Prevent serious damage to the environment Assist in assessment and management of patient Never use restraints for convenience
290
pharmalogical management of violent behaviour
Benzodiazepines (avoid in elderly) Diazepam 5-10mg PO/IV (max 30mg per event) Lorazepam 2mg (max 10mg in 24h) Midazolam 5-10mg IM (max 20mg per event) Short-acting, rapid sedation (peak in 10mins, lasts up to 2h) Antipsychotics Olanzapine 5-10mg oral (max 30mg per event) Quetiapine 25-200mg PO Risperidone 0.25-2mg PO/SL Haloperidol 5-10mg IM (max 20mg per event) Risk of dystonia Acute dystonia - Benztropine 2mg PO or IM or IV
291
conditions that increase risk of depression (5)
Comorbid medical disorders (CAD, Hypothyroidism) Comorbid psychiatric disorders (anxiety, substance use) Chronic pain Low SES Postpartum
292
management of Suicidal ideas
Hospitalization vs. close outpatient follow-up Emergency psychiatric consultation and in-patient treatment if unsafe to self/others If low risk of suicide, consider safety plan*** -Keep home environment safe (remove access to weapons) -Recognize early warning signs -Coming up with ways to cope personally with suicidal thoughts -Identify people to contact for help/distraction -Identify place to go to for safety (eg. hospital) **provide specific instructions for follow up Consider psychiatric referral for substance use disorder or psychiatric comorbidity (bipolar, anxiety, personality) Persistent subthreshold depressive symptoms or mild-moderate depression -CBT, CCBT (computerized), structured group physical activity program Drug treatment if -Past history of moderate/severe depression -Long period (>2y) of subthreshold depressive symptoms -Persistent symptoms after other interventions -Moderate/severe depression in combination with CBT or IPT
293
8 symptoms of depression
≥ 5 (with depressed or decreased interest) for >2w with change in functioning Depressed mood most of the day Sleep Interest Guilt Energy Concentration Appetite Psychomotor agitation/retardation Suicidal ideation
294
psychiatric DDx (6) of depression
Bipolar (≥1w of energy/activity with ≥3 GST PAID) Depressive disorder due to another medical condition Persistent Depressive Disorder (>2y of 2SIGECAPS, with no MDE) Adjustment disorder with depressed mood (stressor <3mo, resolves in <6mo) Grief reaction (loss, usually <3mo) Schizoaffective Anxiety ADHD
295
Medical DDx of depression
Adrenal insufficiency, hypercortisolism, hypothyroidism, Mononucleosis, Multiple sclerosis, Huntington disease, Parkinson disease, systemic lupus erythematosus Obstructive sleep apnea Stroke, traumatic brain injury Vitamin B12 insufficiency Medication: Corticosteroids, interferon, antiretrovirals Substance-induced
296
investigation for depression
CBC (anemia), electrolytes (creat), TSH, B12/folate, LFTs B-hCG UA, urine toxicology EKG (QT) Neuroimaging if focal neurological sign or elderly
297
elements that increase suicide risk
SADIPERSONS Sex (male) Age>60yo Depression Previous attempts Ethanol abuse Rational thinking loss (psychosis) Suicide in family Organize plan No spouse/support Serious illness/pain
298
name 5 questions to assess suicide ideation
Passive vs. Active ideation Plan (time/place), Intent (would you actually carry out this plan) Past Attempts (Practiced/Aborted) Access to means Provocative/Protective factors
299
lifestyle modification for depression (3
Regular exercise, adequate food, housing, sleep Stress management (mindfulness-based stress reduction, engaging in ≥1 pleasurable activity per day) Avoiding substance abuse
300
4 types of therapies to help with depression
Cognitive behavioural therapy Interpersonal psychotherapy Behavioural activation Group (less effective than individual but lower costs)
301
name 5 common side effects of SSRI
Side effects: Nausea (21%), xerostomia (20%), diaphoresis (20%), drowsiness (18%), insomnia (15%), sexual dysfunction (up to 50%), weight gain, headache
302
name 5 dangerous complications of SSRIs
Serotonin syndrome, suicidality, upper GI bleed, osteoporosis, hyponatremia, prolonged QT
303
2 most common drugs to screen in patients who present in ER with suicide attemps
Acetaminophen and ASA also consider attempted suicide in patients with trauma
304
How to know if someone is responding well to antidepressants
Use objective scales (eg. PHQ-9) to monitor improvement -If >20% improvement at 2-4w continue treatment and reassess at 6-8w -If <20% improvement at 2-4w ---Increase dose ---Switch to another medication: Consider Escitalopram, Mirtazapine, Sertraline, Venlafaxine ---Adjunct/Augment (if ≥ 2 antidepressant trials, well tolerated, partial response, specific symptoms to target, less time to wait (severe, functional impairment), patient preference) -Consider Aripripazole, Quetiapine, Risperidone -Other options may include lithium, thyroid hormone
305
name 4 adjuncts in antidepressors in treating depression
Consider Aripripazole, Quetiapine, Risperidone Other options may include lithium, thyroid hormone
306
for how long do you keep the prescription of antidepressor
Maintenance until 6-9 months minimum after remission -Consider 2y minimum especially if high risk (frequent/recurrent episodes, severe, chronic, comorbid, residual symptoms, difficult to treat) Discontinuation by slow taper over weeks
307
sx of SSRI withdrawal 5
-Symptoms include FINISH (Flu-like symptoms, Insomnia, Nausea, Imbalance, Sensory disturbance, Hyperarousal) -Typically resolves in 1-2 weeks
308
other non pharmalogical treatments of depression
Neurostimulation -Repetitive transcranial magnetic stimulation (rTMS) if failed ≥1 antidepressant ECT if severe (active suicidal ideation), psychotic, treatment-resistant -Consider in medication intolerance, catatonic features, rapidly deteriorating physical status (eg. malnutrition due to food refusal) Complementary: Light therapy (phototherapy) -10,000 lux for 30 minutes per day during early morning up to 6 weeks (response usually within 3 weeks) -Consider especially in seasonal, shift work, sleep dysregulation Acupuncture Sleep deprivation (total for 40h or partial allowing 3-4h of sleep per night, employed 2-4 times over one week) Natural health products St John's Wort (care for medication interactions) Omega-3 fatty acids (3-9g/day) or 1-2g of EPA + 1-2g of DHA per day SAM-e Zinc Social skills training, vocational rehabilitation
309
first line of tx for under 18 yo in depression
First line CBT/IPT or internet-based psychotherapy Second line Level 1 evidence: Fluoxetine Level 2 evidence: Escitalopram, sertraline, citalopram
310
treatement of depression in pregnancy
Pregnancy/Breastfeeding First line CBT/IPT Second line Citalopram, escitalopram, sertraline
311
counsel on the risk of malformations when taking antidepressants in pregnancy
Most antidepressants not linked to major congenital malformations Paroxetine: CV malformations (OR 1.5) Fluoxetine: Small increase in congenital malformations Very modest link for spontaneous abortion (OR 1.5) , 4-day shortened gestational duration and reduced birth weight (74g) Exposure to antidepressants in breastfed infant is 5-10 times lower than in utero Sertraline has lowest relative infant dose (milk-to plasma ratio)
312
perimenopausal first line antidepressant
First line Desvenlafaxine CBT
313
first line of antidepressant for patients over 60 yo
Level 1 evidence: Duloxetine, mirtazapine, nortriptyline Level 2 evidence: Buproprion, citalopram/escitalopram, desvenlafaxine, sertraline, venlafaxine, vortioxetine
314
Forty-four year old Susan presents with a 4 month history of fatigue and weight gain in spite of not changing eating habits and maintaining regular exercise. She is otherwise healthy and not on any medications. On further questioning, Susan mentions that she had a painful neck swelling for a few weeks about 6 months ago following a cold. What is your most probable diagnosis?
hypothyroidism/thyroiditis
315
What are SIX signs or symptoms of hypothyroidism
weight gain fatigue Hypoventilation Intolerance to cold Slow HR tongue swelling Infertility Menorrhagia memory impairment Mood change: (depression) Constipation dry, thickened skin (previously, this answer said cold, clammy skin, which is more likely for hyperthyroid rather than hypo) course hair brittle nail Paresthesia periorbital edema goitre myalgias delayed reaction phase of deep tendon reflexes
316
which labs to ask for if there is fatigue, weight gain, tender neck/suspicion of hypothyroidism
TSH Free T4 Hemoglobin Mean corpuscular volume low density lipo-protein (because a high TSH can cause high LDL) serum creatinine ferritin
317
what is the starting dose of synthroid in healthy patient
0.05 - 2.0 ug/kg (FYI: standard starting dose is 1.6ug/kg - this is the safest option for the exam, unless your patient is old with co-morbidities, then you would start lower. Also, a question asking for this dose would be unusual on the exam.)
318
If the patient is > 80 years old or with cardiac disease, what will you choose for a starting synthroid dose in ug/dose?
25ug
319
In an asymptomatic 60 year old patient with a slightly elevated TSH, at what TSH level would you consider treatment?
TSH>10
320
name 10 signs and sx of hypothyroidism
Depression Decreased mental function Physical tiredness Paresthesia Hypokinesis Hyporeflexia Weight gainA Coarse, dry skin Periorbital edema Hoarseness Bradycardia Isolated diastolic hypertension Goitre Diminished sweating Cold intolerance Constipation Menorrhagia
321
Hyperthyroidism:signs and sx (10)
Anxiety, irritability, restlessness Fatigue, restless sleep Increased appetite Decreased attention span Tremors Proximal muscle weakness Hyperreflexia Weight loss Hair loss Palpitations, tachycardia Atrial fibrillation Isolated systolic hypertension Goitre Increased sweating Heat intolerance Blurred or double vision Dry eyes, conjunctivitis, proptosis or dysconjugate gaze Increased frequency of stools Amenorrhea/oligomenorrhea
322
6 risk factors of thyroid disease
Risk factors for thyroid disease include1: men: age ≥ 60 years2 women: age ≥ 50 years2 personal history or strong family history of thyroid disease diagnosis of other autoimmune diseases past history of neck irradiation previous thyroidectomy or radioactive iodine ablation drug therapies such as lithium and amiodarone dietary factors (iodine excess and iodine deficiency in patients from developing countries); or certain chromosomal or genetic disorders (e.g., Turner syndrome3, Down syndrome4 and mitochondrial disease5)
323
which test to ask in suspicion of thyroid disease
thyroid stimulating hormone free T4 free T3 rarely indicated, only relevent if thyroid disease is suspected clinically and TSH is abnormal, but fT4 is inappropriately normal. anti-thyroide peroxidase (TPO): not routinely indicated -can be used in goitre or mildly elevated TSH to see if cause is autoimmune thyroiditis -TPO antibody positivity increases the risk of developing hypothyroidism in patients with subclinical hypothyroidism, autoimmune diseases (e.g., type 1 diabetes), chromosomal disorders (e.g., Turner syndrome and Down syndrome) or patients who are on certain drug therapies (e.g., lithium, amiodarone) or are pregnant or postpartum (see Thyroid Disease in Pregnancy section below)13, 14. Once a patient is known to be TPO antibody positive, repeat analysis is not indicated. thyroid ultrasound scan is not routinely recommended in patients with abnormal thyroid function tests, unless there is a palpable abnormality of the thyroid gland
324
when to retest TSH in patient with confirmed thyroid disease
6 weeks after start or change in treatment if there is a change in patient's clinical status annually once TSH is stabilized q 6 months if patient is taking lithium and amiodarone(3-6m) q 6-12 months in subclinical hypothyroidism
325
when to treat subclinical hypothyroidism
A decision to treat is often made if the TSH is >10 mU/L even if the fT4 is within the reference range. Treatment can be considered when TSH is between the upper limit of the reference interval but ≤10 mU/L and any of the following are present13: symptoms suggestive of hypothyroidism elevated TPO antibodies evidence of atherosclerotic cardiovascular disease, heart failure, or associated risk factors for these diseases; or pregnancy (see Thyroid Disease in Pregnancy section below)
326
name 4 causes of high TSH
autoimmune hypothyroidism subclinical hypothyroidism recovery from non-thyroidal illbess (sick euthyroid syndrome) rare: pituitary disease, resistance to thyroide hormone
327
4 causes of low TSH
Hyperthyroidism or other causes of thyrotoxicosis Excessive thyroid hormone replacement (levothyroxine) Graves’ disease Subacute thyroiditis (viral) Painless/postpartum thyroiditis (autoimmune) Toxic (multinodular) goitre Hyperthyroidism or other causes of thyrotoxicosis T3 thyrotoxicosis (e.g., autonomous nodule) Excessive thyroid hormone replacement (liothyronine or desiccated thyroid) Subclinical hyperthyroidism Recovery of hyperthyroidism Pregnancy related14, 20 Assay artefactB Sick Euthyroid Syndrome Hospitalized patients, recovery from severe illness Very rare causes Central hypothyroidism (hypopituitarism) Assay artefactB
328
4 causes of low TSH
Hyperthyroidism or other causes of thyrotoxicosis Excessive thyroid hormone replacement (levothyroxine) Graves’ disease Subacute thyroiditis (viral) Painless/postpartum thyroiditis (autoimmune) Toxic (multinodular) goitre Hyperthyroidism or other causes of thyrotoxicosis T3 thyrotoxicosis (e.g., autonomous nodule) Excessive thyroid hormone replacement (liothyronine or desiccated thyroid) Subclinical hyperthyroidism Recovery of hyperthyroidism Pregnancy related14, 20 Assay artefactB Sick Euthyroid Syndrome Hospitalized patients, recovery from severe illness Very rare causes Central hypothyroidism (hypopituitarism) Assay artefactB
329
risks of taking synthroid
hyperthyroidism bone loss in post menopausal women atrial fibrillation (in elderly)
330
which population to screen for hyperthyroidism
atrial fibrillation osteoporosis other endrocrine disorders
331
when to test pregnant women for TSH/risk factors of thyroid disease
age > 30 years more than 2 prior pregnancies history of pregnancy loss, preterm delivery, or infertility type 1 diabetes or other autoimmune disorders morbid obesity (BMI ≥ 40 kg/m2) history of hypothyroidism/hyperthyroidism or current symptoms or signs of thyroid dysfunction family history of autoimmune thyroid disease or thyroid dysfunction (1st degree relative32) history of head or neck radiation or prior thyroid surgery known TPO antibody positivity or presence of a goitre currently receiving levothyroxine replacement33 use of amiodarone or lithium, or recent administration of iodinated radiologic contrast residing (or recently resided) in an area of known moderate to severe iodine insufficiency
332
when to treat pregnant women for thyroid disease and what is the target TSH
connection between untreated overt maternal hypothyroidism and neuropsychological impairment in the offspring3 A preconception TSH between the lower reference limit and 2.5 mU/L is recommended in women being actively treated for hypothyroidism If hypothyroidism has been diagnosed before or during pregnancy, treatment should be adjusted to achieve a TSH level within the normal trimester specific reference interval. If the TSH value is above 2.5 mU/L but within the reference interval, some practitioners would consider treating if the TPO antibody is positive.
333
normal range of TSH
TSH high (>4-5mU/L) TSH low (<0.2mU/L)
334
additional tests to do in patients with hyperthyrodism without obvious cause
Thyrotropin receptor antibodies (TRAb) Radioactive iodine uptake (contraindicated in pregnant/breastfeeding) Ultrasound with thyroidal blood flow Thyroid ultrasound (if abnormal thyroid size, nodules) FNA for nodules >1cm or 5mm and suspicious features (r/o cancer)
335
drugs causing hypothyroidism (name3)
thionamides, lithium, amiodarone, interferon-alfa, interleukin-2, perchlorate, tyrosine kinase inhibitors
336
when to treat for subclinical hyperthyroidism
Consider treatment if TSH <0.1 mIU/L and Symptomatic (palpitations, tremor, nervousness) >65yo Comorbidities such as heart disease or osteoporosis Postmenopausal (<65yo) and not taking estrogen/bisphosphonates
337
treatment of Subacute granulomatous thyroiditis (viral infection, painful thyroid)
NSAIDs, steroids, beta blockers for sx treatment
338
sx of myxedema coma
Altered mental status, hypoventilation, hypothermia, hypotension, bradycardia, hyponatremia, hypoglycemia
339
tx of myxedema
Levothyroxine (T4) loading dose 200-400mcg IV, then 1.6mcg/kg/day IV Liothyronine (T3) 5-20mcg followed by 2.5-10mcg q8h given with T4 Glucocorticoids (hydrocortisone 100mg IV q8-12h x2d) until coexisting adrenal insufficiency can be excluded Supportive measures (ventilation, fluids, correction of hyponatremia and hypothermia)
340
graves disease lab and treatment
(TSH receptor antibodies=TRAb) Thionamides (Methimazole - MMI or Propylthiouracil - PTU) If persistently high TRAb, consider continuing MMI or radioiodine/sugery beta blockers for sx control
341
Toxic adenoma/multinodular goiter treatment
First-line: Radioiodine or surgery May consider thionamide initially for short-term Beta-blockers for symptomatic treatment
342
thyroid storm sx and treatment
Hyperthermia, tachycardia, N/V/D, dehydration, delirium, coma Causes: Trauma, surgery, RAI Treatment B-Blockers (Propranolol 60-80mg q4-6h) PTU 200mg PO q4h Iodine solution (delayed 1h after PTU) Iodinated radiocontrast High-dose IV hydrocortisone 100mg IV q8h
343
ample history
Allergies, Meds, PMH, Last meal, Events
344
normal urine output/goal
Urine output goal of 0.5mL/kg/h in adults (1mL/kg/h in pediatric, 2mL/kg/h in <1yo)
345
name 5 life threatning thoracic trauma conditions
Tension pneumothorax Needle thoracostomy at 2nd ICS mid-clavicular line or 5th ICS anterior/mid axillary line, do not wait for X-ray (can do bedside ultrasound) Chest tube at fifth intercostal space at anterior axillary line Cardiac tamponade -Penetrating chest wound, ----Beck triad (hypotension, distended neck veins, muffled heart sounds), pulsus paradoxus, Kussmaul sign (rise in JVP on inspiration) -Confirm with echochardiogram, guide pericardiocentesis Hemothorax Flail chest Upper airway obstruction Aorta lesion
346
name the types of choc and one example for each
hypovolemic -hemorrhagic -Non-hemorrhagic (GI, skin-burns, renal, third space, pancreatitis) distributive -Sepsis -Neurogenic (TBI, spinal cord injury) -Anaphylactic -Inflammatory obstructive -Pulmonary vascular (PE) -Mechanical (Tension pneumothroax, pericardial tamponade) cardiogenic -Cardiomyopathic (MI) -Arrhythmogenic (tachy/bradyarrhythmia) Mechanical (valvular) neurogenic: -trauma to spinal cord endocrine -adrenal insufficiency, thyrotoxicosis, myxedema coma metabolic: -acidosis, hypothermia Drugs: -CCB, BB, Digoxin
347
In trauma what is in the primary survey?
Danger: check if it is safe Response: chceck response to stimulus to determine level of consciousness Circulation: pulse -Consider defibrillation, hemorrhage control, leg elevation, IV access, fluid therapy Airway: check if patent consider C spine immobilisation, simple airway maoeuvers, suctionning, basic and advanced airway adjuncts Breathing: consider Oxygen and IPPV
348
secondary survey in trauma
obtain Hx using OPQRST and SAMPLE vital signs, EKG, GCS PE from head to toe and fast echo
349
signs of difficult intubation
previous hx of difficult intubation trauma on face, upper airway or C spine early difficulty to ventilate with face mask severe aspiration risk small mouth, short mandibule, large tongue, short neck, prominent central incisors limited mouth opening C spine decrased ROM, trauma, degenerative changes obesity, Mallampati score thyromental distance laryngeal oedema (infection, inhalation thermal injury)
350
indication for intubation
unprotected airways, trauma to the airway, a Glascow Coma Scale (GCS) less than eight, a rapid decline or loss of consciousness, and procedural sedation and paralysis
351
absolute contraindication to direct laryngoscopy
facial trauma
352
name 4 precipitants of trauma
seizure, drug intox, hypoglycemia, attempted suivide
353
who to treat in mass casualties
ff. In such cases, patients having the greatest chance of survival and requiring the least expenditure of time, equipment, supplies, and
354
when to transfer a patient in trauma
Use ABCDE for transfer consideration: -airway compromise, high risk for airway loss, tension PTx, hemothorax, open PTX, hypoxia, hypoventilation, hypotension, pelvic fx, vascular injury, open fx, abdo distension or peritonitis, GCS under 13, secvere hypotermia, depressed skull fx or penetrating injury, eye injury, complex lacerations, complex traumas is important not to delay transfer to perform an indepth diagnostic evaluation. Only undertake testing that enhances the ability to resuscitate, stabilize, and ensure the patient’s safe transfer e. Patients who exhibit evidence of shock, significant physiologic deterioration, or progressive deterioration in neurologic status require the highest level of care and will likely benefit from timely transfer Stable patients with blunt abdominal trauma and documented liver or spleen injuries may be candidates for nonoperative management, requiring the immediate availability of an operating room and a qualified surgical team. r. Patients with specific injuries, combinations of injuries (particularly those involving the brain), and/or a history indicating high-energy-transfer injury may be at risk for death and are candidates for early transfer to a trauma center. Elderly patients should be considered for transfer for less severe injuries (e.g., multiple rib fractures and patients on anticoagula
355
tips to minimize trauma
do no drive drunk, use seatbelts, helmetsfhypo
356
definition and 3 classes of hypothermia
Hypothermia is defined as a core body temperature below 35°C (95°F). In the absence of concomitant traumatic injury, hypothermia may be classified as mild (35°C to 32°C, or 95°F to 89.6°F), moderate (32°C to 30°C, or 89.6°F to 86°F), or severe (below 30°C, or 86°F). in the presence of injury, different thresholds for classification are recommended: mild hypothermia is 36° C (96.8° F), moderate hypothermia is <36° C to 32° C (< 96.8° F to 89.6° F), and severe hypothermia is < 32° C (89.6° or stage 135°C to 32°C stage 2 32-28 stage 3 24-28 stage 4 below 24
357
rewarming techniques in Mild (HTI) hypothermia 35°C to 32° C (95-89.6 F)
* Dry patient * Warm environment * Shivering * Blankets or clothing * Cover head External * Heating pad * Warm water, blankets, and warm water bottles * Warm water immersion * External convection heaters (lamps and radiant warmers)
358
rewarming technique in moderate (HT II) hypothermia < 32°C to 28° C (< 89.6-82.4 F)
External * Heating pad * Warm water, blankets, and warm water bottles * Warm water immersion * External convection heaters (lamps and radiant warmers) Internal * Heated intravenous fluids * Gastric or colonic lavage * Peritoneal lavage * Mediastinal lavage * Warmed inhalational air or oxygen
359
severe hypothermia rewarming technique
Extracorporeal Rewarming * Hemodialysis * Continuous arteriovenous rewarming (CAVR) * Continuous venovenous rewarming (CVVR) * Cardiopulmonary bypass
360
physical exam findings suspicious of child abuse
General assessment of alertness, eye opening, and responsiveness Intracranial hemorrhage, head injury Height, weight, head circumference (compared with past measurements, if possible) Failure to thrive, neglect, or growth failure with concurrent physical abuse Mouth and teeth examination Dental caries suggestive of neglect Scalp examination Patchy hair loss caused by traumatic alopecia or severe malnutrition Funduscopic examination of the eyes Retinal hemorrhages Skin examination for bruising or burns Multiple patterns of bruising suggestive of abuse: bruise in child younger than four months; bruise in torso, ear, and neck areas; ear bruising (suggests “boxing ears”); buttocks bruising; patterned bruises (hand, cord, belt, object); bruises at different stages of resolution; burn injuries Palpation for tenderness, especially of the neck, torso, and extremities Occult fracture Deep tendon reflexes, muscle tone, or responsiveness to tactile stimuli Spinal cord injury
361
suspicious xr findings of child abuse
Highly specific injuries* Classic metaphyseal lesions Rib fractures, especially posteromedial Sternal, scapular, and spinous process fractures Moderately specific injuries* Multiple fractures Fractures in different stages of healing Epiphyseal separations Vertebral body fractures and subluxations Digital fractures Complex skull fractures Common but low specificity Clavicular fractures
362
labs to ask in suspected child abuse
cbc, fibrinogen, von willebrand factor, platelet aggregation studies, clotting factor assyas, ALt, AST, amylase, lipase, tox screen, UA, renal and lytes, ca, alk phosp, phosphorus, albumin, PTH for malnutrition, rickets
363
5 general advice to give to people travelling
get up to date information from reliable travel website discuss prevention of accidents, safer sex, alcohol, safe travel for women provide prevention and treatment advice and prescribe meds for common conditions (traveler's diarrhea, altitude sickness) ensure pts know how to manage their chronic disease update routine vaccinations check insurance coverage have adequate medical supply, put in carry on bags
364
list common infections patients can get from travelling and their sources
Sick contact (TB) Fresh water (shistosomiasis, leptospirosis) Unclean water, unpasteurized milk, raw food (Traveler's diarrhea, giardiasis, nontyphoidal salmonellosis, enteric fever, shigellosis, campylobacter, hepatitis A and E, brucellosis, listeriosis) Skin contact with soil - walking barefoot (Strongyloidiasis, melioidosis) Farm animals Sexual contact (Herpes virus, HIV, Hep A/B/C, syphilis, gonorrhea, Zika, viral hemorrhagic) IVDU, tattoo, piercing (Hep B/C, HIV, CMV, malaria, babesiosis) Insect bites/Animal bites
365
malaria prevention
Clothing, DEET, bed nets with permethrin
366
when does malaria (plasmodium) sx appear
7 days to months after anopheles mosquito bite
367
malaria treatment, prophylaxis
atovaquone, proguanil (malarone) daily (start 1 day prior and 7 days after), avoid in children under 5 kg Mefloquine (Lariam) weekly -Start 3w prior, continue 4w after -AE: Severe intolerance in some patients Chloroquine weekly -Start 1-2w prior, continue 4w after -Resistance Doxycycline also option for prophylaxis (risk of sun sensitivity, and avoid in children <8yo due to teeth staining) treatment: IV antimalarials (Quinidine with doxycycline or Artesunate) Consider outpatient treatment if <4% parasitemia and no severe features as above Chloroquine (if sensitive) 600mg base orally immediately, then 300mg base orally 6, 24, 48h (total of 1500mg base) Artemisinin combintation therapy if Chlororoquine-resistant region (eg. Artemether-lumefantrine) Monitor parasitemia with daily blood smears until no parasitemia
368
name 5 germs causing traveller's diarrhea
Escherichia Coli Campylobacter jejuni Salmonella Shigella Yersinia Norovirus Rotavirus Giardia Entamoeba histolytica Bacterial causes: 50-80% of travel-related diarrheal illness Viral causes: 5-25% Protozoal causes: <10%
369
for how long should patients avoid pregnancy after travelling to areas with zika
Avoid pregnancy after return from Zika area (2 months for women, 6 months for men)
370
non pharmacologic measures to prevent traveller's diarrhea
Wash hands with soap and water before eating/frequent hand hygiene Only eat fruit that they can peel themselves Avoid uncooked vegetables (FYI: because these have likely been exposed to local tap water) Avoid salads (FYI: because these have likely been exposed to local tap water) Heat food to piping hot Eat only thoroughly- and recently-cooked meats and fish Drink only boiled or bottled beverages Purify drinking water/Boil drinking water for 1 minute Only eat pasteurized dairy products Avoid food from street vendors/unknown sources Avoid ice cubes Only use purified/bottled water for brushing teeth and washing face
371
is vaccine against cholera useful
No, the vaccine (dukoral) is not recommended. It is no more effective than placebo for prevention of diarrhea. It is no more effective than placebo for prevention of enterotoxigenic E. Coli (ETEC)
372
t treatments she can utilize right away if she develops diarrhea abroad.
use oral rehydration solution or salts/ensure adequate hydration loperamide/Imodium bismuth subsalicylate/Peptobismal 2 bismuth subsalicylate tablets 4 times daily (prevents up to 60%)
373
which antibiotics to treat traveller's diarrhea Consider antibiotics if severe (> four unformed stools daily, fever, or blood, pus, or mucus in the stool) or high risk (child, pregnant, elderly)
Ciprofloxacin 500mg PO BID x 3 days Azithromycin 1000mg PO x 1 in children, pregnant women, or travellers to Asia (resistance to fluoroquinolones)
374
labs for traveller's diarrhea or fever
CBC (anemia, lymphopenia, thrombocytopenia, eosinophilia) Thick and thin blood smear r/o Malaria (consider repeat q12h until three negative smears as parasitemia is cyclical) Liver/Renal studies Electrolytes Blood culture x2 Urinalysis/Urine culture CXR Consider ESR/CRP PPD r/o TB Dengue Serology Widal test r/o typhoid fever LP If >10-14d, stool culture and O+P should be done for targeted therapy
375
treatment of scrub typhus (or other rickettsial infection)
Doxycycline
376
complications of malaria
organ dysfunction, anemia, electrolyte abnormalities, altered mental status, seizure, coma
377
name general travel vaccines and country specific vaccines: -south asia -meningitis belt-sub-Saharan Africa, Hajj -Africa, south american -rural asia
General travel vaccines Hepatitis A/B Rabies vaccine (adventure trips lasting more than 4 weeks) Country specific vaccines Typhoid vaccine (South Asia) Meningitis vaccine (Meningitis belt, Hajj) Yellow fever vaccine (African, South American countries) -Must be given at designated clinic for official certificate Japanese encephalitis vaccine (Rural Asia) Antimalarials-arge areas of Africa and Asia. Central and South America.
378
treatment of altitude sickness
Consider symptomatic treatment (analgesic, antiemetic) Consider prophylaxis, Acetazolamide 125mg PO q12h In High Altitude Cerebral Edema (encephalopathy and ataxia, usually above 4000m) consider immediate descent, dexamethasone and oxygen
379
treatment of motion sickness
Visual cues congruous with vestibular cues (eg. view the horizon from the deck of a ship) Lying supine Ginger, acupressure Anticholinergic medication (care in elderly or risk of angle closure glaucoma) Dimenhydrinate, diphenhydramine, transdermal scopolamine (patch 72h)
380
symptoms of malaria
fever (which may be periodic), chills, rigors, sweating, diarrhea, abdominal pain, respiratory distress, confusion, seizures, hemolytic anemia, splenomegaly, and renal abnormalities
381
symptomatic management of common cold
Analgesics (Acetaminophen/NSAIDs) Combination products (Antihistamine, decongestant, analgesics) Consider Zinc lozenges 75mg PO daily, Pleragonium sidoides, Andrographis paniculata Risk of irreversible anosmia in intranasal zinc preparations Nasal symptoms Nasal saline irrigation (poor evidence) Intranasal cromolyn sodium 1 spray (5.2mg) in each nostril q2h PRN x 2 days then 4 times daily x 5 days Intranasal ipratropium bromide 0.06% solution two sprays (42mcg/spray) in each nostril 3-4 times daily PRN x 4 days Cough suppressant Brompheniramine plus sustained-release pseudoephedrine Ipratropium bromide inhaled Dextromethorphan 30mg PO q6-8h PRN
382
prevention of common cold
Handwashing Flu vaccine (6mo-5yo, ≥65yo, chronic disease, pregnancy/postpartum, healthcare worker, frequent contact with above) Pneumococcal 23-valent ≥65 years old, or if specific risk factors
383
treatment of flu (2) and indication
Zanamivir (Relenza) two inhalations (10mg) PO BID x 5d or oseltamivir (Tamiflu) 75mg PO BID x 5d Amantadine not first-line due to high rates of resistance May extend therapy in severely ill patients Treatment with antiviral should be considered for the following patients Severe disease (requiring hospitalization or evidence of lower respiratory tract infection, eg. dyspnea, tachypnea, oxygen desaturation) High risk for complications (pregnancy) Most efficacious within first 48h of illness, but indicated to treat if severe illnessor pregnancy Indications to consider X-ray
384
indications to consider XR in URTI sx
Hemoptysis Pleuritic chest pain Dyspnea Systemic symptoms (fever, tachycardia >100, tachypnea>24) Abnormal physical exam (crackles, decreased breath sounds, bronchial breathing)
385
how to counsel on someone with viral URTI who wants antibiotics
Compassionate communications Describe infection as viral illness Discuss expected course of illness and cough duration (2-3w) Explain antibiotics do not shorten illness duration, and may cause adverse effects and antibiotic resistance Treatment plan including symptom management (analgesia, antiinflammatory) Consider -Delayed prescription strategies (agree on time frame, eg. 1 week that symptoms should improve - and only to use prescription after the specified time) -Immediate prescribing if suspect pneumonia or high-risk (immunosuppressed)
386
who are considered high risk patients in upper respiratory infections:
COPD, cancer, immunodeficiency virus infection
387
otitis media signs
bulging or distorted light reflex (i.e., not all red eardrums indicate OM).
388
otalgia DDx
AOM, acute mastoiditis, acute facial nerve palsy, labyrinthitis, venous sinus thrombosis, meningitis, trauma, cholesteatoma, tumor, otitis externa, r/o necrotizing/malignant otitis externa, Herpes zoster , Secondary otalgia, otitis media with effusion, otitis extera Herpes zoster (Ramsay Hunt syndrome) Secondary otalgia Sinusitis / Stomatitis / Parotitis / Pharyngitis Dental infection / abscess TMJ dysfunction syndrome Auricular lymphadenopathy Facial nerve palsy Trigeminal neuralgia Temporal arteritis*
389
complications of AOM
Acute mastoiditis (pain/swelling over mastoid bone) Acute facial nerve palsy - associated with temporal bone inflammation Sixth CN palsy (failure of ipsilateral eye abduction) due to petrous bone inflammation or infection (Gradenigo's syndrome) Labyrinthitis Venous sinus thrombosis Meningitis
390
treatment of otitis externa
Keep dry (Avoid water sports x 7-10d) Clean ear canal Analgesia Mild, Buro-Sol 2-3 drops TID-QID Moderate, Ciprodex 4 drops TID If perforated consider systemic antibiotics.
391
which dangerous otitis to rule out in high risk patients
r/o necrotizing/malignant otitis externa (elderly, diabetic, immunocompromised, otalgia despite antibiotics, granulation tissue in ear canal) ESR, CRP, osteomyelitis on CT/MRI Ciprofloxacin 750 mg PO BID PLUS Ciprodex 4 drops BID x 4-8w
392
physical exam findings to diagnose AOM
loss of light reflex impaired mobility bulging TM acute perforation with purulent discharge
393
when to treat for AOm
Immediate therapy if < 6months of age -Send to ER if <3 months old with T>38, suspect meningitis or mastoiditis, toxic looking Healthy children ≥6 months with mild disease, consider: Watchful waiting, and reassess in 24 to 48h (return if worsens anytime within 48h) Antimicrobial prescription to start course if child does not improve Pediatric: Amoxicillin 75 to 90mg/kg/day (max 2000mg) ÷BID Adults: Amoxicillin 500mg PO TID x 5-10d (can use 1g PO TID if high risk) in adults Acetaminophen 10-15mg/kg/dose q4-6h (max 75mg/kg/day) Ibuprofen 5-10mg/kg/dose q6-8h (max 40mg/kg/day) Bulging TM, febrile (≥39°C), moderately systemically ill, or severe otalgia, or significantly ill for 48h should be treated with antimicrobials
394
second line treatment of AOM (no response x 2-3d or recent amoxicillin use in 30 days)
Amoxicillin-clavulanate (7:1 formulation, 400 mg/5 mL suspension) 45 to 60 mg/kg/day ÷ TID (max 500mg PO TID) x 10d Adults: 875/125mg BID or 2000/125mg BID x 10 days Ceftriaxone 50 mg/kg IM/IV daily (max 1000mg) x 3 days
395
name 5 pharyngitis redflags
Drooling/Secretions Dysphonia Dysphagia Muffled "hot potato" voice Neck swelling
396
dangerous ddx + other ddx to rule out in case of suspected pharyngitis
Submandibular space infections (Ludwig's angina - woody induration, crepitus) Primary HIV (mucocutaneous ulcerations) Peritonsillar abscess (trismus) Epiglottitis (out of proportion to findings on exam) Retropharyngeal space infection infectious mononucleosis (fever, pharyngitis, fatigue, lymphadenopathy, splenomegaly, palatal petechiae) HIV, Gonorrhea CMV, toxoplasmosis Suppurative complication (peritonsillar abscess) Infectious thrombophlebitis of the internal jugular vein (Lemierre's) Fusobacterium necrophorum (in 15-30yo)
397
labs to test in mono
WBC, AST, ALT, Monospot (or EBV serologies)
398
diagnosis of pharyngitis
CENTOR: Cough absent Exudate/erythema tonsils, Neck nodes, Temp, Range of age (3-14=+1, 15-45=0, >45=-1) If CENTOR ≥3 (>30%): Rapid Antigen Detect Test (RADT) and/or culture Negative RADT consider throat culture back-up in children or immunocompromised (sensitivity 86%) Positive RADT do not need back-up culture (specificity 96%)
399
symptomatic treatment of pharyngitis + when to return to school
Acetaminophen/NSAIDs Topical (Benzocaine 10mg lozenge q2h PRN, Benzydamine 0.15% 15mL gargle q3h PRN) Consider Dexamethasone 0.6mg/kg (max 10mg) PO x 1 (NNT 12) After full dose of amoxicillin, 91% of children the next morning had negative RADT/culture Consider returning to school on Day 2 of antibiotics if improved/afebrile
400
pharmacologic tx of strep throat + 2 options in case of allergy
Penicillin V (50mg/kg/day ÷ BID) 600mg PO BID x 10d Can consider Pen V QID x 5d Pediatrics: Amoxicillin 50 mg/kg PO daily (max 1g) x 10d if allergy: Cephalexin (50mg/kg/day ÷ BID) 500mg PO BID x 10 days If anaphylactic Clarithromycin (15mg/kg/day ÷ BID) 250mg PO BID x 10d
401
diagnosis of sinusitis
Diagnosed clinically using symptoms and signs >7d duration Must have one of "OD" and one other "PODS" symptom Facial Pain (or pressure), Nasal Obstruction, Discharge, Smell loss
402
imaging in sinusitis
Radiological imaging usually not required (unless diagnosis unclear) X-ray (3 views) diagnosis with air/fluid level or complete opacification CT scan if complication
403
causes of sinusitis and criteria to treat
Most are viral and resolve spontaneously within 10-14d Suspect bacterial if Deterioration of symptoms 5-7d after improvement (biphasic) Persistent symptoms without improvement >10-14d as per INESSS >7d without improvement (or >10d persisting symptoms) as per Canadian guidelines Treat bacterial if severe symptoms impacting function/sleep
404
when to follow up after treating fo rsinusitis
Lack of response within 72h suggests treatment failure Referral to ENT if (and consider CT if long waiting time) Complications Persists >8w Recurrent rhinosinusutis >3 episodes per year
405
Alarm symptoms of sinusitis (4)- Consider urgent referral to ER
toxic, altered mental status Persistent fever (>38C) Periorbital erythema/swelling or decreased visual acuity Meningeal signs/severe headache or neuro signs
406
Predisposing conditions of sinusitis
Recent viral URTI History of allergic/nonallergic/medication-induced rhinitis Concomitant conditions (pregnancy, immunodeficiency, migraine) Anatomic causes (deviated septum, enlarged tonsils, nasal polyp)
407
non pharmalogical tx of sinusitis
Prevention: Smoking cessation, hand hygiene Symptom management: Analgesics (acetaminophen, NSAIDs) Saline irrigation BID
408
treatment of sinusitis and tx in case of PNC allergy
Oral decongestants <10d (when worse congestion, eg. night) Topical decongestants <3d (risk of rebound congestion) Consider topical intranasal corticosteroids (eg. nasonex) in mild-moderate ARS (NNT 15) If no improvement after 72h, consider antibiotics Consider treatment for suspected acute bacterial rhinosinusitis (as above) with severe symptoms or mild-moderate not responsive to INCS after 72h (NNT 17, NNH 8) Amoxicillin 500mg PO q8h x 5-10 days Second-line (or first-line if suspect resistance, immunosuppressed, frontal/sphenoidal sinusitis due to higher rates of complications) Amoxicillin/Clavulanate 875/125mg PO BID x 7d Moxifloxacin 400mg PO daily x 5d Levofloxacin 500mg PO daily x 10d If non-severe penicillin allergy, consider cefuroxime 250 BID x7d or cefixime 400 daily x10d If anaphylaxis, consider clarithromycin, doxycycline or TMP-SMX
409
treatment of chornic sinusitis
Oral glucocorticoids PLUS empiric oral antibiotics x 4w Prednisone 20mg PO BID x 5d, then 20mg daily x 5 days (total 10 days) Amoxicillin-clavulanate 875mg PO BID or Clindamycin 450 mg PO TID Topical glucocorticoid spray and intranasal saline irrigation or sprays
410
normal menstural bleeding in terms of frequency , days and blood loss
s regularly (every 24–38 days) for 4 to 8 days with blood loss of 5 to 80 ml
411
4 types of AUB
Heavy menstrual bleeding (most common AUB complaint) * Excessive blood loss that interferes with quality of life and daily function. * Can occur with other symptoms (e.g., menstrual pain). Prolonged menstrual bleeding * Menses lasts > 8 days. Frequent menstrual bleeding * Bleeding at intervals < 24 days apart. Irregular, non-menstrual bleeding * Intermenstrual—Bleeding (often light/short) between normal menstrual periods. * Post-coital—Bleeding after intercourse. * Premenstrual/postmenstrual spotting—Bleeding on a regular basis (≥ 1 days) before or after regular menses.
412
PALM COEIN
Polyps (cervical or endometrial) -Intermenstrual bleeding Ademonyosis -Endometrial glands and stroma present focally or globally in uterine musculature. Heavy or prolonged bleeding. Menstrual pain. Dense enlarged uterus. Leiomyoma (myoma or fibroids -Myomas or fibroids. Heavy or -prolonged bleeding. -Pelvic pain/pressure. -Enlarged uterus. Malignancy Malignancy of vagina, uterus, cervix. Variable bleeding patterns. Coagulopathy Inherited bleeding disorders, including von Willebrand disease. * Acquired coagulopathy. Heavy bleeding Ovarian dysfunction Polycystic ovary syndrome. * Thyroid diseases. * Ovarian follicle decline (perimenopause). Irregular bleeding. Heavy or prolonged bleeding. Endometrial -Pelvic inflammatory disease. * Endometritis. Iatrogenic Hormonal contraceptives. * Anticoagulants. * Antiepileptics. * Tricyclic and SSRI/SNRI antidepressants. * Antipsychotics. * Corticosteroid-related drugs. * Tamoxifen. * Herbs (ginseng, chasteberry, danshen, motherwort).* Not yet specified * Arteriovenous malformations. * Caesarean scar defects.
413
difference between anovulatory AUB and ovulatory AUB
Ovulatory AUB is typically regular and often accompanied by premenstrual symptoms and painful periods. * Anovulatory AUB is common near menopause with irregular, heavy, and/or prolonged bleeding. * In a cohort of 804 women (42–52 years), anovulation occurred in 20% of cycles, mostly in the early perimenopause. Anovulation was associated with both shortened and prolonged cycle intervals and bleeding duration. Short-cycle intervals occurred more frequently in early perimenopause.14 Anovulatory cycles were less likely to be associated with heavy menstrual bleeding than were ovulatory cycles. Anovulatory AUB is more likely than ovulatory AUB to be associated with endometrial hyperplasia and cancer
414
questions to ask to someone with AUB
bleeding, anemia sx, vaginal discharge, pelvic pain, galctorrhea, sexual and reproductive hx, systemic illness, presence of comorbidities, meds, family history
415
systemic illness that could cause AUB
hypothyroidism hyperprolactinemia coagulation disorders PCOS adrenal or hypothalamic disorders
416
range of thicknes sof normal endometrium in premenopausla woman
4 mm in follicular phase to 16 mm in luteal phase
417
initial investigation in AUB
Pap smear. * STI testing if there is a risk. * CBC for women with a history of heavy or prolonged bleeding . * Serum BHCG if there is a risk of pregnancy. * TSH—only if there are symptoms or findings that suggest thyroid disease [Low Evidence]. * Ferritin—there is no evidence that the addition of ferritin changes management if CBC is normal. Test only if there are symptoms of iron deficiency without anemia. * Coagulation tests—only for women with a history of heavy menstrual bleeding that began at menarche or a personal or family history of abnormal bleeding. · Endometrial biopsy (see Endometrial Biopsy section). other: blood type and screen if acute blood loss, consider prolactin if sx, vWF, fibrinogen, gono/chlam
418
name 6 meds causing AUB
Hormonal contraceptives. * Anticoagulants. * Antiepileptics. * Tricyclic and SSRI/SNRI antidepressants. * Antipsychotics. * Corticosteroid-related drugs. * Tamoxifen. * Herbs (ginseng, chasteberry, danshen, motherwort).*
419
when to do imaging in AUB and which imaging to choose
when the history or examination suggests structural causes for bleeding, conservative management has failed, or there is a higher risk of malignancy. TVUS is considered a firstline imaging test for AUB because it has adequate test performance and is relatively noninvasive.3 TVUS can help diagnose endometrial polyps, adenomyosis, leiomyomas, uterine anomalies, and endometrial thickening associated with hyperplasia and malignancy (see Box 1)..3 In some cases (particularly the detection of intrauterine pathology such as submucosal fibroids or polyps), saline infusion sonohysterography and diagnostic hysteroscopy are preferred due to better test performance and can be used as second-line tests.
420
when to consider endometrial biopsy
Are > 40 years of age. * Have high risk or findings suggesting malignancy -overall risk for endometrial cancer -risk of progression to cancer in women with hyperplasia (see risk factors) * Do not respond to medical treatment. * Have substantial intermenstrual bleeding (
421
indicators of difficult endometrial biopsy
1) previous Caesarean sections; 2) nulliparity; 3) structural issues (e.g., cervical stenosis, pelvic organ prolapse); or 4) anxiety with office procedures TVUS and/or gynecological referral may be offered in these cases.1
422
specificity and sensitivity for endometrial cancer
It has high specificity for endometrial cancer (almost 100%) but sensitivity is lower (~90%)
423
risk factors of endometrial cancer
obesity, diabetes, nulliparity, history of polycystic ovary syndrome, and family history of hereditary non-polyposis colorectal cancer Lynch Syndrome 40-60% endometrial CA
424
risk of hyperplasia to progress to endometrial cancer
* Atypical hyperplasia is associated with higher risk of progression to endometrial cancer. Up to 60% of patients will have co-existent endometrial cancer and ideally require definitive surgical management with hysterectomy and bilateral salpingo-oophorectomy. Medical management can be considered for patients wishing to preserve their fertility.26 * Hyperplasia without atypia has a much lower rate of progression (1–3%) and can be managed conservatively with progesterone or with watchful waiting, if the patient chooses, as spontaneous regression rates of over 75% have been reported.3,27,28 By comparison, progesterone treatment of any type appears to have higher regression rates (89–96%),28 although this data is derived from small observational studies. If watchful waiting is chosen, the SOGC recommends reassessment (with biopsy) every 3 to 6 months.26
425
how to reduce endometrial hyperplasia without atypia
Continuous oral or monthly injectable progestins or the LNG-IUS over a 6-month period. 9 Disease regression rates are the highest with the LNG-IUS (80–95%) and injectable progestins (> 90%) compared with about 70% for oral therapy.30 Endometrial biopsy (which can be performed with the IUD in place) should be performed every 3 to 6 months to monitor for disease progression and eventual resolution Obesity is associated with a lower rate of regression. * Persistent abnormal bleeding despite therapy, intolerance to therapy, inability to comply with surveillance, or failure of hyperplasia to regress after 6 to 12 months should prompt referral. * Following resolution of hyperplasia without atypia, the question of how often and how long to continue performing endometrial biopsies has not been directly addressed by research. The UK Royal College of Gynaecologists and Obstetricians guideline recommends performing endometrial biopsies every 6 months until 2 consecutive negative biopsies occur.28
426
how to manage uterine bleeding in non-acute/outpatient context, name 4 pharmalogical methods
Regular (cyclic) heavy menstrual bleeding: hormonal and non-hormonal treatments. * Irregular or prolonged bleeding: hormonal treatments, such as oral contraceptive pills or progestins, can help regulate cycles, but non-hormonal treatments can help to control any associated heavy bleeding. Note: Women with anemia should receive iron supplementation -Levonorgestrel Intrauterine Releasing System (LNG-IUS) (IUD) -> reduces ovarian and endometrial risk of cancer but does not increase risk of breast cancer e etonogestrel implant -reduces bleeding days but menstrual bleed can remain unpredictable -Combined Hormonal Contraception (CHC) -Oral Progestins: Treatment consists of medroxyprogesterone acetate, norethindrone, or micronized progesterone, -Injected Progestin 25. Depot medroxyprogesterone acetate (DMPA) is used to suppress ovulation and ovarian steroidogenesis, eventually leading to endometrial atrophy -Danazol 26. Danazol inhibits ovarian steroidogenesis and results in endometrial atrophy -Gonadotropin-Releasing Hormone (GnRH) Agonists 27. GnRH agonists (leuprolide, goserelin, nafarelin) stop ovarian steroidogenesis and lead to endometrial atrophy and amenorrhea within 3 to 4 weeks.3 However, long-term use leads to adverse effects associated with a hypoestrogenic state and should only be considered for women in whom other options are contraindicated Non-hormonal Medical Treatment -Nonsteroidal Anti-Inflammatory Steroids (NSAIDs) -Antifibrinolytics Tranexamic acid
427
when to consider surgery in AUB
y may be considered in women in whom 1) medical treatment has failed; 2) medical treatment is contraindicated or side effects are considered intolerable; 3) significant anemia is present; 4) uterine pathology (e.g., large uterine fibroids, endometrial hyperplasia with atypia, malignancy) is present; or 5) AUB has a severe impact on quality of life.3 Surgical options include hysteroscopic polypectomy, endometrial ablation, myomectomy, and hysterectomy. Uterine artery embolization is a radiological intervention that can be used to treat fibroids
428
when to refer AUB
Investigative tests show: * Malignancy, or atypical hyperplasia is present. * Hyperplasia without atypia, if this is the patient’s preference or the clinician is not comfortable managing. * No primary care practitioner is available to perform a required endometrial biopsy, or technical issues prevent the ability to perform a satisfactory biopsy. * AUB (including hyperplasia without atypia) fails to respond to medical treatment options or if GnRH agonists are being considered. * Patient wishes to explore surgical options (after being informed about or having trialled available medical treatments).
429
when does b HCG start to be positive
Serum positive 9d post-conception Urine positive 28d after LMP
430
how to treat acute vaginal bleed in non pregnant patient
Hypovolemia/Hemodynamic instability -blood type and screen, consider transfusion if necessary -if pregnant give rH immunoglobulin (winrho or rhogam ) Acute Non pregnant Conjugated equine estrogen 25mg IV q4-6h x24h Consider antiemetic due to side effects of nausea/vomiting Combined OCP TID x7d Medroxyprogesterone acetate 20mg TID x7d Tranexamic acid 1g PO/IV TID x5d Procedure (D&C, endometrial ablation, uterine artery embolization, hysterectomy) Treat underlying primary pathology Correct anemia (iron replacement) Rule out malignancy (if high risk)
431
First trimester vaginal bleed DDx
implantation bleed abnormal prenancy (ectopic, molar) Abortion (threatened, inevitable, incomplete, complete, missed, septic) Non-Obstetrical (Uterine, Cervical Vaginal Pathology)
432
P/E vaginal bleed in pregnancy T1
Vitals (r/o hemodynamic instability, fever) Abdominal exam (r/o surgical abdomen) Speculum Source of bleeding (Vagina/Cervical/Uterine) Cervical os (r/o cervical dilation) Bedside ultrasound (r/o free fluid, confirm IUP)
433
investigations vaginal bleed in pregnancy T1
CBC Blood type Serial b-hCG Rising b-hCG >35% over 48h consistent with viable IUP (but ectopic may also display rising hCG) hCG <35% over 48h suggest ectopic or abnormal IUP Abdominal Ultrasound IUP if b-hCG >6000 IU/L Transvaginal Ultrasound Gestational sac and yolk sac at 5w gestation Cardiac activity at 6w gestation IUP if b-hCG >1500IU/L Absence of IUP does not always ectopic (eg. early multiple gestation)
434
treatment of ectopic pregnancy -3 meds for excessive bleeding
-tranexemic acid1g IV over 10-20 mins -Misoprostol 800mcg SL/PO/PR/(avoid PV if excessive bleeding), then 400mcg q3h PRN -vasopressin injected on anterior lip of cervix
435
treatment of incomplete abortion
dilation and aspiration -prophylactic antibiotics Azithromycin 500mg PO x1 or Doxycycline 200mg PO x1
436
2nd and 3rd trimester vaginal bleed ddx
Bloody show (onset 72h prior to labor, PPROM) Placenta previa (20%) -Touching/covering internal os (low-lying is within 2cm) Placental abruption (30%) -Painful contractions, hypertonus tender uterus, vaginal bleeding may be concealed Uterine rupture (rare) -Suspect in shock, acute abdominal pain, change in station, abnormal FHR, vaginal bleeding Vasa previa (rare) -Suspect in painless bleeding with change in FHR
437
6 risk factors of placenta previa
previous placenta previa, previous C/S, uterine surgery, advanced age, multiparity, smoking/cocaine, multiple gestation, in vitro
438
placental abruption risk factors
Prior abruption, thrombophilia, iron deficiency, PROM, Hypertension, Overdistended uterus, maternal age/parity, smoking/cocaine, abdominal trauma, c/s
439
diagnosis of placental abruption
Clinical diagnosis, not well diagnosed on ultrasound Kleihauer-Betke test (fetal cells in maternal blood)
440
3 risk factors of uterine rupture
Risk: Uterine scar, hyperstimulation (IOL), multiparity
441
vasaprevia risk factors
Twins, placenta previa (consider TVUS screen at 32w), IVF
442
diagnosis of vasa previa
transvaginal color doppler ultrasound Apt test (positive = fetal blood, negative = maternal blood) - alkali denaturation test, also known as A or Apt test, is a medical test used to differentiate fetal or neonatal blood from maternal blood found in a newborn's stool or vomit, or from maternal vaginal blood Wright stain (nucleated RBC on smear)
443
P/E to do in 2-3rd T vaginal bleed
Vitals (r/o hemodynamic instability) Abdominal exam (including uterine tone/activity) Bedside ultrasound (r/o placenta previa) Sterile speculum Avoid digital cervical exam until placenta previa ruled out by ultrasound (also if possible prior to speculum)
444
investigation to do in vaginal bleed in 2-3 trimester + management
Type (Rh) and Crossmatch CBC Kleihauer-Betke if abruption Bedside clot test INR Fetal monitor bedside US management: Get help, oxygen, IVF (LOTS!), foley Massive transfusion protocol Follow Hb and Coag
445
ddx vaginitis sx
Infectious vaginal discharge Bacterial vaginosis (most common cause of vaginal discharge 30%) Candida vulvovaginitis Trichomonas vaginalis (STI) Cervicitis (Gono/Chlam) Non-infectious vaginal discharge Physiologic Atrophic vaginitis (scant discharge) Foreign body Non-infectious vulvovaginal pruritus without discharge Irritant or allergic contact dermatitis (latex, soaps, perfumes) Lichen planus Lichen sclerosus Vulvar cancer Psoriasis Colovaginal fistula
446
bacterial vaginosis dx
Clinical (Amsel's), require 3 of 4 1-Adherent and homogenous vaginal discharge (smoothly coats vaginal walls) 2-Vaginal pH >4.5 3-Clue cells on saline wet mount 4-Positive whiff-amine test -Fishy amine odour (before or) after addition of 10% KOH Other Gram stain vagina smear with Nugent scoring system (gold standard) Commercial test DNA probe (eg. Affirm VP III) Note: Vaginal culture positive for G. vaginalis is not diagnostic due to low specificity (cultured in >50% of healthy asymptomatic women)
447
treatment of BV
Oral: Metronidazole 500mg PO BID or Clindamycin 300mg PO BID x 7-14d -Preferred in pregnancy as they have been shown to reduce preterm birth Topical: Metronidazole gel 0.75% one applicator (5g) PV daily x 5d Longer courses if multiple recurrences Consider Metronidazole gel 0.75% one applicator (5g) PV daily x10d then two times per week for 3-6 months Alternatives: Vaginal metronidazole gel Oral or vaginal clindamycin cream
448
trichomonas vaginalis dx
Malodorous, green/yellow frothy discharge, pruritus, dyspareunia, petechiae - strawberry cervix Motile trichomonads on wet mount microscopy, NAAT PCR vaginal swabs, culture
449
trichomonas vaginalis tx
Metronidazole 2g PO x1 or Metronidazole 500mg PO BID x7d High-dose therapy may be needed for resistance Partner treatment enhances cure rates Abstain from intercourse until both patients treated and asymptomatic
450
candida vulvovaginitis dx
Erythema, edema of vulvovaginal tissues with thick, white clumped vaginal discharge, pH<4.5 Budding yeast and pseudohyphae on wet mount microscopy (negative in 50%) Consider culture in negative microscopy or persistent/recurrent symptoms after treatment
451
candida vulvovaginitis tx
Uncomplicated (Sporadic, infrequent ≤3/y, healthy, immunocompetent, nonpregannt) -Fluconazole 150mg PO x1 or topical intravaginal/suppository (clotrimazole, miconazole) -Topical antifungal azoles may require longer courses, but are first-line in pregnancy eg. Clotrimazole Combi Pak (Canesten 500mg vag tab/1% cream) or cream 10% x 1 Complicated -Fluconazole 150mg PO x3 doses 72h apart (day 1, 4, 7) -Consider maintenance with Fluconazole 150mg PO weekly x 6 months -Monitor for hepatotoxicity with long-term use and drug interactions Non-albicans species may not respond to fluconazole For C glabrata, consider vaginal boric acid capsules at compounding pharmacist (avoid in pregnancy) For C krusei, consider topical clotrimazole
452
prepubescent vaginal discharge ddx
Non-specific (most common) Causal factors Thin vaginal mucosa Moisture (tight clothing) Irritants (soap, bubble bath, prolonged contact with urine/feces) Bacterial: Group A beta-hemolytic strep H. influenzae E. coli Candida (unusual) Dermatologic: Lichen sclerosis Psoriasis Atopic dermatitis Foreign body:, usually toilet paper (recurrent symptoms or bloody discharge) Flush with sterile saline or refer to gyne for vaginoscopy Pinworms (nocturnal perineal pruritus) -Treat with mebendazole Systemic infection (varicella, measles, rubella, diphtheria, shigella) Rule out STIs and sexual abuse, especially in recurrent cases
453
investigation for prebubescent vaginal discharge
Introital (not vaginal) swab if profuse discharge -Bacterial culture (GAS, Haemophilus influenzae, Gardnerella) -if positive bacterial culture, can treat with antibiotics Candida unusual, consider if immunosuppression
454
management of vulvovaginal complaints in prepupertal girls
Treat underlying cause If non specific, Reassurance Hygiene (wipe front to back) Avoid causal factors (soaps, baby wipes, tight-fitting clothing, wet bathing suits, bubble bath, scented detergents) Warm soaks, gentle drying Sleep without underwear Gentle emollients and barrier creams
455
management of placenta previa
excessive or continuous vaginal bleeding: cesarean section regardless of gestational age. If bleeding subsides: expectant management if less than 36 weeks. -If at or greater than 36 weeks of gestation then cesarean delivery is recommended. Admission magnesium sulfate (before 32 weeks) for fetal neuroprotection and steroids for fetal lung maturity if indicated. Bedrest, reduced activity, and avoidance of intercourse are commonly mandated, though there is no clear benefit. If the vaginal bleeding subsides for more than 48 hours and the fetus is judged to be healthy, then inpatient monitoring is continued, or the patient may be discharged for outpatient management. Inpatient vs. outpatient management depends on the stability of the patient, the number of episodes of bleeding, proximity to the hospital, as well as compliance.
456
acute cough, within 3 weeks DDX (5)
URTI post nasal drip COPD exacerbation asthma PNA, Sinusitis acute bronchitis
457
chronic cough ddx
chronic bronchitis post nasal drip post nasal drip post infection cough (hyper responsiveness gerd foreign body primary or secondary tumor smoker's cough meds (ACEI, betablocker (asthma exacerbation)
458
cough ddx with high mortality
PE pneumothorax cancer TB, HIV sarcoidosis pertussis
459
name 3 RX that are cough suppressant
codeine, diphendydramine dextromethorphan chlophedianol guaifenestin for wet cough (expectorant) gabapentine can be tried for chronic cough
460
redflags sx of cough
hemoptysis, dyspnes, weight loss, TB/HIV exposure, decrased SP)2, increased RR, exposure to toxins
461
asthma PFT diagnosis
FEV/FVC less than 0.8-0.9 and increace of FEV over 12 % or increase of PEF more than 20 % with bronchodilator
462
Name 4 signs of pna on exam
egophony, dullnes to percussion, decreased air entry, crackles
463
acute cough in children
URTI pneumonia croup pertussis foreign object asthma gerd ro bacterial tracheitis, pe, ptx, cancer, TB, pertussis, foreign body, PNA
464
chronic chough more than 8 weeks ddx in children
chronic bronchitis post nasal drip post infection cough GERD Bronchiectasis/Cystic fibrosis (wet productive cough, weight loss)
465
when to give antibiotics for acute bronchitis
cough more than 3 weeks, more than 75 yo, clarithromycine, azithromycine, doxycycline
466
post nasal drip/ allergic rhinitis tx
nasal corticosteroids allergen avoidance second generation antihistamines combination corticosteroids/antihistamine inhaler or cromolyn eye drops if non allergic rhiniris: -first generation antihistamine plus decongestiant (care in hypertension), glaucoma -sanal ipratropium bromide
467
management of cough sensitivity syndrom (idiopathic refractory cough)
Speech pathology treatment Neuromodulating medication Gabapentin (300-1800mg daily x 10w), Pregabalin 300mg PO daily x4w CT scan if suspect lung cancer, bronchiectasis or ILD Referral to specialty
468
Ayesha, a 9 year old girl, presents in your office with a cold and cough for the last ten days. It started with a runny nose, headache and mild fever for 2 days and has progressed to a dry cough with wheeze over the last four days. The cough is worse at night. She has a history of asthma diagnosed first at age 6. She takes salbutamol by metered dose inhaler intermittently. She has never been hospitalized for asthma. Her father had asthma as a child. What further history about her asthma should you elicit? Name FOUR items.
Acceptable answers: Is she symptomatic when she is not sick? Can she identify triggers? Compliance: How often does she take her meds? Inhaler technique/Using a spacer? Co-morbidity: Does she have allergies? Co-morbidity: Does she have rash/eczema?
469
Name FIVE features on history and/or investigations that would indicate a person’s asthma is well controlled? 5 points
Daytime symptoms < 4 days/week No nighttime symptoms No limitation to physical activities Mild infrequent exacerbations No school absences No need for beta agonists FEV1 or PEF > than 90% of personal best PEF diurnal variation less10-15%
470
indicators of persistent asthma? Name THREE
Parental history of asthma, Asthma diagnosed after age 3 Likely allergic rhinitis Persistence/recurrence of symptoms
471
what non-pharmacologic management items are indicated in child with asthma? Name SIX items.
Use of aerochamber if metered dose Education for child/parent Use of patient symptom diary Regular assessment of peak expiratory flow (PEF) Pulmonary function testing Allergy testing Environmental allergen/irritant control Written action plan
472
A 9 yo patient on ventolin and flovent returns after four weeks of daily medication. Her mother reports that in spite of good compliance and environmental control, she is improved but still having night cough and using salbutamol each night. What changes or additions to pharmacologic therapy would you consider? Name THREE.
Leukotriene receptor antagonists Long acting beta agonists Increasing inhaled corticosteroid dose Medium-dose inhaled corticosteroid + long-acting beta agonist combination (recommend do not abbreviate)
473
diagnosis of asthma
typical clinical features: -wheeze, sob, chest thightness and cough -variable expiratory airflow limitation Reduced FEV1/FVC (<0.75-0.8 in adults and <0.9 for children) AND variable expiratory airflow limitation: Post-bronchodilator reversiblity increase in FEV1 >12% (minimum of 200mL in adults) Excessive variability in twice-daily (diurnal) PEF over 2 weeks (adults >10%, children >13% daily diurnal variability) Significant increase in lung function after 4 weeks of anti-inflammatory treatment (adults FEV1 >12% and >200mL increase from baseline) Positive exercise challenge test (adults decrease FEV1 >10% and >200mL or in children decrease FEV1>12% predicted or PEF >15%) Positive bronchial challenge test/methacholine (Fall FEV1≥20% or ≥15% with standard hyperventilation, hypertonic saline or mannitol challenge) Excessive variation in lung function between visits *less reliable (FEV1>12% and 200mL in adults)
474
triggers of asthma
exercise, laughter, allergens, cold air, viral infection, occupational hazards
475
asthma ddx
GERD, post nasal drip, chronic sinusitis, ace inhibitor induced cough,eosinophilic bronchitis, CHF in elerly, COPD, TB, aids/HIV, parasitic or fungal lung disease
476
comorbidities of asthma
rhinitis, chronic rhinosinusitis, GERD, obesity, OSA, depression, anxiety
477
determinants that asthma is well controlled
in the pst 4 weeks: -daytime sx less than twice per week -no night waking due to asthma -saba reliever needed no more than 2 x per week -no activity limitation due to asthma
478
modifiable asthma exacerbation risk factors
-SABA over use -inadequate ICS -comorbidities like obesity, chronic rhinosinusitis, GERD, food allergy, anxiety, depression -smoking, vapijg, air pollution, allergen, major socioeconomic problems, lpw lung function, high blood eosinophils
479
how often to do PFT for asthma
at diagnosis, 3-6 months after starting tx and periodically q 1-2 years
480
in adults with asthma, what is the first line of treatment + 5 general management points
GINA recommends adding an ICS-formeterol (eg. Symbicort) even in mild intermittent asthma in 12+ year old, as adding any ICS significantly reduces the risk of severe exacerbations ICS formoteral as needed (preferred) -ICS + LABA PRN (reliever) in 12+ years old Symbicort Turbuhaler or regular low dose ICS + as needed SABA -like Flovent HFA (fluticasone) 50, 125, 250mcg 1 inh BID -Pulmicort Turbuhaler (budesonide) 100, 200, 400mcg 1 inh BID -Ciclesonide (Alvesco) 400 mcg once daily DO not treat with SABA without ICS management: decrease allergens and modificable risk factors, comorbidities asthma information inhaler skills adherence written asthma action plan self monitoring of sx and or peak flow regular med review PFT for dx
481
asthma second line treatment if ICS and LABA PRN or ICS + SABA PRN not enough
ICS + LABA maintenance and PRN in 12+ years old Symbicort Turbuhaler (budesonide/formoterol) Refer for add-on treatment (LAMA Tiotropium, anti-IgE, anti-IL5, oral steroids, Bronchial thermoplasty, SC/SLIT) LTRA are less effective than ICS Consider if unable/unwilling to use ICS or in concomitant allergic rhinitis Singulair (Montelukast) 5, 10mg 1 tab PO PRN In <5yo, use MDI with spacer and face mask or nebulizer, and dose-adjust
482
recommendations for initial controller therapy
If symptoms <2/month and no risk factors -Consider no controller If symptoms >2/month or risk factors -Consider Low-dose ICS If symptoms >2/week -Low-dose ICS Asthma most days or waking due to asthma ≥1/week -Medium/high-dose ICS or Low dose ICS/LABA Severely uncontrolled asthma or acute exacerbation -Short course oral corticosteroids AND High-dose ICS or Moderate-dose ICS/LABA
483
when to FU pts with asthma
Ideally 1-3 months after starting treatment, and q3-12 months after Step-up vs. Step-down
484
when to refer patient for asthma
difficult confirming dx occupational asthma uncontrolled asthma risk factors for asthma related death (ICU, anaphylaxis or confirmed food allergy)
485
give example of asthma action plan
Early intervention in worsening asthma is key Increase reliever frequency Increase usual controller Double ICS or Quadruple maintenance ICS/formoterol (max formoterol 72mcg/day) Severe exacerbation (PEF <60%) or not improving after 48h Oral corticosteroids and contact doctor Prednisolone 1mg/kg/day (40-50mg)/day
486
asthma exacerbation inER
O2 target 93095% SABA MDI with spacer 4-8 puffs or 5 mg nebulizer q 20 min x 3 early oral corticosteroids ipratropium bromide (atrovent) consider MgSO4 2 g IV over 20 min transfer to acute care facility
487
asthma patient in acute setting severity level
Mild-moderate Talks in phrases, not agitated, Pulse 100-120, O2>90% Severe Talks in words, agitated, RR>30/min, Accessory muscle use, Pulse >120bpm, O2 <90%
488
asthma patient in acute setting DDX / comorbidities to not miss
CHF, COPD
489
general skin care for eczema
Eliminate exacerbating factors Excessive bathing (without subsequent moisturization) Low humidity environment Overheating/hot water exposure Avoid potential allergens and irritants Exposure to solvents/detergents Avoid fragrant/perfumed topic agent Avoid coarse fiber clothing (wool/synthetic) Emotional stress/anxiety Xerosis (dry skin) Treat skin infections (S. aureus, herpes simplex) Sunscreen/protection Hydration/Emollients multiple times per day 💡 Occlusiveness of topical preparations (from most to least): ointments (use for dry lesions) > creams (use for wet lesions) > lotions (use for weeping/intertriginous lesions)
490
Stevens-Johnson syndrome (<10% skin involved) / Toxic epidermal necrolysis (>30% skin involved) symptoms
Prodromal flu-like illness: Fever >39C, sore throat, rhinorrhea, cough, aches Sudden onset tender/painful skin rash on face/limbs, 90% with involvement of mucous membranes (mouth, eyes, genital) Tender red/purple macules, diffuse erythema, targetoid lesions, bullae and/or vesicles (may have positive Nikolsky)
491
treatment of stevens johnson or toxic epidermal necrolysis
stop causative drug (Sulfas, Alloprurinol, Tetracyclines, anticonvultivants, NSAIds Treat infections (eg. Mycoplasma pneumoniae) Admission to ICU IV fluid resuscitation and wound management
492
Necrotizing soft tissue infections (cellulitis, fasciitis, myositis, gas gangrene) presentation
Diffuse erythema, swelling, warmth, shiny, exquisite tenderness Late findings include crepitus, bullae, skin necrosis, loss of sensation
493
Necrotizing soft tissue infections (cellulitis, fasciitis, myositis, gas gangrene) labs
↑ WBC, ↑ CRP/ESR, ↑ CK, subcutaneous air on XR/CT/MRI
494
Necrotizing soft tissue infections (cellulitis, fasciitis, myositis, gas gangrene) treatment
ICU admission plus aggressive surgical exploration and debridement and broad-spectrum antibiotics: e.g., Tazo/Clinda/Vanco IV
495
Meningococcal infection rash presentation
Can present with abnormal skin color pallor, mottling Petechial rash involving trunk, lower body, mucous membranes (oral and ocular), may have purpura, ecchymotic lesions
496
chemical and non chemical burns management
When in doubt, consult Poison Control for additional guidance Fluid Resuscitation for burns >15% BSA in children and >20% BSA in adults Modified Brooke/Parkland Formula 2-4mL x %BSA x kg Ringer's Lactate, 1/2 in first 8 hours, 1/2 in next 16 hours Wound management Keep moist Apply antibiotic ointment to non-adherent dressing (Adaptic) then apply to wound Pain control Ensure tetanus vaccine status up-to-date Follow-up at <72h, to re-assess burn to better characterize partial vs. full thickness Refer to burn center PRN
497
Diagnosis and treatment melanoma
Diagnosis and treatment: full-thickness excisional biopsy with 0.5-2cm safety margin (according to Breslow thickness) Prognosis highly dependent on Breslow thickness, 5-year survival drops with depth > 1-2 mm
498
squamous cell carcinoma treatment
Treatment: Surgical excision + biopsy (e.g., punch biopsy, Mohs micrographic)
499
actinic keratosis treatment
Treat local AK with cryotherapy (eg. two freeze thaw cycles of 5s) Treat widespread AK with fluorouracil 5% cream BID x 2-6 weeks
500
types of pemphigus and compications
Refers to a group of life-threatening autoimmune blistering and erosive diseases affecting the skin and mucosa ( Complications include infection, fluid loss, electrolyte disturbances Types: Vulgaris (most common; 70% of all pemphigus), Foliaceus, IgA, Paraneoplastic
501
treatment of phemphigus
Systemic steroids (1-2mg/kg prednisone daily or 0.5-1mg/kg in combination with rituximab) Azathioprine or mycophenolate mofetil are often used to attempt to reduce steroids Consider adjunctive high potency topical steroid (e.g., clobetasol propionate) for larger erosions Cover erosions with antibiotic ointment or a bland emollient (eg, petroleum jelly) +/- non-adhesive wound dressings
502
systemic skin disease ddx
granulomatosis with polyangiitis (wegener's) systemic lupus erythematosus dermatitis herpetiformis psoriasis kaposi's sarcoma in HIV
503
treatment of scabies
Treatment: Topical permethrin 5% cream applied to the whole body from the neck to the soles of the feet, including areas under the fingernails and toenails (plus scalp in infants & young children) and washed off after eight hours. Can be repeated 1 week later if necessary. Can manage pruritus with oral antihistamines or topical corticosteroids if severe All textiles, bedding, clothing should be washed and dried at hottest temperature Strongly consider prophylactic treatment for close contacts (even if asymptomatic as incubation period can be ~1 month) Watch for superficial bacterial infection and treat accordingly with oral antibiotics
504
impetigo treatment
Topical mupirocin 2% ointment (Bactroban) TID x 5 days Can consider topical fusidic acid (although some resistance)
505
acne DDx
Drug-induced acne Tropical acne - Extreme heat Acne aestivalis (Mallorca acne) - Sun exposure Rosacea - Late age onset, erythema, talengiectasia, papules, pustules, no comedones Periorificial dermatitis - Around mouth, nose or eyes sparing vermilion border Pseudo/Folliculitis, no comedones Keratosis pilaris - Follicular prominence and roughness (usually on arms, but may resemble acne on cheeks) Favre-Racouchot syndrome - Comedones on cheek due to sun damage
506
treatment of acne depending on severity (comedomal, mild-moderate papulopustular, severe_
Comedonal Topical retinoids gel/cream (Tretinoin 0.025%, Adapalene 0.1%, Tazarotene 0.1%) Benzoyl peroxide (BPO) 2.5% or 5% gel or Azelaic acid (AA) 20% cream (possible better tolerability than BPO) Mild-moderate papulopustular Topical Retinoid + BPO or Topical Abx + BPO Adapalene 0.1% and BPO 2.5% (Tactupump) Clindamycin 1% and BPO 5% Treat with all three topicals (Retinoid, BPO, Abx) if no response x 3 months Combined OCP or systemic antibiotics High estrogen (ethinyl estradiol) concentration associated with decrease in inflammatory lesions Tetracycline (eg. doxycycline 100mg PO BID or daily x 3-4 months) Risk in pregnancy or <9yo (teeth discoloration/bone growth) Side effects: GI, photosensitivity Severe papulopustular Oral isotretinoin (pregnancy-prevention measures due to teratogenicity) 0.5-1mg/kg daily divided BID for 15-20 weeks or 0.5mg/kg daily divided BID for 1 month, then 1mg/kg/day divided BID, until a cumulative dose of 120-150 mg/kg Consider lower dose 20mg every alternate day or 0.25-0.4mg/kg/day for moderate Consider monitoring labs Fasting lipid and LFTs at 4 weeks and 8 weeks, and then stop if normal Other Oral zinc has been shown to have effect against inflammatory lesions Diet: Some evidence for low glycemic index diet, lack of evidence concerning dairy consumption Chemical peels have minimal evidence but are safe and inexpensive
507
what to monitor when giving oral isotretinoin
fasting lipid LFTs
508
A 17 year-old male comes to the office complaining of moderate amount of papules and pustules on the face and the upper back, ongoing for the last two years and getting worse. You diagnose him with acne. He would like his acne to improve in time for his high school graduation. Name FOUR different classes of medications that can be used for the treatment of acne in this patient.
antibiotics benzoyl peroxides retinoids salicylates intralesional steroids
509
Name ONE combination topical medication that you could prescribe for mild-mod papulopustular acne
clindamycin/benzoyl peroxide erythromycin/benzoyl peroxide erythromycin/Vitamin A adapalene/benzoyl peroxide
510
Name ONE oral antibiotic for acne
minocycline, doxycycline, tetracycline, erythromycin, trimethoprim duration of therapy: 6-12 weeks
511
At his follow-up visit, he patient reports little change, and describes frequent outbreaks of deep cystic lesions. You notice scarring. You recommend isotretinoin. What blood tests would you order prior to prescribing it? List THREE
triglycerides white blood cell count and differential ALT/alanine aminotransferase
512
Other than laboratory abnormalities and nausea and vomiting, what side effects of isotretinoin are any patients taking it at risk for? Name FIVE.
dry skin, dry mouth, dry mucous membranes (any one of these three) sun sensitivity teratogenicity/birth defects impaired night vision joint pain epistaxis cheilitis headaches psychosis abdominal pain/hepatitis pancreatitis initial exacerbation of acne low mood/suicidality
513
associated health conditions to psoriasis
crohn's disease ulcerative colitis inflammatory arthritis (psoriatic arthritis) and spondyloarthropathy uveitis metabolic syndrome
514
treatment of psoriasis
Dovobet (Calcipotriol 50 mcg/g and betamethasone 0.5 mg/g) ointment apply once daily x 4 weeks High-potency topical corticosteroids (eg. Clobetasol 0.05% ointment) with ONE of the following: Vitamin D analogs (Calcitriol, Calcipotriol) Retinoids (Tazarotene 0.1% Gel) UVB phototherapy Alternatives Tar / Anthralin (15% LCD solution) Severe may need phototherapy, systemic therapy (methotrexate, retinoid), biologic immune modifying agents (infliximab) Psoriatic arthritis: NSAID, DMARD (MTX), biologics (TNF inhibitor) Facial/intriginous/genital psoriasis Low-potency Hydrocortisone 1% cream or ointment often sufficient Calcineurin inhibitors may be used (Tacrolimus 0.1% ointment, Pimecrolimus 1% cream)
515
scalp psoriasis tx
Consider topical treatments above in different forms, eg. Clobetasol shampoo, betamethasone valerate foam or Dovobet gel.
516
P/E and description of a rash (SCALDA)
Size/shape/texture: well vs. poorly demarcated, targetoid, verrucous, umbilicated Colour: erythematous, violaceous, hyper/hypopigmented, depigmented, jaundiced Arrangement: solitary, grouped, linear, reticular/mottled, dermatomal Lesion type (primary/secondary): Primary (< 1cm/>1cm) = macule/patch, papule/plaque, nodule/tumour, vesicle/bulla Secondary = lichenification, maceration, erosion/ulceration Distribution Always look at nails (e.g, pitting, oil spots), hair (e.g., scalp plaques, hair thinning), mucous membranes (e.g., white lacy patches, open sores), intertriginous areas
517
important elements of HPI of rash
Previous episodes Previous treatment Contact/exposure/travel (e.g., infectious, new detergents/fabric softeners/lotions/deodorants, metal belt buckles/glasses, different humidity/climates) Medication/drugs (e.g., antibiotics [penicillin, sulfonamides], corticosteroids, NSAIDs, anti-epileptics) PMH/family history Associated symptoms (pain, pruritus, bleeding, exudate, blistering/ulcerations, fever, aches) Occupational history Impact on patient's life (function, sleep, mood, social life)
518
types of rosacea
Erythemotelangiectatic (flushing/redness, telangiectasias) Papulopustular Phymatous (fibrotic skin thickening) Ocular (blepharitis, conjunctivitis)
519
non pharmalogical treatment of rosacea
Behavioural changes Avoid triggers Extreme temperature Sunlight Spicy food Alcohol Exercise Acute psychological stressor Medication Menopausal hot flashes frequen skin moisturization gentle skin cleansing sun protection
520
ddx of rosacea
Unlike acne, no comedones in papulopustular rosacea Unlike systemic lupus, no cheilitis in erythematotelangiectic rosacea Perioral dermatitis Seborrheic dermatitis and rosacea may co-exist
521
pharmalogical tx of papulopustular rosacea
First-line Metronidazole 0.75-1% gel or cream daily Note: There is no clinical difference between 0.75% and 1% metronidazole, but 0.75% may cost more Azelaic Acid (Finacea) 15% gel BID Ivermectin (Rosiver) 1% cream daily If Moderate-Severe Add oral antibiotics to topical above Doxycycline 50-100mg PO BID or 40mg modified-release daily or tetracycline or isoretinoin Taper after 2-3 months and maintain on topical laser and intense pulsed light or vascular laser
522
treatment of erythemainrosacea
First-line Brimonidine (Onreltea) 0.33% gel Metronidazole 0.75-1% gel or cream daily Azelaic Acid (Finacea) 15% gel BID Second-line Alternative first-line or combination of first-line Intense pulsed light device or vascular laser
523
treatment of phyma in rosacea
topical retinoid or PO doxycycline or PO tetracycline, irotretinoin severe: surgical/ electrosurgical /laser ablation
524
5 stages of changes and tips for smoking cessation
Precontemplation -not yet considering change or unwilling/unable to change -Increase awareness of risks in nonjudgmental manner (avoid resistance) Contemplation -sees possibility of change but is ambivalent or uncertain -Discuss pros/cons of quitting (understand ambivalence) Preparation -committed to changing, still considering what to do -Offer practical advice and anticipate diffiiculties -identify appropriate change strategies Action -taking steps towards change -primary task to help implement change strategies and eliminate relapses -Support, reward, prevent relapse -Review action plan maintenance -has achieved the goals and is working to maintain change -task: develop new skills for maintaining
525
benefits of smoking cessation
Leading cause of preventable death (6.5-9y premature death) Financial gains (1ppy = $3650 per year) Somebody who smokes a pack a day will smoke through almost $1 million after forty years (if they had invested that money) Reduce risks of erectile dysfunction 8h - Carbon monoxide eliminated 24h - Risk of heart attack begins to drop 2w - Improved in lung function, walking easier 1mo - Decreased coughing, nasal congestion, shortness of breath 1y - Risk of coronary heart disease halved 5y - Risk of stroke same level as non-smokers 10y - Risk of mouth, throat and esophageal cancer halved, death rate from lung cancer also halved 15y - Risk of heart attacks similar to that of non-smokers
526
smoking cessation non-pharmalogical ways
Tell family, friends, coworkers about quitting for support Remove tobacco products from environment Exercise program Alternative oral behaviours (gum, lozenges) Obstacles (withdrawal, weight gain, triggers) Support groups (eg. 1-800-QUIT-NOW) Combining counselling and smoking cessation medication is more effective than either alone Counselling by a variety or combination of delivery formats (self-help, individual, group, helpline, web-based) Multiple counselling sessions Practical counselling on problem solving skills or skill training Regular follow-up to assess response, provide support and modify treatment as necessary Peak withdrawal at 2-3d Highest relapse at 2-3w Refer patients/clients to relevant resources where appropriate
527
3 pharmacotherapy for smoking cessation
varenicline -Varenicline begin 1w before quit date 0.5mg/d x3d then 0.5mg BID x3d then 1mg BID >12 weeks (evidence up to 12 months) [OR 2.89] Nicotine -gum, patch, inhaler, lozenge bupropion nortriptyline
528
side effects of varenicline
AE: Insomnia, headache, abnormal dreams, GI upset
529
bupropion side effects and C-I
AE: Insomnia, headache, dizziness, tachycardia, xerostomia, weight loss Avoid in seizure disorder, eating disorder, alcohol withdrawal
530
name 3 typical and 3 atypical bacterias for pneumonia
Typical: Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis Atypical: Mycoplasma pneumoniae, Chlamydophila pneumoniae, Legionella spp
531
definition of community acquired pneumonia
No hospitalization within 14d of onset OR <4d prior to onset
532
diagnosis of PNA
Two symptoms (fever, rigors, cough change, pleuritic chest pain, SOB), AND auscultatory findings (localized crackles, bronchial breath sounds), AND X-ray opacity
533
investigations of PNA
chest XR (PA and lateral) Labs: CRP pro calcitoin leukocytosis if severe: -urine legionella/pneumococcal Ag sputum gram stain and culture (r/o MRSA, P aeruginosa) -legionella culture Nasopharyngeal swat viral PCR (influenza, coronavirus)
534
how to determine if a patient needs hospitalization for pneumonia
CURB-65: -confusion -BUN> 9 mmol/L urea -RR over 30 -systolic BP under 90 -age >65 PSI: Sex M (0 points) F (-10 points) Demographic factors Age (1 point for each year) Nursing home resident (10 points) Comorbid illnesses Neoplastic disease (30 points) Liver disease (20 points) Congestive heart failure (10 points) Cerebrovascular disease (10 points) Renal disease (10 points) Physical examination findings Altered mental status (20 points) Respiratory rate ≥30/minute (20 points) Systolic blood pressure <90 mmHg (20 points) Temperature <35 degrees C or ≥40 degrees C (15 points) Pulse ≥125/minute (10 points) Laboratory and radiographic findings Arterial pH <7.35 (30 points) Blood urea nitrogen ≥30 mg/dL (11 mmol/L) (20 points) Sodium <130 mEq/L (20 points) Glucose ≥250 mg/dL (14 mmol/L) (10 points) Hematocrit <30 percent (10 points) Partial pressure of arterial oxygen <60 mmHg or oxygen saturation <90% (10 points) Pleural effusion (10 points)
535
pneumonia outpatient treatment in adults
If no antibiotics in past three months Clarithromycin 500mg PO BID x7d or Azithromycin 500mg PO daily x1 day then 250mg PO daily x 4 days or Doxycycline 100mg PO BID x 7 days Promote less resistance to macrolides by using clarithromycin Amoxicillin 1g PO TID x7d (less emphasis on covering atypicals) Pediatrics - Amoxicillin 90 mg/kg/d PO divided TID x7-10d (consider atypical coverage in children ≥5 years old)
536
in adults, pna tx If comorbidities (chronic cardiac or pulmonary, hepatic or renal issues, immunosuppression, chimio, db) or recent antibiotics
Amoxicillin OR amoxicilline/clavulanate with atypical coverage (Clarithromycin or Azithromycin or Doxycycline) Second-line (after failed 72-96h) -Levofloxacin 750mg PO daily x 5 days or Moxifloxacin 400mg PO daily x 7d
537
pna tx in adults if hospitalized
Cefotaxime 1-2g IV q8h or Ceftriaxone 1-2g IV q12-24h AND Levofloxacin or Moxifloxacin or Azithromycin Note: Ceftriaxone superior to Pip/Tazo (as 15% Strep pneumo resistant to Pip/Tazo in community-acquired pneumonia)
538
risk factors and sx of pna with legionella
Risk factors: Elderly, immunosuppression, smoker, lung disease T>39ºC Neurological (Confusion/Weakness/Gen det) GI (diarrhea) Electrolytes (Hyponatremia. hypophosphatemia, renal/hepatic dysfunction, thrombocytopenia, leukococytosis) Hematuria Hotel, cruise ships, residence (water reservoir contamination)
539
when to repeat cxr in pna fu
Repeat CXR in 6w (r/o underlying disease) if >50yo or immunosuppressed, lung disease, alcohol, smoker, >5% weight loss in past month Extensive/necrotizing pneumonia
540
prevention of pna
smoking cessation Hygiene (handwashing) Vaccination Influenza Pneumococcal >65yo or comorbidity Prevents invasive pneumococcal disease (bacteremia)
541
pna treatment if allx to pnc in adults
If non-anaphylactic penicillin allergy -Cefuroxime or Cefadroxil + atypical coverage (consider monitor in office 1-2h) -or cefprozil Anaphylactic penicillin allergy -Levofloxacin or Moxifloxacin as below
542
indications d'hospitalisation pour pneumonie chez enfants
* Âge < 3 à 6 mois; * Enfant toxique ou léthargique; * Détresse respiratoire importante; * Besoin en oxygène; * Maladie cardiaque ou pulmonaire sousjacente; * Immunodéficience; * Pneumonie compliquée (épanchement, empyème, abcès, etc.); * Contexte épidémiologique d’un pathogène virulent/ multirésistant; * Déshydratation, incapacité de s’alimenter; * Vomissements; * Non-réponse à une antibiothérapie orale; * Faible participation parentale permettant d’assurer l’adhésion au traitement.
543
treatment of pna in children
amoxicilline 90 mg /kg/TID x 7-10 days if usage of antibiotics in past 30 days; amoxicilline and clavulanate if suspicion of atypical PNA: clarythromycine or azithromycine
544
community acquired pneumonia in children tx if allx to PNC
cefuroxime cefprozil if anaphylactic: clarithromycine azithromycine
545
sx of flu
Apparition soudaine de fièvre1 (≥ 38,5°C) OU de toux (sèche), ET d’au moins l’un des symptômes suivants: „ Mal de gorge „ Arthralgie „ Myalgie „ Prostration2 ou fatigue extrême Chez les adultes : „ Maux de tête Chez les enfants : „ Symptômes gastro-intestinaux (ex. : nausées, vomissements, diarrhée et douleurs abdominales) Chez les personnes âgées : „ Toux parfois tardive „ Fièvre gériatrique3 ou parfois absente
546
severity of flu
PEU SÉVÈRE Symptômes typiques parfois accompagnés de diarrhée et de vomissements MODÉRÉMENT SÉVÈRE Symptômes typiques ET signes ou symptômes plus sévères : „ Douleurs thoraciques „ Hypoxie légère „ Insuffisance cardiopulmonaire (ex. : hypotension artérielle) „ Atteinte légère du système nerveux central (ex. : confusion, altération de l’état mental) „ Déshydratation grave „ Exacerbation des maladies chroniques existantes SÉVÈRE Signes et symptômes associés aux conditions suivantes : „ Insuffisance respiratoire nécessitant une oxygénothérapie „ Anomalies du système nerveux central (ex. : encéphalite, encéphalopathie) „ Complications liées à une hypotension artérielle (ex. : choc, défaillance d’organe) „ Myocardite ou rhabdomyolyse „ Infection bactérienne secondaire invasive (ex. : fièvre élevée persistante et autres symptômes audelà de 3 jours)
547
risk of complications of influenza and high risks of complications
2 yo and below 75 yo and above resident from elderly residence chronic disease (heart/lung/renal/hepatic/hamatologic, immunosuppressed, obesity) children with chronic ASA treatment pregnant women in T2-3 high risks of complications: „ Personnes immunosupprimées (ex. : receveurs d’une allogreffe ou d’une greffe d’organe solide récente, personnes sous chimiothérapie) „ Personnes avec pneumopathies sévères „ Personnes avec comorbidités multiples
548
indications to treat influenza with oseltamivir or zanamivir
Peu sévère „ Enfant âgé d’un an et plus1 avec un facteur de risque de complications de l’influenza (en plus de l’âge) „ Personne âgée de moins de 75 ans avec un facteur de risque de complications de l’influenza „ Personne qui vit sous le même toit qu’une personne à risque de complications de l’influenza ou qui prend soin d’elle à domicile „ Personne âgée de 75 ans et plus „ Personne à haut risque de complications de l’influenza „ >>Amorcer l’antiviral si les symptômes sont apparus depuis 48 heures ou moins si moderement ou severe: traiter même si les symptômes sont apparus depuis plus de 48 heures treat all regardless of severity if: „ Résident d’un centre d’hébergement et de soins de longue durée, d’une résidence pour aînés ou d’une ressource intermédiaire, qu’ils soient publics ou privés „ Personne hospitalisée avec influenza
549
diagnosis of COPD
Spirometry FEV1/FVC <0.70 post-bronchodilator Grade Mild = FEV1>80% predicted Moderate = 50-80% Severe = 30 to <50% Very Severe <30%
550
risks factors for having COPD
Smoking, air pollution, occupational exposures (dusts, chemical agents), genetic factors (alpha-1 antitrypsin), age and female, abnormal lung development, chronic bronchitis, childhood infections
551
who to screen for alpha-1 antitrypsin deficiency
WHO recommends all patients with COPD should be screened once, especially if high prevalence area Consider if early onset COPD, family history of AATD, <20py smoker, asthma poorly responsive to therapy Classic <45yo with panlobular basal emphysema
552
non pharmalogical treatment of COPD
Smoking cessation, exercise Yearly influenza vaccine and pneumococcal vaccine (>65yo or risk) Pulmonary rehabilitation for exercise-limited patients or FEV1<50% Oxygen therapy for severe resting chronic hypoxemia (PaO2 <55mmHg, SaO2<88%) Non-invasive ventilation (CPAP) for OSA or chronic hypercapnia with history hospitalization Bronchoscopic and surgical treatments for advanced COPD
553
prevention of COPD
Lifestyle Stop smoking Exercise Vaccine Influenza Pneumococcal 23-valent Meds LA bronchodilators/anticholinergics Teach inhaler technique Action plan When to go to Emergency Department Refer Pulmonary Rehab Resp therapy/Respirology/Specialty clinic Smoking cessation group
554
treatment of COPDe
Non-invasive ventilation for respiratory failure Mild SABA (eg. 4-8 puffs inhaled q20mins up to 4h then q1-4h PRN) +/- LAMA Moderate Antibiotics and corticosteroids (Pred 40mg PO daily x5d) indicated if increased sputum purulence with one of: sputum volume or dyspnea (or if requires ventilation) If simple COPDE, Amoxicillin 500mg TID x 7d, or clarithromycin 500 BID x 7d, or azithromycin, or cefuroxime, or doxycycline, or TMP-SMX If complicated (FEV1<50%, >3 COPDE/y, comorbidity, oxygen needs, chronic inhaled steroid, recent antibiotic use) Moxifloxacin 400mg PO daily x 5d, Levofloxacin 500mg PO daily x 7, or Clavulin if pseudomonas risk: ciprofloxacin Consider -Procalcitonin -Sputum cultures if recurrent or severe, r/o pseudomonas Severe: Magnesium sulfate 2g IV over 20 minutes may reduce hospitalizations (NNTB = 7) Hospitalization/ER visit
555
pharmalogical tx of COPD
Bronchodilators Short-acting bronchodilator (beta-agonist and/or anticholinergic) SABA Salbutamol (Ventolin) 100 mcg/actuation 1 to 2 puffs inhaled PO q4h PRN, Levalbuterol SAMA (if not on long-acting anticholinergic) Ipratropium (Atrovent HDA) MDI 17mcg/actuation 2 inh QID, then additional actuations PRN Combination SAMA/SABA Ipratropium/Salbutamol (Combivent Respimat) 20/100mcg 2inh q4-6h PRN Long-acting LABA Indacaterol (Onbrez Breezhaler) 1 capsule (75mcg) inhaled once daily using Breezhaler inhalation device Olodaterol (Striverdi Respimat) 2.5mcg/actuation two inhalations once daily LAMA (anticholinergic- muscarinic) Tiotropium (Spiriva Respimat) 2.5mcg/actuation two inhalations once daily Umeclidinium (Incruse Ellipta) 1 inhalation (62.5mcg) once daily Combination if symptomatic ICS/LABA: Fluticasone furoate/vilanterol trifenalate (Breo Ellipta) 100/25 mcg/dose one inhalation once daily LAMA/LABA: Umeclidinium-vilanterol (Anoro Ellipta) 62.5mcg/25mcg one inhalation once daily Inhaled glucocorticoid if repeat exacerbations/symptoms despite combination long-acting bronchodilators Combination LABA and ICS Formoterol/budesonide (Symbicort Turbuhaler) 12/400mcg inhaled BID Salmeterol/fluticasone (Advair Diskus) 50/250mcg inhaled BID Vilanterol/fluticasone (Breo Ellipta) 1puff inhaled once daily
556
chronic bronchitis definition
chronic cough and sputum for more than 3 months per yeat, more than 2 years
557
ddx of COPD
Asthma, CHF, GERD,TB, Bronchiolitis, alpha1 antitrypsin deficiency
558
COPD complications
skeletal muscle deconditioning, right heart failure, polycythemia, MDD
559
somatic sx disorder definition
One or more somatic symptoms that are distressing or result in significant disruption of daily life. Excessive thoughts, feelings, or behaviors related to the somatic symptoms or associated health concerns as manifested by at least one of the following: Disproportionate and persistent thoughts about the seriousness of one’s symptoms. Persistently high level of anxiety about health or symptoms. Excessive time and energy devoted to these symptoms or health concerns. Although any one somatic symptom may not be continuously present, the state of being symptomatic is persistent (typically more than 6 months).
560
Illness anxiety disorder
Preoccupation with having or acquiring a serious illness. Somatic symptoms are not present or, if present, are only mild in intensity. If another medical condition is present or there is a high risk for developing a medical condition (e.g., strong family history is present), the preoccupation is clearly excessive or disproportionate. There is a high level of anxiety about health, and the individual is easily alarmed about personal health status. The individual performs excessive health-related behaviors (e.g., repeatedly checks his or her body for signs of illness) or exhibits maladaptive avoidance (e.g., avoids doctor appointments and hospitals). Illness preoccupation has been present for at least 6 months, but the specific illness that is feared may change over that period of time.
561
conversion disorder (functional neurological symptom disorder)
One or more symptoms of altered voluntary motor or sensory function. Clinical findings provide evidence of incompatibility between the symptom and recognized neurological or medical conditions. The symptom or deficit is not better explained by another medical or mental disorder. The symptom or deficit causes clinically significant distress or impairment in social, occupational, or other important areas of functioning or warrants medical evaluation.
562
treatment of somatisation
Rule out comorbid psychiatric disorders that require treatment (Anxiety, Depression) Schedule regular visits Acknowledging symptoms Focus on psychosocial and not just physical symptoms Assessing and treating diagnosable medical and psychiatric disorders Limiting tests and referrals Reassuring the patient that grave medical diseases have been ruled out (emphasize mind-body connection) Functional improvement the goal of treatment Pharmacotherapy (eg. Fluoxetine 20mg PO daily and titrate up, or Amitriptyline) Psychotherapy (CBT or Mindfulness-based therapy) Consult Psychiatry once to clarify diagnosis and reduce investigations
563
questions to ask to determine if they have a substance abuse disorder
Impaired Control Had times when you ended up using X more, or longer, than you intended? More than once wanted or attempted to cut down or stop X but couldn’t? Spent a lot of time using/getting/recovering from X Craving: Wanted X so badly you couldn’t think of anything else? Social Impairment Obligations: Found that X—or being sick from X—often interfered with taking care of your home or family? Or caused job troubles? Or school problems? Interpersonal: Continued to use X even though it was causing trouble with your family or friends? Given up or cut back on activities that were important or interesting to you, or gave you pleasure, in order to use X? Risky Use More than once gotten into situations while or after using X that increased your chances of getting hurt (such as driving, swimming, using machinery, walking in a dangerous area, or having unsafe sex)? Continued to drink even though it was making you feel depressed or anxious or adding to another health problem? Or after having had a memory blackout? Pharmacological indicators *Tolerance: Had to use X much more than you once did to get the effect you want? Or found that your usual number/amount had much less effect than before? *Withdrawal: Found that when the effects of X were wearing off, you had withdrawal symptoms (e.g., alcohol: trouble sleeping, shakiness, restlessness, nausea, sweating, racing heart, seizure? Or sensed things that were not there?)
564
elements in history of substance use disorder to ask
Amount Frequency Duration of use Last use Signs of tolerance/withdrawal Affect on function Safety of patient and others Consider substance-specific screening tools (eg. AUDIT, CAGE)
565
risk factors of substance use
Psychiatric disease, chronic disability, family or personal history of substance use disorder Associated symptoms, eg. Functional decline, confusion, delirium, syncope Associated medical problems, especially if not responding to appropriate intervention (alcohol in hypertriglyceridemia, inhalation drugs in asthmatic) Prescription medication that are commonly misused (opioids, sedatives, hypnotics, or anxiolytics, stimulants)
566
Safety recommendations for opioids, sedatives, hypnotics, or anxiolytics, stimulants
Do not share medication Do not receive medications from other sources Store medication in secure location (out of reach of children, adolescents) Ensure regular visits to healthcare provider, and regular urine samples for drug screens as requested Inform your healthcare provider of any changes to health, and if you would like to adjust your prescribed dose Avoid concurrent use of sedatives/depressants (eg. Alcohol, benzodiazepines)
567
transient ischemia attacks definition
Brief episode of neurological dysfunction without evidence of acute infarction, back to baseline <24h 3% risk of stroke in first 2 days after TIA, risk stratify with ABCD2 score >3 admission
568
definition of stroke
Sudden onset focal neurological dysfunction from infarction or hemorrhage in the brain lasting >24h
569
sx of stroke
Acute onset Hemiparesis / Motor weakness Neglect Amaurosis fugax Slurred speech Dysphagia Sensory deficits / Decreased reflexes Mental status change / Confusion / Inattention Impulsivity
570
stroke risk factors
smoking obesity Hypertension family history sedentary lifesty;e diabetes hyperlipidemia alcohol prior TIA/stroke
571
ddx of stroke
transient ischemic attack [TIA], brain tumour hypoglycemia subdural hematoma, subarachnoid bleed Recrudescence of old stroke from metabolic or infectious stress Todd’s paralysis after seizure Complex migraine Psych Mass/tumor CNS infections Bells palsy (central causes will spare the forehead) Subarachnoid hemorrhage (sudden onset severe headache, stiff neck, photophobia, diplopia) Subdural hematoma
572
presentiaon of L supratentorial stroke
Aphasia, right hemiparesis / right hemianopia
573
R supratentorial stroke presentation
Left hemispatial neglect, left hemiparesis / hemianopia
574
posterior or infratentorial stroke presentation
Mental status changes / Confusion Diplopia Dysphagia Unilateral dysmetria/incoordination
575
acute management of stroke
ABC Vitals, serum glucose 12-lead EKG, cardiac monitor IV x 2 Oxygen >90% Determine onset of stroke symptoms (or last observed normal)
576
labs to ask in stroke
CBC INR PTT Creat lytes glucose Blood type and screen consoder troponine
577
investigation other than labs in stroke
Brain imaging (CT or MRI) with vascular imaging (CTA or MRA from aortic arch to vertex, or carotid doppler) >50% symptomatic (>60% asymptomatic) carotid stenosis should be offered carotid endarterectomy as soon as possible ECG and 24-hour cardiac monitoring + Holter (if no Afib on ECG and 24h monitor) TTE (or TEE if high suspicion) Thrombi, endocarditis, calcifications, tumour Patent foramen ovale (No clear evidence for PFO closure) Antiphospholipid Vasculitis
578
Management of hemorrhagic stroke
reverse anticoagulation monitor ICP consult neurosurgery
579
managemetn of ischemic stroke
tPA if elligible IV thrombolysis alteplase control BP to target consider Eligibility for endovascular neurointerventional care ASA if no tPA
580
elligibility for tPA in stroke
Age 18 years or older Clinical diagnosis of ischemic stroke causing neurological deficit Time of symptom onset <3-4.5 hours One study showed benefit up to 9 hours or on awakening
581
contraindication to tPA (6)
Active or history of intracranial hemorrhage <3 months neurosurgery, head trauma, stroke Uncontrolled hypertension >185/110 Known intracranial AV malformation, neoplasm, aneurysm Active internal bleeding Suspected endocarditis, suspected subarachnoid hemorrhage Bleeding disorder (Plat<100, heparin with elevated aPTT, INR>1.7, DOAC) Abnormal glucose <2.7mmol/L
582
target BP in stroke
<185/110 prior to treatment, and <180/105 for first 24h if thrombolytic therapy If no thrombolytic, only treat if >220/120 or other indication Consider Labetalol, Nicardipine, Clevidipine
583
Eligibility for endovascular neurointerventional care (large vessel occlusion [MCA, ACA, Carotid], small infarct, large penumbra)
National Institutes of Health Stroke Scale (NIHSS) >6 Vision, aphasia, neglect (VAN) assessment + Pronator drift x10s, only continue if positive (mild drift, severe weakness, or paralysis) Stroke vision Aphasia Neglect
584
non pharmalogical management of stroke
Early mobilization (<24h post-stroke), NPO until Swallowing assessment Nutritional support Dedicated stroke unit Assess for functional impairment
585
complications of stroke
Cardiac Depression Dementia Dysphagia Fatigue Ulcer Venous thromboembolus (25% early death post-stroke is from PE, consider prophylaxis) Pain Seizure (no evidence for prophylaxis)
586
non disabling stroke and TIA risk of stroke and recurrence
High Risk of Stroke Recurrence -<48h of TIA or nondisabling stroke and transient, fluctuating and/or persistent unilateral weakness or speech disturbance -Immediate referral to ER with capacity for advanced stroke care (access to tPA) -CT or MRI and noninvasive vascular imaging (eg. CTA or MRA from arch to vertex) -ECG <48h without motor weakness or speech disturbance -Same-day assessment (ER or stroke prevention clinic) Increased risk: -48h-2w with symptoms of transient, fluctuating or persistent unilateral weakness or speech disturbance 24h clinical evaluation and investigation -48h-2w without motor weakness or speech disturbance 2w clinical evaluation and investigation ->2w of TIA or nondisabling ischemic stroke <1 month by neurologist
587
6 preventive measuresof stroke
Antiplatelets -Clopidogrel (75mg daily) vs. aspirin/dipyridamole (25/200mg BID) vs. aspirin alone (delay 24h if given tPA) For minor stroke and TIA, consider dual antiplatelet for 10-21d Lifestyle: Smoking / Alcohol Obesity (Weight loss) Diet (avoid fat, sodium, sugar) Physical activity Atrial fibrillation (anticoagulate as per CHADS65) If ECG negative, can consider prolonged ECG monitoring (Holter) Lipids (Statin in all ischemic stroke/TIA) Screen and Treat: Diabetes (HbA1c) Blood pressure Hormone (Consider stopping hormone replacement therapy and OCP) OSA Review FAST (symptoms of stroke)
588
causes of ischemic stroke
cardioembolic from a fib atheroemboli from athrosclerotic dz arterial dissection vasospasm vasculitis hypercoagulable state
589
ddx of abdominal pain according to systems
Cardiovascular: ACS, pericarditis Aortic dissection, mesenteric ischemia, sickle cell crisis Pulmonary: Pneumonia, embolus Biliary: Cholecystitis, cholelithiasis, cholangitis Gastric: Esophagitis, gastritis, peptic ulcer, small-bowel mass or obstruction Colonic: Appendicitis, colitis, diverticulitis, IBD, bowel obstruction, peritonitis, celiac disease Hepatic: Hepatitis, abscess, mass Pancreatic: Pancreatitis, mass Renal: Cystitis, nephrolithiasis, pyelonephritis Splenic: Abscess Gynecologic: Ectopic pregnancy, ovarian mass, ovarian torsion, PID, fibroids, endometriosis, ovulatory pain, ruptured ovarian cyst Abdominal wall: Herpes zoster, muscle strain, hernia Metabolic: Uremia, DKA, porphyria, adrenal insufficiency, narcotic withdrawal, heavy metal poisoning Psych: IBS
590
Do NOT Miss Dx in Acute Pelvic Pain in Women
Life-threatening Ectopic pregnancy Appendicitis Ruptured ovarian cyst Fertility-threatening PID Ovarian Torsion
591
red flags of abdominal pain
Fever (after onset of vomiting or pain) Bilious vomiting Bloody diarrhea Absent bowel sounds Voluntary guarding Rigidity Rebound tenderness ** Do not forget testis **
592
abdo pain ddx in less than 1 yo
Common: Colic, constipation, GERD, food protein allergy Urgent: Acute gastroenteritis, malrotation without volvulus, pyloric stenosis Emergent: Trauma (abuse), midgut volvulus, NEC, omphalitis, incarcerated hernia, intussusception
593
abdo pain ddx in 1-5 yo
Common: UTI, constipation Urgent: Acute gastroenteritis, HSP, pneumonia, Meckel diverticulum Emergent: Trauma, appendicitis, asthma
594
abdo pain in 5-12yo ddx
Common: UTI, constipation, functional Urgent: Acute gastroenteritis, IBD, HSP, pneumonia Emergent: Trauma, appendicitis, gonadal torsion, DKA, asthma
595
>12yo abdo pain ddx
Urgent: Gastroenteritis, IBD, pneumonia, hepatitis, pancreatitis, nephrolithiasis, PID Emergent: Trauma, appendicitis, gonadal torsion, ectopic pregnancy, DKA, asthma
596
investigations in abdominal painin children
Consider urinalysis, CBC, pregnancy test, ESR/CRP Consider ultrasound prior to proceeding with abdominal CT
597
high morbidity mortality ddx of abdo pain
MI, AAA, dissection, neoplasia, PID, peritonitis, cholangitis, abscess, pancreatitis, ectopic, SBO/strangulated hernia, perforation, appendicitis, PE, pneumonia, zoster, depression, DKA, drugs, anemia, UTI
598
Chest Pain DDx according to systems
Cardiac Acute Coronary Syndrome (ACS) Myocarditis Pericarditis -Pleuritic chest pain, decreased on leaning forward -Diffuse ST elevation, PR depression, pericardial friction rub -Treatment -Supportive, NSAIDs, steroids Pulmonary Pulmonary Embolism Tension pneumothorax (see trauma) Pneumonia COPDE Acute chest syndrome (sickle cell) Thoracic aortic dissection -Sudden, severe pain radiating to back Widened mediastinum on CXR, >20mmHg -difference in BP on left vs. right -Treatment -Decrease contractility and BP (target sBP <120)] -ABC, surgery/ICU GI Boerhaave's sydrome (esophageal rupture) -Treatment -NPO -IV Abx, IV PPI, Endoscopy/surgical repair GERD/PUD Chest wall Costochondritis MSK Herpes Zoster Psychogenic (Anxiety)
599
Marburg Heart Score (MHS)
Age/sex: men 55 years or older, women 65 years or older Known clinical vascular disease (CAD, occlusive vascular disease, cerebrovascular disease) Pain worse with exercise Pain not elicited with palpation Patient assumes pain is of cardiac origin 0-1 points predicts a 1% CAD risk 0-2 points predicts a 3% CAD risk
600
Cholelithiasis (Gallstone) Risk factors
Female Fat (Obesity), also recent weight loss Fertile (Estrogen), Pregnancy Forty (Elderly) Fair (Caucasians/Northern European but also Hispanic) Family history Liver transplant
601
Choledocolithiasis / Cholangitis tx
Antibiotics Endoscopic Retrograde Cholangiopancreatography (ERCP) with stone removal/cholecystectomy
602
investigations of cholecystitis
Abdominal Exam Murphy's sign Labs Leukocytosis (left shift) Bilirubin Alk Phos ALT Amylase Abnormal LFTs are not common in uncomplicated acute cholecystitis, as obstruction limited to gallbladder Ultrasonography Sonographic Murphy's sign Gallbladder wall thickening >4mm or edema (double wall sign) Pericholecystic fluid CT vs. MRCP if ultrasound unclear or if complications suspected
603
management of gallstones
Surgery referral for symptomatic gallstones (biliary colic) Analgesia (NSAIDs, narcotic as second-line) Expectant management for asymptomatic gallstones (only 10-20% will become symptomatic within 5-20y) Surgery may be considered in asymptomatic gallstones in the following situations: Calcification of the gallbladder (porcelain gallbladder) because of high risk for gallbladder cancer Hemolytic anemia (e.g., sickle cell disease) Large gallstones (greater than 3 cm) because of high risk for gallbladder cancer Morbidly obese undergoing bariatric surgery because of high risk to becoming symptomatic during rapid weight loss Aboriginals because of high risk for gallbladder cancer Planning for a transplant
604
cholecystitis vs biliary colic
Lack of pain resolution, fever, peritonitis, abnormal labs
605
2 different types of cholecystitis
Calculous cholecystitis Acalculous cholecystitis - 10% (usually in critically ill patients)
606
cholecyctitis tx
Treatment No need for antibiotic prophylaxis in low risk Cholecystectomy Untreated, resolves within 7-10d but risk of complications (20% gallbladder gangrene, 2% perforation)
607
charcot's triad
fever, jaundice, RUQ pain (risk of pancreatitis and acute cholangitis) + raynaud's pentad confusion and shock
608
ddx of appendicitis
DDx: IBD, ruptured cyst, abscess, ectopic pregnancy, testicular torsion
609
management of appendicitis
ABC Intravenous fluids NPO/ Bowel rest Consider antibiotics Consider prophylactic antibiotics (Cefoxitin/Cefotetan/Cefazolin PLUS Metronidazole) 60 mins prior to surgery If surgery delayed until next day, consider empiric antibiotics (Ertapenem, Pip-Tazo, Cefazolin/Ceftriaxone/Cipro/Levo PLUS Metronidazole) Surgical consult for appendectomy
610
risk factors of diverticulitis
Use of Aspirin and NSAIDs Older age Obesity Lack of exercise
611
imaging in diverticulitis
CT abdomen with double contrast (PO and IV) Colonoscopy is contraindicated in acute diverticulitis but patients should have a colonoscopy in 4-6 weeks after resolution to assess extent of diverticular disease and to r/o colon cancer
612
Treatment of mild uncomplicated diverticulitis (if mild symptoms, able to tolerate oral intake, and no signs of peritonitis):
Clear liquid and FU in 2-3 days Consider broad spectrum oral antibiotics against gram-negative rods and anareobic bacteria Septra DS 160/800mg po BID Ciprofloxacin 500-750mg po BID + Metronidazole 500mg po Q6H for 7-10 days
613
Treatment of moderate to severe diverticulitis
Hospital admission IVF IV antibiotics with PipTazo 3.375g IV Q6H or 4.5g IV Q8H until resolution of symptoms then transition to 10-14 days of oral antibiotics NPO CT abdomen
614
Complications if diverticulitis
Abscess (CT guided percutaneous drainage) Bleeding Perforation Fistula Obstruction
615
Prevention of recurrences in diverticulitis
Increase dietary fibers Smoking cessation Regular exercise Weight loss if BMI > 30
616
which grain contian gluten
wheat rye barley
617
clinical spectrum of celiac disease
Classical Malabsorption (diarrhea, steatorrhea, weight loss, growth failure) Nonclassical Absent signs of malabsorption but intestinal/extraintestinal symptoms Subclinical (found on screening) Below clinical detection but abnormal serological test and villous atrophy Potential (latent) Abnormal antibody but normal intestinal mucosa - may develop intestinal lesion (requires monitoring)
618
conditions increasing risk of celiac disease
1st degree relative celiac (5-20%) DM1 (3-10%) Consider serology screening q1-2y Down syndrome Turner syndrome Autoimmune thyroid disease Autoimmune liver disease Selective IgA deficiency
619
sx of celiac disease
Malabsorption Abdominal pain/Bloating/Distension Chronic diarrhea/Constipation/IBS Weight loss/Fatigue Iron deficiency anemia Vit-D/Calcium - Dental enamel defects/Premature Osteoporosis B12/Folate - Neurological symptoms (Peripheral neuropathy, ataxia, seizures) Skin Dermatitis Herpetiformis ("Celiac of the skin" - pruritic papulovesicular rash on extensor) Recurrent aphthous stomatitis Infertility Abnormal LFTs Additional features in children Irritability Recurrent vomiting Delayed puberty Growth failure/Short stature
620
investigation/ diagnosis of celiac disease
IgA tTG antibody (Sensitivity and Specificity 95%) False-negative -Age<2yo -Consider in <2yo, screen with both IgA tTG and IgG DGP Ab -Lab error -Reduction/elimination of gluten (may be negative within weeks of GFD) --Gluten-containing diet should be resumed before ordering test --Consider HLA-DQ2/DQ8 for patients on a GFD -Note: HLA present in almost all patients with Celiac (95% DQ2, 5% DQ8) -Selective IgA deficiency -Immunosuppressed (eg. steroids) -Seronegative Celiac disease (rare) - if high suspicion, consider referral for small intestinal biopsy or HLA testing Total IgA If <0.2g/L, consider testing IgG DGP antibodies Positive IgA tTG Ab requires endoscopic small intestinal biopsies to confirm -Do NOT start GFD prior to biopsy (as this will heal mucosa) -If GFD started, resume 3g gluten daily x 2-6w and referral to GI
621
diagnosis of celiac disease in children
In children can avoid biopsy with three criteria: Positive tTG Ab >10x ULN Positive endomysial Ab Positive HLA-DQ2 or HLA-DQ8
622
treatment of celiac disease
Strict Gluten-free diet (avoid wheat, barlet, rye - caution with oats) Referral to dietician Consider iron, folic acid, vitamin D and B12 testing Consider TSH and liver transaminase q1-2y
623
complications of celiac disease
Nutritional deficiency (anemia) Osteoporosis Growth failure Autoimmune disorders (thyroid, liver) Malignancy (GI, LYMPHOMA)
624
pancreatitis etiology
IGETSMASHED" I - Idiopathic G - Gallstones E - Ethanol T - Tumors S - Scorpion bite M - Microbiology (TB, mumps, rubella, varicella, hepatitis, CMV, HIV) A - Autoimmune (SLE, polyarthritis nodosa, Crohn's) S - Surgery / trauma H - Hypertriglyceridemia (TG >11.3), hypercalcemia, hypothermia E - Emboli / ischemia D - Drugs (furosemide, estrogen, H2 blockers, valproate, antibiotics, ASA)
625
treatment of pancreatitis
Early goal-directed fluid resuscitation Analgesia : hydromorphone, fentanyl, Nutritional support severe pancreatitis treatment: Intensive care unit (ICU) care Enteral nutrition preferred over parenteral nutrition Antibiotics for extrapancreatic infections and infected necrosis Necrosectomy (removal of necrotic tissue) for infected necrosis Endoscopic retrograde cholangiopancreatography (ERCP) for acute pancreatitis and concurrent acute cholangitis Drainage of pseudocysts
626
crohn's disease vs ulcerative colitis
Crohn's Disease Any part of GI tract from the mouth to the rectum Transmural involvement Endoscopy: Skip lesions, cobblestoning, ulcerations, strictures Histology: Neutrophilic inflammation, noncaseating granulomas, Paneth cell metaplasia, and intestinal villi blunting Ulcerative Colitis Continuous lesions starting in rectum (generally only in colon) Mucosa and submucosal involvement only Endoscopy: Pseudopolyps, continuous areas of inflammation
627
risk factors for IBD
Smoker in CD, but may be **protective for the development UC** Ashkenazi Jewish, White (compared to Black, Hispanic) Sedentary lifestyle, Obesity "Western" diet (processed, fried, sugar) Acute gastroenteritis, recent antibiotic use NSAID use Family history of IBD
628
Extraintestinal manifestations of IBD (CD and UC)
Arthritis Peripheral arthritis Ankylosing Spondylitis (UC) Sacroileitis Dermatological Aphthous stomatitis Erythema nodosum Pyoderma gangrenosum Ocular Episcleritis and Scleritis (CD) Uveitis Primary sclerosing cholangitis (UC)
629
DDx of IBD
Infectious colitis Ischemic colitis Radiation-induced colitis Diverticulitis Appendicitis Colorectal malignancy (obstructing/perforating), lymphoma Celiac IBS
630
initial testing and subsequent labs for IBD
CBC BUN Creatinine Liver enzymes CRP and ESR Consider stool Cx and C. diff toxin PCR Consider fecal calprotectin if IBS vs. IBD Subsequent testing Iron profile Vitamin B12, Folate Albumin, prealbumin Vitamin D, calcium
631
imaging diagnosis of IBD
Colonoscopy with ileoscopy and biopsy Capsule endoscopy (avoid in strictures) CT enterography MR enterography Small bowel follow-through Esophagogastroduodenoscopy recommended if upper GI symptoms, unexplained iron deficiency anemia, active Crohn's disease with normal colonoscopy
632
preventative measures for IBD (8)
Smoking cessation Consider avoid NSAIDs (may exacerbate disease) Avoid pregnancy in women of childbearing age Conflicting data about OCP and IBD, may have small risk of association Ensure routine immunizations Tetanus and diphtheria, Polio, MMR, Varicella, Meningitis HPV Herpes zoster Influenza Pneumococcal Hepatitis A and B Prior to starting anti-TNF agents, obtain PPD testing and CXR (rule out TB), and update immunizations including Hep B Anxiety/depression Osteoporosis Screening/prevention if on chronic systemic steroids Colorectal Cancer Screening for colorectal cancer based on extent of disease Usually begin 8y after onset, q1-2 years (with random biopsies) Cervical Cancer Consider more frequent screening if on immunosuppressive therapy
633
treatment of IBD
Induction of Remission 5-ASA (sulfasalazine, mesalamine) Pentasa total 4g daily divided QID or BID If achieve remission, maintain dose or reduce to 3g daily Creat at 6w, 3mo, 6mo, 12mo, then yearly Glucorticoids (Topical Ileal release budesonide (Entocort EC), prednisone) Prednisone 40 mg PO x 1 week and then taper 5mg weekly for total duration of 8 weeks Maintenance 5-ASA (sulfasalazine, mesalamine) Immunomodulators (azathioprine and 6-mercaptopurine, methotrexate) Anti-TNF agents (infliximab, adalimumab) Consider Probiotics Lactobacillus GG and Escherichia coli Nissle 1917 Symptomatic Loperamide if no systemic (fever, tachycardia) Avoid opioids as may mask acute abdomen Consider avoid NSAIDs (limited data may worsen disease)
634
heart failure sx
Breathlessness Fatigue Weight gain Peripheral edema Orthopnea (LR 2.2) Paroxysmal nocturnal dyspnea (LR 2.6) Confusion in elderly
635
CHF risk factors (8)
Hypertension Ischemic heart disease (LR 3.1) Valvular heart disease Diabetes mellitus Alcohol, substance use Chemotherapy/radiation therapy Family history cardiomyopathy Smoking Hyperlipidemia
636
heart failure P/E findings
Bilateral lung crackles Elevated JVP (LR 5.1) Positive abdominal jugular reflex Peripheral edema (LR 2.3) Laterally isplaced apex S3 (LR 11), S4 or any heart murmur Low BP or HR>100 Note: In heart failure with narrow pulse pressure, think high output heart failure (eg. anemia, thyrotoxicosis)
637
2 types of heart failure
HFrEF (reduced) LVEF <40% _________________________________ HFmrEF (mid-range) LVEF 40-49% Elevated natriuretic peptide Relevant structural heart disease (LVH +/- LAE) or diastolic dysfunction __________________ HFpEF (preserved) 💡 A preserved ejection fraction on a routine echocardiogram does not rule out the clinical syndrome of heart failure LVEF >50% Elevated natriuretic peptide Relevant structural heart disease (LVH +/- LAE) or diastolic dysfunction
638
NYHA classification for severity of symptoms
I = No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea (shortness of breath). II = Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea (shortness of breath). III = Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, or dyspnea. IV = Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest. If any physical activity is undertaken, discomfort increases.
639
labs to ask in context of CHF
CBC Ferritin Glucose Electrolytes Creat/eGFR TSH UA LFTs Lipids & A1c (risk factor management) Consider if diagnosis uncertain or if high suspicion Troponin → r/o ACS and prognosis NT-proBNP >125pg/mL → consider echocardiography HF unlikely if < 300; highly likely if > 900 (1800 if age >75) BNP>50 pg/mL → consider echocardiography HF unlikely if < 100; highly likely if >400
640
investifation other than blood test to ask in CHF
ECG -Afib, new T-wave change, Q waves, LVH, LBBB, HR>100, Lung ultrasound -B-profile bilaterally, pleural effusion CXR -Cardiomegaly, pulmonary venous redistribution, pulmonary edema, pleural effusion, Kerley B lines Echocardiography -Decreased LVEF -Increased LV diameter/LVH -Wall motion abnormalities, diastolic dysfunction -Increased RV size, RV dysfunction -Valve dysfunction -Elevated pulmonary arterial pressures (PAP)
641
acute management of CHF
Acute Management 💡 LMNOP (Lasix, Modify medications, Nitroglycerine, Oxygen, Position (upright) +/- Positive Pressure (BiPAP) Oxygen ≥ 90-92% NIPPV (BiPAP > CPAP) if SpO2 < 90% despite supportive O2 Position upright Hypotension (cardiogenic shock)→ Pressor (eg. Norepinephrine) to maintain MAP 65-80 Hypertension (SCAPE)→ High-dose nitroglycerin IV Nitroglycerine (NTG) SL 0.4mg x 3 q5 mins until IV nitroglycerine started (note SL nitro only 40% bioavailable) Nitroglycerine 100mcg/min IV infusion, increase by 20mcg/min every 10 mins until sBP decreases Then maintain until improvement in symptoms, then gradually reduce IV infusion until stop Alternatively may give intermittent nitroglycerin bolus 1-2mg IV q3-5 minutes Avoid in PDE5 inhibitors (e.g., sildenafil) or concomitant inferior STEMI (preload dependent) If suspect total body hypovolemia, no B-lines on lung ultrasound, hypoperfusion, Consider careful fluid bolus challenge (250mL isotonic crystalloid) If suspect total body hypervolemia (eg. B-lines on lung ultrasound, pedal edema, jugular vein distension, history of nonadherence to diuretics or missed hemodialysis) Note: Many patients may be euvolemic and have a maldistribution of fluids into the lungs Furosemide (Lasix) 20-80mg IV bolus (once stable) If taking regular furosemide at home, can give home PO dose as IV Consider the addition of acetazolamide 500mg IV daily to improve loop diuretic efficiency Monitor diuretic effect ~q6h while stabilizing Monitor daily weights and urine output, goals: urine output 3-5 L; 0.5-1.5 kg weight loss Increase/decrease diuretic by ~25-50% to meet above criteria If not responsive, consider adding metolazone 1.25-5mg one to seven times per week Consider consultations (e.g., cardiology, ICU) for advanced measures (e.g., intra-aortic balloon pumps, LVAD, ECMO, etc.)
642
pharmalogical management of congestive heart failure + sx management threapies
💡 The classic “triple” therapy for HFrEF has recently expanded to “quadruple” therapy with the addition of SGLT2 Inhibitors in the updated CCS 2021 Guidelines. Quadruple Therapy for most patients with HFrEF (LVEF < 40% and symptoms) ACEi (or ARB if not tolerated) ACEi: Target Ramipril 10mg, Perindopril 8mg, or Lisinopril 20-35mg ARB: Target Candesartan 32mg BB (Careful initiating in NYHA III-IV) Target Bisoprolol 10mg or Metoprolol CR/XL 200mg MRA (Monitor potassium, creatinine) Target Spironolactone 50mg SGLT2 Inhibitor Target Empagliflozin 10-25mg or Dapagliflozin 10mg Convert from ACEi/ARB to ARNI if persistent/worsening symptoms despite adequate quadruple therapy (hospitalization and mortality benefit) Target Sacubitril/Valsartan 200mg BID (97mg:103mg) 💡 There is less evidence supporting the benefit of pharmacotherapy for patients with preserved EF (HFpEF). For patients with HFpEF consider SGLT2 and MRA as first-line therapies. Symptom Management Additional therapies should be considered for patients with HFrEF and persistent NYHA II-IV symptoms, despite optimization of quadruple therapy: Diuretic at lowest effective dose to maintain euvolemia Consider (with specialist involvement) Ivabradine if NSR and HR ≥ 70 bpm despite BB Vasodilators (e.g., hydralazine/Isosorbide dinitrate) if renal intolerance to ACEi/ARB/ARNI Digoxin (e.g., if poorly controlled AF despite BB) Device therapy (ICD, CRT) if LVEF ≤ 35% and NYHA I-IV (ambulatory)
643
clinical sx of parkinson's
>60yo Resting tremor, often unilateral, 4-6 Hz (cycles per second), pill-rolling, increased with stress, decreased with voluntary activity Muscle rigidity/cogwheeling (resistance to passive movement) Bradykinesia (slow movements) Postural instability, falls Shuffling gait, decreased arm swing, unsteady turning, difficulty stopping, stooped/flexed posture Mask-life facial expression, infrequent blinking Speech changes (hypophonia), micrographia Non-motor: Constipation, rapid eye movement (REM) sleep disorder, depression, olfaction impairment, personality changes
644
non pharmalogical management of parkinson
Improve quality of life and function Refer to neurology untreated within 6w Physical therapy Gait, balance, flexibility Occupational therapy Mobility, self-care, safety Speech therapy Vocal loudness, swallowing Parkinson Society of Canada / Support Groups Monitor for Depression, Dementia, Psychotic symptoms, Sleep disturbance, Autonomic dysfunction Psychosis Consider antipsychotics that have less antidopamine effects (Clozapine, Pimavanserin, Quetiapine) Postural hypotension Increase salt, head up, elastic stockings Midodrine or fludrocortisone
645
name 5 tx rx parkinsons
First-line: Levodopa/carbidopa (Dopamine precursor) Dopamine agonists - pramipexole (best early in disease) Anticholinergics - benztropine NMDA-receptor antagonist - amantadine MAOIs - selegiline COMT inhibitor - entacapone
646
side effects of levodopa
Impulse control disorder (eg. compulsive gambling, hypersexuality, binge eating and obsessive shopping) Dyskinesia Somnolence Orthostatic hypotension/dizziness Nausea, Dyspepsia Psychotic symptoms and hallucinations
647
poisons not bound by activated charchoal
caustic acids and alkalis, alcohols, lithium, heavy metals
648
activated charchoal is usefulwith wich toxines
Dose: 1 to 2g/kg Multiple dosing q2-6h effective in phenobarbital, phenytoin, carbamazepine, salicylates, digitalis, theophylline and dapsone
649
indications of bowel irrigation in intox
Toxic foreign bodies (drugs packets), sustain release drugs, or toxic materials not bound by AC Contraindications: Mechanical obstruction, ileus, perforation
650
in which intox should you do gastric lavage + contraindication + complications
Indications: Highly toxic substances or large ingestions, substances not adsorbed by activated charcoal (lithium, iron, lead, methanol) and potential jeopardized airway (altered mental status) Contraindications: Ingestion of corrosives, hydrocarbons, depressed gag reflexes who are not intubated, clinically insignificant ingestions Complications: Aspiration, perforation of esophagus/bronchus
651
poisoning management
ABC, Oxygen (consider intubation), Mental status Vitals q5 mins Temperature, glucose IV access Cardiac monitor, EKG DON'T forget in Universal Antidotes in altered mental status: Dextrose, Oxygen, Naloxone (Narcan), Thiamine *CALL POISON CONTROL*
652
investigations in poisonning
Labs CBC, electrolytes, glucose Hepatic and renal function High creatinine with normal BUN consider isopropyl alcohol or DKA Urinalysis Serum osmolarity VBG + lactate Quantitative drug serum levels: Acetaminophen, Salicylates, Ethanol Other: Digoxin, iron, lithium, theophylline, anticonvulsants, methanol, ethylene glycol Qualitative urine drug screen Pregnancy test Other EKG QRS, QTc CXR for aspiration, or medications (salicylates, narcotics, sedative-hypnotics) for pulmonary edema
653
osmolar gap equation
Osmolar gap = Measured - (2 x [Na+] + [glucose] + [urea]) > 10 AGMA ([Na+] – [Cl−] – [HCO3−]>12)
654
drugs causing Excitation (high HR, BP, RR, T)
Anticholinergic, sympathomimetic, hallucinogenic, drug withdrawal Treat with benzodiazepines and supportive care
655
recreative drugs causing depression
Ethanol, sedative-hypnotic, opiates, cholinergic (parasympathomimetic), sympatholytics, toxic alcohol (methanol, ethylene glycol)
656
toxic dose of acetaminophen
Toxic above 150mg/kg (7.5-10g for an adult)
657
sx of acetaminophen intox within 24 h and after 24h
0.5-24h: Asymptomatic (possible nausea, vomiting, diarrhea) 24-72h: RUQ pain (hepatic injury)
658
labs for acetaminophen intox
Initial and more importantly >4h Acetaminophen Level evaluate on Rumack-Matthew normogram ALT and INR (if ALT abnormal)
659
treatment for acetaminophen intoxication
Activated Charcoal 50g within 2h (up to 4h) of ingestion unless contraindicated (unable to protect airway) N-acetylcysteine (NAC, Mucomyst) -If known time of ingestion, and above treatment line as per normogram -Time of ingestion not known or >24h, or chronic ingestion, treat if any acetaminophen concentration or abnormal AST/ALT -First dose, if serum level not available until >8h post-ingestion -Continue NAC if serum acetaminophen >10mcg/mL or elevated AST/ALT -ANY signs of liver injury (preferable to start NAC prior to elevated ALT)
660
aspirin fatal dose
Fatal above 10g in adults, 3g in children
661
clinical sx of aspirin intox
Tinnitus, tachypnea, vertigo, vomiting, diarrhea Respiratory alkalosis initially, mixed, then metabolic acidosis
662
investigations in aspirin intox
Serum salicylate levels >40mg/dL (2.9mmol/L) possible toxicity Measure q2h until decreasing, below 40mg/dL, asymptomatic and normal respiratory effort Blood gas
663
treatment of aspirin intox
AVOID intubation (risk of neurotoxicity in acid pH from apnea) Consider multi-dose activated charcoal in enteric-coated (50g q4h) Alkalinization (serum and urine) with IV sodium bicarbonate (3 amps NaHCO3 in 1L D5W at maintenance rate x 2 ) Target urine pH >7.5 (repeat q1h) Monitor for hypokalemia Glucose especially if altered mental status Early nephrology for possible dialysis
664
Methanol, ethylene glycol intox Clinical Manifestations:
Profound metabolic acidosis (HCO3<8mEq/L) and osmolal gap (>25mOsm), status epilepticus, shock, ischemic bowel Visual blurring, scotoma, blindness -> Methanol Flank pain, hematuria -> Ethylene glycol
665
Investigations of methanol, ethylene glycol intox
Blood gas Electrolytes (anion gap), serum osmolality, ethanol (determine osmolal gap), calcium (ethylene-glycol associated hypoglycemia) Methanol, ethylene glycol and isopropranol Urinalysis (oxalate crystals)
666
treatment of methanol, ethylene glycol intox
Blood gas Electrolytes (anion gap), serum osmolality, ethanol (determine osmolal gap), calcium (ethylene-glycol associated hypoglycemia) Methanol, ethylene glycol and isopropranol Urinalysis (oxalate crystals)
667
treatment of methanol, ethylene glycol intox
Fomepazole (alcohol dehydrogenase inhibition) or ethanol Sodium bicarbonate Hemodialysis in severe toxicity
668
benzodiazepine poisoning toxicity
Rarely toxic, rule out coingestant Risk of propylene glycol poisoning if receiving large IV BZDs (used as a diluent)
669
investigation fo benzodiazepine intox
Urine BZD identifies metabolites of 1,4-BZD (oxazepam), may not detect clonazepam, lorazepam, midazolam, alprazolam
670
treatment of benzodiazepine poisoning
Intubate if needed Consider avoid Flumazenil given risk of seizures in chronic benzodiazepine use Avoid GI decontamination (risk of aspiration) unless airway protected and coingestant treatable by charcoal
671
beta blocker treatment
Airway NS IV bolus with atropine 1mg IV (up to 3 doses) Glucagon 5mg IV bolus (may be repeated) Calcium chloride (central venous access) Vasopressor (eg. epinephrine) IV high-dose insulin and glucose IV lipid emulsion
672
opioids clinical manifestation
Respiratory depression Miotic pupils (coingestants may make pupils normal/large)
673
treatment of opioids
Naloxone (Narcan) titrated to RR>12 (not until normal LOC) Consider very small doses 0.04mg IV (or IO/IM/SC) q1min In cardiorespiratory arrest, no evidence of benefit, may consider 2mg IV (or IO/IM/SC) q1min If overshoot, manage withdrawal symptoms expectantly (not with opioids) If no effect after 5-10mg consider other diagnoses
674
antipsychotics antidote (acute dystonic reaction)
Benztropine, diphenhydramine
675
anticholinergic antidote
Physostigmine salicylate (Antilirium)
676
betablocker antidote
glucagon
677
CCB antidote
calcium
678
cholinergic antidote
Atropine, Pralidoxime
679
digoxine antidote
Digoxin immune Fab (Ovine, Digibind) Consider MgSO4 to stabilize if delay in digoxin antibodies
680
iron antidote
Deferoxamine (Desferal)
681
TCS antidote (Cardiotoxicity, convulsion, coma)
Sodium Bicarbonate 1-2mEq/kg
682
wellchild care to avoid intoxication
Keep items locked and out of reach/sight Keep in original containers (safety lids) Don’t take medications in view of children Don't refer to medicine as “candy”
683
BPH risk factors
Age, obesity, diabetes, family history
684
BPH complications
UTI, bladder stone, urinary retention, hydronephrosis, renal failure
685
ddx of urinary retention
BPH, UTI, urothelial cancer, BPH, prostate CA, urethral stricture, urethral diverticulum (women), medication, infection, trauma, neuro (spinal cord injury)
686
sx of BPH
Lower Urinary Tract Symptoms (LUTS) Voiding - predominant in bladder outlet obstruction (BOO) secondary to BPH Hesitancy, Weak Stream, Intermittence, Straining Storage - r/o overactive bladder (OAB) Urgency, Frequency, Urgency Incontinence, Nocturia Postmicturition Dribbling, Incomplete Emptying
687
investigation for BPH
Urinalysis +/- culture (r/o infection) PSA PVR if considering anticholinergics (eg. storage symptoms suggesting OAB)
688
management of nocturnal polyuria
Voiding/Frequency chart 2-3 days If urine output ≥3L Decreased intake, aim for urine output 1L If nocturnal urine output >33% nocturnal polyuria diagnosed Consider Desmopressin
689
non pharmalogical Management of BPO/ BPH for mild sx
Follow IPSS, DRE, PSA (if on 5-ARIs) as response to treatment Mild (Symptom score <8, or if not bothered by symptoms) Lifestyle and watchful waiting Fluid restriction particularly prior to bedtime Avoidance of alcohol, caffeine, spicy foods Avoidance/monitoring of some drugs (e.g., diuretics, decongestants, antihistamines, antidepressants) Timed or organized voiding (bladder retraining) Pelvic floor exercises Avoidance or treatment of constipation Phytotherapy/herbal medicine (Saw Palmetto) has very weak evidence, although minimal side effects
690
mod-severe sx in BPH management
Moderate-Severe (SS≥8) For smaller prostates, Alpha-blockers alone (relax smooth muscle, onset 3-5 days) eg. Tamsulosin (Flomax) CR 0.4mg PO daily (avoid in sulfa allergy) Side effects: Orthostatic hypotension, retrograde ejaculation (ejaculation failure) For larger prostates (eg. DRE>25mL or PSA>1.5 ng/dL), combination therapy more effective with 5-alpha reductase inhibitors (onhibit conversion of testosterone to DHT, onset 4-6 months) eg. Dutasteride (Avodart) 0.5mg PO daily , or Finasteride (Proscar) Side effects: Decreased libido, erectile dysfunction After 6-9 months of combination therapy, consider stopping alpha blocker Consider addition of PDE-5 inhibitors for LUT symptoms, eg. Tadalafil (Cialis) 5mg PO daily Consider addition of anticholinergics (eg. Tolterodine, Oxybutynin, Mirabegron) especially if component of OAB (storage symptoms), caution if PVR >250mL
691
when to refer to urology in BPH
Failure of symptom control despite combination therapy, for possible Surgery (TURP) Complications: Hematuria, recurrent UTIs, urinary retention, renal failure Suspect prostate cancer (DRE/elevation in PSA) PSA<10 low risk (routine), PSA 10-20 (semiurgent referral), PSA>20 high risk (urgent) Upgrade urgency if DRE abnormal (firm or irregular)
692
prostatitis categories
Acute Bacterial Prostatitis Tender prostate Chronic Bacterial Prostatitis Intermittent UTIs with same bacteria Chronic Prostatitis / Chronic Pelvic Pain Syndrome Inflammatory Chronic Prostatitis Non-inflammatory Chronic Prostatitis Asymptomatic Inflammatory Prostatitis Leukocytosis
693
prostatitis sx
Fevers, chills, dysuria, pelvic or perineal pain, and cloudy urine, obstructive symptoms
694
risk factors of prostatitis
Indwelling catheter, urogenital instrumentation, prostate biopsy, HIV/immunosuppression, STI risk factors, BPH
695
bacterias in cause of prostatitis
Enterobacteriaceae (typically Escherichia coli or Proteus species). STIs (Neisseria gonorrhoeae and Chlamydia trachomatis) in sexually active men, may have concurrent urethritis or epididymitis.
696
investigations of prostatitis
Urinalysis, urine culture and-sensitivity testing, gono/chlam urethral/rectal PCR and culture
697
treatment of prostatitis
Acute/Chronic Bacterial Septra DS 1 tab q12h x 6 weeks (or 12 weeks for chronic) or Ciprofloxacin 500mg PO q12h x 6 weeks (for both acute and chronic) Consider Urine culture at 7 days (if still positive, consider change in management) Rule out prostatic abscess in immunosuppressed or poor response to therapy
698
treatment of non infectious prostatitis
Target UPOINTS Urinary (storage/voiding symptoms) Tamsulosin 0.4mg PO daily (a-blocker), antimuscarinics Psychosocial CBT, counselling, antidepressants, anxiolytics Organ specific (prostate tenderness, hematospermia) Quercetin, pollen extract Infection (positive cultures in prostate sample, previous UTI) Fluoroquinolone x 6 weeks Neurologic / Pain Acetaminophen, NSAIDs Gabapentinoids, TCA, acupuncture Tenderness (pelvic floor spasm, trigger points) Physiotherapy (pelvic floor relaxation), exercise, heat therapy Sexual dysfunction PDE-5 inhibitors Refer to urologist if does not improve significantly with initial treatment
699
hypertensive urgency definition
(dBP≥130mmHg) or emergency (severe elevation of BP in the setting of any below) → Immediate diagnosis management Emergency Cerebrovascular Hypertensive encephalopathy Intracranial hemorrhage Cardiac Acute aortic dissection Acute LV failure Acute coronary syndrome Renal Acute kidney injury Pre-eclampsia/eclampsia Catecholamine-associated HTN
700
diagnostic value of BP for HTN with AOBP and non AOBP in non DB
AOBP over or equal to 135/85 non AOBP over 140/90
701
diagnostic value of BP for HTN with AOBP and non AOBP in DB patients
130/80
702
out of office measurements diagnostic value of BP for HTN with ABPM and home BP series
ABPM daytime mean over 135/85 24h mean over 130/80 home BP mean over 135/85
703
gold standard of BP measuring
automated office blood presssure (AOBP)
704
when to take home BPq
2 readings before breakfast, 2 readings 2h after dinner, eliminate day 1 readings and average other 6 days (total 24 readings)
705
how to measure BP accurately
Cuff with appropriate bladder size (Bladder width 40% of arm circumference and length 80-100% of arm circumference) Nondominant arm, unless SBP difference >10mmHg (use higher value arm) Rest comfortably for 5 minutes in seated position, back support, arm supported at heart level No caffeine/tobacco 1h, no exercise 30mins preceding
706
diagnosis of HTN in children
Consider BP measured annually in children and adolescents ≥3 y of age. Diagnosis of HTN if a child or adolescent if auscultatory-confirmed BP readings ≥95th percentile at 3 different visits.
707
HTN target organ damage examples
Cerebrovascular Stroke Dementia (Vascular) Hypertensive retinopathy Cardiac LV dysfunction LV hypertrophy CHF CAD (MI, angina, ACS) Renal (CKD, albuminuria) PAD (claudication)
708
target BP in DB and all
Diabetes <130/80 All (including elderly and CKD) <140/90 High risk consider ≤120 SPRINT population ≥ 50yo CV disease CKD FRS ≥15% Age ≥75yo
709
routine tests for HTN
Urinalysis (Grade D); Blood chemistry (potassium, sodium, and creatinine; Grade D); Fasting blood glucose and/or glycated hemoglobin (Grade D); Serum total cholesterol, low-density lipoprotein, high-density lipoprotein (HDL), and non-HDL choles-terol, and triglycerides (Grade D); lipids may be drawn fasting or nonfasting (Grade C); and Standard 12-lead electrocardiography (Grade C).
710
global cardiovascular risk factors
Age ≥55yo Male Family Hx CAD (Age <55 in men, <65 in women) Sedentary lifestyle Poor dietary habits Abdominal obesity Dysglycemia Smoking Dyslipidemia Stress Nonadherence
711
when to FU on pts with HTN
Adjusting antihypertensive drug therapy q1-2 months Modify health behaviours q3-6 months
712
lifestyle modifications for HTN
Exercise 30-60 mins of moderate-intensity dynamic exercise (walking, jogging, cycling, swimming) 4-7 days per week in addition to routine ADLs Weight loss (dietary education, physical activity, behaviour modification) -BMI 18.5-24.9 and waist circumference <102cm for men <88cm for women Alcohol consumption ≤2 drinks per day (Men <14/week, women <9) Diet Dietary Approaches to Stop Hypertension [DASH] Reduce saturated fat, cholesterol Emphasis on fruits, vegetables, low-fat dairy products, dietary and soluble fibre, whole grains, and protein from plant sources Sodium <2000mg (1 tsp salt) per day Potassium increase dietary intake to reduce BP (if no risk of hyperkalemia) Stress management (cognitive behaviour interventions with relaxation techniques) Smoking cessation Re-assess habits (steroids, licorice), meds (NSAIDs, OCP), OTC meds
713
causes of secondary HTN
renovascular hypertension endocrine hypertension Hyperaldosteronism Pheochromocytoma/paraganglioma
714
INVESTIGATION for secondary HTN
Rule out renovascular hypertension with imaging (eg. duplex ultrasound of renal arteries, MRA, CTA, captopril-radioisotope renal scan) if ≥2 of below Sudden onset, worsening HTN and age >55 or <30* Abdominal bruit* HTN resistant to ≥3 drugs* Serum creatinine ≥30% increase with ACE-I or ARB Atherosclerotic vascular disease (smoke/DLP) Recurrent pulmonary edema with hypertensive surges Consider r/o fibromuscular dysplasia with CTA/MRA if any of three above* or unexplained asymmetry of kidney sizes (>1.5cm), family history of FMD, or FMD in other territory _________________ Rule out endocrine hypertension Hyperaldosteronism (Plasma aldosterone and renin/renin activity) K<3.5mmol/L or marked diuretic-induced hypokalemia (K<3) HTN resistant to ≥3 drugs Incidental adrenal adenoma ---------------- Pheochromocytoma/paraganglioma (24h urinary total metanephrines and catecholamines or 24h urine fractionated metanephrines, plasma free metanephrine/normetanephrines) Paroxysmal, unexplained, labile, severe (≥180/110) HTN refractory to usual therapy Symptoms of catecholamine excess (headache, palpitations, sweating, panic attacks, pallor) HTN triggered by BB, MAO-i, micturition, changes in abdominal pressure, surgery, anesthesia Incidental adrenal mass Hereditary (MEN2A/B, neurofibromatosis type 1, Von Hippel-Lindau)
715
initial therapy for HTN
No other indications Long-acting Thiazide diuretic (eg. Chlorthalidone, indapamide) BB (<60yo) ACE-i (nonblack) Long-acting CCB (eg. Amlodipine) ARB
716
therapy for HTN for DB
ACE-i, ARB
717
Cardiovascular disease CAD HTN med
ACE-i, ARB BB or CCB in stable angina
718
HTN med for pt with recent MI
ACE-i (or ARB), BB
719
Heart failure htn med
ACE-i (or ARB), BB Aldosterone antagonist (spironolactone) in recent CV hospitalization, acute MI, elevated BNP or NYHA class II-IV Monitor potassium
720
LV hypertrophy htn med
ACE-i, ARB, Long-acting CCB, Thiazide
721
previous stroke/TIA htn med
ACE-i and thiazide combination
722
Non-diabetic CKD
ACE-i (or ARB) if proteinuria, Diuretics as additional therapy
723
Routine use of aspirin in healthy women younger than 65 years is not recommended to prevent myocardial infarction T or F
T
724
why the diagnostic evaluation process for obstructive CAD is challenging
because of lower pretest probability, atypical symptom presentation, and greater prevalence of microvascular disease
725
key points to reduce cardiovascular risk in pts with DB2
A = A1C – Blood glucose control. The target is usually 7.0% or less. B = BP – Blood pressure control (less than 130/80 mmHg). C = Cholesterol – LDL-cholesterol less than 2.0 mmol/L. Your physician/nurse practitioner may advise you to start cholesterol-lowering medication. D = Drugs to protect your heart – These include blood pressure pills (ACE inhibitors or ARBs), cholesterol-lowering medication (“statins”), and, in people with existing cardiovascular disease, certain blood glucose lowering medications. These blood glucose-lowering medications can protect your heart even if your blood pressure and/or LDL-cholesterol are already at target. E = Exercise/Eating — Regular physical activity, which includes healthy eating, and achievement and maintenance of a healthy body weight. S = Stop smoking and manage stress.
726
should we start ASA in patints with diabetes for primary CVD prevention
Pooled estimates suggest that, for primary prevention of CVD events in people with diabetes, ASA results in no reduction of MI and stroke, but an important increase in gastrointestinal hemorrhage (61–64). Despite a plethora of data, there remains uncertainty about the use of ASA in the primary prevention of CVD events in persons with diabetes, and its routine use in primary CVD event prevention is not recommended. However, some people with multiple CV risk factors and evidence of vascular inflammation, as reflected by C-reactive protein levels, may cross the risk-benefit threshold in which the potential benefits justify the potential increase in hemorrhagic events.
727
red flags of HA
Systemic - fever, weight loss, HTN, myalgias, scalp tenderness Neuro - confusion, decreased LOC, papilledema, visual field defect, CN asymmetry, extremity drift/weakness, reflex asymmetry, seizure Onset - Sudden Older - New onset or progressive >50yo Pattern change/progressive - Different or new Papilledema Postural aggravation Precipitated by valsalva (cough, sneeze) Secondary risk factors- HIV, malignancy, trauma, early morning/nocturnal
728
primary Headache differential dx
Primary: Migraine 4-72h (untreated) 2 of unilateral, pulsatile, moderate-severe pain, worse with or avoid routine physical activity 1 of nausea/vomiting, photo/phonophobia Tension 2 of Bilateral, non-pulsating (pressing), mild-moderate intensity, not worse with or avoid routine physical activity No N/V, no more than one of photo/phonophobia Cluster Severe unilateral orbital, supraorbital and/or temporal pain, 15-180mins (untreated) One symptom/sign ipsilateral (Conjunctival injection, lacrimation, nasal congestion, rhinorrhea, eyelid edema, sweating, flushing, ear fullness, miosis, ptosis) Sense of restlessness or agitation If ≥15d/mo for ≥3mo Chronic migraine Chronic tension Medication overuse headache (usually present on wakening) ≥15d/mo simple analgesics (acetaminophen, aspirin, NSAID) ≥10d/mo ergotamine, triptan, opioids Hemicrania continua Strictly unilateral, persistent with exacerbations, cranial autonomic symptoms, restlessness, responsive to indomethacin New daily persistent headache Abrupt onset, daily, unremitting from onset (or within 3d of onset) typically in patients without history of headache
729
Secondary HA ddx
Infection: Meningitis, sinus, mastoid, dental Hypertension: Preeclampsia Systemic illness Carbon monoxide Extracranial: Eye disorder (refractory errors, glaucoma), Carotid dissection, TMJ
730
intracranial HA ddx
Vascular: Subarachnoid hemorrhage (thunderclap), Temporal arteritis, Venous Sinus Thrombosis, SDH (worsening over time), Cervical artery dissection (TIA/neuro deficit in young) Nonvascular: Increased/decreased (eg. CSF leak) ICP, Tumor, Chiari malformation (Valsalva)
731
HA investigation’s
Neuro exam, fundoscopy r/o increased ICP CT if red flags or risk of intracranial pathology Lumbar puncture if symptoms of secondary cause Valsalva/exercise, systemic illness (fever/rash/neck stiffness/meningismus), neuro sign (papilledema/seizure) Consider ESR/CRP if suspect temporal arteritis Consider CT/LP to rule out subarachnoid hemorrhage (SAH) Ottawa SAH Rule (100% sensitive, 15% specific - if negative helpful to rule out, excluded neuro deficits, brain tumors, chronic recurrent headache) Age≥40, Neck Pain/Stiffness, LOC, Onset during Exertion, Thunderclap, Limited Neck Flexion on exam CT (diagnosis 90% SAH within 24h) Lumbar Puncture (If negative CT) Elevated opening pressure, elevated RBC count that does not significantly diminish, Xanthochromia (hemoglobin degradation if blood in CSF >2h) If diagnosed SAH, proceed to angiography to rule out aneurysmal
732
non pharmalogical tx of HA
Keep headache diary, record frequency, intensity, triggers, medication Lifestyle changes Reduce caffeine Regular aerobic exercise Avoid irregular/inadequate sleep or meals Avoid triggers Fluids Stress management Relaxation training CBT Pacing activity Biofeedback therapy Acupuncture Transcutaneous electrical nerve stimulation
733
4 pharmalogical tx of migraines
Ibuprofen 400mg, ASA 1000mg, Naproxen 500mg, Acetaminophen 1000mg Second Line: Triptans (eg. Sumatriptan 100mg PO) Sumatriptan 6mg subcutaneous if vomiting or resistant to oral triptans Contraindicated in CV diseases, pregnancy, ergots Consider Gepants (Ubrogepant and Rimegepant) for patients with cardiovascular disease (for whom triptans are contraindicated)
734
prophylaxis pharmalogical tx of migraines and criterias
Prophylaxis if 4+/month, or >12h, or increased in frequency or rebound (trial of at least 2 months needed, treat for 6-12 months then taper to reassess need) Betablocker (Propranolol, Metoprolol, Timolol), Antidepressants (Amitriptyline, Venlafaxine), Anticonvulsants (Valproate, Topiramate) Less evidence: Calcium channel blockers (Verapamil) Melatonin 3mg (as effective as amitriptyline in one RCT) Riboflavin (Vit B2) 400mg/d after three months
735
ER IV medication for migraines
1L bolus NS, Prochlorperazine 10mg, Diphenhydramine 25mg , Ketorolac 30mg, Dexamethasone 10mg Maxeran (metoclopramide )
736
tension type HA treatment
Ibuprofen 400mg, ASA 1000mg, Naproxen 500mg, Acetaminophen 1000mg Prophylactic: TCA (Amitriptyline, Nortriptyline)
737
cluster HA treatment
100% oxygen 12L/min x 15 mins through non-rebreather mask Sumatriptan 6mg subcutaneous, Zolmitriptan 5mg intranasal Triptans contraindicated in Cardio/Cerebrovascular disorders Bridge with Corticosteroids (prednisone), Ergotamine, Occipital nerve block Prophylactic Verapamil 240-480mg/d or steroids Early specialist referral
738
medication overuse treatment
Stop offending medication Can bridge with NSAID (naproxen) or prednisone
739
Hemicrania Continua or Daily Persistent Headache treatment
Indomethacin Specialist referral Consider MRI Brain
740
meds that can cause overuse HA
ergots, triptans, analgesics or codeine, opioids more than 10 adays a month or tylenol or NSAIDS more than 15 a month
741
Mandatory Immigration Medical Examination (before arriving to Canada)
Complete physical examination (including vision/hearing screen) >5yo - Urinalysis for protein, glucose (think diabetes), blood (think shistosomiasis) If abnormal, urine microscopy >11yo - CXR r/o TB >15yo or risk factor (eg. known infected mother, unprotected sex) HIV testing, Syphilis
742
Recommended Screening (by Canadian Collaboration for Immigrant and Refugee Health 2011)
Hep B (Africa, Asia, Eastern Europe and parts of South America) Vaccinate susceptible, refer chronic infection for treatment (and consider screen HCC as indicated) Hep C (specifically subSaharan Africa [10%]; eastern Europe, especially Uzbekistan and Tajikistan [27%]; Egypt [25%–50%]; Vietnam [10%]; and Pakistan [5-35%]) and exposure to contaminated blood, usually as nosocomial transmission through unscreened blood products, surgery or receipt of intramuscular injections) If positive, vaccinate Hep A/B, limit alcohol and refer for treatment TB PPD skin test (Sub-Saharan Africa, Asia, and Central and South America, and some in Eastern Europe) CXR to rule out active disease HIV (sub-Saharan Africa, Caribbean, Thailand) Post-test counselling and refer to HIV treatment program Intestinal parasites if from endemic area, compatible sign/symptoms of infection (asthma) or evidence of peripheral eosinophilia Strongyloides serology (consider in immigrants from Southeast Asia and Africa) If positive, treat with ivermectin (or albendazole) Shistosomiasis serology (Africa) If positive, treat with praziquantel DM2 >35yo South Asian, Latin American and African Iron-deficiency anemia with hemoglobin for women of reproductive age, and children 1-4yo Dental disease (ask all if any pain, and look for evidence of disease) Refer to dentist (and treat pain with NSAID)
743
history to take with new immigrant
Medical Interpreter (consider CanTalk - telephone interpreter) Document findings (scars) Medication review, including alternative/herbal remedies Infection Consider malaria, TB, hepatitis, HIV, parasitic disease in differential Chronic disease Age-appropriate screening Screening for immigrants as above (Hep B/C, TB, HIV, parasites, DM2, Iron-deficiency anemia, Dental) Consider other screening Sickle cell, Thalassemia Vision Mental Health Depression, PTSD Trauma (child neglect, genital mutilation, intimate partner violence, torture, abuse, war) Culture/tradition/religion/gender roles Women's health Contraception Cervical cancer screening HPV vaccine Vaccination Primary immunization schedule according to age (Tdap, MMRV, etc...) Consider Hepatitis A/B If positive for sickle cell or thalassemia -Consider pneumococcal, H influenzae, meningococcal
744
definition of obesity in adults
Adult BMI ≥25 Overweight ≥ 30 Obese class 1 ≥ 35 Obese class 2 ≥ 40 Obese class 3 Overestimated/underestimated depending on muscle:fat distribution eg. South Asian criteria for BMI ≥23 Overweight ≥25 Obese
745
comorbidities of obesity
Hypertension, diabetes, coronary artery disease, sleep apnea, osteoarthritis
746
secondary causes of obesity
Endocrine (hypothyroidism, Cushing's, PCOS) Medications (insulin, sulfonylureas, antipsychotics)
747
hx and pe of obesity
History and physical exam rule out secondary causes (Endocrine, OSA) Vitals (Blood pressure) Weight, height, waist circumference Impact personal and social life Rule out depression, eating disorder
748
investigations in obesity
HbA1c or fasting blood glucose Lipid profile Consider Thyroid (avoid repeating if confirmed normal)
749
non pharmalogical management of obesity
Readiness to change Support Multidisciplinary approach Dietician Personal Trainer Psychology/Psychiatry (Cognitive behavioural therapy) Obesity specialist/Endocrinologist Lifestyle Diet May consider a weight los diet (reduction in dietary energy) High protein - Low fat diet Exercise 30 minutes daily of moderate intensity, increase to 60 minutes daily BMI ≥30 (Obesity class 2-3) after lifestyle/behavioural changes have failed Structured behavioural interventions (weight loss program)
750
pharmacotherapy for BMI over 30 in obesity
Orlistat 120mg PO daily-TID Stop medication if weight loss <5% at 3 months No effect on mortality Adverse effects: Bloating, steatorrhea, fecal incontinence Lack of longterm safety data Supplement with multivitamin 2h before or after medication Consider GLP-1/SGLT2 for weight loss in diabetes (in addition to Metformin)
751
when to consider bariatric surgery
BMI ≥ 40 or ≥ 35 with comorbidity (OA, OSA), consider Bariatric Surgery Weight loss Reduce prevalence of chronic disease (eg. DM, HTN, DLP, MSK pain - RR decrease by 25%)
752
obesity in childhood definition
Normal - BMI < 85th percentile Overweight- BMI > 85th percentile Obese > 97th percentile Severe Obesity >99th percentile
753
management of obesity in children
Structured behavioural interventions Family-wide changes in diet and activity (family-oriented behaviour therapy) Avoid counterproductive interventions (e.g., berating or singling out the obese child) Encourage positive reinforcement Diet Family meals Healthy snacking Decreased sugar consumption (juices, drinks) Decrease portion size Increase vegetables Activity (WHO recommends 60 minutes moderate-vigorous daily) Focus on fun/recreational activity Limit screen time Limit motorized transport Limit time spent indoors Limit sitting (eg. stroller) Sleep
754
when to do CT before LP
(r/o midline shift, hydrocephalus - enlarged ventricles, posterior fossa mass) Do CT head prior to LP if any of the following (prevent brain herniation): Age >60yo Immuncompromised (HIV, immunosuppressive therapy) CNS disease (mass lesion, stroke, or focal infection) Seizure (new onset within 1 week) Focal neurological deficit (excluding cranial nerve palsies) Papilledema Altered mental status (GCS<10) Unable to answer two consecutive questions or follow two consecutive commands
755
common bacterias and viruses causing meningitis
Neonates (0-1mo) = LEG Listeria monocytogenes E Coli Group B Strep (S agalactiae) >1mo = SHiN S Pneumonia H influenza N Meningitidis If >50yo or immunocompromised, alcoholism Listeria monocytogenes Viral (aseptic) Enterovirus HSV Lyme (Borrelia burgdorferi)
756
risk factors of bacterial meningitis
Age ≥65 years old, Neonates, Aboriginal groups, Students living in residence Immunocompromised (16%), Alcoholism, IVDU Infection Recent otitis or sinusitis (25%), mastoiditis Pneumonia (12%) Endocarditis Recent neurosurgery, Head trauma Recent travel to area with endemic meningococcal disease (eg. sub-Saharan Africa) recent abdominal surgery
757
sx of meningitis
Headache, fever, neck stiffness, and altered mental status (two of the following 95% sensitive) 99% have at least one classic feature - thus absence of all four findings above essentially excludes bacterial meningitis Nausea, vomiting Photophobia Seizure and focal neurologic deficits (especially in Listeria) Rhombencephalitis (manifested as ataxia, cranial nerve palsies, and/or nystagmus) Petechiae and palpable purpura (especially in N meningitidis) Arthritis (especially in N meningitidis)
758
physical exam findings of meningitis
Meningeal signs Neck stiffness (31% sensitive) Kernig's (9%) Inability or reluctance to allow full extension of the knee when the hip is flexed 90 degrees Brudzinski (11%) Spontaneous flexion of the hips during attempted passive flexion of the neck Jolt accentuation (97%) Accentuation of headache by horizontal rotation of the head at a frequency of two to three times per second Bulging fontanelle in children Neurological Papilledema, seizure, focal deficit Petechiae and palpable purpura
759
treatment of meningitis
Droplet precautions (until 24h after antibiotics) Empiric Antibiotics (do not delay beyond 1h if possible) 0-1mo: Ampicillin + Cefotaxime (or Ampicillin + aminoglycoside) >1mo: Vancomycin + 3rd gen cephalosporin (Ceftriaxone 2g IV q12h or Cefotaxime 2g IV q4-6h) Vancomycin 15-20mg/kg IV q8-12h (pre 4th dose trough levels 15-20mcg/mL) + Ceftriaxone 2g IV q12h >50y: Add Ampicillin 2g IV q4h to cover Listeria monocytogenes Dexamethasone 10mg q6h x 4 days if suspect S. pneumoniae (reduce mortality), or H influenzae (reduce hearing loss) Best to administer prior or with initial antibiotic therapy Consider Rifampin instead of vancomycin if bacteria not sensitive to ceftriaxone, as vancomycin may not enter CSF as well after steroids decreased inflammation Consider Acyclovir if suspect HSV encephalitis (changes in personality, behaviour, cognition, AMS) Consider covering for P. aeruginosa in immunocompromised with Cefepime or Meropenem 2g IV q8h Consider covering for tuberculous and cryptococcal meningitis in immunocompromised
760
true of false: in meningitis, Do not delay treatment for investigations, increase in mortality of 13% per hour of delay
T
761
when to do LP in meningitis
Consider delaying LP if unstable, signs of herniation, coagulopathy, overlying infection, If no concerns or negative CT head, proceed to lumbar puncture
762
what to analyse in LP for meningitis
CSF opening pressure (if done in left lateral decubitus) CSF leukocyte count, protein, glucose CSF culture (70-85% positive, antibiotics decreases yield by 10-20%) CSF Gram stain (60-90% positive with excellent specificity, yield decreases 20% if antibiotics) Gram-positive rods and coccobacilli (think L monocytogenes) add Ampicillin Gram-positive diplococci = pneumoccocal Gram-negative diplococci = meningococcal Small pleomorphic gram-negative coccobacilli = H influenzae CSF PCR (Meningococcal, Pneumococcal, Enteroviral, HSV, VZV) Consider CSF lactate and CRP to differentiate bacterial from aseptic (limited value if received antibiotic or CNS disease)
763
note: Neonates or immunocompromised may have normal CSF findings in bacterial meningitis Consider using Clinical Decision Rule in children L monocytogenes may present with CSF profile similar to viral, WBC >100 and normal glucose
764
labs in meningitis
CBC Electrolytes (Mild hyponatremia) LFTs Coags VBG (AGMA) Blood cultures x2 (60% positive) before first dose of antibiotics if possible Consider If sexual history or substance use: serum RPR, CSF VDRL, serum HIV Ab and HIV PCR In children (to guide diagnosis): Serum CRP and pro-calcitonin Throat swab for meningococcal culture
765
prevention of meningitis and treatment of ppl in close contact
Droplet precautions Chemoprophylaxis to close contacts and direct exposure to respiratory secretions Contact public health for post-exposure prophylaxis for close contacts (7d prior to symptom onset until 24h treatment) N meningititidis (>8h close contact or oral secretions) -Ciprofloxacin 500mg PO x1, Rifampin 600mg PO q12h x2d, Ceftriaxone 250mg IM x1 H influenzae (household with unvaccinated) -Rifampin Vaccination (H influenzae B, Pneumococcal, N Meningitidis) Pregnancy -Pen G to cover GBS as indicated -Avoid soft cheeses with unpasteurized milk, raw sprouts, melons, cold cuts, smoked seafood (Listeria monocytogenes)
766
Anorexia nervosa definition
Restriction of energy intake relative to requirements, leading to a significantly low body weight (BMI<18.5 or <5th percentile in children, or rate of weight loss) in the context of age, sex, developmental trajectory, and physical health. Intense fear of gaining weight or of becoming fat, or persistent behavior that interferes with weight gain, even though at a significantly low weight. Disturbance in the way in which one’s body weight or shape is experienced, undue influence of body weight or shape on self-evaluation, or persistent lack of recognition of the seriousness of the current low body weight. Subtypes Restricting type: During the last 3 months, the individual has not engaged in recurrent episodes of binge eating or purging behavior (i.e., self-induced vomiting or the misuse of laxatives, diuretics, or enemas). This subtype describes presentations in which weight loss is accomplished primarily through dieting, fasting, and/or excessive exercise. Binge-eating/purging type: During the last 3 months, the individual has engaged in recurrent episodes of binge eating or purging behavior (i.e., self-induced vomiting or the misuse of laxatives, diuretics, or enemas).
767
Bulimia Nervosa (BN) diagnostic criteria
A. Recurrent episodes of binge eating, as characterized by both: Eating, within any 2-hour period, an amount of food that is definitively larger than what most individuals would eat in a similar period of time under similar circumstances. A feeling that one cannot stop eating or control what or how much one is eating. B. Recurrent inappropriate compensatory behaviors in order to prevent weight gain such as self-induced vomiting; misuse of laxatives, diuretics, or other medications; fasting or excessive exercise. C. The binge eating and inappropriate compensatory behaviors occur, on average, at least once a week for 3 months D. Self-evaluation is unjustifiability influenced by body shape and weight. E. The disturbance does not occur exclusively during episodes of anorexia nervosa. Specify if: Partial remission: After full criteria were previously met, some but not all of the criteria have been met for a sustained period of time. Full remission: After full criteria were previously met, none of the criteria have been met for a sustained period of time. Current severity1: Mild: An average of 1–3 episodes of inappropriate compensatory behaviors per week. Moderate: An average of 4–7 episodes of inappropriate compensatory behaviors per week. Severe: An average of 8–13 episodes of inappropriate compensatory behaviors per week. Extreme: An average of 14 or more episodes of inappropriate compensatory behaviors per week.
768
Avoidant/Restrictive Food Intake Disorder (ARFID) diagnostic criteria
An eating or feeding disturbance (e.g., apparent lack of interest in eating or food; avoidance based on the sensory characteristics of food; concern about aversive consequences of eating) as manifested by persistent failure to meet appropriate nutritional and/or energy needs associated with one (or more) of the following: Significant weight loss (or failure to achieve expected weight gain or faltering growth in children). Significant nutritional deficiency. Dependence on enteral feeding or oral nutritional supplements. Marked interference with psychosocial functioning. The disturbance is not better explained by lack of available food or by an associated culturally sanctioned practice. The eating disturbance does not occur exclusively during the course of anorexia nervosa or bulimia nervosa, and there is no evidence of a disturbance in the way in which one’s body weight or shape is experienced. The eating disturbance is not attributable to a concurrent medical condition or not better explained by another mental disorder. When the eating disturbance occurs in the context of another condition or disorder, the severity of the eating disturbance exceeds that routinely associated with the condition or disorder and warrants additional clinical attention.
769
screening questions to ask patients with eating disorder
Does your weight/body shape cause you stress? Recent weight changes? Dieted in the last year? SCOFF Do you make yourself Sick (induce vomiting) because you feel uncomfortably full? Do you worry that you have lost Control over how much you eat? Have you recently lost more than One stone (14 lb {6.4 kg}) in a three-month period? Do you think you are too Fat, even though others say you are too thin? Would you say that Food dominates your life? ate/amount of weight loss Dietary intake (quantity, restriction) Compensatory behaviour (vomiting, laxatives, diuretics, exercise) Attitudes about weight / Body image Mood symptoms, suicidality Menstrual history Associated symptoms
770
Risk Factors of eating disorder
Early puberty Poor or abnormal growth curves in children and adolescents Low or high body mass index, or weight fluctuations Weight concerns among normal weight individuals Activities and occupations that emphasize body, shape, and weight (e.g. ballet, gymnastics, modeling) Amenorrhea (primary or secondary) Type 1 diabetes Family history of ED
771
associated physical sx of ED
Exertional or chronic fatigue, weakness, dizziness, pre/syncope, hot flashes, cold intolerance, depression Cardio: Palpitations, CP, SOB, peripheral edema Dental: Tooth pain (decay/cavities), mucosal bleeding/trauma and parotid gland enlargement GI: Abdominal pain, early satiety, bloating, constipation Endo: Amenorrhea, decreased libido, infertility Derm: Hair loss, brittle nail and skin changes, poor healing
772
physical exam findings of of ED
Vital Signs (eg. HR<60, BP<90/60, Temp<36) Orthostatic vitals (supine, standing) General Appearance Height/Weight and BMI; weight in kilograms divided by height in meters squared Hydration status HEENT Enlargement of parotid or submandibular salivary glands in BN Dental erosion due to frequent vomiting Cardiac, r/o murmur Skin Brittle hair and fingernails Lanugo hair Dry skin Pretibial edema Russell sign (callous on MCP from teeth abrasion during self-induced emesis) MSK Muscle strength Sit-up Squat Stand test (muscle weakness)
773
investigations for ED
EKG Bradycardia, non-specific ST-T wave changes including ST segment depression, U waves in the presence of hypokalemia and hypomagnesemia CBC (hemoglobin, leukocytes, platelets) Serum electrolytes (Na, K, Glucose, Blood urea nitrogen, Creatinine, Calcium, Magnesium, Phosphate) TSH, T4, T3 Liver function tests (AST, ALT, bilirubin) Amylase/lipase Albumin, transferrin UA BhCG r/o pregnancy Consider celiac screen If underweight > 6 months Bone densitometry to assess for osteopenia and osteoporosis Abdominal ultrasound to assess maturity of ovaries and uterus FSH, LH, and estradiol levels in females Testosterone levels in males
774
non pharmalogical treatment of ED
Medical stabilization Assess outpatient vs. admission if needed for safety Assess and treat coexisting psychiatric conditions (MDE, anxiety, substance use) Nutritional rehabilitation with multidisciplinary approach Family-based treatment Individual Psychotherapy, FBT/CBT Psychiatry Dietician / nutritional rehab School Support groups / resources Target weight range in AN (90% of expected weight) Gradual weight gain in AN (1lb/week) Limit exercise Regular appointments with vitals, weight/BMI, and blood tests repeated Complications (tooth decay, amenorrhea, electrolyte) Disease activity (eating patterns, exercise, laxative)
775
pharmacotherapy of ED
SSRI / Fluoxetine at higher doses (60mg/d) in BN Multivitamins with iron and Vitamin D Consider Zinc 50mg PO daily (aids in weight gain) Treat acne (as patient re-experience puberty as they gain weight)
776
indication for hospitalization
suicide risk, food refusal Vitals unstable Core temperature < 35.5°C or 95.5°F Heart rate < 40 beats per minute or severe bradycardia Blood pressure < 90/60 mm Hg or orthostatic hypotension ECG arrhythmia Electrolyte abnormalities Sodium < 127 mmol/l Potassium < 2.3 mmol/l Hypoglycaemia; blood glucose < 2.5 mmol/l Hypophosphataemia; phosphorous below normal on fasting Magnesium < 0.6 mmol/l (normal above 0.7 mmol/l) Rapid and progressive weight loss Acute medical complications of malnutrition Signs of inadequate cerebral perfusion (confusion, syncope, loss or decreased level of consciousness, organic brain syndrome, ophthalmoplegia, seizure, ataxia) Seizure Heart failure Pancreatitis Severe acrocyanosis Dehydration that does not reverse within 48 hrs Muscular weakness Comorbid psychiatric or medical (poorly controlled diabetes type 1) Pregnancy with an at risk foetus Inadequate weight gain, failure of outpatient treatment
777
indication for hospitalization
suicide risk, food refusal Vitals unstable Core temperature < 35.5°C or 95.5°F Heart rate < 40 beats per minute or severe bradycardia Blood pressure < 90/60 mm Hg or orthostatic hypotension ECG arrhythmia Electrolyte abnormalities Sodium < 127 mmol/l Potassium < 2.3 mmol/l Hypoglycaemia; blood glucose < 2.5 mmol/l Hypophosphataemia; phosphorous below normal on fasting Magnesium < 0.6 mmol/l (normal above 0.7 mmol/l) Rapid and progressive weight loss Acute medical complications of malnutrition Signs of inadequate cerebral perfusion (confusion, syncope, loss or decreased level of consciousness, organic brain syndrome, ophthalmoplegia, seizure, ataxia) Seizure Heart failure Pancreatitis Severe acrocyanosis Dehydration that does not reverse within 48 hrs Muscular weakness Comorbid psychiatric or medical (poorly controlled diabetes type 1) Pregnancy with an at risk foetus Inadequate weight gain, failure of outpatient treatment
778
risks associated with refeeding syndrome
Metabolic changes during refeeding of a malnourished patient Risk of hypophosphatemia leading to heart failure, arrhythmia, respiratory failure Prevent with careful slow refeeding/monitoring and phosphate supplementation
779
Diagnosis of menopause
Perimenopause Irregular periods and VMS until menopause Menopause >45yo and no period for 12 consecutive months and not using contraception If no uterus, diagnose based on symptoms Consider FSH <40-45yo If elevated FSH on 2 blood samples 4-6w apart and <40yo, diagnose premature ovarian insufficiency
780
6 sx of menopause
Vasomotor symptoms (VMS) Hot flashes, sweats Genitourinary syndrome of menopause (GSM) - previously vulvovaginal atrophy Urinary frequency/urgency/incontinence, dysuria Vaginal dryness/burning/pruritus, post-coital bleeding, sexual dysfunction, dyspareunia Mood, irritability Sleep changes Joint and muscle pain
781
non pharmalogical treatment of menopause
Healthy weight Diet (low sodium, low sugars - increase vegetables/fibers) Avoid VMS triggers (hot drinks, alcohol, caffeine) Exercise >150mins moderate-vigorous per week Routine Vitamin D +/- calcium STOP Smoking, alcohol Optimize sleep, relationship, mood Assess for HTN/DM/DLP
782
pharmalogical tx for menopause, VMS
Hormone replacement therapy first-line if <60yo or <10y past menopause (can be continued beyond 65yo in cases where risk>benefit) Offer choice of preparations Estrogen-progesterone (EP) or tissue-selective estrogen complex (eg. Duavive) Transdermal Climara Pro (matrix patch) 45mcg Estradiol + 15mcg LNG once weekly Estalis 50mcg Estradiol + 140mcg NETA (or 250mcg NETA) twice weekly Oral FemHRT 2.5mcg EE + 0.5mg NETA once daily Premplus continuous 0.625mg CE + 2.5mg MPA (or 5mg MPA) once daily Premplus cycle 0.625mg CE + 10mg MPA 2 tabs once daily If post-hysterectomy (no need for endometrial protection), estrogen only If comorbidities (Diabetes mellitus, HTN, smoking, obesity, DLP/CVD risk, gallstones), Transdermal preparation recommended Consider off-label transdermal testosterone therapy for menopausal women with low sexual desire if HRT alone is not effective Consider tissue-selective estrogen complexes (eg. Duavive) for breast/endometrial safety Non-hormonal (Clonidine, Pregabalin, SSRI, SNRI) are second-line, if failed HRT or contraindicated
783
contraindications of HRT
unexplained vaginal bleeding, pregnancy, history of breast cancer, coronary heart disease, a previous venous thromboembolic event or stroke, or active liver disease
784
Risks per 1000 women with five years of hormone use (HRT for VMS)
Coronary heart disease (CHD) – 2.5 additional cases Invasive breast cancer – 3 additional cases Stroke – 2.5 additional cases Pulmonary embolism – 3 additional cases Colorectal cancer – 0.5 fewer cases Endometrial cancer – no difference Hip fracture – 1.5 fewer cases All-cause mortality – 5 fewer events
785
treatment of genitourinary sx of menopause
Water-based lubricants/moisturizer (equivalent to vaginal estrogen in a recent RCT) Vaginal estrogen (even if on systemic HRT) Estradiol 10mcg intravaginal tablet (Vagifem) daily x 2 weeks, then twice per week Estradiol 2mg intravaginal ring (Estring) in place for 90 days Estradiol 0.1mg/g cream (Estrace) 2-4g daily x 1-2w, then half dose 1-2 weeks, then maintenance dose of 1g 1-3x/week Conjugated estrogens 0.625mg/g cream (Premarin), dose 0.5-2g cream twice weekly (or cyclic 21 days on, 7 days off) CBT for mood and anxiety Limited evidence (efficacy and safety) for complementary and alternative medicine
786
CV comorbidities of CAD
CKD, Stroke, peripheral vascular disease, heart failure, valvular heart disease
787
initial tests for stable coronary disease
Hb, full cholesterol panel, fasting glucose, HbA1c, creatinine, LFT, TSH, 12 lead EKG
788
in suspicion of CAD< who should go for non invasive testing
adults over 30 yo with 2-3 angina criteria men over 40 or women over 60 with 1 of 3 anginal features men under 40 and women under 60 with only 1 of 3 anginal features with CV risk (abnormal baseline EKG, DB, smoking, DLP, HTN, chronic kidney disease)
789
for dx of CAD which are the non invasive testing options
treadmill exercise testing with 12 lead ECG and BP monitoring if cannot exercise: consider pharmalogical testing with vasodilator perfusion imaging or dobutamine echocardiography if LBBB or ventricular paced rhythm consider vasodilator perfusion imaging (with adenosine or persantine) in pts with very low pre test probability: cardiac CT angiography can be considered -avoid if arrythmia, significant renal dysfct or contreast media allx
790
all patients with suspicion of stable ischemic heart disease should have rest left ventricular function test
true
791
classical chest pain 3 features
Dull RSCP (discomfort, heaviness, aching, pressure; not changing in intensity with inspiration, cough or position change; with or without radiation into jaw, neck, shoulders, arms) Provoked by exertion or emotional stress (lying down, post-prandially) Relieved within <5 min by rest or Nitroglycerin. Non-classical symptoms might include: SOB(OE), N/V, diaphoresis, fatigue, dizziness Atypical chest pain in DM, women, patients without risk factors (eg. young) New CP Duration >20 min Occurrence at rest
792
8 modifiable RF of ischemic heart disease
Smoking DLP DM2 CKD HTN Obesity or Metabolic syndrome Physical Inactivity Diet Depression
793
4 non modifiable RF of CVD
Age Sex (male) Ethnicity (Hispanic, Native American, African American, Asian) Family history of premature CVD (1st degree relative, <55yo men, <65yo women)
794
criterias to do non invasive testing for dx of CAD
All ≥30 years of age with ⅔ or more anginal features → noninvasive testing Men ≥ 40 and women ≥ 60 years of age with ⅓ anginal features → noninvasive testing
795
criterias for low test probability (<7%) of ischemic heart disese
Men <40 or Women <60 + ⅓ symptoms → assess for other causes, non-invasive testing not recommended Consider non-invasive testing only if other risk factors (abnormal baseline ECG, diabetes, smoking, hyperlipidemia, hypertension, chronic kidney disease)
796
when to consider coronary angiography in CAD (not ACS)
Indicated if High pretest probability of stable ischemic heart disease High-risk features on non-invasive testing Persistent symptoms or inadequate QOL despite optimal medical treatment History of ACS Life-threatening arrhythmias
797
non pharmalogical management of stable ischemic heart disease
Counselling Review treatment options Medication adherence for symptom relief and prevent disease progression Explanation of CV risk Treat any concurrent DM2 or DLP or HTN Lifestyle Smoking cessation Weight loss Diet (high intake of vegetables, whole grains, fresh fruit; reduce salt, saturated/trans fat) Physical activity (150 min/week of moderate or vigorous activity) Assess and manage stress/depression Red flags when to seek medical care Non-invasive testing as above within 2w Then referral to cardiologist/specialist within further 6w referral to a comprehensive cardiac rehab program
798
meidcation improving prognosisi of ischemic heart diseease
ASA 81mg (or Clopidogrel 75mg if ASA intolerance) High-intensity Statin (eg. Rosuvastin 20-40mg daily, Atorvastatin 80mg daily) ACEI (or ARB) if HTN, DM2, CKD, LVEF ≤ 40% b blocker   Revascularization therapy (PCI or CABG) in patients who underwent coronary angiography
799
sx relief of ischenic heart disease
Nitroglycerin (short-acting) 0.4mg SL tab or spray q5 mins PRN, seek prompt medical attention if pain persists after 3 doses Beta-blockers especially if prior MI, HF, LVEF ≤ 40%, eg. Bisoprolol, target HR 55-60 bpm If cannot tolerate BB or symptomatic on monotherapy, start/combine Long-acting CCB (eg. Amlodipine or Diltiazem) Avoid non-dihydropyridine CCB in combination with BB if risk of AV block and excessive bradycardia Nitroglycerin transdermal patch 0.2mg/hour titrate up to 0.8mg/hour (remember to remove patch 12-14h, eg. apply 8AM-8PM)
800
what to assess during FU of stable ischemic heart disease
Severity and progression of symptoms Impact on daily function and QOL NYHA Class I-IV Complications of CAD (arrhythmia, heart failure, ACS) Medication compliance Appropriate use of medication (Nitro SL prn) ECG if symptom change or annually Routine CBC, creat, FBG/HbA1c, lipids
801
in patients with suspicion of SIHD, within how long should pt have non invasive testing and specialist assessment
Non-invasive testing as above within 2w Then referral to cardiologist/specialist within further 6w revascularization if indicated within 6 w
802
when to give bblocker to pts with SIHD
chronic stable angina with MI, or reduced LVEF or heart failure target HR 55-60 GIve bblocker or long acting CCB chronic stable angina in uncomplicated patients if not tolerated, add long acting nitrate
803
when should optimization of medical therapy be achieved after initial evaluation
within 12-16 weeks
804
initial management of ACS
ABC vitals, exam ASA 160-325 mg to chew O2 for sat over 90% 12 lead EKG activate cardiac cath lab morphine for pain control nitroglycerin sublingual or spray IV access cardiac markers, CBC, coag studies, CXR
805
management of STEMI
PCI goal of 90 minutes door to needle fibrinolysis goal of 30 min nitro heparin Acei statin consider: b blocker, clopidogrel, glycoprotein 2b/3a inh
806
NSTEMI management
consider early invasive strategy if: refractory ischemic chest pain recurrent or persistent ST deviation V tach hemodynamic instability signs of Heart failure start tx: nitro heparin Acei statin consider: b blocker, clopidogrel, glycoprotein 2b/3a inh
807
in ED management of low/intermediate risk ACS
consider admisison for CP serial cardiac markers repeat EKG, telemetry consider non invasive dx test
808
ddx of syncope
Reflex (neurally-mediated) syncope Orthostatic syncope Cardiac arrhythmias Structural cardiopulmonary disease Pseudosyncope Seizure Sleep disturbances Accidental falls Psychiatric
809
investigation for LOC
EKG Orthostatic BP Sustained decrease in sBP ≥20 mmHg or dBP ≥10 mmHg within 3 min of assuming upright posture Labs (only if indicated) Consider CBC, BhCG, troponin Cardiac (if abnormal EKG or suspect cardiac) Consider echocardiogram if abnormal EKG or suspect structural abnormality Consider Holter 24-48h only if symptoms reoccur daily Consider carotid sinus massage if >40yo and no contraindications -Patient supine 5-10 seconds of massage to each carotid sinus (start with right) -Positive if asystolic or ventricular pause > 3s or decrease in sBP of 50 mm Hg -If negative, repeat with patient upright at approximately 60 to 70 degrees -Avoid in recent stroke/TIA <3mo or if carotid bruits Neurologic (only if suspect epilepsy, focal neuro deficit) -Consider EEG, CT head
810
criterias of high risk of syncope with hospital recommended
Clinical history suggestive of arrhythmic syncope (e.g., syncope during exercise, palpitations, or without warning or prodrome) Comorbidities (e.g., severe anemia, electrolyte abnormalities) ECG suggestive of arrhythmic syncope (e.g., bifascicular block, sinus bradycardia < 40 beats per minute in absence of sinoatrial block or medication use, QRS preexcitation, abnormal QT interval, ST segment elevation leads V1- V3 [Brugada pattern], negative T wave in right precordial leads and epsilon wave [arrhythmogenic right ventricular dysplasia/cardiomyopathy]) Family history of sudden death Hypotension (sBP < 90 mm Hg) Older age Severe structural heart disease, congestive heart failure, or coronary artery disease
811
EKG suggestive of arrhythmic syncope
bifascicular block, sinus bradycardia < 40 beats per minute in absence of sinoatrial block or medication use, QRS preexcitation, abnormal QT interval, ST segment elevation leads V1- V3 [Brugada pattern], negative T wave in right precordial leads and epsilon wave [arrhythmogenic right ventricular dysplasia/cardiomyopathy
812
low risk criterias of syncope
Age less than 50 years No history of cardiovascular disease Normal electrocardiographic findings Symptoms consistent with neurally mediated or orthostatic hypotension syncope Unremarkable cardiovascular findings
813
low risk criterias of syncope
Age less than 50 years No history of cardiovascular disease Normal electrocardiographic findings Symptoms consistent with neurally mediated or orthostatic hypotension syncope Unremarkable cardiovascular findings
814
non pharmalogical management of syncope
Education and reassurance Avoid triggers Lying down quickly with onset of presyncope Salt and water intake Removal of offending medications Counter-pressure manoeuvers (leg-crossing, limb/abdominal contractions, squatting), compression garments, and head-up tilt sleeping assess fitness to drive (can drive right away if single episode of typical vasovagal syncope, otherwise 1 month if recurrent)
815
phamracological management of syncope and orthostatic hypotension
Fludrocortisone 0.2mg PO daily or Midodrine 5-15mg PO TID (eg. q4h)
816
important questions to ask in LOC
duration, trauma, preexisting conditions, drugs, toxins, medications and seizure activity
817
Examine unconscious patients for localizing and diagnostic signs (e.g., ketone smell, liver flap, focal neurologic signs). In patients with a loss of consciousness and a history of head trauma, rule out intracranial bleeding. In patients with a loss of consciousness who are anticoagulated, rule out intracranial bleeding.
818
Assess and treat unconscious patients urgently for reversible conditions (name 5)
shock, hypoxia, hypoglycemia, hyperglycemia, and narcotic overdose)
819
syncope ddx
arrythmia, VT, VF, AV block Ao stenosis, hypertrophic hypermyopathy, myxoma, PE CHF, cardiomyopthy vasovagal, orthostatic, acs, arrythmia, ao dissection, valvular disease HF, hypoglycemia meds: alpha blocker ,antihypertensives, b blockers, CCB, diuretics, antiepileptic, nitrates
820
red flags of syncope
cp, palpitations, dyspnea, HA, no warning or during exertion or supine without warning, p,hx cvd, fx hx sudden death
821
statin indicated conditions
DB2: age over 40, over 30 yo with 15 y duration (type 1), microvasc disease AAA over 3 cm or previous surgery clinical atherosclerosis (MI, ACS, angina, over 10% stenoses, stroke, TIA, carotid disease, PADm claudication or ABI below 0.9) CKD (over 3 months, ACR ober 3, eGFR under 60)
822
indications to start statin
FRS over 20% FRS 10% -19% with LDL over 3.5 or Non HDL over 4.3 or apoB over 1.2 -or men over 50 or women over 60 with additional RF: low HDL C, impaired fasting glucose, high waist circumference, smoker, HTN statin indicated conditions LDL over 5 (genetic dlp)
823
health modifications to decrease cholesterol
exercise 150 min per week (mod to vigourous) smoking cessation mediterranean diet
824
target LDL, apoB or non HDL after starting a statin
LDL-c under 2 or 50% reduction apoB under 0,8 g/L or non HDL C under 2.6 mmol/L
825
if pt on statin and target not achieved, what to add on
-target maximally tolerated dose of statin consider add on: -ezetimibe as 1st line -BAS as alternative -for statin indicated conditions: consider PCSK9
826
who to screen for DLP
men and women over 40 yo women post menopausal until 75 yo regardless of age: clinical evidence of atherosclerosis AAA DB2 arterial HTN smoking stigmata of dlp (arcus cornea, xanthelasma, xanhoma) family hx of premature CVD family hx of DLP CKD obesity IBD HIV infx erectile dysfct COPD hypertensive dz of pregnancy automatically high risk if pre existing CVD
827
risk assessment of DLP tool
Framingham (2x risk if first degree relative F<65yo or M<55yo) Sex, Age, Total Chol, HDL, Smoker, sBP (or if treated) QRISK2 if CKD
828
tests to do in dlp
screening; LDL-c, TC, HDL-C, TG, non HDL-C, glucose, eGFR optional: apoB, UCR eGFR, A1c, TSH
829
which statin to use in DLP
Rosuvastatin 2.5mg, 5-10mg, 20-40mg PO daily (Cheapest) Alternatives: Atorvastatin, Simvastatin, Lovastatin, Avoid Pravastatin in >65yo risk of cancer
830
what to do if pt has myalgias with statin
Stop statin, follow CK until normal, consider restarting at lower dose / different statin / referral Consider baseline CK, ALT but generally NOT needed to be followed CK or ALT levels only if symptomatic or high risk of adverse events
831
do you need to monitor FLP after starting statins
Cholesterol target for reducing CVD NOT required (statins have been shown to reduce risk regardless of LDL) Monitoring lipid levels during therapy NOT required Note: CCS guidelines still recommend LDL targets despite no conclusive data for using targets LDL-C <2 mmol/L or >50% reduction Alternative target variables are apoB < 0.8 g/L or non-HDL-C < 2.6 mmol/L
832
in ACLS when to defibrillate
fibrillation (V fib), or pulseless or symptomatic ventricular tachycardia (V tach)
833
treatment of digoxin toxicity
EKG: Many arrhythmias (eg. PVCs, ventricrular bigeminy/trigeminy, slow Afib, sinus brady, AV block, regularized AF, VT) Suspect in bradycardia and GI symptoms Consider activated charcoal if <2h, alert and protected airway Treat arrhythmia, end organ dysfunction or hyperkalemia with antidote digoxin-specific antibody (Fab) fragments (Digibind) If antidote not available, can use atropine 0.5mg IV for bradycardia
834
cocaine intox management
EKG: Tachycardia +/- ischemic changes ABC, vitals Airway management (avoid succinylcholine, consider rocuronium or other nondepolarizing agent) Manage hypothermia/hyperthermia Diazepam 5mg IV q3-5 mins for agitation (and hypertension) Phentolamine 1-5mg IV for hypertension Avoid beta-blockers Sodium bicarbonate 1-2mEq/kg IV push for QRS widening Look for emergencies (eg. arrythmias, seizures, ICH, ACS, dissection, arterial thromboembolism)
835
BLS principles and how to do compressions
nspecter les lieux (sécurité du site), le patient Identifier l’arrêt cardiaque: état de conscience, vérifier pouls pendant max 10 sec (carotidien chez adulte) et respiration (agonale) en même temps Demander de l’aide, 911 (services préhospitaliers d’urgence ou équipe de réanimation) et DEA Massage (en l’absence de pouls) et DEA C: Compressions 100-120 par minute, entre 5-6 cm, relaxation thoracique après chaque compression 30 compressions pour 2 insufflations ou 3 x 200 compressions avec insufflateur passif d’O2 A: Voies respiratoires Ouvrir voies aériennes en basculant la tête avec soulèvement du menton OU subluxation mandibulaire Restriction de la mobilité cervicale manuelle Collier cervical par SMU B: Ventilation (1 insufflation par seconde) 2 x 1 sec en 10 sec max, entre 2 cycles Si advanced airway: q 6 secondes pendant les compressions Si IPO: faire 200 compressions avant Dès que DEA arrive: Vérifier si c’est un rythme défibrillable: choquer si oui RCR 2 min Revérifier avec DEA et choquer
836
opioid intox BLS management
Évaluer état de conscience, appeler 911, obtenir DEA et naloxone Vérifier si le pt respire ou non, ou respi agonale RCR 2min Naloxone 2 mg intranasale ou 0.4 mg IM q 4 min Répéter et utiliser DEA dès que c’est dispo
837
FV TV no pulse ACLS algorhytm
Donner de l’O2 Fixer le dispositif de surveillance ou le défibrillateur Défibrillation biphasique Choc 200 J (dire: Défibrillateur en charge! Je vais choquer à 3. Je suis prêt à choquer (s’assurer qu’il n’y a personne autour).) RCR en continue x 2 min Massage RCR en continue Ouvrir 2 grosses voies antécubitales Trouver les causes réversibles Ventilation q 6-8 secondes avec O2 maximale et envisager intubation, capnographie Épinéphrine 1 mg et finir cycle de 2 min. Choc 200 J Amiodarone 300 mg et cycle de 2 min. Choc 200 J Épinéphrine 1 mg et cycle de 2 min Choc 200 J Amiodarone 150 mg et cycle de 2 min Choc 200 J Épinéphrine 1 mg et cycle de 2 min Choc 200 J Lidocaïne 1.5 mg/ kg et cycle de 2 min Choc 200 J Épinéphrine 1 mg et cycle de 2 min Choc 200 J Lidocaïne 0.75 mg/ kg et cycle de 2 min
838
asystoly ou PEA management
Donner de l’O2 Fixer le système de surveillance ou défibrillateur Rythme défibrillable: choc; si asystolie, AESP: RCR 2 min Massage RCR en continue Ouvrir 2 voies antécubitales et intra-osseux PRN Épinéphrine 1 mg q 3-5 min Envisager intubation, capnographie Défibriller après 2 min si défibrillable Trouver les causes et traiter les causes de DEM, AESP 6 H/6T
839
6H and 6 T in PEA
6 H: Hypothermie Viser 35 degré Acidose Bic IV Hypoglycémie Glucose IV Hypo ou hyperkaliémie Hypo: 1 perf de K Hyper: chlorure de calcium, hyperventilation, bic 1 meq/ kg, insuline et glucose IV Hypoxie: intuber Hypovolémie Crystalloïdes 6T: Pneumothorax sous tension, trachée déviée décompression immédiate à l'aiguille par l'insertion d'une aiguille de gros calibre (p. ex., 14 ou 16) dans le deuxième espace intercostal sur la ligne médio-claviculaire Vérifier DT 5e espace mid-axillaire Tamponnade Péricardiocentèse à l’aiguille Trauma ATLS Trouver le saignement Toxicologie DDR Thrombose cardiaque IDM Thrombolyse, coro Thrombose pulmonaire Thrombolyse ou embolectomie chirurgicale
840
soins post arret cardiaque ACLS
Fio2 minimale pour sat ≥ 94% Envisager intubation et capnographie, ne pas hyperventiler Traiter/éviter hypotension (MAP<65mmHg, systolique <90mmHg) Bolus 1-2L LR IV, IO perfusion d’adrénaline IV 0.1-0.5 microgramme par kg par min OU perfusion dopamine IV 5-10 microgramme par Kg par min OU perfusion noradrénaline IV 0.1 à 0.5 microgramme par kg par min Traiter causes traitables ECG 12 dérivations: si IM STEMI: reperfusion coronarienne Gestion ciblée de la température (viser 32 à 26 C en 24 h) Soins intensifs
841
tachycarda with pulse QRS fin ACLS
Déterminer et traiter la cause sous-jacente Garder les voies aériennes dégagées, O2, ventilation PRN Moniteur cardiaque pour déterminer le rythme, surveiller la pression artérielle et l’oxymétrie Si persistante avec hypotension, altération état d’éveil, signes d’un choc, inconfort thoracique ischémique, insuffisance cardiaque aiguë Sédation si possible: (ex) diazépam, fentanyl Cardioversion synchronisé ss sédation À complexe étroit synchronisé: 50-100 J À complexe étroit irréguliers: 120-200 J en biphasique ou 200 J en monophasique FA: 120-200 J TV 100J TSV, Flutter: 50-100J Dire défibrillateur charge!, appuyer sur charge Je vais choquer à 3!, je suis prête à choquer! Si tachy persiste, augmenter le niveau d’énergie et rechoquer Si tachycardie à complexes étroits réguliers, envisager adénosine 6 mg IV push suivi de rinçage avec du soluté physiologique Si pas de hypotension, altération état d’éveil, signes d’un choc, inconfort thoracique ischémique, insuffisance cardiaque aiguë: Accès IV et ECG à 12 dérivations Viser FC 220-âge Tachycardie avec pouls réguliers (>150 bpm) QRS fin SI pas de souffles carotidiens: Manoeuvres vagales par massage du sinus carotidien Vérifier si FC baisse Adénosine 6 mg IV push (suivi par rinçage soluté physiologique) Adénosine 12 mg-12 mg IV Métoprolol 5 mg IV en 5 min OU vérapamil 2.5 mg IV en 15 min OU Diltiazem 0.25 mg/ kg IV en 2 min OU amiodarone 450 mg IV en 30 min Tachycardie avec pouls irrégulier QRS fin (FA, extrasystoles, > 150 bpm) Accès IV et ECG à 12 dérivations Métoprolol 5 mg IV en 5 min OU Diltiazem 0.25 mg/ kg en 2 min
842
Tachycardie avec pouls QRS large (> 150 bpm, QRS 0.12 sec+)
Déterminer et traiter la cause sous-jacente Garder les voies aériennes dégagées, O2, ventilation PRN Moniteur cardiaque pour déterminer le rythme, surveiller la pression artérielle et l’oxymétrie Si persistante avec hypotension, altération état d’éveil, signes d’un choc, inconfort thoracique ischémique, insuffisance cardiaque aiguë Cardioversion synchronisée ss sédation À complexe large synchronisé?: 100 J À complexe large irréguliers: Défibrillation non synchronisée 200 J Si pas de persistante avec hypotension, altération état d’éveil, signes d’un choc, inconfort thoracique ischémique, insuffisance cardiaque aiguë Accès IV et ECG à 12 dérivations si disponible Tachycardie avec pouls, régulier, QRS large (> 150 bpm, QRS 0.12 sec+) Adénosine 6mg IV push puis rinçage IV avec soluté physiologique-12 mg -12 mg Sinon: Amiodarone 150 mg en 10 min, répéter PRN. Puis perfusion d’entretien 1-4 mg par min OU Procaïnamide 20-50 mg/min IV, puis entretien de 1-4 mg par min OU sotalol 100 mg (1.5 mg/ kg) IV en 5 min (ATT pour torsade de pointe) Envisager de consulter un spécialiste SI Tachycardie avec pouls irrégulier QRS large (> 150 bpm) Défibrillation (idem FV/TV) car tachycardie pré-code Traiter la cause sous-jacente
843
Bradycardie avec pouls (< 50 bpm) ACLS
Évaluer condition clinique Déterminer et tx cause ss-jacente (garder voies aériennes dégagées, oxygène, moniteur cardiaque, pression artérielle, oxymétrie, accès IV, ECG à 12 dérivations) Si bradyarythmie non persistante: Surveiller et observer Si bradyarythmie persistante causant hypoTA, altération marquée état conscience, signes choc, DRS, IC aigue… Atropine: Bolus de 0,5 mg, répéter toutes les 3 à 5 minutes, dose max 3 mg Après 20 min, on peut retenter atropine ad 3mg ** risque de ne pas être efficace pour Mobitz 2 et BAV 3 Atropine inefficace: Perfusion IV dopamine (2 à 20 microgram par kg par min) Perfusion IV adrénaline (2 à 10 microgram par min) Envisager consultation d’un spécialiste + stimulation transveineuse transcutanée (bloc AV mobitz 2, BAV 3)
844
anaphylaxie management
Épinéphrine 0.3 mg adulte au tiers proximal cuisse en antéro-latéral q 5-15 min Sinon, Bolus IV de 0.05-0.1mg aux 5-15 min avec monitoring hémodynamique Perfusion si choc régractaire: 5-15 mcg/ min Si bronchospasme résistant à l’épinéphrine: b2-agoniste en nébul (2.5-5 mg dans 3 ml salin) Cesser les contacts, perfusions en cours, bannir le latex Caller le code précocément 100% O2 Regarder langue, lèvres, pharynx oral, faire parler le pt Intubation précoce si atteinte des VRS, éveillée à la fibre optique ou au vidéo laryngoscope avec légère sédation et anesthésie locale Décubitus dorsal avec membres inférieurs surélevés 2 grosses voies veineuses Accès intra-osseux PRN Monitoring cardio pulmonaire, prise TA fréquente Donner 2L LR sous pression si coeur sain Diphenhydramine (Benadryl) 25-50 mg IV ad 400 mg en 24h Méthyprednisolone 1-2 mg/ kg/ j Observer ad 4h après résolution des sx non cutanés
845
frequency of breath once advanded airway is in place in ACLS
once q 6 secs
846
ddx low back pain
Serious (RED FLAGS) Cord Compression (Urinary/Fecal incontinence/retention, saddle anesthesia, motor weakness/numbness) Infectious - Discitis/epidural abscess/pyelonephritis (Fever, IV drug use, severe, recent surgery, recent infection, immunocomprised) Metastatic Cancer (Hx, weight loss, age>50, persist, night pain, pain at rest) Vertebral Fracture (Osteoporosis, steroid use, age, trauma) Ruptured AAA (pulsations) Spondyloarthritis (Improvement with exercise, pain at night (with improvement upon getting up/activity), insidious onset, age <40 years, no improvement at rest, inflamamtory arthritis, enthesitis, uveitis, psoriasis, family history) Radicular pain (leg pain, sensory loss, reduced reflex, myotomal weakness) Intervertebral disc herniation Neurogenic claudication (Bilateral buttock/thigh/leg pain, pseudoclaudication) Central spinal canal stenosis Non-specific (mechanical) Beyond lumbar spine Gyne Renal (kidney stones) GI Hip joint DISK MASS: Degenerative (DDD, OP) Infection (PID< UTI, osteomyelitis, prostatitis) Injury Spondyloarthropathy, prondylitis (ankylosing, rhuematoid, SLE) Kidney stone, infarction, infection Multiple myeloma Aneurysm Slipped disc, spinal stenosis Strain, Scoliosis, skin
847
P/E elements in back pain
Vitals (Temperature) Gait/Posture Heel-toe, Squat and Rise Spine Abnormalities ROM Schober's test (marks at 5cm below L5 and 10cm above, flexion should increase distance from 15 to >20cm) Vertebral Tenderness Waddell's Signs (Non-organic) Superficial or nonanatomic tenderness Simulation test Axial loading Rotation of shoulder/Pelvis in same plane Distraction Discrepency between sitting and supine straight leg raise Regional disturbances Cogwheel (give-way) weakness Nondermatomal sensory loss Overreaction Straight Leg Raise Motor/Sensory (Saddle anesthesia, sphincter tone) DF ankle, EHL Reflexes Joint above and below (eg. hip) FABER for SI joint
848
investigations in back pain
CBC, ESR (tumor, infection) SPEP (multiple myeloma) X-ray (fractures) X-ray or CT Sacroiliac joints (ankylosing spondylitis) HLA-B27 antigen (ankylosing spondylitis) MRI (cauda equina)
849
non pharmalogical treatment of acute and chronic low back pain
Superficial heat (moderate-quality evidence) Massage, acupuncture, or spinal manipulation (low-quality evidence) Maintain activity and re-assurance (95% improve in 6 weeks) Chronic low back pain: Exercise, multidisciplinary rehabilitation, acupuncture, mindfulness-based stress reduction (moderate-quality evidence) Tai chi, yoga, motor control exercise, progressive relaxation, electromyography biofeedback, low-level laser therapy, operant therapy, cognitive behavioral therapy, or spinal manipulation (low-quality evidence)
850
pharmalogical tx of acute low back pain
Topical NSAIDs NSAIDs (eg. ibuprofen 600mg PO QID) or skeletal muscle relaxants (eg. cyclobenzaprine 10mg PO TID) (moderate-quality evidence)
851
chronic low back pain pharmalogical tx
NSAIDs as first-line therapy Tramadol (50-100mg PO QID) or Duloxetine (30-60mg PO daily) as second-line therapy Opioids if failed above (weak recommendation, moderate-quality evidence) Keep opioids <90mg morphine equivalents if possible
852
serious spinal disease of low back pain
vertebral fracture metastatic disease spinal infection axial spondyloarthritis cauda equina syndrome other ddx serious dz: -AAA, pyelonephritis, cancer
853
red flags of low back pain
neuro deficit urinary retention, fecal incontinence, saddle anessthesia fever, IV drug use, immunossupressed fracture, trauma, OP tumor, x cancer, B sx inflammation, morning stiffness, improves with exercise
854
investigations to consider in case of possibly compression or pathologic fx
XR BMD, CBC, SPEP, ALP, TSH, Creatinine
855
physical issue ddx of behavioural issues
Hearing/vision impairment CNS (head trauma, seizures) Metabolic (thyroid) Toxin (lead) Anemia Perinatal/Genetic
856
psychosocial ddx of behavioural issues and psychological ddx
Child abuse/neglect Housing/food Substance use Life Stressors (eg. family/peer issues) Parental expectations/parenting style
857
psychosocial ddx of behavioural issues and psychological ddx
Child abuse/neglect Housing/food Substance use Life Stressors (eg. family/peer issues) Parental expectations/parenting style psych: Mood disorder (eg. bipolar) Psychotic disorder ADHD Learning disorders Autism Spectrum Disorder M-CHAT screening If you point at something across the room, does your child look at it? (FOR EXAMPLE, if you point at a toy or an animal, does your child look at the toy or animal?) Have you ever wondered if your child might be deaf? Does your child play pretend or make-believe? (FOR EXAMPLE, pretend to drink from an empty cup, pretend to talk on a phone, or pretend to feed a doll or stuffed animal?) Does your child like climbing on things? (FOR EXAMPLE, furniture, playground equipment, or stairs) Oppositional Defiant Disorder Conduct Disorder
858
P/E to do in behavioural issues
Head circumference (micro/macrocephaly, increase/decreased growth velocity) Weight and height (growth) Dysmorphic features (hypertelorism, micrognathia) Eyes (visual acuity, strabismus, cataracts) Ears (hearing acuity, effusion) Abdomen (organomegaly) Skin (Cafe-au-lait spots for neurofibromatosis) Neuro Tone, strength, deep tendon reflexes, primitive reflexes Midline defects, spina bifida
859
non pharmalogocal management of behavioural issues
Parent management therapy (encourage parents to be more positive and less harsh) Peer support groups for family (Autism Society) Behavioral interventions (positive reinforcement, charts, checklists, reachable goals, set limits and clear consequences for misbehaviour) Time management (schedules) School-based interventions (accomodations) Social skills / psychotherapy Psychometric testing
860
ASD DM5 definition
Persistent deficits in social communication and social interaction across multiple contexts, as manifested by the following, currently or by history Deficits in social-emotional reciprocity, ranging, for example, from abnormal social approach and failure of normal back-and-forth conversation; to reduced sharing of interests, emotions, or affect; to failure to initiate or respond to social interactions. Deficits in nonverbal communicative behaviors used for social interaction, ranging, for example, from poorly integrated verbal and nonverbal communication; to abnormalities in eye contact and body language or deficits in understanding and use of gestures; to a total lack of facial expressions and nonverbal communication. Deficits in developing, maintaining, and understanding relationships, ranging, for example, from difficulties adjusting behavior to suit various social contexts; to difficulties in sharing imaginative play or in making friends; to absence of interest in peers. Restricted, repetitive patterns of behavior, interests, or activities, as manifested by at least two of the following, currently or by history Stereotyped or repetitive motor movements, use of objects, or speech (e.g., simple motor stereotypies, lining up toys or flipping objects, echolalia, idiosyncratic phrases). Insistence on sameness, inflexible adherence to routines, or ritualized patterns or verbal nonverbal behavior (e.g., extreme distress at small changes, difficulties with transitions, rigid thinking patterns, greeting rituals, need to take same route or eat food every day). Highly restricted, fixated interests that are abnormal in intensity or focus (e.g, strong attachment to or preoccupation with unusual objects, excessively circumscribed or perseverative interest). Hyper- or hyporeactivity to sensory input or unusual interests in sensory aspects of the environment (e.g., apparent indifference to pain/temperature, adverse response to specific sounds or textures, excessive smelling or touching of objects, visual fascination with lights or movement). Symptoms must be present in the early developmental period (but may not become fully manifest until social demands exceed limited capacities, or may be masked by learned strategies in later life) Symptoms cause clinically significant impairment in social, occupational, or other important areas of current functioning. Severity Level 1 "Requiring support" Level 2 "Requiring substantial support" Level 3 "Requiring very substantial support"
861
ODD definition
A pattern of angry/irritable mood, argumentative/defiant behavior, or vindictiveness lasting at least 6 months as evidenced by at least four symptoms from any of the following categories, and exhibited during interaction with at least one individual who is not a sibling. **Angry/Irritable Mood Often loses temper. Is often touchy or easily annoyed. Is often angry and resentful. ***Argumentative/Defiant Behavior Often argues with authority figures or, for children and adolescents, with adults. Often actively defies or refuses to comply with requests from authority figures or with rules. Often deliberately annoys others. Often blames others for his or her mistakes or misbehavior. ***Vindictiveness Has been spiteful or vindictive at least twice within the past 6 months. Impacts negatively on social, educational, occupational, or other important areas of functioning.
862
conduct disorder definition DSM5
A repetitive and persistent pattern of behavior in which the basic rights of others or major age-appropriate societal norms or rules are violated, as manifested by the presence of at least three of the following 15 criteria in the past 12 months from any of the categories below, with at least one criterion present in the past 6 months: Aggression to People and Animals Often bullies, threatens, or intimidates others. Often initiates physical fights. Has used a weapon that can cause serious physical harm to others (e.g., a bat, brick, broken bottle, knife, gun). Has been physically cruel to people. Has been physically cruel to animals. Has stolen while confronting a victim (e.g., mugging, purse snatching, extortion, armed robbery). Has forced someone into sexual activity. Destruction of Property Has deliberately engaged in fire setting with the intention of causing serious damage. Has deliberately destroyed others’ property (other than by fire setting). Deceitfulness or Theft Has broken into someone else’s house, building, or car. Often lies to obtain goods or favors or to avoid obligations (i.e., “cons” others). Has stolen items of nontrivial value without confronting a victim (e.g., shoplifting, but without breaking and entering; forgery). Serious Violations of Rules Often stays out at night despite parental prohibitions, beginning before age 13 years. Has run away from home overnight at least twice while living in the parental or parental surrogate home, or once without returning for a lengthy period. Is often truant from school, beginning before age 13 years. Clinically significant impairment in social, academic, or occupational functioning. If the individual is age 18 years or older, criteria are not met for antisocial personality disorder.
863
antisocial disorder
A pervasive pattern of disregard for and violation of the rights of others, occurring since age 15 years, as indicated by three (or more) of the following: Failure to conform to social norms with respect to lawful behaviors, as indicated by repeatedly performing acts that are grounds for arrest. Deceitfulness, as indicated by repeated lying, use of aliases, or conning others for personal profit or pleasure. Impulsivity or failure to plan ahead. Irritability and aggressiveness, as indicated by repeated physical fights or assaults. Reckless disregard for safety of self or others. Consistent irresponsibility, as indicated by repeated failure to sustain consistent work behavior or honor financial obligations. Lack of remorse, as indicated by being indifferent to or rationalizing having hurt, mistreated, or stolen from another. The individual is at least age 18 years. There is evidence of conduct disorder with onset before age 15 years. The occurrence of antisocial behavior is not exclusively during the course of schizophrenia or bipolar disorder.
864
conduct disorder treatment
psychothera[y -parent management training, individual therapy, family therapy and social skills training pre scholl: no evidence for stimulants, meds, focus on parent management therapy school aged children: if very disruptive, parenting skills training and training for child adolescents: decreased importance of parenting and incrased internal selft regulation strategies
865
RF of conduct disorder
male, low socioeconomic status, familial aggregation
866
pharmacotherapy of conduct disorder:
insufficient monotherapy adjunts + crisis management + short term intervention ritalin, dexedrine to reduce aggression bupropion, prozav to deal with impulsiveness in ADHD + CD dilantin, tegretol, valproic acid, lithium to decrease aggression clonidine to decrease agression and impulsivity
867
T or F :in conduct disorder, No evidence for boot camps, shock incarcerationk isolated medication trials, psych hospitalization, 12 session CBT
T
868
sx domains of ASD
1) social communication impairments 2) restricted repetitive patterns of behaviours and interests
869
secondary causes of ASD
fragile X, neuro cutaneous disorder, phenylketonuria, fetal alcohol syndrome, angelman syndrome, rett syndrome, smith lemli opitz syndrome
870
RF of ASD
male, first degree relative, older parents (over 35), maternal obesity, DM, HTN, infection, close spacing of pregnancies, low birth wt, extreme prematurity
871
investigations in ASD
hearing test CBC, ferritin, TSH, thyroxine
872
ASD
refer to developmental peds, child psych or psychologist with expertise in ASD
873
red flags suspicious of ASD at 6-12 m, 9-12 m, 12-18m, 15-24m
any age: parental concerns, developmental regression, decreaed loss of social behaviour, communication 6-12 months: decreaed smiles, joyful expressions, limited eye contact, limited reciprocal sharing or sounds, smiles or facial expressions, decreased babbling/gestures/response to name 9-12 m: repetitive behaviours, unusual play 12-18 months :no single word, no compensatory gestures, no pretend play, no joint attention 15-24 m: diminished, atypical , or no spontaneous or meaningful 2word phrases
874
reasons to end physician patient relationship
Irreconcilable breakdown of relationship Fraud, theft Threats, abuse to staff Give patient adequate notice to find another physician In QC, physician must have reasonable and just cause to end relationship Call CMPA for help
875
reasons to end physician patient relationship
Irreconcilable breakdown of relationship Fraud, theft Threats, abuse to staff Give patient adequate notice to find another physician In QC, physician must have reasonable and just cause to end relationship Call CMPA for help
876
breast lump DDX
Not a lump Prominent rib Costochondral junction Firm margin at edge of breast Defect secondary to previous biopsy Lump Normal glandular tissue (upper/outer quadrant) Fibrocystic changes (25%) Nodular nondiscrete tender mass, changes with menses, cyclical or constant pain Cancer (10%) Infiltrating ductal (most common) Infiltrating lobular and inflammatory breast cancer often present with no discrete mass Gross Cyst Galactocele - milk retention cyst in breasfeeding women Fibroadenoma Fat necrosis Trauma, associated with ecchymosis
877
breast cancer risk factores
Female Age >70 (RR 18) Prior hx of breast CA BRCA1/2 (RR 3-7) Prior hx of biopsy (RR 1.7-3.7) 1st degree relative with breast CA (RR 2.6) Unopposed estrogen Bone density - High (RR 2.7-3.5) Nulliparity/Age at first birth* >30 (RR 1.9-3.5) Menarche<12 (RR 1.5) Menopause >55yo (RR 2) HRT* (RR 1.2) OCP* (RR 1.07-1.2) Alcohol* (RR 1.4) Radiation (Mantle radiation in Hodgkin's) Benign breast disease
878
protective factors of breast cancer
Oophorectomy <35yo (RR 0.3) Postmenopause BMI* <22.9 (RR 0.63) Exercise* (RR 0.70) Parity* ≥5 (RR 0.71) Breastfeeding* ≥16mo (RR 0.73) Aspirin* ≥weekly for ≥6 mo (RR 0.79)
879
questions to ask when assessing breast cancer/mass
Change in breast mass (increase/decrease in size, change in symmetry) Changes with menstrual cycle (benign if prominent premenstrual and regress during follicular phase) Skin changes Nipple discharge New (acquired) nipple inversion Benign (ectasia) Central, symmetric, transverse slit with normal areola Malignant Asymmetrical, areola changes, flattened nipple, varied nipple position
880
P/E elements of breast cancer
Inspection with arms by side, raised above head, pressing on hips leaning forward Regional lymph nodes Cervical, supraclavicular/infraclavicular, axillary, mammary chain Skin changes Ecchymosis/erythema Peau d'orange Ulceration Dimpling/retraction Nipple/Areolar changes Discharge/crusting Inversion/retraction Breast Mass Obvious/Subtle Well-defined/Nondiscrete margins Density - Soft/Firm/Hard Mobile/Fixed to chest wall or skin Tender/Non-Tender
881
initial management of breast cancer
Feature of cancer (hard irregular fixed mass, palpable ipsilateral nodes, peau d'orange) -Mammography, U/S, core biopsy, breast surgeon referral Benign -Ultrasound or initial aspiration to differentiate between cystic vs. solids lesions
882
diagnosis of breast cancer and first line imaging accordin gto age
Clinical exam, Imaging, Non-excision biopsy (FNAC/Core) Any abnormal result requires surgical referral +/- further investigation 1st line imaging <35yo or Pregnancy/Lactation - Ultrasound* Mammography in all age groups if suspicious findings 35-50yo - Mammography + Ultrasound >50yo - Mammography
883
screening age in women for breast cancer
Women 50-74yo routine mammography q2-3y
884
benefits and risks of breast cancer screening
Benefits: Reduces absolute risk of death from breast cancer by 0.13-0.22% Risks: False positive mammogram 20-25% Unnecessary breast surgery 0.5%
885
which women to send to genetics for assessment of risks of breast cancer
Personal Hx Breast CA ≤ 40 or Ovarian CA at any age Fam Hx Breast CA ≤ 50
886
sx of a fib
Palpitations, tachycardia, angina, dyspnea Fatigue, weakness, dizziness, lightheadedness, reduced exercise capacity, presyncope Increased urination (due to the release of atrial natriuretic peptide) Right-sided heart failure (peripheral edema, weight gain, ascites) Embolic event
887
causes of a fib
Cardiac Hypertension (1.4 x risk) Coronary heart disease (ischemia/MI) Valvular heart disease (including rheumatic heart disease) Heart failure Cardiomyopathy (hypertrophic, dilated, restrictive) Congenital heart disease (ASD) Venous thromboembolic disease (DVT/PE - likely due to right atrial strain from resistance/afterload) Myocarditis/Pericarditis Pulmonary COPD OSA Metabolic Hyperthyroidism (including subclinical hyperthyroidism) Obesity Diabetes (1.5 x risk) Metabolic syndrome (hypertension, obesity, diabetes, and dyslipidemia) Chronic Kidney disease Other Age Alcohol (heavy alcohol use in men - holiday heart syndrome), note: no evidence that caffeine can provoke arrhythmias Stroke/TIA Family history Inflammation/infection Medications: Beta-agonists (norepi, epi, dobutamine), theophylline, adenosine Surgery (highest in cardiac surgery)
888
different time categorizations of a fib
New-onset Paroxysmal: Continuous AF episode longer than 30 seconds but terminates spontaneously or with intervention within 7 days of onset (episodes may recur) Persistent: Continuous AF sustained >7 days “Long-standing” persistent: ≥ 12 months Permanent: Joint decision by patient and clinician to cease further attempts to restore/maintain sinus rhythm
889
investigation in a fib
EKG (r/o MI, pre-excitation, conduction disturbances) Transthoracic Echocardiogram (structural/valvular heart disease, function, atrial enlargement) Transesophageal Echocardiogram (TEE) for LA thrombi to guide cardioversion Labs: CBC Serum Na, K, Calcium, Magnesium Serum Creatinine/eGFR TSH LFT A1C, Lipids (risk stratification, can be done as outpatient) INR (baseline) Other Holter monitoring/exercise testing to evaluate rate control CXR if pulmonary disease or heart failure suspected BNP or N-terminal pro-BNP may be elevated in paroxysmal and persistent AF in the absence of clinical heart failure (and decrease in sinus) Electrophysiological Study if AF due to SVT where ablation may be helpful to prevent/reduce recurrences of AF (suspect pre-excitation when delta wave on EKG) Troponin if suspect ischemia/infarction Sleep study if suspect obstructive sleep apnea
890
acute management of unstable a fib
Always ABCs! Unstable if Hypotension or ACS or pulmonary edema (heart failure) Consider other causes of hypotension if HR<130 (MI, PE, sepsis, hypovolemia) Urgent Electrical DC cardioversion (AP pads, 200J synchronized) if hemodynamic instability (especially if >150) or if rate control not effective Consider procedural sedation, eg. Etomidate 0.1mg/kg (7-10mg) IV Immediate anticoagulation x 4 weeks Manage hypotension Fluids (care for pulmonary edema) Vasopressors
891
acute management of stable AF
Treat underlying/reversible causes Review medications Avoid beta-adrenergic vasopressors (epi/norepi/dobutamine), consider using phenylephrine instead Optimize volume status Treat pain, anxiety, withdrawal Treat electrolyte abnormalities (potassium, magnesium) Consider empiric magnesium 2-4g IV if magnesium levels not available Treat hypoxemia or respiratory distress (CPAP/BiPAP/HFNC) r/o sepsis, PE, thyrotoxicosis, etc… r/o WPW or pre-excitation syndrome (bizarre QRS change in width beat to beat and HR >220) If WPW, do NOT start AV node slowing medications (Amiodarone, BB, CCB), consider only electrical cardioversion Rate vs. Rhythm control
892
when to consider rate control over rhythm in a fib
Asymptomatic Chronic AF (eg. >1y diagnosed AF) Onset AF>48h and not anticoagulated (risk of thrombus)
893
medication to use for acute rate control in a fib
LVEF≥40%: Beta-blockers Metoprolol IV 5mg q5mins x 3 PRN (max 15mg) Convert to PO with a 1:2.5 (IV:PO) ratio, start 30mins after effective IV rate control Esmolol IV ND-CCBs Diltiazem 15-25mg IV bolus (0.25mg/kg) x1, can repeat q15 mins once, then infusion at 2.5-15mg/h (consider reduce dose after target heart rate reached as diltiazem can accumulate) LVEF<40%: B-blockers Severe heart failure and longstanding AF: Digoxin 0.25mg IV x1 Borderline hemodynamic instability: Amiodarone
894
when to chose acute rhythm control in a fib
Highly symptomatic (especially if symptomatic despite adequate rate control) Risk of hemodynamic instability (heart failure, pulmonary hypertension, mitral stenosis) Newly diagnosed AF (within 1 year) Low risk (NVAF<12h with no recent stroke/TIA, or <48h with CHADS2<2) or if on OAC≥3w Atrial Flutter Associated with reduced CV deaths and rates of stroke
895
DCCV vs pharmalogical rhythm control in a fib
Electrical more effective (150J biphasic, or greater) -Ideal if unknown medical history -Consider paddles with force in obese patients -Consider preparation of atropine and pacing in the event of prolonged sinus pause -Consider second trained operator managing sedation and airway Pharmacological ideal on non-fasting patient and does not require procedural sedation -AVOID if hypotension, ischemic heart disease, heart failure, conduction system disease/significant structural heart disease, and Brugada syndrome.
896
which medication to use for rhythm control (chemical cardioversion)
Procainamide 1g (or 15-18 mg/kg) IV over 60 min Time to conversion 60 minutes, avoid in Brugada Amiodarone 150-300mg IV bolus then infusion at 1mg/min, can repeat bolus x1 OAC x 4w, then as per CHADS65
897
who to hospitalize in a fib
YES if highly symptomatic with acute medical illness/complex medical conditions, inability to achieve rate control, or require monitoring/testing not available as outpatient
898
which patient with a fib to give OAC
Short-term OAC x 4 weeks after cardioversion Long-term OAC if CHADS65
899
when to consider long term rate control in a fib
persistent a fib
900
target of resting HR in a fib
100
901
which long term rate control agent to chose in a fib depending on comorbidities
CHF: BB preferred+/- Digoxin CAD: BB preferred No CHF/CAD: CCB preferred if no compelling indication for BB, Digoxin or combo HTN or reactive airway disease: CCB
902
name 3 beta blockers and 3 other agents used in long term a fib rate control
Beta-blockers as initial therapy in MI or LV systolic dysfunction: -Bisoprolol 2.5mg PO daily (target 10mg PO daily) -Preferred if LV dysfunction Metoprolol 12.5-25mg PO BID (target 100-200mg PO BID) -Preferred if CAD, HTN Carvedilol 6.25mg BID (target 25 mg BID) -Preferred if LV dysfunction ___________- Diltiazem extended release 120-360mg PO daily Verapamil extended release 180-480 mg PO daily or immediate release divided TID-QID Digoxin 0.0625-0.25mg PO daily (max trough 1.2mcg/mL) in selected older/sedentary individuals with HF and for those with inadequate response or contraindication to BB/CCB
903
when to chose acute rhythm control in acute stable a fib
Highly symptomatic (especially if symptomatic despite adequate rate control) Risk of hemodynamic instability (heart failure, pulmonary hypertension, mitral stenosis) Newly diagnosed AF (within 1 year) Low risk (NVAF<12h with no recent stroke/TIA, or <48h with CHADS2<2) or if on OAC≥3w Atrial Flutter Associated with reduced CV deaths and rates of stroke
904
when to consider rhythm control in rate-controlled patients
Symptoms or extreme impairment QOL Recently diagnosed within 1 year Multiple recurrences Arrhythmia-induced cardiomyopathy. However long-term oral antiarrhythmic therapy when AF becomes permanent AVOID IF: advanced sinus or AV nodal disease unless PPM or ICD Intermittent antiarrhythmic "pill in pocket” if 1-2 episodes / year
905
which medication for long term rhythm control to use for a fib , depending on the LV function + 1 other non pharmalogical intervention
Normal Systolic Function -Dronedarone 400mg PO BID (avoid in permanent AF or CHF) -Flecainide (50-75mg daily, max 150mg) or Propafenone (150mg daily, max 300mg) used with BB (eg. Metoprolol 25mg) or ND-CCB --Time to convert 2-6h -administer BB or ND-CCB ≥ 30mins before Class Ic antiarrhythmic (prevent risk of Atrial Flutter 1:1 AV conduction) -sotalol (40mg BID, max 160mg) -Amiodarone LV systolic dysfunction or CHF -Amiodarone: -loading: 400 mg PO twice daily x 1 week then 400 mg daily x 2 weeks, or 400 mg daily x 1 month -maintenance: 100-200mg daily CAD: -Amiodarone, Dronedarone, Sotalol Catheter Ablation -First line for symptomatic Atrial Flutter Consider if symptomatic despite antiarrhythmics, if rhythm control strategy remains desired Not an alternative to anticoagulation – still need anticoagulation after successful catheter ablation
906
CHADS65
(Congestive Heart Failure, Hypertension, Age 65, Diabetes, Stroke/Transient Ischemic Attack)
907
when to start OAC in a fib or ASA
OAC alone if age >65, or stroke/TIA, or HTN or HF or Diabetes ASA alone if CHADS65=0, and arterial vascular disease (coronary, aortic, peripheral) with none of above
908
which anticoagulation to use in a fib
DOAC (apixaban, rivaroxaban, edoxaban, dabigatran) warfarin
909
when to chose warfarin rather than DOAC in anticoagulation of a fib (4 pros)
DOAC preferred over warfarin in non-valvular AF (warfarin recommended in valvular AF, breastfeeding, liver failure, gastric bypass) -Careful in low eCrCl, measure CrCl regularly (6-12 months) and with acute illness
910
name 4 doacs
Apixaban 5mg PO BID (2.5mg PO BID if two of creat>133mcmol/L, age>80y, wt ≤60kg), avoid in CrCl<15) Rivaroxaban 20mg PO daily (15mg PO daily in CrCl 30-49, avoid in CrCl<30) Edoxaban 60mg PO daily (30mg PO daily in CrCl 30-49, weight ≤60kg, P-glycoprotein inhibitors) Edoxaban 15mg PO daily can be considered in elderly patients when standard oral anticoagulants are considered inappropriate (eg. bleeding risk) Dabigatran 150mg PO BID (110mg PO BID if age≥80y or >75y and high risk of bleed, avoid in CrCl<30)
911
lifestyle counselling in prenatal care
Smoking cessation Weight control (under or overweight) Avoid alcohol/drugs Avoid consumption of undercooked meats and unpasteurized foods (risk of toxoplasmosis, CMV, listeria) Avoid mosquito (clothing, repellents) Optimizing natural fertility Intercourse timing Simple = 3x/week Fertile during 5 days prior to ovulation until ovulation (14 days prior to onset of menses) So take longest and shortest cycles (eg. 28-32 days) so ovulation on D14-18, so intercourse D9-18 q2-3d >10 days of abstinence can decrease sperm quality Avoid lubricants Reasonable time frame to conceive (85% pregnant in one year) Advise that risk of spontaneous pregnancy loss and chromosomal abnormalities increases with age of both of mother and father Disease optimization (eg. glycemic control) Folic acid 0.4-1mg/d (high risk 5mg daily)
912
prenatal investigations and indications for certain genetic screening
STI screen HbA1c Rubella and Varicella If lack of immunity, immunize and wait one month before conception Genetic screening based on family history Thalassemia (AR): CBC, Hb electrophoresis Mediterranean, South East Asian, Western Pacific Sickle Cell (AR) same as Thalassemia African, Caribbean CF (AR): CFTR gene DNA Mediterranean, Finnish, Caucasian, or FHx Tay Sachs (AR): Enzyme HEXA or DNA HEXA gene Ashkenazi Jewish* (Canavan disease, Familial Dysautonomia, ask for Fam Hx of Gaucher, CF, Bloom, Niemann-Pick), French Canadian, Cajun Fragile X (X-linked): FMR 1 gene DNA Fam Hx
913
common medication to stop during pregnancy
Stop retinoids / Vitamin A >10,000 units/day (risk of malformations in T1) Stop ACE-i/ARB (risk of fetal kidney disease in T2/T3) Change to methyldopa, labetalol, calcium channel blocker (Nifedipine XL) Stop oral anti-hyperglycemic Consider metformin or glyburide Stop warfarin (risk of malformations in T1) Consider heparin/LMWH Avoid lithium (very low risk of Ebstein anomaly and malformations in T1) Avoid valproic acid/anticonvulsants (risk of malformations in T1) Avoid Sulpha drugs and Trimethoprim (anti-folate risk in T1, and kernicterus in T3) Avoid tetracycline (bone development, teeth staining) Avoid NSAIDs (cardiac defects, spontaneous abortion) Risks of untreated depression often outweigh risks of antidepressants Low risk of teratogenicity (some data suggests paroxetine may have small increase in congenital heart defects, other studies have not found this association) May be associated with a small reduction in gestational age at birth that is not clinically significant
914
pregnancy 1st visit investigations
Confirm pregnancy with urine or serum bhCG Accurate dates by LMP Confirm with T1 dating ultrasound Requisition for 20w morphology ultrasound
915
in pregnancy Consider low-dose 80-160mg ASA at bedtime ideally before 16 weeks gestation, if either 1 high risk factor or 2 moderate risk factors (name the risk factors)
1 high risk factor: history of preeclampsia, multifetal gestation, chronic hypertension, DM1 or DM2, renal disease, autoimmune disease (SLE, antiphospholipid) 2 moderate risk factors: Nulliparity, Obesity (BMI≥30), family history of preeclampsia, age 35 years and older, sociodemographic risk factors (low socioeconomic status, etc), or personal history factors (fetus is small for gestational age, previous adverse pregnancy outcomes, etc)
916
routine T1 bloodwork
Blood type and screen (Rh and Ab) CBC HIV Rubella Syphilis HepBsAg HepCAb UA, UCx Gono chlam Consider VZV, TSH (Target <2.5, then <3 for third trimester), ferritin, Hb electrophoresis, random glucose/HbA1c/fasting glucose
917
types of T21 screening
Serum Integrated Prenatal Screen (85% detection rate [DR], 4.4% false positive [FP], covered in Quebec) 9-13.6 (best 10-11.6) PAPP-A 15-20.6 (best 15.2-16) AFP, uE3, hCG, inhibin-A Integrated Prenatal Screen (87% DR, 1.9% FP) SIPS + Nuchal Translucency ultrasound (11-13.6w, best at 12-13.3w) Quad screen (77% DR, 5.2% FP) 15-20.6 (best 15.2-16) AFP, uE3, hCG, inhibin-A Cell-free Fetal DNA screen (99.9% DR, however confirm with amniocentesis as 33% FP) After 9w Chorionic villus sampling (amniocentesis to rule out false positive for mosaic karyotype) 10-12w Amniocentesis (if abnormal serum screen, anomalies on U/S or previously affected fetus) After 15w Risk <1/200 for loss of pregnancy
918
when to administer winrho
If Rh negative, schedule for Rh Ig (WinRho) 300mcg IM at 28w everytime there is a bleed
919
when to do ultrasounds in pregnancy
T1 US for dating 20 w morphology ultrasound
920
labs in pregnancy to be done at 26-28w
50g OGT, CBC, ferritin, repeat type and screen in RH neg repeat HIV, gono chlam, syphilis if high risk
921
when to do GBS screen in pregnancy
35-36w - GBS vaginal and rectal swab (results valid for 5w)
922
when to start cervical examination and membrane stripping
38 weeks
923
what to use to UTI in pregnancy: Treat midstream culture positive >10^5 cfu/mL or symptomatic with >10^2cfu/mL to prevent pyelo, chorio, preterm birth
amoxicillin 500 PO TID x 7 days Nitrofurantoin 100mg PO BID x 7 days (avoid at labour because of hemolytic anemia) TMP SMX 1 DS tab BID x 3 days (avoid in first trimester and near term) Amoxicillin-clavulanate 500 mg PO BID x 7 d consider repeat culture 1-2 weeks after tx
924
how to prevent GBS intrapartum
IV Pen G 5mill units + 2.5 units q4h (cefazolin if low risk, clinda if high risk and sensitive or vanco if not sensitive) Adequate intrapartum Abx is >4h of IV Abx
925
which pt to give pen G for GBS coverage in pregnancy
Treat if Previous infant with GBS GBS bacteriuria during current pregnancy Positive screen GBS unknown and one of: Preterm or ROM>18h or T>38C
926
in neonates, who to do CBC and blood cultures 9high risk of sepsis_
If infant well, but inadequate Abx AND Preterm <37w OR ROM>18h → consider Blood culture, CBC If WBC <5, high risk of sepsis and consider Abx If symptomatic (apnea, fever, tachypnea, tachycardia, lethargy, poor feeding) → septic workup (CBC, cultures, CXR, lumbar puncture) and early treatment
927
risk factors of prelabour rupture of membranes
Amniocentesis Cervical insuff/cerclage Prior conization/LEEP PPROM, preterm Vaginal bleed, Placental Abruption Polyhydramnios Multiple pregnancy Smoking STI, BV Low SES
928
investigations of PROM
No Digital Sterile speculum Look for fluid from cervix, cord Pooling in posterior fornix of vaginal vault Ferning on microscopic examination Liquid pH (>6) will turn nitrazine test blue (positive) Commericial tests (AmniSure, Actim PROM, ROM Plus) Consider collect fluid for lung maturity (fibronectin) Culture for STI and GBS Ultrasound for low AFI (Max vertical pocket <2cm or AFI ≤5 cm)
929
Complications of PROM
infection (fetal/maternal), umbilical cord prolapse, compression
930
management of PROM if term
Admit and regular vitals with daily BPP and WBC Term PROM Avoid Digital until labour/induction Consider antibiotics if indicated (no evidence in term PROM) IV Oxytocin for induction of labour in all term PROM Vaginal Prostaglandin higher chorio rates (but consider in unfavourable cervix) PO Misoprostol easier to administer If patient chooses expectant management >24h, need to evaluate for infection, avoid digital exams
931
management of pretern PROM PPROM
Admit and regular vitals with daily BPP and WBC Preterm <37w (PPROM) Unclear if expectant vs IOL (preterm vs infectious risks) If <34w generally expectant, prophylaxis with antibiotics (prolongs latency) Glucocorticoids (betamethasone x2) <34w Magnesium sulphate for neuroprotection <32w
932
treatment of intrahepatic cholestasis of pregnancy
Ursodeoxycholic acid 15mg/kg/day Early delivery at 36w Follow LFTs up to 8w post-partum
933
at what gestational age to cover with Mg SO4 for neuroprotection
under 32 w
934
at wahat gestational age to cover with dexamethasone for lung development
under 34w
935
gestational diabetes in pregnancy complications (fetal and maternal, 5 each)
Maternal Hypertension Polyhydramnios Retinopathy Hypoglycemia Pyelonephritis/UTI Fetal Macrosomia IUGR Hypoglycemia Polycythemia Fetal lung immaturity
936
RF for GDM (3)
Obesity Previous pregnancy with GDM or IGT Family history of DM
937
diagnosis of GDM and values
Screen at 24-28w with 50g OGTT, consider early HbA1c or fasting glucose if higher risk 1h 50g OGTT <7.8 mmol/L = normal 7.8-11.0 -> Indication for 2h 75g OGTT ≥ 11.1 GDM 2h 75g OGTT FPG ≥ 5.3 mmol/L 1h ≥ 10.6 mmol/L 2h ≥ 9.0 mmol/L
938
management of GDM
Dietary advice Pharmacotherapy (insulin, metformin, glyburide) Target A1C ≤6.5 (ideally ≤6.1) Blood glucose targets: Prepandial <5.3, 1h Postprandial <7.5 (or <7.8), 2h Postprandial <6.7mmol/L Serial ultrasound to monitor growth Induce by 40w gestation Blood sugars hourly during labour Follow-up with repeat 75g OGTT between 6 weeks and 6 months postpartum (risk of DM2)
939
targe A1c in pregnancy
≤6.5 (ideally ≤6.1
940
target blood glucose in pregnancy
Blood glucose targets: Prepandial <5.3 1h Postprandial <7.5 (or <7.8), 2h Postprandial <6.7mmol/L
941
stages of labour
First stage - regular contractions + cervical change (dilation/effacement) Latent (days): Nulliparous up to 3-4cm dilation Parous up to 4-5cm Active Contractions leading to cervical change after above cervical change Second stage - Full dilation to delivery (active = pushing) Third stage - Delivery of baby to placenta Fourth stage - Placenta to one hour postpartum
942
dystocia definition
First stage (active) 4h of <0.5cm/hr dilation or no cervical dilation>2h Obstructed (lack of dilation/descent) if evidence of strong contractions Second stage (active) >1h active pushing without descent
943
causes of dystocia
Power (50-60mm Hg above baseline by IUPC, >60 seconds) -oxytocin Passenger (fetal position, attitude, size, abnormalities) - reposition Passage (pelvic/soft tissue factors) - ensure bladder empty Psyche (pain/anxiety)
944
management of dystocia
Prevent If epidural analgesia, augment ARM/oxytocin early Analgesia, hydration, rest Amniotomy Oxytocin augmentation, IUPC to assess contractions, Start at 1-2 mU/min increase q30mins to reach target 8-12mU/min (max at 20-30), or high-dose protocol start at 2-4mU/min Assisted vaginal Birth C-section
945
risk factors of shoulder dystocia
Antepartum: Suspected macrosomia (induction does not prevent risk), diabetes, GA>42w, multiparity, previous hx dystocia, previous macrosomia, weight gain, obesity Intrapartum: Prolonged labour, operative vaginal delivery, labour induction, epidural anesthesia
946
complications fo shoulder dystocia
fetal: hypoxia, asphysia, fracture, brachial plexus palsy, death Brachial plexus injury most common at C5-6 (forearm flexor/supinator) → waiter’s tip = Erb-Duchenne, most recover C8-T1 = Klumpke (claw-hand) is rare Maternal: PPH, uterine rupture, 4th degree tears
947
management of shoulder dystocia (ALARMER)
Avoid the 4 P’s (Pull, push, panic, pivot head) Do ALARMER: Ask for help, Tell patient to STOP pushing until manoeuvre completed Lift legs in McRoberts Flatten head of bead and hyperflex legs Anterior Shoulder disimpaction (apply suprapubic pressure to the posterior anterior shoulder) If steady pressure not working, try rocking pressure Adduct anterior shoulder by applying pressure to posterior shoulder (Rubin) to push towards chest of baby Rotate posterior shoulder like screw (Wood’s) Manual removal posterior arm - Grab posterior hand and sweep across chest and deliver (can lead to fracture) Roll onto all fours - allows easier access for rotation and removal of posterior arm Episiotomy can facilitate above maneuvers but does not relieve dystocia
948
diagnosis of chorioamnionitis
Fever (T (≥39°C or ≥38°C on two occasions 30mins apart) One of Baseline FHR >160/min for ≥10 mins (excluding periods of variability) Maternal WBC >15 in absence of corticosteroids (ideally showing left shift) Purulent fluid from cervical os visualized by speculum
949
treatment of chorioamnionitis
Broad-spectrum antibiotics, eg. Ampicillin 2g IV 6h and Gentamicin 5mg/kg once daily Consider Clindamycin or Metronidazole to cover aneaerobes if undergoing surgery Prompt induction or augmentation of labor (cesarean only for standard obstetrical indications)
950
normal Fetal heart monitoring
Normal FHR baseline 110-160, at least 2 accelerations (≥15bpm lasting ≥15s) in 40mins strip Moderate variability (5-25bpm)
951
abnormal features of FHR
Abnormal >160 for 10 mins or <110 for 10 mins, changing FHR baseline, decelerations Tachy: Reposition (alleviate cord compression), rule out fever/dehydration/drug/prematurity, IV fluids, maternal pulse/BP Brady: As above, check for cord prolapse Decelerations: As above, check amniotic fluid for meconium, oxygen if mother hypoxic or hypovolemic Early: gradual decrease, usually same time beginning, peak and ending Due to fetal head compression Late: gradual decrease, peak after contraction peak Uteroplacental insufficiency Variable: abrupt decrease (onset to nadir <30 seconds) Complicated : <70bpm for >60 seconds, loss of variability, biphasic, prolonged secondary acceleration, fetal tachy/brady Cord compression If unresponsive to resuscitation → consider continuous EFM, fetal scalp sampling, delivery Decreased variability Sleep <40 mins Meds (sedative, BB, MgSO4, steroids) Preterm <32w Fetal tachycardia Congenital Anomalies Uterine activity (frequency averaged over 30 mins, duration, intensity, resting tone) Normal uterine contractions = <5 in 10 minutes, lasting <90 seconds between 25-75 mmHg, resting tone <7-25mmHg
952
fetal rescucitation steps
Stop/decrease oxytocin Change position (left/right lateral) Improve hydration with IV fluids Vaginal exam r/o cord Amnioinfusion if variable decelerations Reduce maternal anxiety Consider oxygen if needed
953
DSM 5 dx of schizophrenia
≥2 for most of the month (with one of the first three) Delusions (eg. perscution, passivity [thoughts/actions controlled by external force]) Hallucinations Disorganized Speech Grossly disorganized or catatonic behavior Negative symptoms (eg. avolition, diminished emotional expression) Marked dysfunction r/o schizoaffective, depression, bipolar Schizophrenia >6mo
954
types of delusions (6)
Persecutory Grandiose Erotomanic (eg. movie star is in love with them) Somatic (eg. sinuses infested by worms) Delusions of reference (eg. dialogue on TV directed towards patient) Delusions of control (eg. thoughts/movements controlled by others)
955
types of hallucinations
Auditory (most common) Visual Tactile Olfactory Gustatory
956
types of though disorganisation
Alogia/poverty of content – Very little information conveyed by speech Thought blocking – Suddenly losing train of thought, exhibited by abrupt interruption in speech Loosening of association Tangentiality – (circumstantiality if content eventually returns to original topic) Clanging or clang association – Using words in a sentence that are linked by rhyming or phonetic similarity (eg, “I fell down the well sell bell.”) Word salad – Real words are linked together incoherently, yielding nonsensical content Perseveration – Repeating words or ideas persistently, often even after interview topic has changed
957
psychiatric DDX of psychosis
Brief psychotic disorder >1d-1mo Schizophreniform >1mo - <6mo Schizophrenia >6mo Schizoaffective (major mood episode, and >2w of delusions/hallucination in absence of mood) Bipolar I with psychotic features Major depressive disorder with psychotic features Personality disorder (schizotypal, borderline) PTSD ADHD, CD, ODD Substance-induced psychotic disorder
958
Medical DDX of schizophrenia
Autoimmune (SLE, MS) Infection (HIV, Neurosyphilis, HSV encephalitis, Lyme, Prion disorders) Endocrine (Thyroid, parathyroid, adrenal) Metabolic (Wilson's disease, acute intermittent porphyria) Dementia Neurologic (trauma, lesion, seizure, stroke) B12 deficiency Malignancy Medication Delirium
959
screening questions for schizophrenia
Do you ever hear voices when you are alone? What do these voices say to you? Do you ever feel that people are talking about you behind your back? Or that they are out to get you? Do you ever think that people can pick up on or control what you are thinking?
960
investigation of schizophrenia
CBC +/- blood culture Electrolytes LFT TSH Syphilis screen HIV UA +/- urine culture Urine drug screen B12 Consider Head CT/MRI Consider baseline EKG, lipids
961
management of schizophrenia
Family intervention and CBT Housing, vocational, financial support, social worker Admission, day-time inpatient care Detoxification Agitation PRN Cocktail (LAB) - can mix all three in one syringe -Loxapine 25-50mg PO/IM q1-2h or Haldol 5mg IM q1-2h (max 4/24h) -Ativan 1-2mg PO/IM q1-2h -Benadryl 25-50mg PO/IM q1-2h atypical antipsychotic -Risperidone 1-6mg/day smallest risk for metabolic side effects -Clozapine for non-responders
962
adverse effects of clozapine
Adverse: agranulocytosis, seizure, myocarditis, cardiomyopathy
963
what to do during FU of schizophrenia
Positive and negative symptoms Suicidal, homicidal ideation Function (social, home, ADLs) Psychosocial supports Medication adherence Medication side effects Signs/symptoms Function Suicidal/aggressive thoughts/behaviour Substance use BMI Labs: Fasting glucose/Lipids baseline, 3mo, then yearly
964
side effects of antipsychotics
EPS, hyperprolactinemia, cardiometabolic risk (weight gain, diabetes, dyslipidermia), anticholinergic, antihistamine (sedation), antiadrenergic (orthostatic hypotension)
965
name 4 extrapyramidal sx
acute dystonia akathisia parkinsonism tardive dyskinesia
966
management of EPS
Consider antipsychotic dose reduction Consider switching to agent with less EPS Consider dystonia prophylaxis if treating with haloperidol or high risk
967
treatment of acute dystonia
Acute Dystonia (hours-5days, involuntary contractions of major muscle groups) Severe - Benztropine 1-2mg IM/IV or Diphenhydramine 25mg IM Mild - Benztropine 1-2mg PO daily
968
akathisia (restlessness, most common EPS) treatment
Beta-blocker - Propranolol 10mg (to 40mg) PO BID Anticholinergic - Benztropine 1-2mg PO BID Benzodiazepine - Lorazepam 0.5mg PO BID
969
parkinsonism sx in EPS side effects of antipsychotics treatment
Anticholinergic - Benztropine 1-2mg PO BID Non-anticholinergic - Amantadine 100mg PO BID-TID
970
tardive dyskinesia treatment and definition
(years of treatment - lip smacking, facial grimace, jaw movements, choreiform movements of extremities/trunk) Switch to antipsychotic with low risk TD (quetiapine, clozapine) Benzodiazepine - Clonazepam Other - Botox injections, tetrabenazine, anticholinergic, deep brain stimulation
971
neuroleptic malignnat syndrome definition
Altered mental status, rigidity, hyperthermia (>38-40C), dysautonomia (tachycardia, hypertension, tachypnea In the setting of neuroleptic use of dopamine withdrawal r/o infection (eg. meningitis) or drug-induced r/o serotonin syndrome (shivering, hyperreflexia, myoclonus, ataxia, GI symptoms)
972
neuroleptic malignant syndrome treatment
Stop neuroleptic ICU - aggressive supportive therapy Treat hyperthermia Follow serum CK Consider benzodiazepines, dantrolene, bromocriptine, amantadine if no response to supportive care within 1-2d
973
types of seizures
Generalized: Tonic-clonic (grand mal), absence (petit mal), myoclonic Diffuse motor activity and LOC at onset Partial (focal, eg. one extremity) Complex = Consciousness affected Partial = No LOC Status epilepticus if >5-15mins or multiple seizures without full return to consciousness Pseudoseizure Diffuse motor activity (moving all extremities) with preservation of consciousness (eg. speaking) Eyes squeezed shut (most epileptic patients do not resist eyelid raising) Responsive noxious stimuli (nasal swab) Out-of-phase movement of limbs (usually limbs move synchronously) Unusual movmeents (pelvic thursting, side-to-side head movement)
974
status epilepticus management
Protect airway, oxygen, intubation if unable to terminate seizure IV access if possible Terminate seizure (prevent brain damage) First-line: Benzodiazepines Lorazepam 0.1mg/kg IV up to max 8mg IV, Midazolam 10mg IM Diazepam 10mg IV/rectal/ET q5 mins x 3 r/o hypoglycemia - Glucose 1-2 amps of D50W (25g-50g) IV (can be given empirically if no glucose test available) r/o hyponatremia - 150mL of 3% NaCl (with repeat bolus if persistent seizure) or 2 amps of NaCO3 (100mEq in 100mL) Anti-epileptic for ALL status epilepticus (seizure >5mins) If seizure persists, prepare for intubation Propofol 1.5mg/kg + Ketamine 2mg/kg + Rocuronium 0.6mg/kg (lower dose so that does't last to long) Then propofol infusion at 3-5mg/kg/hour (avoid propofol infusion syndrome, keep <5mg/kg/h) Prepare pressors PRN (norepinephrine) If severely hypotensive, consider Midazolam 0.2mg/kg loading dose with 0.1mg/kg/h infusion If seizure persists, consider re-bolus propofol and ketamine or high-dose ketamine 1-2mg/kg q5mins PRN (up to 10mg/kg cumulative dose) Consult neurology, ICU
975
anti-epileptic medication for status epilepticus (after benzo)
Keppra 60mg/kg IV (up to 4500mg) over 10 minutes Preferred as safe, no contraindications, and minimal side effects (SIADH) Valproic acid 40mg/kg (up to 3000mg) over 10 minutes Fosphenytoin Phenobarbital (usually in alcohol withdrawal)
976
anti-epileptic medication for status epilepticus (after benzo)
Keppra 60mg/kg IV (up to 4500mg) over 10 minutes Preferred as safe, no contraindications, and minimal side effects (SIADH) Valproic acid 40mg/kg (up to 3000mg) over 10 minutes Fosphenytoin Phenobarbital (usually in alcohol withdrawal)
977
ddx of seizure
TIA Eclampsia Syncope Migraine Cardiac disorders (Dysrhythmias, Long QT syndrome, HOCM) Sleep disorders (Narcolepsy) Movement disorder Acute dystonia Rigors Pseudoseizure
978
causes of seizures
Stroke Metabolic / Electrolyte Hypo/hyperglycemia Hypo/hypernatremia Hypophophatemia Hypocalcemia Hyperammonemia/hepatic encephalopathy Uremia Hypoxia Hyperthermia Hypertension (encephalopathy, PRES, eclampsia) CNS trauma, tumor, bleed, stroke (ischemic>hemorrhagic), infection (meningitis, encephalitis, abscess) Drug intoxication (anticonvulsants, antidepressants, antipsychotics, isoniazid, opioids, theophylline, sympathomimetics) Drug withdrawal (alcohol, barbiturates, benzodiazepines) Low dilantin (in known epilepsy)
979
investigations of seizures
Known seizure Serum anticonvulsant levels First seizure Glucose Chem (Sodium, Creat, Calcium, Magnesium, Phos, Urea) Consider LFT, ammonia in cirrhosis B-hCG CBC Consider CK for rhabdo Consider anti-epileptic drug levels (for adherence) Consider toxicology (cocaine, methamphetamine) Head CT generally recommeneded unless obvious cause (non-adherence to anti-epileptic) In children, if <1yo and in those with cognitive or motor developmental delay, unexplained neurologic abnormalities, a history of focal seizures, or findings on electroencephalography (EEG) that are incompatible with benign partial epilepsy of childhood or primary generalized epilepsy EEG within 24-48h LP if immunosuppressed (r/o meningitis, encephalitis)
980
when to start Keppra
Do not need to start antiepileptic medication in first seizure Consider if risk factor (eg. abnormal EEG results or brain injury/lesion) If no risk factor, counsel on excellent prognosis, and can consider medication if second seizure episode occurs Consider as per patient's preference or work (eg. pilot) Anticonvulsants (valproic acid, phenytoin) are teratogenic, advise taking folic acid and be on lowest dose
981
side effect of keppra
Osteoporosis, hematologic (decreased WBC, pancytopenia), liver failure (phenytoin), GI symptoms, fatigue Antibiotics may interfere with anticonvulsant levels
982
what to counsel ppl with seizure on safety issues
Dangers of swimming, living alone, operating machinery, chewing gum, heights Seizure free x 1 year before driving
983
indication for screening for CKD/RF
Hypertension Diabetes Age 60-75 with Cardiovascular disease Age 18+ First Nations, Inuit, Metis Other: Hereditary kidney disease, vasculitis, auto-immune (SLE)
984
diagnosis of CKD
eGFR and urine ACR (Albumin-to-Creatinine ratio) If eGFR <60, repeat test in 3 months (or sooner if suspect clinical concern for rapid decline) Adjust for black patients (eGFR multiplied by 1.21) If urine ACR ≥ 3 mg/mmol, repeat total of three times in next three months (at least 2 out of three should be elevated to diagnose) Acute illness/acute kidney injury (AKI) which may require more rapid evaluation Reversible causes (NSAIDs, contrast, BPH/urinary retention)
985
rapidly reversible causes of AKI
(NSAIDs, contrast, BPH/urinary retention)
986
CKD workup
Once CKD diagnosed, Urine R+M (urinalysis and microscopy), electrolytes Repeat eGFR and urine ACR q6 months ___ If eGFR<60 UA, CBC, HBsAg, HBcAb, HBsAb, PPD If UA 2+ blood/moderate or >10RBC/hpf, suspect autoimmune, anemia, or hypercalcemia Add C3, C4, ANA, ANCA, SPEP, Ig's, free light chains If history of stones, obstruction, frequent UTIs, family history PCKD, gross hematuria Renal ultrasound ____ Consult nephrology if eGFR<30 ACR>60 Progressive decline in eGFR Unable to achieve blood pressure targets Electrolytes abnormalities (potassium) RBC casts or hematuria >20RBC/hpf
987
lifestyle management of CKD
Smoking cessation Healthy weight (nutrition, exercise) Diet modification if eGFR<60 (not on dialysis) Limit sodium (<2g/day or <5g salt/day), protein (0.8g/kg/day), phosphate (0.8g/day), calcium (1.5g/d), potassium (1.5g/d) Consider Vaccination Influenza annually Pneumococcal with repeat five years after
988
pharmalogical management of CKD
Manage hypertension (sBP<120 as per KDIGO 2021, or <130/80 for transplant and diabetic) -ACEI or ARB (Consider in non-hypertensive if Urine ACR >30mg/mmol) --Follow creatinine and potassium 2 weeks after starting --Stop if eGFR >25% drop from baseline Manage diabetes (A1c<7) Manage hyperlipidemia Statin if -≥50 years old -≥18 years old AND diabetes or CAD or CVA or 10 year Framingham risk >10% Renally dose medications Minimize further kidney injury -Avoid NSAIDs, Aminoglycosides, Lithium, contrast media Sick Day Medications list (to avoid if unable to maintain hydration) -SADMANS (Sulfonylureas, ACEI, Diuretics, Metformin, ARB, NSAIDs, SGLT2i)
989
management of complications of CKD
volume overload hyperkalienia metabolic acidosis hyperphosphatemia hyperparathyroidism hypertension anemia decrease in EGFR
990
management of volume overload in CKD
Restrict dietary sodium (eg. <2g/d) Diuretic therapy (usually daily loop diuretic, eg. furosemide 80mg)
991
management of hyperkalemia in CKD
Low-potassium diet (<1.5g/d) Avoid medications that raise serum potassium (NSAIDs)
992
management of metabolic acidosis in CKD
Sodium Bicarbonate (NaHCO3) 1000 mg BID to maintain normal serum bicarbonate (>20-22mEq/L)
993
management of hyperphosphatemia in CKD
Restrict dietary phosphate (<0.8g/d) Phospate binders (eg. Sevelamer 800mg PO TID meals)
994
management of hyperparathyroidism
Treat hyperphosphatemia, vitamin D deficiency If >150-200pg/mL, consider calcitriol or vitamin D analog -Do not use calcitriol if serum phosphate or corrected serum total calcium is elevated -Adjust dose to maintain PTH <150pg/mL
995
management of hypertension in CKD
Sodium restriction ACEi/ARB If edema, loop diuretic +/- thiazide diuretic If no edema, diuretic or CCB (consider non-DHP CCB in proteinuria) Resistent hypertension, consider spirinolactone
996
investigation and management of anemia in CKD
Work-up: CBC, retic, iron studies, ferritin, B12/folate, r/o GI loss Replete iron stores if TSAT ≤30% and Ferritin ≤500ng/mL -eg. Venofer 300 mg IV q 2 weeks x 3 doses If Hb<90 and iron replete or treated for iron deficiency consider Erythropoiesis-stimulating agents (ESA) -Aranesp 0.45 mcg/kg/week --Adverse: CVA, AVF clotting hypertension, cancer recurrence --Target Hb 100-115 Monitor Hb monthly until stable, Fe q3 months
997
causes for decrease in EGFR in CKD
Progression of disease Hypovolemia (vomiting, diarhea, excessive diuresis) UTI NSAID, medications Obstruction
998
complications of end stage renal disease
Pericarditis/pleuritis Uremic encephalopathy/neuropathy (confusion, asterixis, myoclonus, wrist/footdrop, seizures) Uremic bleeding Fluid overload refractory to diuretics (CHF/LVH) Hypertension poorly responsive to medications Metabolic disturbances -Hyperkalemia -Hyponatremia -Hyper/hypocalcemia -Hyperphosphatemia -Metabolic acidosis Malnutrition Other Complications AKI Drug toxicity Infection Hypothyroidism
999
analgesia in renal failure
Encourage non-pharmacological Acetaminophen Topical capsaicin Hydromorphone, fentanyl, methadone, buprenorphine Gabapentin, Pregabalin TCA (amitriptyline, nortriptyline) Avoid NSAIDs, morphine, codeine, tramadol
1000
ckd pain sources
Nociceptive pain is usually due to tissue injury. Causes of nociceptive pain common to patients with advanced CKD include (but are not limited to) osteoarthritis, renal osteodystrophy, dialysis-related amyloid arthropathy, and kidney or liver capsule distension from autosomal dominant polycystic kidney disease (ADPKD) -tx with acetaminophen, hydromorphone, fentanyl, methadone or buprenorphine Neuropathic pain arises from abnormal neural activity secondary to disease, injury, or dysfunction of the nervous system. Common examples of neuropathic pain among patients with advanced CKD include diabetic neuropathy, phantom limb pain, and carpel tunnel syndrome. -treat with acetaminophen, gabapentin or pregabalin
1001
elements of geriatric assessments
Immunizations (influenza, tetanus/diphteheria, pneumococal, herpes zoster) Habits (smoking, alcohol, substance, sexual) Nutrition (diet, appetite, weight loss, dentition,m swallowing) Bowel and Bladder (incontinence, constipation, diarrhea) Communication (vision, hearing) Pain Cancer screening ____ Cognition: MCI vs dementia vs. Delirium– MMSE / MOCA BPSD (Behavioural and Psychological Symptoms of Dementia)- SMART approach Safety – remove patient to safe environment Medical – perform an organic workup to treat reversible causes; reduce medication load Assess competency – decisions regarding personal care, finances, driving; protect assets Rest, nutrition, hydration ensured; address problems with pain, ambulation, vision, hearing, constipation Trial of medication – cholinesterase inhibitor/antipsychotic/antidepressant/ mood stabilizer Mood – Depression (MSIGECAPS) – PHQ-9 or geriatric depression scale Elder mistreatment/abuse -__ Function ADLs (dressing, eating, ambulating, toileting, transferring, hygiene/bath) IADLs (shopping, housework, accounting, food prep, telephone, transportation, taking meds) Fall risk (postural hypotension, vertigo) Vision Hearing Physical activity Mobility Driving _____-- Polypharmacy - Meds Non-prescription medication (herbal, OTC, vitamins) Consider efficacy/side effect profiles Convenient dosing/route Dispill / Blister pack Avoid treating side effect with another medication (medication cascade) Beer's Criteria STOPP/START criteria Social and Environmental Social activities, hobbies, interests Care support, POA Local resources Managing at home (financial, legal) Anticipate need for increased services Advance care planning (resuscitation)
1002
Modifiable Risk Factors in the Elderly (10)
Medical Visual/hearing impairment Polypharmacy Dizziness or orthostasis Incontinence Diabetes Depression Cognitive impairment/Dementia Vaccines Cancer, AAA screening Osteoporosis (Calcium, vitamin D, BMD) ___ Mobility Balance/gait impairment Muscle weakness Exercise level Environmental lighting Footwear ___ Habits Smoking Alcohol
1003
Commonly missed dx in elderyl
Lack of symptoms (eg. fever), or may present with confusion/delirium Commonly missed diagnoses are cancer, pulmonary embolus, coronary disease, aneurysms, appendicitis Depression can present with somatic complaints (cognition, functional, sleep, energy)
1004
4 features of parkinson's
resting Tremor (FYI: 4-6 Hz, pill rolling) muscle Rigidity (FYI: with cogwheeling) Akinesia/bradykinesia (slow movements, difficulty initiating movements) - (this answer changed from akathisia to akinesia, Feb 2021) Postural instability (FYI: late feature)
1005
Other than changes in vital signs, what other features might you find on physical exam of parkinson's?
masked facies/stare/reduced blink rate hypophonia (quiet voice/speech) drooling seborrhea of face/scalp micrographia positive glabella tap reflex stooped, shuffling gait difficulty initiating gait dysarthria
1006
ddx of parkinsonism
Dementia Depression Essential tremor Huntington's disease Multiple system atrophy Progressive supranuclear palsy Wilson's disease Multiple sclerosis Primary cerebellar dysfunction EtOH withdrawal or toxicity Liver failure
1007
ddx of parkinsonism
Dementia Depression Essential tremor Huntington's disease Multiple system atrophy Progressive supranuclear palsy Wilson's disease Multiple sclerosis Primary cerebellar dysfunction EtOH withdrawal or toxicity Liver failure
1008
side effects of levodopa
Somnolence Dizziness/orthostatic hypotension Headache Dyskinesia/impairment in voluntary movement (FYI: this is the #1 side effect) Confusion Brief duration of action/need for frequent dosing Psychosis: Hallucinations/delusions Agitation Disinhibition/impulse control problems
1009
other than levodopa, name other tx of parkinsons
Dopamine agonists FYI: bromocriptine, pramipexole COMT (catechole-o-methyl transferase) inhibitors FYI: Entacapone, tolcapone MAOIs (Monoamine oxidase inhibitors) FYI: Selegiline Anticholinergics FYI: Benztropine NMDA receptor antagonist FYI: Amantadine
1010
non pharmalogic interventions that can be used in patients who are receiving no benefit from optimal medical management for parkinsons
deep brain stimulation
1011
Urinary Tract Infection women 1st line atbx, pna and children
Nitrofurantoin 100mg PO BID x 5-7d fosfomycin tmpsmx Man/Complicated/Pyelonephritis: Ciprofloxacin 500mg PO BID x 7d Pediatrics: Amoxicillin 50 mg/kg/day PO ÷ TID x 5d afebrile, 10d febrile Complicated: Cefixime 16mg/kg first day, then 8mg/kg daily
1012
Uncomplicated Cellulitis (no MRSA coverage) tx
Adult: Cefadroxil 1g PO daily (or BID) x 5-14d Pediatrics: Cephalexin 50-100mg/kg/d ÷ QID x 10-14d
1013
Acute Otitis Media antibiotics for adults and children
Adult: Amoxicillin 500mg PO TID x 5-7d Pediatrics: Amoxicillin 90 mg/kg/day PO ÷ BID x 5d-10d (10d if <2yo or severe symptoms)
1014
otitis externa tx
Ciprodex otic suspension 4 drops BID x 5d
1015
Strep Pharyngitis treatment in adults and peds
Adult: Penicillin V 600mg PO BID x 10d Pediatrics: Amoxicillin 50 mg/kg PO daily (max 1g/day) x 10d
1016
Community Acquired Pneumonia tx in children and adults
Adult: Clarithromycin 500mg PO BID x 7d (or Amoxicillin 1g PO TID x7d if do not need to cover atypicals) Pediatrics: Amoxicillin 90mg/kg/day (max 3g/day) ÷ TID x 7-10d
1017
acute rhinusinusitis tx in adults and children
Adult: Amoxicillin 500mg PO TID x 5-10d Pediatrics: Amoxicillin 90mg/kg/day (max 2g/day) ÷ BID x 10-14d Second-line or if suspect resistance (S pneumo) Amox/Clav 40-80mg/kg/day ÷ BID (or 875/125 mg PO BID)
1018
Bacterial Vaginosis tx
Metronidazole 500mg PO BID x 7d
1019
Herpes Simplex Virus tx
First episode Acyclovir 400mg PO TID x 7-10d Recurrent Episode: Acyclovir 400mg PO TID x 5d (or 800mg PO TID x 2d)
1020
Gonorrhea/Chlamydia tx
Ceftriaxone 250mg IM or Cefixime 800mg PO x1 + Azithromycin 1g PO x1 or Doxycycline 100mg PO BID x 7d
1021
Moderate-Severe Gastroenteritis (>3BM/d, blood, fever)
Consider Cipro 500mg PO BID x 3 days or 750mg PO x1 Consider Azithromycin 1g PO x1 if travel to Asia (resistance to fluoroquinolones)
1022
C-difficile Colitis tx
Vancomycin 125mg PO QID x 10-14d Pediatrics: 40mg/kg/d PO (max 2g/d) ÷ TID-QID x 10-14d
1023
Peptic Ulcer Disease (non-NSAID related) treatment
PPI PO BID + Amoxicillin 1g PO BID + Clarithromycin 500mg PO BID x14d (eg. HP-PAC) Second-line or if high resistance, add Metronidazole 500mg PO BID (CLAMET)
1024
antibiotic rash tx
Stop antibiotic, and avoid further antibiotics until cleared Unlikely true IgE-mediated allergy IgE-independent reaction (eg. Red Man Syndrome with vancomycin) Delayed T-cell reaction (usually concomitant viral infection, eg EBV) Referral to Allergy for challenge testing
1025
ddx of rash after starting antibiotics
Unlikely true IgE-mediated allergy IgE-independent reaction (eg. Red Man Syndrome with vancomycin) Delayed T-cell reaction (usually concomitant viral infection, eg EBV) Rule out Serum Sickness (Type 3) - vasculitic rash, arthralgias, flu-like symptoms, fever DRESS (fever, rash, lymphadenopathy, blood count abnormality [eosinophilia, thrombocytopenia]) SJS/TEN (desquamation, positive Nikolsky's sign, mucosal-involvement)
1026
featuers of serum sickness
vasculitic rash, arthralgias, flu-like symptoms, fever
1027
clinical features of DRESS
(fever, rash, lymphadenopathy, blood count abnormality [eosinophilia, thrombocytopenia])
1028
clinical features of SJS/TEN
desquamation, positive Nikolsky's sign, mucosal-involvement
1029
sx of grief
Denial, anger, disbelief, yearning, anxiety, sadness, helplessness, guilt, sleep and appetite changes, fatigue, and social withdrawal
1030
management of grief
Acknowledge the loss and the associated grief Actively listen to and explore patients' concerns, reinforce patients' strengths in coping with their illness Encourage external sources of support including family, friends, and faith communities, or support groups Consider psychotherapy if requests or in complicated grief
1031
weight loss definition
Loss of ≥5% weight over 6-12 months
1032
definition of weight loss
Loss of ≥5% weight over 6-12 months
1033
ddx of weight loss
Malignancy GI (PUD, celiac, IBD) Psychiatric (depression, eating disorders) Endocrine (hyperthyroidism, diabetes, adrenal insufficiency) Infectious (HIV, viral hepatitis, tuberculosis, parasite) Chronic disease (heart failure, renal failure, autoimmune) Neuro (stroke, dementia) Medications/substances
1034
labs for weight loss
CBC (Hb, WBC) Chem (Creat, Calcium) Glucose, A1C TSH LFT (Alk Phos), Albumin ESR/CRP, LDH UA FOBT CXR Consider PPD (TB), HIV, Hep C Abdominal ultrasound Age-appropriate cancer screening
1035
treatment of weight loss
Limited evidence for nutritional and pharmacological agents Treat underlying cause Consider Mirtazapine in Depression Watchful waiting 3-6 months Can consider exercise and nutritional supplements at meal times
1036
DDx of neck pain
lymphoma, carotid dissection myocardial infarction, pseudotumour cerebri Axial Neck Pain Syndromes: Cervical strain Cervical spondylosis Cervical discogenic pain Cervical facet syndrome Whiplash injury Cervical myofascial pain Diffuse skeletal hyperostosis Extremity pain/neurological deficit: Cervical spondylotic myelopathy Cervical radiculopathy Brachial plexus injury (eg. burner/stinger) Non-spinal: Thoracic outlet syndrome Herpes Zoster Diabetic neuropathy Other (Malignancy, vascular, cardiovascular -MI, carotid/basilar artery dissection, infection, visceral, referred, rheumatologic, neurologic)
1037
red flags of neck pain
Trauma Cancer or constitutional symptoms Infectious symptoms, Immunosuppression or IVDU (Epidural abscess, discitis) Neurological signs/symptoms (cord compression, demyelinating process) Severe ripping neck pain, unstable (carotid/vertebral dissection) Chest pain, SOB, diaphoresis (MI) History of rheumatoid arthritis (atlanto-axial disruption)
1038
physical exam of neck pain (nerve roots and motion)
Neurological examination of upper limbs (strength, sensory, reflex) C1, C2 - Neck flexion C3 - Neck lateral flexion C4 - Shoulder elevation (Trapezius) C5 - Shoulder abduction/external rotation, bicep reflex C6 - Biceps/brachioradialis reflex C7 - Triceps reflex C8 - Finger abduction, grip T1 - Hand intrinsics
1039
criterias for CT C spine in cervical injuries
Consider NEXUS criteria (caution using criteria in <2yo, and>65yo) Neuro deficit (focal) Spinal (midline) tenderness Altered LOC Intoxication Distracting injury There is some data showing that you may consider clearing C-spine even in distracting injury Consider Canadian C-Spine Rule in alert, stable trauma patients (excluded known spine disease/surgery, non-trauma, GCS<15, age <16 years - consider NEXUS) -Can clear C-spine if no high risk factor: Age ≥ 65 years Extremity paresthesias Dangerous mechanism (Fall ≥3 ft/5 stairs, axial load to head [eg. diving], MVC >100km/h or rollover or ejection, motorized recreational vehicles, bicycle crash) -One low risk factor present AND able to actively rotate neck 45° left and right: Sitting position in the ED Ambulatory at any time Delayed (not immediate onset) neck pain No mid-line tenderness Simple rear-end motor vehicle collision
1040
Name antibiotics classes
Penicilin cephalosporines carbapenems monobactam chloramphenicol lincosamides oxalidinome macrolides/ketolides tetracyclines aminoglycosides fluoroquinolones lipoglycopeptides (vancomycin) sulfonamides (TMP SMX)
1041
types of antibiotics in PNC family and indications
Penicillin G (IV) Used in Strep pneumo, GAS, N meningitidis, Syphilis, Pasteurella multocida, Listeria monocytogenis, Actinomyces Israeli Pencillin V (oral) Strep throat from GAS Amino penicillins (Ampi, Amox) Broader gram -neg, covers enterococci Penicillinase-resistant penicillins IV (Methicillin, Naficillin, Oxacillin) Skin infections (not MRSA) Pencillinase-resistant penicillins Oral (Cloxacillin, Dicloxacillin) Skin infections (not MRSA) Antipseudomonal penicillins (Carbenicillin, Ticarcillin, Piperacillin) Anaerobic and pseudomonas coverage Combination with beta-lactamase inhibitors (Amoxi/Clav, Ticarcillin/Clav, Ampi/sulfabactam, Pip/Tazo) Broad coverage, including anaerobes, Timentin and Pip/Tazo cover pseudomonas Used for hospital-acquired pneumonias
1042
types of cephalosporines
Each generation has increasing spectrum against gram negatives but less against gram positives (except fourth) Note: MRSA and enterococci resistant to cephalopsporins First gen (eg. cephalexin, cefazolin, cefadroxil) Excellent gram-positive coverage Used as alternative to penicillin for staph/strep infection when penicillin allergy Used before surgery as prophylaxis Second gen (eg. cefuroxime, cefoxitin, cefotetan) Cefuroxime good coverage against strep pneumoniae and H influenza Used for CAP, sinusitis, otitis media Cefotetan, cefoxitin, cefmetazole have good anaerobic coverage (bacteroides fragilis) Used for intraabdominal infection, aspiration pneumonias, colorectal surgery prophylaxis Third gen (eg. ceftriaxone, ceftazidime, cefotaxime, cefixime) Ceftriaxone and cefotaxime excellent CSF penetration for meninigits Cefotaxime in neonates/children (ceftriaxone can interfere with bilirubin metabolism in neonates) Ceftriaxone for N gonorrhea (many resistant to penicillin and tetracycline) Ceftazidime, cefoperazone antipseudomonal Fourth gen (Cefepime) Added benefit against gram positives (and covers gram negatives like 3rd gen) and pseudomonas Pseudomonas (Pseudomonas coverage with Ceftazidime, Cefepime) Fifth gen (Ceftaroline) Only cephalosporin with activity against MRSA
1043
types of cephalosporines
Each generation has increasing spectrum against gram negatives but less against gram positives (except fourth) Note: MRSA and enterococci resistant to cephalopsporins First gen (eg. cephalexin, cefazolin, cefadroxil) Excellent gram-positive coverage Used as alternative to penicillin for staph/strep infection when penicillin allergy Used before surgery as prophylaxis Second gen (eg. cefuroxime, cefoxitin, cefotetan) Cefuroxime good coverage against strep pneumoniae and H influenza Used for CAP, sinusitis, otitis media Cefotetan, cefoxitin, cefmetazole have good anaerobic coverage (bacteroides fragilis) Used for intraabdominal infection, aspiration pneumonias, colorectal surgery prophylaxis Third gen (eg. ceftriaxone, ceftazidime, cefotaxime, cefixime) Ceftriaxone and cefotaxime excellent CSF penetration for meninigits Cefotaxime in neonates/children (ceftriaxone can interfere with bilirubin metabolism in neonates) Ceftriaxone for N gonorrhea (many resistant to penicillin and tetracycline) Ceftazidime, cefoperazone antipseudomonal Fourth gen (Cefepime) Added benefit against gram positives (and covers gram negatives like 3rd gen) and pseudomonas Pseudomonas (Pseudomonas coverage with Ceftazidime, Cefepime) Fifth gen (Ceftaroline) Only cephalosporin with activity against MRSA
1044
Carbapanems (Meropenem, Imipenem, Ertapenem) examples
Broad coverage (except MRSA) Ertapenem IV once a daily Drug of choice for severe diabetic foot infections (usually polymicobic) Ertapenem is only carbapenem that does NOT cover pseudomonas
1045
Monobactam (Aztreonam) indications
Magic bullet for gram negative aerobic bacteria, including pseudomonas Used with gram positive antibiotics like Vancomycin and Clindamycin for broad-coverage
1046
Lincosamides (Clindamycin) indications
Anaerobic, gram positive and MRSA coverage Not useful against gram-negative Side effects pseudomembranous colitis (C-diff) Used with aminoglycoside (cover gram-neg) in wound infections of the abdomen Female genital tract infections Septic abortions Alternative to metronidazole for bacterial vaginosis Used with beta-lactam (penicillin) or vancomycin for toxic shock syndrome with GAS or staph aureus Aspiration pneumonia
1047
Oxalidinones (Linezolid) indications
Gram-positive, MRSA, VRE Expensive Side effects Serotonin Syndrome (avoid if on antidepressants) Used with beta-lactam to cover hospital acquired pneumonia
1048
Macrolides/Ketolide antibiotics
Erythromycin, Azithromycin, Clarithromycin, Telithromycin (Ketolide)
1049
Macrolides/Ketolide indications
Gram-positive, some gram-negative, atypicals (Legionella, Chlamydia pneumoniae, Mycoplasma) Use for outpatient community-acquired pneumonia Telithromycin efficacy against macrolide resistant Strep pneumo Black box warning for respiratory failure in myasthenia gravis
1050
Tetracyclines (name 1 )
Doxycycline
1051
DOxycycline indication
Chlamydia trachomatis Mycoplasma pneumoniae (Walking pneumonia) Animal/Tick-borne Bruciella and Rickettsia Acne Side effects: Phototoxic dermatitis
1052
Aminoglycosides (name 4)
Gentamicin, Tobramycin, Amikacin (good against resistant), Neomycin (topical, as toxic)
1053
Aminoglycosides in dications
Break down cell walls, used with beta-lactams Aerobic gram-neg, Pseudomonas Side effects: CN8 toxicity (Hearing loss irreversible), renal toxicity, neuromuscular blockade
1054
fluoroquinolone name 3
Ciprofloxacine levofloxacine moxifloxacine
1055
Fluoroquinolones Ciprofloxacin indication
Gram-negatives, best for Pseudomonas Enterobacteriacae except anaerobes (E coli, salmonella, shigella, Campylobacter) Complicated UTI, prostatitis, epididymitis Gram-neg intracellular (Legionella, Burcella, Salmonella, Mycobacterium)
1056
Levofloxacin indication
Expanded gram-positive Community acquired pneumonia, skin infections
1057
Moxifloxacin indication
Strep pneumo and anaerobic (intraabdominal infections) Poor urinary concentration
1058
Lipoglycopeptides (Vancomycin) indication
All Gram-posiitve (MRSA, enterococcus, indwelling IV catheter resistant staph epidermidis) Endocarditis (Strep/staph) in penicillin-allergic Red man syndrome (rapid infusion, treat with slow infusion and antihistamine) Daptomycin similar to vancomycin with some side effects: Monitor CPK levels (myopathy risk) Eosinophilic pneumonia (stop dapto and give steroids)
1059
Sulfonamides (TMP SMX) indication
Gram positive, gram negative, some protozoans (Pneumocystis carinii, Toxoplasma gondii, Isospora belli) Increases INR T (Resp Tree): Otitis media, sinusitis, bronchitis, pneumonia M (Mouth): Shigella, Salmonella, E coli P (Pee): UTI, prostatitis, urethritis S (AIDS): PCP prophylaxis
1060
name 4 antibiotics covering pseudomonas aeruginosa
Penicillins (Ticarcillin, Ticarcillin/Clav, Piperacillin, Pip/Tazo) Third gen cephalosporins (Ceftazidime) Fourth gen cephalosporins (Cefepime) Carbapenems (Imipenem, Meropenem, Doripenem) Aztreonam Ciprofloxacin Aminoglycosides (Amikacin, Gentamicin, Tobramycin) Polymixins
1061
antibiotics for anaerobes (bacteroides fragilis)
Penicillins with beta-lactamase inhibitor (Amoxi/Clav, Ticarcillin/Clav, Ampi/subactam, Pip/Tazo) Second gen cephalosporins (Cefoxitin, Cefotetan, Cefmetazole) Carbapenems (Imipenem, Meropenem, Doripenem, Ertapenem) Chloramphenicol Clindamycin Metronidazole Moxifloxacine Tigecycline
1062
Atypical (Mycoplasma pneumoniae, Chlamydia pneumoniae, Legionella)antibiotics
Fluoroquinolone (levofloxacin, moxifloxacin) Macrolide (erythromycin, azithromycin) Doxycycline
1063
MRSA antibiotics
Vancomycin Linezolin Daptomycin Quinupristin/dalfopristin Tigecycline Ceftaroline Clindamycin TMP/SMX Tetracycline (Doxycycline/Minocycline)
1064
VRE antibiotics
Linezolid Daptomycin Tigecycline
1065
C-diff antibiotics
Oral vancomycin (or metronidazole)
1066
in which bacterias should u avoid tazo
SPACE (Serratia, Pseudomonas, Acinetobacter, Citrobacter, and Enterobacter) infections (inducible β-lactamase AmpC Avoid Tazo as 30% treatment failure Use Cipro/Carbapenem
1067
management in case of fluoroquinolone allx
If history of anaphylaxis reaction to one fluoroquinolone, avoid entire class For delayed on-set maculopapular nonpruritic rash, may consider graded challenge of another fluoroquinolone
1068
vancomycin allergy presentation and management
Avoid if bullous reaction or thrombocytopenia If Red Man Syndrome (flushing, pruritus, urticaria), premedicate with antihistamine (diphenhydramine) and acetaminophen, hold opiates if possible, and infuse slower (eg. half rate, or 1g over >100 mins)
1069
management of spinal cord compression in oncology
New/escalating back pain at rest, may progress to motor/sensory neurologic deficits MRI whole spine Treat with steroids, and consider surgery/radiotherapy
1070
Superior Vena Cava Obstruction management in oncology
Lung cancer, lymphoma Treat symptoms (SOB, pain, anxiety) Treat with steroids, radiotherapy, chemotherapy, stents
1071
treatment of hypercalcemia in oncology
Multiple myeloma, breast, NSCLC Symptomatic (weakness, confusion, coma) above corrected calcium >3mmol/L Treatment Stop calcium intake (supplements) IV hydration (eg. NS 200-300mL/h for urine output of 100-150mL/h) Severe if calcium>3.5mmol/L and symptomatic Consider calcitonin +/- zoledronic acid/pamidronate Consider denosumab in longterm control Consider glucocorticoids in lymphomas, sarcoid, granulomatous Consider calcimimetic and hemodialysis if renal failure or calcium >5mmol/L
1072
pericardial tamponade treatment in oncology
Percutaneous or surgical drainage of pericardial effusion
1073
tumor lysis synndrome presentation and management
Myalgia, dark urine, seizure, AKI Supportive care Hydration, follow potassium, creatinine, phosphate, calcium and uric acid Consider rasburicase for uric acid
1074
febrile neutropenia management in oncology
T>38, ANC<0.5 Empiric antibiotics and pan-culture
1075
definition of infertility
No conception after 12 months of unprotected and frequent intercourse Primary (no previous pregnancy) Secondary (after previous conception) Always ask about pregnancy with other partners!
1076
when to start investigating for infertility
>1 year of trying to conceive (85% will conceive after one year) >35yo at 6mo >40yo immediately Sooner if history of infertility, PID, pelvic surgery/CT/RT (in either partner), recurrent pregnancy loss, moderate-severe endometriosis
1077
DDX of female infertility
Ovulatory dysfunction - 20% PCOS Premature ovarian failure Hypothalamic suppression (exercise, eating disorder, stress, hyperprolactinemia) Thyroid disease Advanced maternal age Turner syndrome Medications (contraceptives, corticosteroids, antidepressants, antipsychotics, chemotherapy) Uterine/tubal factors - 20% PID Prior ectopic pregnancies Endometriosis Adhesions Fibroids Asherman syndrome Cervical factors (eg. cervical stenosis) Peritoneal factors
1078
medication causing infertility (female and male)
female: contraceptives, corticosteroids, antidepressants, antipsychotics, chemotherapy male: chemotherapy, steroids, spironolactone, phenytoin
1079
male infertility causes
Testicular (sperm disorders - eg. azoospermia) Cryptorchidism Irradiation Varicocele Androgen insensitivity Klinefelter syndrome Infection (Mumps orchitis) Drugs (Marijuana, spirinolactone, ketoconazole, alcohol) Pre-Testicular Hypogonadotropic hypogonadism Hypothyroidism Hyperprolactinemia Pituitary tumor Drugs, alcohol, smoking Medications (chemotherapy, steroids, spironolactone, phenytoin) Post-Testicular Hypospadias Vas deferens obstruction Congenital absence of Vas deferens in Cystic Fibrosis Infection (prostatitis) Retrograde ejaculation Erectile dysfunction Iatrogenic (vasectomy)
1080
investigations (labs) of infertility in women
Prolactin, TSH, testosterone Ovarian reserve testing Day 3 FSH, LH, estradiol -Ovarian aging if FSH >14IU/L and high estradiol -Clomiphene challenge has poor predictive value Mid-Luteal Day 21 (or LMP -7d) progesterone -Progesterone >5ng/mL (15.9 nmol/L) r/o anovulatory -Consider repeating progesterone weekly if irregular until menses Consider Clomiphene citrate challenge test (CCCT) AMH (anti-mullerian hormone) DHEA r/o STI (HIV, Hep B, Hep C, G+C) Preconception Rubella, Varicella titres Pap Genetic testing if indicated/ caryotype if RPL, POIm suspicion x fragile or turner
1081
Imaging in infertility
Hysterosalpingography Pelvic U/S (antral follicle count, r/o fibroids, cysts) Hysteroscopy Laparoscopy (endometriosis)
1082
infertility labs in men
Semen analysis: Count (>20mill), motility (>50%), volume (2-5mL), morphology (>30%), pH, WBC (<1mil/mL) 3-6 days abstinence Repeat if abnormal in one month
1083
non pharmalogical management of infertility
Encourage weight loss if BMI >30 Stop smoking, drugs, alcohol regular unprotected vaginal intercourse home ovulation kits (LH peak 1-2 days before ovulation) Limit caffeine, alcohol, avoid tabacco (for both partners) Referral to fertility specialist Assisted reproductive technology (IVF, ICSI) Sperm/ovarian donation Consider adoption
1084
medication for infertility
-folic acid 0,4 mg -subclinical hypothyroidism to treat -Consider Clomiphene Citrate 50mg PO daily x 5 days on day 3-5 -femara (letrozole 2.5 mg day 3 or 7 or cycle (or post withdrawal bled) -Counsel on risks of multiple pregnancy, hyperstimulation syndorme, thrombosis, ovarian cancer -If no pregnancy after 3-6 cycles, refer to specialist Referral to fertility specialist Ovulation induction Clomiphene citrate Metformin (PCOS) Gonadotropin Bromocriptine (to lower prolactin)
1085
surgical treatment of infertility
Tuboplasty Lysis of adhesions
1086
surgical treatment of infertility
Tuboplasty Lysis of adhesions
1087
causes of infertility
combined factors: 40% male factors: 26-30 % ovulatory dysfunction 21-25% tubal factors 14-20 % other : cervical, peritoneal, uterine) 10-13 % unexplaned 25-28%
1088
3 classes of ovulatory dysfunction
1) hypothalamic (low FSH, LH, low estradiol) -low BMI, amenorrhea, athletes, ED, pituitary tumors, prolactinoma) 2) hypothalamic ituitary ovarian axis: -Normal FSH LH, normal Estradiol -oligomenorrha and other signs of hormonal imbalance 3) hypogonadic - ovarian insufficiency (high FSH LH, low estradiol) -amenorrhea, signs of estrogen deficiency -hot flashes, vaginal dryness, POI, post chemo
1089
aim of TSH in fertility/conception
TSH under 2.5
1090
folate sensitive defects:
neural tuve defects, congenital heart and urinary tract defects, oral facial clefts, limb reduction anaomalies
1091
dose for folic acide in rpe conception and indication for high dose
(0.4֪-1.0 mg) If a woman with obesity has had a previous fetus or child with a folate-sensitive fetal anomaly other than a neural tube defect, she should take a folic acid supplement containing the recommended dosage for women at increased risk (4e5 mg) (conditional, low) 1 to 4-5 mg /d if: -previous pregnancy iwth neural tube defect or women with a previous fetus or neonate with another folic acidesensitive congenital anomaly, such as: ! congenital heart defects ! oral facial clefts ! limb-reduction defects ! urinary-tract defects -neural tube defect in mother, -first relative with neural tube defect -pre-gestationl diabetes, GI pathologies, surgical bypass -use of methotrexate, phenytoin, carbamazepine, valproate, sulfasalazine -alcohol use disorder -hx non compliance iwth oral med 1 mg if moderate risk -from pre-conception to 12 weeks gestation and switching to the standard low-dose regimen of 0.4 mg of folic acid daily after 12 weeks
1092
how long should the high dosage supplementtation of folic acide in conception last?
2 separate periods of supplementation: from pre-conception to 12 weeks gestation (see below), and from 12 weeks gestation until completion of breastfeeding, when the folic acid supplementation dosage reverts to the low-dosage regimen (strong, high
1093
for how long should pregnant women take folic acid?
2-3 months before conception, throughout the pregnancy, and for 4e6 weeks postpartum or as long as breastfeeding continues
1094
for how long should pregnant women take folic acid?
2-3 months before conception, throughout the pregnancy, and for 4e6 weeks postpartum or as long as breastfeeding continues
1095
cranial nerve root associated with different reflexes
biceps C6 tricep C7 brachioradialis C5-6 hyperreflexia: check upper motoneuron signs and check lower extremity plantar reflexes
1096
open fracture management
irrigation of wound reduction splint tetanus booster IV antibiotics Cefazolin (ancef) 1st line
1097
scaphoid fracture management
Snuffbox tenderness * Ulnar deviation If no snuffbox tenderness but still high index of suspicion? * Splint and repeat X-ray in 10-14 days * OR CT/MRI/bone scan and cast q2 weeks until clinically healed * Fracture clinic
1098
complication sof scaphoid fx
Risk of non-union and avascular necrosis * Highest risk in the proximal 1/3 of the scaphoid
1099
type of splint for scaphoid fx
* Thumb spica splint
1100
supracondylar fracture signs on XR
* Posterior sail sign * When in doubt, compare with X-ray of opposite elbow High risk of neurovascular injury
1101
most common elbow fracture
supracondylar fracture
1102
most commonly injured artery and nerves in supracondylar fracture
brachial artery Most commonly injured nerve? * Anterior interosseous nerve (extension) * Ulnar nerve (flexion)
1103
management of supracondylar fracture
Non-circumferential sugartong and gutter splint * Sling 1-3 weeks * Orthopedic follow-up
1104
complications of fracture in splint
compartment syndrome
1105
shoulder dislocation exam
neuro exam: -axillary nerve, radial and ulnar nerves
1106
shoulder dislocation associated bony injuries
Bony Bankart lesion (anterior glenoid rim #) * Hill-Sachs deformity (cortical depression in the posteriolateral head of the humerus) * Avulsion of greater tuberosity CT/MRI for bony Bankart
1107
most common type of dislocation
anterior 95%
1108
management of acute shoulder dislocation without a fracture
* Cunningham (gentle downward traction while massaging) * Stimson (prone with affected arm hanging down) * Milch (longitudinal traction and external rotation) * Traction – countertraction Analgesia (conscious sedation vs. intra-articular lidocaine)
1109
post reduction management of shoulder dislocation
Repeat neuro exam * Repeat X-ray * Sling immobilization 1-3 weeks, ortho follow-up, and physiotherapy
1110
diagnosis if rapid development of knee after acute injury
hemarthrosis
1111
knee XR ottawa rules
age 55 or older isolated tenderness to patella tenderness to head of fibula connot flex 90 degrees unable to bear weight both immediately and in the ER for 4 steps
1112
associated fractures with ACL tear
segond fracture tibial spine fracture
1113
management of ACL tear in ER if no fracture seen
tensor bandage, crutches reassess in 2 weeks ortho FU physiotherapy
1114
Gwen, 86 * From semi-autonomous residence, history of hypertension, diabetes, COPD * Unwitnessed fall, found face down * Pain left knee and groin * No obvious shortening or internal rotation * No swelling or pain on palpation of her left knee * Cannot walk or raise her leg What would you like to do first?
ABCs, vitals, glucose * Mental status exam. Confused? Agitated? * CT head? CT C-spine? * ECG * Labs (eg. CK, creatinine) * Imaging
1115
hip fracture presentation in elderly
* Hip injury may present as knee pain, especially in the elderly * Findings suspicious for hip #: * New inability to weight bear * Hip pain on axial loading of leg * Inability to straight leg raise
1116
pt pt has suspcion of fracture but not seen on Xr, what is the next step
CT/MRI of the left hip
1117
hip fracture management
Admission * Orthopedics consult (need for ORIF depends on baseline function and operative risk) Analgesia (acetaminophen, opioids) * Consider fascia iliaca block
1118
what to Suspect if tenderness of instability on palpation of ASIS, ecchymosis of pelvis/perineum, blood from urethral meatus
Pelvic fracture Consider pelvic binder/tourniquet
1119
limb-threatening injury - urgent orthopedic consultation (VONCHOP)
Vascular compromise Open fracture Neuro compromise (Cauda equina syndrome) or potential neuro compromise (unstable C-spine fracture) Compartment syndrome Hip dislocation Osteomyelitis / Septic arthritis Unstable Pelvic fracture
1120
salter components
1- Same = Transverse through growth plate 2 - Above = Through metaphysis 3 - Low = Through epiphysis 4 - Through = Both metaphysis/epiphysis 5 - Ram = Crush injury
1121
types of orientation and alignment of fractures
Orientation (eg. Transverse, oblique, comminuted, intra-articular) Alignment (displacement, distracted angulation, translation, rotation)
1122
Common occult fractures (negative initial imaging)
Scaphoid fractures (see below) Distal radius, femur neck fracture, radial head fracture, supracondylar fracture, growth plate fracture in children
1123
indications for Open reduction (Surgery)
Open fracture (irrigate/clean/debride wound) Displaced / Non-union Intraarticular (Salter-Harris 3,4,5) Polytrauma / Comminuted Spiral/Oblique (Easily to be displaced)
1124
Closed reduction procedure
Local nerve block, hematoma block, procedural sedation Three-way slab splint if significant swelling or cast (ensure joint immoblized) Post-reduction X-ray Antibiotics and Tetanus as needed
1125
complications of fractures
Arterial injury / Avascular necrosis Nerve injury Compartment syndrome Thromboembolic disease / Fat embolism Infection / Open fracture Fracture blisters Non-acute Osteomyelitis Nonunion / Malunion Osteoarthritis / Post-traumatic arthritis Complex Regional Pain Syndrome
1126
testssca for scaphoid
Radial deviation of wrist (scaphoid compressed between radius and second metacarpal) Scaphoid compression test (axial loading/telescope thumb into wrist, to compress scaphoid between radius and first metacarpal) Ulnar deviation with Snuffbox tenderness (use pinky to be more precise) Wrist extension and tenderness on volar-side scaphoid tubercle (only will be positive in proximal injuries) Watson's Test (extend wrist and then radial/ulnar deviate while pushing on volar-side of scaphoid looking for pain/click) Rule out scapholunate dissociation (ligament injury that should be treated like scaphoid fracture)
1127
findings on Xr for scaphoid fracture
Widened space (>3mm) between scaphoid and lunate = Scapholunate dissociation
1128
distal radius ulnar joint injury findings on exam
pain over distal ulna after FOOsh injury Piano Key sign (ballot ulnar styloid) Crepitus in pronation/supination Ulnar fovea sign (point tenderness over ulnar capsule)
1129
Xr findings of distal radius ulnar joint injury
AP wrist Widening distal ulna/radius >2mm Lateral wrist Dorsal displacement (in most DRUJ dislocations) Reduce and above-elbow splint in forearm supination
1130
management of lisfranc injury
Posterior back slab, non weight-bearing Follow-up orthopedics
1131
calcaneal fracture xray finding
Suspect in fall from height (Calcaneus, ankle, pelvic, spinal) Harris view X-ray - look for Bohler's Angle <20% Consider Ortho
1132
knee dislocation imaging to do
Consider CT angiogram in suspected knee dislocations (3+ ligament laxity
1133
what to suspect if acute pain, inability to actively extend knee, suprapatellar gap
quadriceps tear -immobilize (zimmer splint) and ortho FU
1134
what to suspect in Young <25yo, with hip/buttock/groin pain usually after running, jumping, kicking
pelvic apophyseal avulsion fracture Management Non-weight-bearing (crutches) then weaning as tolerated
1135
findings on exam for hio fracture
Percussion test (stethoscope on pubic symphysis and percuss on patella each side) Groind tenderness Inability to SLR Painful hip movement Pain on axial loading
1136
ottawa ankle and foot rule criterias
bone tenderness at posterior edge or tip of lateral malleolus (6 cm) or medial mallolus, or base of 5ft metatarsal or navicular bone inability to bear with immediately and in er department
1137
canadian c spine rule criteria
over 65 yo dangerous mechanism paresthesias in extremities able to actively rotate neck low risk factors to assess ROM: -simple rearend MVC stitting position in ED ambulatory at any time delayed onset of neck pain absence of midline C spine tenderness dangerous mechanism -fall from elevation more than 3 feet or 5 stairs axial load to head (ex diving) mvc high speed (over 100km/h), rollover, ejection motorized recreational vehicles bicycle collision
1138
contraindication to vaccines
Anaphylaxis or other serious reaction (eg. Guillain-Barre syndrome) upon administration of previous dose of a particular vaccine Anaphylactic reaction or other serious reaction to a component of a vaccine (eg. egg, gelatin, latex, neomycin, thimerosal) Pregnant or immunocompromised/suppressed, active TB should not receive LIVE vaccines (BCG, Zostavax, LAIV, MMRV, rotavirus, Smallpox Typhoid [oral], Yellow fever) Consider delaying inactivated vaccines 1-3 months after immunosuppressive therapy
1139
name live vaccines
BCG, Zostavax, LAIV, MMRV, rotavirus, Smallpox Typhoid [oral], Yellow fever
1140
contraindications to Live attenuated influenza vaccine:
Severe asthma Medically attended wheezing in the 7 days prior to vaccination
1141
Rotavirus vaccine containdication
Uncorrected congenital malformation of GI tract Previous intussusception
1142
Measles vaccine contraindications
Neomycin/gelatin allergy
1143
can Minor acute illness receive vaccines
yes except; GI illness for rotavirus (if does not affect dose scheduling age limit), oral cholera, and traveller's diarrhea vaccine Significant nasal congestion that will impede delivery of live-attenuated influenza vaccine
1144
Adverse events that are not contraindications to vaccination
Limb swelling, febrile seizure, hypotonic-hyporesponsive episode, inconsolable crying, oculo-respiratory syndrome (except influenza contraindicated)
1145
when to immunize
In infancy Before pregnancy Before traveling When new to the country if not previously immunized
1146
how to answer to myths about vaccines side effects
Most common side effects are mild fever and sore extremity. Serious reactions (death, encephalopathy) are so rare that their incidence cannot be calculated.
1147
how to counsel on link between autims and vaccines
The original paper in the Lancet publishing this association was recently withdrawn and there have been no definitive cases to support this claim. This was originally associated with a preservative agent called thimerosal. The only vaccines in Canada that are given to children and contain thimerosal are the multidose influenza vaccine and Hepatitis B. Both these vaccinations are available in formulations that do not contain thimerosal (ex. Vaxigrip for children and pregnant mothers). The only true contraindication to thimerosal is anaphylaxis.
1148
how to counsel on pts who say Vaccines don’t work
No vaccine is entirely effective. If a vaccine-preventable disease outbreak does occur, some vaccinated individuals will contract the disease. However the proportion of unvaccinated individuals who contract the disease will be much higher than the proportion of vaccinated individuals.
1149
how to counsel on pts who say Vaccine-preventable diseases no longer exist in Canada
Certainly some vaccine-preventable diseases are rarely, if ever, seen in Canada and herd immunity for unvaccinated individuals does occur. However, unvaccinated individuals may still be exposed in their lifetime given the immigrant population that may not have been vaccinated or if the unvaccinated chooses to travel later in life.
1150
why vaccinate
To protect yourself from common (HiB, Influenza, Varicella) or serious (Tetanus, Hepatitis, Meningococcemia) preventable infectious diseases. To protect individuals in society who are unable to receive vaccinations (newborns, immunocompromised, elderly)
1151
when should premature infants receive immunization
Premature infants should receive immunizations at the same time (chronological age) as term infants, ie. do not delay vaccinations - in Quebec first vaccines at 2 months old
1152
which vaccine to give patients who have asplenia, hyposplenia
Pneumococcal (most common infection in asplenia) Meningococcal Haemophilus Influenza Type B Influenza Hep A and B if repeated transfusions
1153
which vaccine to give pts who have chronic liver disease
Hepatitis A and B Influenza +/- Pneumococal
1154
indications for Pneumococcal 23-valent vaccine
≥65yo, <65 with specific risk factors
1155
indications for Herpes zoster vaccine
≥60yo (consider 50-59yo), immunosuppressed Live attenuated (Zostavax) vs. Non-live recombinant adjuvanted (Shingrix) -1 dose vs. 2 doses (2 months apart) -Herpes Zoster relative risk reduction 51% (NNT 59) vs. 97% (NNT 37) -Post-herpetic neuralgia RR reduction 67% (NNT 364) vs. 89% Adults ≥50yo who are known VZV seronegative should be given univalent varicella vaccine rather than herpes zoster
1156
HPV4 or HPV9 vaccination age and indications
9-26yo and ≥27yo who are at ongoing risk PIQ recommends vaccinating women 9-45yo, men 9-26yo even if previous HPV exposure
1157
Tetanus/Diphtheria (Td) vaccine indication
Primary series for unimmunized, and booster every 10y (Note: In Quebec, current guideline is for one single booster after 50yo) Earlier if non-clean/minor wound (if fully vaccinated >5y, if not fully vaccinated needs complete series with Ig)
1158
Rabies vaccines indication
Pre- or post-exposure if high-risk, consider call local public health for risk assessment
1159
pertussis indication
Once in adulthood (Tdap), as early as possible if close contact with young infants One dose during each pregnancy ideally between 26-32 weeks gestation
1160
Influenza indication
Annually for all, focus on high risk (6mo-5yo, ≥65yo, chronic disease, pregnancy/postpartum, healthcare worker, frequent contact with above) Not recommended in <6 months old as effectiveness not proven Children <9yo are recommended to get 2 doses one month apart for their first influenza vaccine
1161
Hep A&B indication
Risk or anyone who wants protection from hep B
1162
Meningococcal conjugate vaccine indication
Up to 24yo not immunized, or risk
1163
MMR vaccine indication
For susceptible adults born in or after 1970 or risk of exposure (traveller, healthcare worker, student, military)
1164
varicella vaccine indication
If susceptible or seronegative (2 doses)
1165
mental competency definition
legal status judged by a legal professional Situation-specific (care for self, sign out AMA, stand trial, sign a POA, change a will, financial decisions) May be competent to make care decisions but not financial decisions
1166
how is consent considered valid
Must be voluntary (without duress/coercion) Patient must have the mental capacity to consent Understands nature of proposed options, anticipated effect of options, and consequences of refusing Patient must be properly informed Diagnosis, proposed investigation/treatments, chance of success, alternatives, consequences of refusing
1167
elements to discuss with patient who has no more mental competency
advance care directive (living will) Substitute decision maker If not assigned, by hierarchy: Guardian appointed by the court Power of Attorney for personal care Representative appointed by Consent and Capacity Board Spouse, common-law spouse or partner Child (if >16yo) or parent (custodial) Parent with right of access only (non-custodial parents) Brother or sister Any other relative Office of the Public Guardian and Trustee
1168
diagnosis that may increase the likelihood of cognitive and/or functional impairment
dementia, stroke, severe mental illness, head injury
1169
wound treatment
Wound irrigation Foreign body removal, necrotic tissue debridement Tetanus vaccine as needed (minor clean wound >10y, otherwise >5y + Ig if not fully vaccinated) priamry vs secondary closure
1170
primary closure time frame
up to 18h (Facial wounds up to 24-72h if no risk factors for infection)
1171
types of sutures for primary suture
Extends through dermis, careful approximation (eg. vermillion border), tension Simple interrupted standard Vertical mattress if tension and edges fall or fold into wound Horizontal mattress for eversion in areas of high tension
1172
procedure for primary closure
Clean with antiseptic around wound (but not inside wound to avoid impaired wound healing) Local anesthetic 25-30G needle with lidocaine 1% with epi between dermis and subcutaneous tissue Avoid dose exceeding: Lidocaine without epi 5mg/kg (max 300mg = 30mL lidocaine 1%, 15mL lidocaine 2%) Lido with epi 7 mg/kg (max 500mg = 50mL lido 1% with epi) Irrigate wound vigorously (60mL syringe with splash guard) Drape wound + sterile gloves Explore wound (look for vessels, nerves, tendons, structure) Suture (ensure depth greater than width, entering and exiting wound at 90 degrees) 6-0 for face, 3-0 for thick skin (back, scalp, palms, soles), 4-0 for rest
1173
when to remove sutures
5 days (face), 7-10 days (scalp, arms), 10-14 days (trunk, legs, hands, feet), 14-21 days (palms, soles, high tension)
1174
Tissue adhesive or tape indication
<5cm, low tension, elderly fragile skin
1175
Staples indication
Noncosmetic region, long linear >5cm (faster closure)
1176
when should u not close wound with sutures
Concern about wound infection, risk factors of proper wound healing (eg. immunocompromised, peripheral artery disease) Animal bites (especially if noncosmetic area) Consider prophylactic Amoxicillin/clavulanate (Clavulin) 25-45 mg/kg divided q12h (max dose 875/125) mg every 12 hours x5d (unless dog bite not on hand) Consider post-exposure rabies vaccine and immunoglobulin within 24h if high risk (call public health, send animal to laboratory if available) Consider HIV/Hep B/C in human bites Deep puncture wounds when irrigation not effective Actively bleeding (first hemostasis to prevent hematoma) Superficial wounds (epidermis)
1177
Differentiate joint vs. soft tissue
Arthritis: Pain on ROM, decreased ROM, swelling, erythema Soft tissue: ROM preserved, tendernes over bursae, tendons, or ligaments
1178
ddx of joint pain
Trauma -Hemarthrosis is associated with intraarticular fractures, dislocations, ligamentous injury Infection (Septic arthritis) -Gonoccocal can present as purulent arthritis or a triad of tenosynovitis, vesiculopustular skin lesions, and polyarthralgias -Non gonococcal bacterial infections should be suspected in IVDU, immunocompromised, prosthetic joint Other: Mycobacterial, fungal, Lyme Crystal-induced arthritis Gout (monosodium urate crystal) Pseudogout (CPPD) Osteoarthritis Systemic -Seronegative spondyloarthritis (suspect in enthesitis, dactylitis, conjunctivitis/uveitis, psoriasis) -Reactive arthritis -Psoriatic arthritis -Inflammatory bowel disease-associated arthritis Sarcoid periarthritis Rheumatoid arthritis Myelodysplastic and leukemic disorders Mechanical derangement Neoplasm
1179
joint pain red flags
Hot/swollen joints Constitutional symptoms (high-grade fever, weight loss, malaise) Morning stiffness >30 minutes Night pain Weakness Neurological (burning pain, numbness, or paresthesia)
1180
skin changes related to joint pain
Skin changes (Psoriasis, Malar rash, Erythema nodosum)
1181
investigations for joint pain
Imaging (XR, US, CT, MRI) Consider avoiding imaging in absence of trauma or focal bone pain Joint aspiration Gross appearance Crystal analysis White cell count and differential <2,000/mm3 usually non-inflammatory >20,000 suspect septic arthritis Gram stain and Culture Consider Labs CBC LFT ESR/CRP ANA, RF, Anti-CCP (HLA)-B27 Coags (in hemarthrosis)
1182
ddx of liver disease
Noninfective Alcohol NAFLD/NASH Drug-induced (Acetaminophen, INH, tetracyclines, antiepileptics/phenytoin) Autoimmune Infective Hepatitis B/C/D (Blood/body fluid/sexual) Hepatitis A/E (Fecal/oral, usually self-limited)
1183
risk factors of hepatitis
Medication history (OTC, herbal and dietary supplements) Alcohol consumption IVDU / Needle stick exposures Tattoos or body piercings High-risk sexual contact Blood transfusion prior to 1992 Travel to areas endemic for hepatitis Prior hepatobiliary disease (including gallstones) Prior inflammatory bowel disease (autoimmune) History of diabetes, skin pigmentation, cardiac disease, arthritis, hypogonadism (hemochromatosis) History of blood disorders (hemolysis) Family history of inherited liver disorders
1184
signs and sx of hepatitis
Light-colored stools, pruritus, dark urine (bilirubinuria) Acute pain in RUQ, ascites (hematologic diseases, may have hepatic vein thrombosis) Fever/weight loss/night sweats (acute viral hepatitis of any etiology)
1185
P/E findings of liver disease
Jaundice Malnutrition Temporal and proximal muscle wasting Hormonal Spider nevi, caput medusa, palmar erythema, gynecomastia, testicular atrophy Hepatomegaly, splenomegaly Decompensated Cirrhosis Ascites, peripheral edema Neuro Hepatic encephalopathy Asterixis Alcohol abuse Dupuytren’s contracture, parotid enlargement, testicular atrophy
1186
Anti-HAV Ab positive interpretation
Past or current infection
1187
Anti-HCV Ab positive interpretation
past or current infection
1188
Infection (if persists >6 months = chronic infection)
Infection (if persists >6 months = chronic infection)
1189
Anti-HBs
Immunity due to infection or immunization
1190
Anti-HBc total (IgM and IgG)
Past or current infection (IgG usually persists for life)
1191
HBeAg
High infectivity (viral replication)
1192
Anti-HBe
Appears with recovery from acute infection In chronic infection, the presence of Anti-HBe suggests low infectivity
1193
Isolated Anti-HBc positive DDx
False positive result/lab error (most common) Positive Anti-HBe infers prior HBV exposure, and unlikely false positive "Window phase" - resolving acute infection before the appearance of anti-HBs "Remote resolved HBV infection" - undetectable anti-HBs due to a decline in antibody titre over time "Occult HBV", chronic infection with undetectable HBsAg (rare)
1194
HBV DNA viral load interpretation and management
If negative Booster (or complete series) and follow-up HBsAb after 1-2 months if responds with immunity If no response to booster to ensure not occult HBV, consider repeat viral load q3-6 months until undetectable x 2-3 Test co-infection HIV/HCV See below (Positive Hepatitis) if chronic carrier
1195
Hepatitis B screening labs and who to screen
HbsAg, anti-HBs, anti HBc total Review HBV immunization history, previous testing Consider screen if high-risk (eg. exposures, travel, family history, abnormal liver tests) Screen all pregnancy, HIV/HCV, immunocompromised (or planned therapy)
1196
who to screen for hep C
IVDU, needle-stick injury, hemodialysis, pregnancy Canadian Taskforce does not recommend people born in Canada between 1950-1975 be screened
1197
prevention from hepatitis
Abstain from alcohol Vaccination against Hep A/B Screen pregnancy Mothers with high HBV viral loads should be given antiviral therapy to further reduce the risk of infection in the newborn Follow-up infants (HBV vaccine and HBIG within 12h after birth, with repeat vaccine at 1 and 6 months)
1198
management of pregnant women with high viral load
antiviral therapy infants HBV vaccine and HBIG within 12h after birth repeat vaccine at 1 and 6 months
1199
management of hepatitis post exposure
Clean wounds, avoid any further blood/body fluid exchange until cleared Vaccinate Hep A/B as indicated Screen all contacts and offer PEP as indicated
1200
Hepatitis A preventative measures
Hygiene practices: Handwash, avoid tap water, raw foods, heating foods >85°C
1201
who to offer PEP for Hep A
close personal contacts, child care contacts, food handlers (not warranted in a single case of Hep A in school or hospital) For healthy individuals aged 12 months to 40 years HAV Vaccine (Havrix 1mL IM x1) For individuals ≥41 years or <12 months, immunocompromised, chronic liver disease, allergic to the vaccine Hepatitis A immune globulin 0.02 mL/kg IM x1 The combination vaccine TWINRIX should not be used for postexposure prophylaxis
1202
hep B PEP
PEP not required if either source or exposed has either Recorded previous (at any time) anti-HBs ≥10 IU/L History of recovery from HBV infection Hep B vaccine (0, 1-2, and 4-6 months) if source HBsAg-positive or HBV-unknown Within 24 hours of exposure, and complete three-dose series (zero, one, six months) if not vaccinated HBIG 0.06 mL/kg IM x1 if source HBsAg-positive or high risk (e.g., IVDU, MSM) As soon as possible, within 7 days of percutaneous exposure or within 14 days of sexual exposure Repeat dose at 28-30 days after exposure in non-responders to Hepatitis B vaccine or in patients who refuse vaccination If PEP given, do anti-HBc and HBsAg after 6 months to assess for HBV transmission
1203
Hepatitis C PEP
No PEP recommended Close observation for those who had percutaneous or high-risk sexual exposure (unless source negative HCV RNA) If source HCV RNA positive, repeat HCV RNA at 4w, and HCV RNA + HCV Ab at 3 and 6 months If source HCV RNA unknown, repeat HCV Ab six months after exposure Delay treatment for six months minimum to monitor for spontaneous clearance of HCV RNA
1204
if pt is Hep B or C positive, how to do harm reduction
Inform health care providers (dentist, nurse, other physicians) and other providers eg. (acupuncturist, tattoo artist) of infection Do not donate blood/semen/tissues Safely dispose of blood (hygiene products, floss, bandages, needles) Cover cuts/sores Do not share personal hygiene materials and sharp instruments (razors, nail clippers, toothbrushes, glucometers) Ensure all partner/household members/drug use partners are tested and immunized if susceptible (Hep B vaccine free for susceptible contacts) Condom-use until partners test immune Avoid medication or alternative therapies (herbals) that may affect or be affected by liver Go to ER if black stools or vomiting blood
1205
labs to do in hep B or C positive patient
Bilirubin (total and direct), albumin, INR (PT), creatinine ALT, AST, ALP CBC Test co-infection HIV status, Hep B/C Assess infectiousness - HBV DNA, HbeAg
1206
how to manage HBsAg positive
Management focus on relief of symptoms, monitoring, prevention of complications and transmission Does not require antiviral treatment for acute Hep B as most (95%) will clear Refer if deteriorating liver failure (INR, bilirubin, platelet, encephalopathy)
1207
management of chronic hep B carrier
If confirmed chronic carrier HIV/HCV (if not done already) HBeAg Repeat labs ALT q6 months HBV DNA (viral load) q1 year Ultrasound (+/- AFP) q6-12 months for HCC Cirrhosis HIV/HCV co-infection African descent>20yo Men>40yo, Women>50yo Family history of hepatoma Referral to specialist (treatment with interferon injections or oral nucleoside/nucleotide analogues) Usually if elevated ALT or HBV DNA >2000 IU/mL
1208
HRR risk factors
Cirrhosis HIV/HCV co-infection African descent>20yo Men>40yo, Women>50yo Family history of hepatoma
1209
treatment of upper GI bleed
Gown, gloves, face shield mask Oxygen, monitor, BP cycle NPO Two large IVs NG + Elective endotracheal intubation if ongoing hematemesis, altered mental status, or risk of aspiration Fluid resuscitation Type and Screen or Cross-match if risk Blood transfusions to maintain Hb >70g/L (consider >90g/L if massive bleeding or comorbid eg. CAD) Avoid overtransfusing patients in variceal bleeding - can worsen bleeding Consider platelets, plasma if receiving massive RBC transfusions In patients with variceal bleeding OR undifferentiated bleeding in cirrhosis, Prophylactic antibiotics (Ceftriaxone 1g IV daily x 7d) as 50% risk of infections when hospitalized for UGIB (UTI, SBP, pneumonia, bacteremia) PPI - Reduces rebleeding in high-risk ulcers treated with endoscopic therapy Omeprazole 40mg IV BID or Pantoloc 40mg IV BID Pantoloc 80mg bolus and 8mg/h drip has not been shown to be superior Prokinetic - Promotes gastric emptying, shown to reduce second endoscopy Consider Erythromycin 3mg/kg or 250mg IV over 30 mins (30 mins-90mins prior to endoscopy) Somatostatin (and analogs) in suspected variceal bleeding, however may have a role in nonvariceal bleeding in settings where endoscopy is unavailable Octreotide 50mcg IV bolus then 50mcg/hour Balance risks and benefits of anticoagulant and antiplatelet agents reversal Warfarin → Vitamin K Heparin → Protamine, Fresh frozen plasma Dabigatran → Praxbind (Idarucizumab) Balloon tamponade for uncontrollable hemorrhage, intubation necessary prior GI consultation for early endoscopy vs. interventional radiologist (angiography) Can risk stratify (AIMS65, or Glasgow-Blatchford Score 0-1 denotes "low-risk" safe for discharge)
1210
t higher risk for GI bleed
previous GI bleed, intensive care unit admission, nonsteroidal anti-inflammatory drugs, alcohol
1211
labs in upper GI bleed
CBC (Hb, platelets), Chem (BUN, creat), Liver enzymes (AST, ALT), Coag (INR), Albumin EKG, Troponin if risk of MI (older, hx of CAD, chest pain or dyspnea)
1212
ddx UGIB
Bleed Peptic ulcer Esophagogastric varices AV malformations Tumor Esophageal (Mallory-Weiss) tear Esophagitis/Gastritis Not bleed Beet Iron Pepto-Bismol
1213
DDx LGIB
Diverticulosis - most common Angiodysplasia Colitis Inflammatory bowel disease Infectious Neoplastic Anorectal (hemorrhoids, anal fissures, rectal ulcers)
1214
labs in sexual assault
Urine and Serum B-hCG STI screen HIV : (0-6w-12w-24w) Syphilis EIA or RPR Gonorrhea and chlamydia PCR HBsAg, HepBsAb Optional Wet mount/culture for trichomoniasis vaginalis HCV (consider in high risk, IVDU)
1215
management of sexual assault
Pregnancy prophylaxis : -ullipristal -plan B - Yuzpe (estrogen + progesterone) -copper IUD Prevention of STI: -cefixime 400mg x 1 for gono -azithro 1g Ix 1 for chlam or doxy 100mg po BID x 7 d -metronidazole if positive for trichomoniasis -tx for syphilis -hep B (HBIG, 3 doses of hep B vaccines 0-1-6m) -HIV prophylaxis
1216
treatment of gonorrhea:
urethral, endocervical or rectal : ceftriaxone 250 mg IM x 1 or Cefixime 800mg PO x1 AND azithromycin 2g PO x 1 if pharyngeal infection : Ceftriaxone 250 mg, IM, en dose unique if oral exposition for partne
1217
chlamydia tx
Doxycycline 100mg PO BID x7d or Azithromycin 1g PO x1 Doxycycline PO preferred for rectal chlamydia Azithromycin PO preferred in pregnancy
1218
syphilis
Primary, secondary, and early latent syphilis: Pen G 2.4 million units IM x1
1219
Trichomoniasis (green-yellow malodorous discharge, burning, dyspareunia)
Metronidazole 2g PO x1 Treat partner Bacterial STI or trichomonas should abstain from unprotected sex until 7d after treatment of both partners complete
1220
HSV1 (gingovostomatitis +/- pharyngitis, then recurrent herpes labialis)
Initial (within 72h or ongoing new lesions/pain): Acyclovir 400mg PO TID, Famciclovir 500mg PO TID , Valacyclovir 1000mg PO BID x 7-10d If severe odynophagia, consider IV acyclovir Recurrent episodic: Famciclovir 1500mg PO x 1 dose or Valacyclovir 2g PO BID x 1 day Chronic: Acyclovir 400mg PO BID or Valacyclovir 500mg PO daily
1221
HSV2 (genital herpes simplex) tx
Initial (within 72h or ongoing new lesions/pain): Acyclovir 400mg PO TID, Famciclovir 250mg PO TID , Valacyclovir 1000mg PO BID x 7-10d Recurrent episodic: Acyclovir 800mg PO TID x2d, Famciclovir 1000mg PO BID x 1 day, Valacyclovir 500mg PO BID x3d Chronic suppressive: Valacyclovir 500-1000mg PO daily
1222
HPV tx
Imiquimod 5% cream qHS 3/week x 15w, wash off after 6-10h Podofilox 0.5% solution BID x3d then none x4d, repeat PRN x4 Cryotherapy
1223
tx for gonorrhea if allergy to pnc or cephaloscporine
Gentamicine6 240 mg IM (en deux injections de 3 ml) ET Azithromycine3 2 g PO en dose unique
1224
une recommandation indiquant de s’abstenir d’avoir des contacts sexuels jusqu’à 7 jours après la fin d’un traitement à dose unique OU jusqu’à la fin d’un traitement à doses multiples ET jusqu’à la résolution des symptômes2 :
1225
In high-risk patients who are symptomatic for STIs, provide treatment before confirmation by laboratory results
1226
when to retest patient for chlamydia and who
Un test de contrôle n’est pas recommandé dans les cas d’infection à C. trachomatis, sauf dans les situations suivantes: „ Persistance ou apparition de signes ou symptômes „ Grossesse „ Problème anticipé d’adhésion au traitement „ Utilisation d’un schéma thérapeutique autre que ceux recommandés „ Infection rectale à C. trachomatis traitée avec azithromycine „ Infection à C. trachomatis de génotype L1-3 (LGV TAAN effectué le plus tôt possible à partir de 3 semaines après la fin du traitement
1227
when to retest for gonorrhea
Un test de contrôle est recommandé dans tous les cas d’infection gonococcique, en particulier dans les situations suivantes: „ Persistance ou apparition de signes ou symptômes „ Grossesse „ Problème anticipé d’adhésion au traitement „ Utilisation d’un schéma thérapeutique autre que ceux recommandés „ Infection pharyngée (même si traitée avec ceftriaxone) „ Utilisation du schéma thérapeutique combinant la gentamicine et l’azithromycine dans le cadre d’un antécédent de réaction allergique „ Résistance démontrée ou sensibilité réduite1 à l’un des antibiotiques utilisés „ Partenaire d’une personne chez qui une résistance ou une sensibilité réduite1 à l’un des antibiotiques utilisés a été démontrée
1228
when and who to retest for gonorrhea after tx
En cas d’infection pharyngée2 : TAAN3 et culture effectués le plus tôt possible à partir de 2 semaines après la fin du traitement OU culture4 effectuée le plus tôt possible à partir de 3 jours et jusqu’à 2 semaines après la fin du traitement. En cas d’infection autre que pharyngée2 : TAAN effectué le plus tôt possible à partir de 2 semaines après la fin du traitement5 . Si la personne présente des symptômes au moment de la visite de contrôle, procéder également à un prélèvement pour culture. Une culture effectuée le plus tôt possible à partir de 3 jours et jusqu’à 2 semaines après la fin du traitement est également envisageable.
1229
management of sexual partners after dx of stds
Partenaires à joindre s'ils ont eu un contact sexuel avec la personne atteinte: „dans les 60 jours précédant les premiers symptômes ou le prélèvement; OU „pendant que la personne avait des symptômes; OU „avant la fin du traitement à doses multiples ou moins de 7 jours après un traitement à dose unique. Il peut être justifié, dans certaines situations, de rechercher des partenaires sur une plus longue période. L’intervention devrait inclure: „une évaluation clinique comprenant l’identification des facteurs de risque d’ITSS; „un dépistage de l’infection à laquelle la personne a été exposée et des autres ITSS selon les facteurs de risque décelés, consulter l’outil ITSS à rechercher selon les facteurs de risque décelés; „en l’absence de signes et de symptômes, un traitement épidémiologique sans attendre les résultats du dépistage: algorithme décisionnel; „en présence de signes ou de symptômes: une approche syndromique; „le soutien auprès de cette personne dans sa démarche visant la notification et le traitement de ses partenaires si les résultats des analyses microbiologiques sont positifs. Pour plus d’informations, consulter les outils Personne exposée à une ITSS : que faire? et Soutenir la personne atteinte d'une ITSS pour qu'elle avise ses partenaires : quatre étapes. Traitement accéléré du partenaire (TAP) : „Il est préférable de faire l’évaluation de la condition de santé du partenaire sexuel avant l’activité de prescription afin qu'il reçoive les meilleurs soins préventifs. „Dans certaines circonstances, le traitement accéléré du partenaire (TAP) peut être utilisé après une analyse judicieuse des avantages et des inconvénients. Le TAP demeure une mesure d'exception. Pour plus d'informations, consulter l'aide-mémoire pour les cliniciens et l'aide-mémoire pour les pharmaciens
1230
* Lorsque le TAAN est positif pour NG demander une culture avant le début du traitement afin de déterminer la sensibilité de la souche. La culture ne doit toutefois pas retarder le traitement.
1231
Délai minimal et période fenêtre pour CT, NG et LGV * Procéder aux prélèvements sans attendre. Si le dépistage est réalisé avant la fin de la période fenêtre : – tenir compte du fait que les infections auxquelles la personne a été exposée pendant ses dernières activités sexuelles comportant un risque de transmission pourraient ne pas être détectées ; – effectuer de nouveaux prélèvements à la fin de la période fenêtre lorsque les résultats sont négatifs. * Délai minimal : inconnu. * Fin de la période fenêtre : 14 jours.
1232
periode fenetre VIH
3 months
1233
post exposure prophylaxis for HIV
(Truvada plus raltegravir 400mg PO BID x 28d) if known HIV (or high-risk, eg. sex worker, MSM, IVDU)
1234
HBV screening
HBsAg, HBsAb, HBcAb Post-exposure baseline serologies (ensure HBsAb immune) Vaccinate Immunoglobulin if contact known HepBsAg positive Repeat serology 2 months after vaccine series
1235
HCV - HCV Ab (IVDU or MSM)
Post-exposure baseline HCV Ab HCV RNA 3w after exposure (or HCV Ab 6 months after exposure)
1236
Window period for STDs Repeat testing at 6w, 12w, 6mo in the case of sexual assault
1w - Gonorrhea 2w - Chlamydia 12w - Syphilis, HIV, HBsAg /HCV Ab
1237
Empiric IV antibiotics and fluids <1 month old with fever
Ampicillin (100-200mg/kg/d IV divided q6h) + Cefotaxime 50mg/kg IV q8h or Gentamycin 2.5mg/kg IV q8h or Tobramycin 6mg/kg IV q24h with dose adjustments
1238
antibiotics for >1month, urinary findings with fever
Cefotaxime 50mg/kg IV q8h
1239
ped empiric IV antibiotics and fluids 1-3 months
Non-meningitic: Ceftriaxone 50mg/kg/day IV divided q12-24h Meningitis: Ceftriaxone 100mg/kg/day IV divided q12-24h Add ampicillin for Listeria or enterococcus concern Add vancomycin for MRSA if concern Consider empiric antivirals (acyclovir), especially if suspect HSV meningitis
1240
labs for kawasaki
WBC, platelet, AST, ALT, CRP, ESR, Urinalysis for pyuria, consider viral testing for alternative diagnoses
1241
kawasaki criterias
Fever ≥ 5 days (if any of the 4 below criteria present at any time during illness, diagnose on day 4 of illness) Conjunctivitis (bilateral nonexudative) Rash (polymorphic) Adenopathy (Cervical lymph node >1.5cm) Strawberry tongue (oral mucous membranes changes, also injected/fissured lips, injected pharynx) Hands and feet edema (acute)/desquamation (convalescent)
1242
investigations ofr encopresis
Abdominal X-ray r/o occult constipation Lab if suspected or failed intervention with laxatives TSH Celiac Electrolytes and calcium Blood lead level Urine culture (if enuresis)
1243
indications for imaging in UTI in children
Renal-Bladder Ultrasound if child <2yo with first febrile UTI within 2w of acute illness Recurrent UTIs Pyelonephritis (Complicated) Family/personal history of urologic/renal abnormalities VCUG if Hydronephrosis on ultrasound that suggests high grade (4-5) VUR, in addition consult urology or nephrology <2yo with second febrile UTI
1244
ttx of UTI in children
Ampicillin 50 mg/kg/dose IV q6h + Gentamicin 7.5 mg/kg IV/IM once daily Cefixime 8mg/kg PO daily (max 400mg/d) TMP/SMX 6-12mg/kg/day divided q12h (max 320mg TMP daily), avoid in newborns Amox/Clav 7:1 suspension, 45mg/kg/day of Amox divided q8h (max 3g Amox daily) Alternatives Amoxicillin 50 mg/kg/day divided q8h (max 3g daily) Cephalexin 50 mg/kg/day divided q6h (max 500mg/dose)
1245
ttx kawasaki
ASA and Ivig
1246
SAMP" When asked what you would do next, state
What I would do Why I would do it How I would do it When I would do it Where I would do it eg. “Inhaled oxygen stat in a resuscitation room to treat the patient’s respiratory distress”
1247
6 hypoglycemics classes + Rx
biguanide, sulfonylurea, DPP4i (-gliptin), GLP1r-agonist (-tide), SGLT2i (-flozin), meglitinide, alpha-glucosidase-i, thiazolidinediones, insulin
1248
5 anti-hypertensives:
BB, CCB, ACE-i, ARB, thiazide, aldosterone antagonist
1249
4 anti-depressants
SSRI, SNRI, NDRI (buproprion), TCA, TeCA (tetracyclic - Mirtazapine), MAOI (Selegiline used in Parkinsons)
1250
3 anti-HIV
NRTI (tenofovir/emtricitabine), Combination (Truvada), Integrase inhibitor (Raltegravir), NNRTI , Protease inhibitor
1251
3 anti migraines
NSAIDs, acetaminophen, triptan
1252
3 migraine prophylaxis
beta blocker tricyclics (amytriptyline) Valproate SNRI: venlafaxine
1253
5 antiparkinsonian
anticholinergics: benztropine levodopa dopamine agonisst MAOB inhibitor (rasagiline, slegiline) NMDA-receptor antagonist COMT inhibitor
1254
side effect of statins
myalgia, nausea, diarrhea, insomnia
1255
NSAIds SE
dyspepsia, N/v/D, GI bleed, CV risk (MI, stroke)
1256
SE of ACei
dry cough, angioedema, HA, fatigue, hyperK, elevated creat
1257
HIV med SE
fatigue, nausea, diarrhea
1258
triptan SE
fatigue, diziness, nausea, palpitations, vertigo, flushing
1259
SSRI SE
Headache, nausea, sexual dysfunction, somnolence/insomnia
1260
OCP se
Irregular/breakthrough bleeding, headache, nausea, breast tenderness
1261
morphine SE
N/V/Constipation, urinary retention, dizziness, sedation, pruritus, resp depression, confusion
1262
If unstable, FIRST STEP ABCs + GMOVIE as above (the first step in acute management is NEVER medication)
A = Assess airway and if compromised begin by attempting secure it with chin lift or jaw thrust if necessary B = Assess breathing, and begin to assist with bag and mask if necessary C = Assess pulse, and start high-quality CPR if not palpable G = Measure plasma glucose M = Get monitors: pacing pads, cardiac monitor, BP monitor, SpO2 monitor O = 100% non rebreather mask with O2 set to flush V = Assess vital signs (6!) I = Place large bore IVs x2 (14-16G) E = EKG stat
1263
Management is more than medication: use the acronym “SNOPQRST” for the exam
Safety: ABCs assessed and addressed? Vital signs stable? Admission to hospital? Stop driving? Next visit: Regular f/u Offer: Labs, imaging, investigations Prevention: Diet, weight loss, exercise, safe sex, helmets, vaccines, screening for associated conditions Quit: Smoking, EtOH, drugs, stress, offending medications Refer: Specialists, clinics, allied healthcare professionals, multidisciplinary teams Report to: Health authority for outbreaks, driving authority if unsafe to drive (eg. seizure) Start: Non-pharmacologic and pharmacologic interventions Teach: Counsel, refer to online resources, patient handouts; instructions to return sooner if Sx persist or worsen
1264
ALWAYS screen for or treat the following if the stem hints at it
HIV Pregnancy Pain Danger to self or others (Suicide) Abuse Vaccines Eating disorders
1265
Acetaminophen (child) dose and route
10-15mg/kg PO q4-6h
1266
Ibuprofen (child) dose and route
4-10mg/kg PO q6-8h in>6mo
1267
child Amoxicillin dose and route for stre, UTI, AOM, sisnusitis, pna
Child (duration usually 5-10d) Strep pharyngitis: 50mg/kg/day PO daily UTI: 50mg/kg/day PO div TID AOM/sinusitis: 90mg/kg PO div BID Pneumonia: 90mg/kg PO div TID
1268
Adult amox dose for PNA
Pneumonia 1g PO TID x7d
1269
STI tx for gono clham
: Cefixime 800mg PO x1 + Azithromycin 1g PO x1 ("fix az" soon as possible)
1270
H pylori eradication dose and route
PPI (eg. Lansoprazole 30mg PO) BID Amoxicillin 1g PO BID Clarithromycin 500mg PO BID
1271
smoking cessation drugs doses
Nicotine replacement, Champix 0.5mg/d x2d then BID , Zyban 150mg/d x3d then BID
1272
ACLS doses (mg)
Epinephrine 1, Amiodarone 300/150, Atropine 0.5, Adenosine 6/12 push with rapid NS flush
1273
dose and routeEpinephrine for Anaphylaxis
Child: 0.01mg/kg IM Adults: Epinephrine 0.5mg IM
1274
Vitamin B12 dosage and route
1mg (1000mcg) PO daily, or IM/deep SC weekly x one month then monthly
1275
Nocturnal enuresis management dose and route
Lifestyle, wet alarm DDAVP 0.2mg PO qHS (up to 0.6mg)